Provinces;Employee strata;Cohorts;ERTEs;Demographic Concepts;Periodo;Total National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.175.582 National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.136.561 National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.190.870 National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.110.581 National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.074.320 National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.050.404 National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.062.357 National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.035.575 National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.014.398 National Total;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.024.559 National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.003.536 National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;983.011 National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;994.419 National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;976.592 National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;952.502 National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,47 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,52 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,2 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,37 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,11 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,18 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,15 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,3 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,55 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,59 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,93 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,98 National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.116.307 National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;972.382 National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.053.423 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;915.073 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.006.960 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;879.880 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;970.603 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;850.920 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;941.626 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;827.437 National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,37 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,11 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,2 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,49 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,95 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,51 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,35 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,09 National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;59.275 National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;164.179 National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;57.158 National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;159.247 National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;55.397 National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;155.695 National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;53.956 National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;152.616 National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;52.793 National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;149.155 National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,43 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,46 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,83 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,03 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,96 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,06 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,85 National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.180.282 National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.137.018 National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.102.738 National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.119.786 National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.087.341 National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.059.378 National Total;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.073.841 National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.047.638 National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.022.614 National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.034.840 National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.013.467 National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;986.485 National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;976.815 National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;950.014 National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 National Total;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,87 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,63 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,07 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,98 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,14 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,73 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,68 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,13 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,46 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,91 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,15 National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.122.675 National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;981.798 National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;852.306 National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.064.037 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;935.775 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;812.240 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.019.625 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;899.208 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;781.490 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;982.021 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;868.703 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;753.187 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;835.962 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;724.018 National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 National Total;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,78 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,31 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,3 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,82 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,59 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,69 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,47 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,48 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,37 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,15 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,95 National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;57.607 National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;155.220 National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;250.432 National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;55.749 National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;151.566 National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;247.138 National Total;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;54.216 National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;148.430 National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;241.124 National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;52.819 National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;144.764 National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;233.298 National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;140.853 National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;225.996 National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 National Total;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,77 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,65 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,68 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,11 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,63 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,28 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,69 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,26 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,16 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,74 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,24 National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.200.910 National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.175.049 National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.141.253 National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.133.593 National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.112.584 National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.085.053 National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.077.291 National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.060.988 National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.033.148 National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.018.275 National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;991.293 National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;987.625 National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;966.184 National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,39 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,68 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,08 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,71 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,29 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,53 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,66 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,86 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,05 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,66 National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.166.975 National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.123.921 National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;962.702 National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.100.667 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.062.703 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;910.591 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.045.250 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.012.815 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;865.189 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;971.426 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;828.387 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;941.834 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;806.621 National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,32 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,55 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,59 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,57 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,11 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,87 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,43 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,05 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,8 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,79 National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;33.935 National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;51.128 National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;178.551 National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;32.926 National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;49.881 National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;174.462 National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;32.041 National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;48.173 National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;167.959 National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;46.849 National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;162.906 National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;45.791 National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;159.563 National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,03 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,56 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,71 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,42 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,22 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,07 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,63 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,24 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,56 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,37 National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.189.333 National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.173.766 National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.149.469 National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.121.025 National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.108.131 National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.080.193 National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.058.391 National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.031.022 National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.020.827 National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.000.340 National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;988.984 National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;973.266 National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,26 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,41 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,97 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,17 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,7 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,97 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,03 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,26 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,67 National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.160.407 National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.109.995 National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;962.114 National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.092.834 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.046.546 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;899.731 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;998.931 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;855.977 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;963.203 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;828.952 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;932.892 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;805.210 National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,18 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,28 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,52 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,99 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,97 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,78 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,16 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,04 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,69 National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;28.926 National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;63.771 National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;187.355 National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;28.191 National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;61.585 National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;180.462 National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;59.460 National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;175.045 National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;57.624 National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;171.388 National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;56.092 National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;168.056 National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,46 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,57 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,32 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,24 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,43 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,36 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,48 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,96 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,7 National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;874.114 National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;855.490 National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;886.684 National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;812.905 National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;796.794 National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;756.210 National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;769.343 National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;761.641 National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;723.750 National Total;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;734.959 National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;732.347 National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;695.670 National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;707.744 National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;708.023 National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;668.592 National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,14 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,29 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,01 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,03 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;81,62 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,08 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,61 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;78,46 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,97 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,76 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;75,4 National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;837.215 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;768.170 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;777.875 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;713.559 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;735.791 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;681.184 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;702.623 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;654.274 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;676.390 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;632.648 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,91 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,89 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,89 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,68 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,92 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,17 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,79 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,36 National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;36.899 National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;87.320 National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;35.030 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;83.235 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;33.552 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;80.457 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;32.336 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;78.073 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;31.354 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;75.375 National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,93 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,32 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,93 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,14 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,63 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,41 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,97 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;86,32 National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;874.197 National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;854.310 National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;825.970 National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;818.113 National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;808.026 National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;785.210 National Total;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;775.542 National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;771.127 National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;751.083 National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;740.395 National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;740.136 National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;718.066 National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;707.163 National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;685.318 National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 National Total;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,58 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,58 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,07 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,71 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,26 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,93 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,69 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,64 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,94 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,78 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,97 National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;838.776 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;769.732 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;676.830 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;784.297 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;726.460 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;638.724 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;743.050 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;692.118 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;609.668 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;709.047 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;664.072 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;583.024 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;634.180 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;556.127 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,5 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,38 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,37 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,59 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,92 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,08 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,53 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,27 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,14 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,39 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,17 National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;35.421 National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;84.578 National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;149.140 National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;33.816 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;81.566 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;146.486 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;32.492 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;79.009 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;141.415 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;31.348 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;76.064 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;135.042 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;72.983 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;129.191 National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 National Total;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,47 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,44 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,22 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,73 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,42 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,82 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,5 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,93 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,55 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,29 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,62 National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;883.149 National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;874.571 National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;853.778 National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;820.049 National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;815.824 National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;800.979 National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;771.171 National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;770.295 National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;754.275 National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;731.887 National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;716.603 National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;704.284 National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;694.215 National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,86 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,28 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,82 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,32 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,08 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,35 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,69 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,93 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,53 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,31 National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;861.875 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;846.766 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;759.705 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;799.681 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;789.096 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;710.308 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;751.489 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;744.825 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;668.408 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;707.461 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;634.589 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;680.705 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;614.694 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,78 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,19 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,5 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,19 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,96 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,98 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,55 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,53 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,39 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,91 National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;21.274 National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;27.805 National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;94.073 National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;20.368 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;26.728 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;90.671 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;19.682 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;25.470 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;85.867 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;24.426 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;82.014 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;23.579 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;79.521 National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,74 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,13 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,38 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,52 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,6 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,28 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;87,85 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;87,18 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;84,8 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;84,53 National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;876.949 National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;873.692 National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;861.639 National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;814.659 National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;813.113 National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;796.865 National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;767.484 National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;751.794 National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;733.651 National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;724.273 National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;704.836 National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;699.781 National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,9 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,07 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,48 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,84 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,25 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,97 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,06 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,67 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,22 National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;859.355 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;832.620 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;764.014 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;797.673 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;773.929 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;704.637 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;730.155 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;663.810 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;697.930 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;639.048 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;670.420 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;617.075 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,82 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,95 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,23 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,69 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,88 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,82 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,64 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,52 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,77 National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;17.594 National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;41.072 National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;97.625 National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;16.986 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;39.184 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;92.228 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;37.329 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;87.984 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;35.721 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;85.225 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;34.416 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;82.706 National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,54 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,4 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,47 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,89 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,12 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,97 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,3 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,79 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;84,72 National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;124.549 National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;116.998 National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;125.748 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;122.442 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;115.037 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;119.746 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;119.929 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;113.082 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;117.857 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;118.092 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;111.610 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;116.016 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;116.475 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;110.232 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;114.126 National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,31 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,32 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,23 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,29 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,65 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,72 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,82 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,39 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,26 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,52 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,22 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,76 National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;116.252 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;89.900 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;114.291 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;88.368 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;111.916 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;86.777 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;110.189 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;85.631 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;108.663 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;84.625 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,31 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,3 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,27 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,53 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,78 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,25 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,47 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,13 National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8.297 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;27.098 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8.151 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;26.669 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8.013 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;26.305 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7.903 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;25.979 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7.812 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;25.607 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,24 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,42 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,58 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,07 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,25 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,87 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,15 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,5 National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;125.746 National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;117.333 National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;113.956 National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;123.339 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;115.449 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;112.601 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;121.490 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;113.946 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;111.102 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;119.297 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;112.122 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;109.297 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;110.064 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;107.283 National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,09 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,39 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,81 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,62 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,11 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,5 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,87 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,56 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,91 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,8 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,14 National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;117.702 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;92.334 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;73.717 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;115.409 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;90.772 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;72.663 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;113.675 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;89.553 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;71.705 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;111.618 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;88.101 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;70.739 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;86.453 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;69.483 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,05 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,31 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,57 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,58 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,99 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,27 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,83 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,42 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,96 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,63 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,26 National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;8.044 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;24.999 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;40.239 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7.930 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;24.677 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;39.938 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7.815 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;24.393 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;39.397 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7.679 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;24.021 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;38.558 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;23.611 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;37.800 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,58 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,71 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,25 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,15 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,58 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,91 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,46 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,09 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,82 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,45 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,94 National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;130.132 National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;124.765 National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;119.956 National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;127.777 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;122.694 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;117.978 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;123.924 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;119.394 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;114.960 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;116.989 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;112.670 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;115.333 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;111.210 National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,19 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,34 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,35 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,23 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,7 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,84 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,77 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,93 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,44 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,71 National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;125.390 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;116.697 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;90.074 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;123.085 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;114.694 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;88.484 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;119.321 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;111.607 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;86.341 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;109.334 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;84.652 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;107.792 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;83.598 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,16 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,28 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,23 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,16 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,64 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,86 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,69 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,98 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,37 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,81 National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4.742 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;8.068 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;29.882 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4.692 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;8.000 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;29.494 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4.603 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;7.787 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;28.619 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;7.655 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;28.018 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;7.541 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;27.612 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,95 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,16 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,7 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,07 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,52 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,77 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,88 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,76 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,47 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,4 National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;127.463 National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;123.997 National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;119.747 National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;124.148 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;121.155 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;117.016 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;118.849 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;114.737 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;116.838 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;113.058 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;115.212 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;111.718 National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,4 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,71 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,72 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,85 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,82 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,23 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,41 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,92 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,3 National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;123.328 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;115.622 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;88.359 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;120.065 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;112.939 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;86.418 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;110.785 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;84.738 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;108.872 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;83.486 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;107.369 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;82.513 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,35 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,68 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,8 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,82 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,9 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,16 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,48 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,86 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,38 National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4.135 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8.375 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;31.388 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4.083 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8.216 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;30.598 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8.064 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;29.999 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;7.966 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;29.572 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7.843 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;29.205 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,74 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,1 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,48 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,29 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,57 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,12 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,21 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,65 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,05 National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;163.320 National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;151.266 National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;164.940 National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;161.717 National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;149.762 National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;161.052 National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;159.625 National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;148.171 National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;159.443 National Total;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;158.127 National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;146.961 National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;158.052 National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;156.876 National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;145.782 National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;156.571 National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,02 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,01 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,64 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,74 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,95 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,67 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,82 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,15 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,82 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,05 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,37 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,93 National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;150.543 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;106.288 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;149.040 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;105.181 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;147.087 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;103.991 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;145.695 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;103.131 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;144.529 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;102.326 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,96 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,7 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,84 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,78 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,03 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,01 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,27 National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;12.777 National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;44.978 National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;12.677 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;44.581 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;12.538 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;44.180 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;12.432 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;43.830 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;12.347 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;43.456 National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,22 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,12 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,13 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,23 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,3 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,45 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,63 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,62 National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;166.450 National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;152.636 National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;150.040 National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;164.493 National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;151.161 National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;148.830 National Total;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;163.054 National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;149.932 National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;147.755 National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;161.455 National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;148.639 National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;146.511 National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;147.097 National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;144.878 National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 National Total;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,82 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,03 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,19 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,96 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,23 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,48 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,38 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,65 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,37 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,56 National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;153.606 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;111.384 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;93.261 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;151.785 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;110.222 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;92.383 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;150.432 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;109.269 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;91.698 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;148.945 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;108.311 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;91.053 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;107.167 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;90.090 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,81 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,96 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,06 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,93 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,1 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,32 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,97 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,24 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,63 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,21 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,6 National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;12.844 National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;41.252 National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;56.779 National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;12.708 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;40.939 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;56.447 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;12.622 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;40.663 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;56.057 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;12.510 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;40.328 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;55.458 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;39.930 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;54.788 National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 National Total;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,94 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,24 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,42 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,27 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,57 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,73 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,4 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,76 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,67 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,8 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,49 National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;173.380 National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;162.690 National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;155.017 National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;171.583 National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;161.089 National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;153.646 National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;168.075 National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;158.391 National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;151.519 National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;156.573 National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;149.706 National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;155.225 National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;148.479 National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,96 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,02 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,12 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,94 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,36 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,74 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,24 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,57 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,41 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,78 National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;166.164 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;148.996 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;105.363 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;164.417 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;147.492 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;104.280 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;161.016 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;145.023 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;102.959 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;143.349 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;101.717 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;142.095 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;100.927 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,95 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,99 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,97 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,9 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,33 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,72 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,21 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,54 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,37 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,79 National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7.216 National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13.694 National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;49.654 National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7.166 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13.597 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;49.366 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;7.059 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;13.368 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;48.560 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;13.224 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;47.989 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;13.130 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;47.552 National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,31 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,29 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,42 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,82 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,62 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,8 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,57 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,65 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,88 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,77 National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;170.547 National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;162.696 National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;155.216 National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;167.898 National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;160.551 National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;153.508 National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;158.833 National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;151.765 National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;157.160 National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;150.320 National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;155.826 National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;149.131 National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,45 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,68 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,9 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,63 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,78 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,6 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,85 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,78 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,08 National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;163.975 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;149.747 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;102.151 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;161.397 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;147.739 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;101.131 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;146.137 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;99.937 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;144.590 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;98.954 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;143.354 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;98.189 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,43 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,66 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,59 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,83 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,56 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,87 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,73 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,12 National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6.572 National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12.949 National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;53.065 National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6.501 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;12.812 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;52.377 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;12.696 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;51.828 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;12.570 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;51.366 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12.472 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;50.942 National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,92 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,94 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,7 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,05 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,67 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,07 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,8 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,32 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96 National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.758 National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.219 National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.715 National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;8.715 National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;8.160 National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;8.634 National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;8.673 National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;8.128 National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;8.600 National Total;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;8.617 National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;8.088 National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;8.549 National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;8.576 National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;8.046 National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.509 National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,51 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,28 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,07 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,03 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,89 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,68 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,39 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,41 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,1 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,92 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,9 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,64 National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.908 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5.257 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.866 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.213 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.829 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.187 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.780 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.161 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.743 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.129 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,47 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,16 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,67 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,38 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,17 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,91 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,57 National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;850 National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.962 National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;849 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.947 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;844 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.941 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;837 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.927 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;833 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.917 National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,88 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,49 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,29 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,29 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,47 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,82 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,48 National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.978 National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.170 National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.183 National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;8.942 National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;8.148 National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;8.155 National Total;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;8.878 National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.094 National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;8.119 National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;8.830 National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;8.052 National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;8.078 National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;8.012 National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;8.025 National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 National Total;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,6 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,73 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,66 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,89 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,07 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,22 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,35 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,56 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,72 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,07 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,07 National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.143 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.493 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.426 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;8.108 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.475 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.402 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8.050 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.435 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.375 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8.004 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.402 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.344 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.377 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.309 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,57 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,67 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,56 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,86 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,94 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,06 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,29 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,34 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,49 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,89 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,84 National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;835 National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.677 National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.757 National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;834 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.673 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.753 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;828 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.659 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.744 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;826 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.650 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.734 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.635 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.716 National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 National Total;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,88 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,85 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,85 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,16 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,33 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,53 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,92 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,99 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,17 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,43 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,51 National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;9.297 National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.416 National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.063 National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;9.247 National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.379 National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.025 National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;9.198 National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.331 National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.991 National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;8.288 National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;7.932 National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;8.257 National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;7.907 National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,46 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,56 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,53 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,94 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,99 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,11 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,48 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,38 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,11 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,07 National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.817 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.463 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4.935 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.769 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.429 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.907 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;8.721 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.385 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4.885 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.346 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.848 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.318 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.828 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,46 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,54 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,43 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,91 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,95 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,99 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,43 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,24 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,06 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,83 National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;480 National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;953 National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.128 National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;478 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;950 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.118 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;477 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;946 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.106 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;942 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.084 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;939 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.079 National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,58 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,69 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,68 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;99,38 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,27 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,3 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,85 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,59 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,53 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,43 National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;9.311 National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.634 National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.288 National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;9.273 National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.585 National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.247 National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;8.541 National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;8.189 National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;8.509 National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;8.164 National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;8.459 National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;8.128 National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,59 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,43 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,51 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,92 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,81 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,55 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,5 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,97 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,07 National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.889 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.774 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4.950 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.854 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.726 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4.920 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.683 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4.881 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.654 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.861 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.608 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.840 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,61 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,38 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,39 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,83 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,61 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,46 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,2 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,86 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,78 National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;422 National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;860 National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.338 National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;419 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;859 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.327 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;858 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3.308 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;855 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3.303 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;851 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3.288 National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,29 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,88 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,67 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,77 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,1 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;99,42 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,95 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,95 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,5 National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.841 National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.588 National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.783 National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;4.802 National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;4.567 National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;4.762 National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;4.787 National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;4.553 National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;4.748 National Total;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.764 National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.530 National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.724 National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.748 National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.509 National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.704 National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,19 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,54 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,56 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,88 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,24 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,27 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,41 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,74 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,77 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,08 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,28 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,35 National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.389 National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.767 National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.351 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.752 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.337 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.741 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.316 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.723 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.301 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.709 National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,13 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,46 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,82 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,06 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,34 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,41 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,99 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,9 National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;452 National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.821 National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;451 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.815 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;450 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.812 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;448 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.807 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;447 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.800 National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,78 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,67 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,56 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,51 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;99,12 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,23 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,89 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,85 National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.911 National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.569 National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.589 National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;4.899 National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;4.557 National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;4.582 National Total;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.877 National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.539 National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.555 National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.863 National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.518 National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.533 National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;4.479 National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;4.510 National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 National Total;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,76 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,74 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,85 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,31 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,34 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,26 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,02 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,88 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,78 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,03 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,28 National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.448 National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.855 National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.072 National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.438 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.846 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.068 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.418 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.833 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.044 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.407 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.817 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.027 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.785 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.009 National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 National Total;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,78 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,68 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,87 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,33 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,23 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,09 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,08 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,67 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,54 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,55 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,95 National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;463 National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.714 National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.517 National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;461 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.711 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.514 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;459 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.706 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.511 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;456 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.701 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.506 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.694 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.501 National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 National Total;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,57 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,82 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,8 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,14 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,53 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,6 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,49 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,24 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,27 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,83 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,95 National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.952 National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.607 National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.439 National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.937 National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.598 National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.425 National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.923 National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.577 National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.403 National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;4.538 National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;4.382 National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;4.526 National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;4.373 National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,7 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,8 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,68 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,41 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,35 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,19 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,5 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,72 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,24 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,51 National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.729 National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.999 National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.625 National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.715 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.992 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.612 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.703 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.975 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.596 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.936 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.581 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.924 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.574 National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,7 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,82 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,5 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,45 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,4 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,9 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,42 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,32 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,12 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,06 National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;223 National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;608 National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.814 National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;222 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;606 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.813 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;220 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;602 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.807 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;602 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.801 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;602 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.799 National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,55 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,67 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,94 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,65 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,01 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,61 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,01 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,28 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;99,01 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;99,17 National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5.063 National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.747 National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.579 National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.047 National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.727 National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.557 National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;4.684 National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;4.537 National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;4.669 National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;4.525 National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.651 National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.508 National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,68 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,58 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,52 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,67 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,08 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,36 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,82 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,98 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,45 National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.860 National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.232 National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.640 National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.845 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.213 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.625 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.171 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.611 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.157 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.603 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.141 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.593 National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,69 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,55 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,43 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,56 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,9 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,23 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,6 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,85 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,22 National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;203 National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;515 National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.939 National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;202 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;514 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.932 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;513 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.926 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;512 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.922 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;510 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.915 National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,51 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,81 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,64 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,61 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,33 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;99,42 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,12 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;99,03 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,76 National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" National Total;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;9.442 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;9.135 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;9.476 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;8.916 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;8.645 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;8.300 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;8.521 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;8.333 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;8.036 02 Albacete;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;8.215 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;8.063 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.804 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.956 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.875 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.605 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,43 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,64 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,59 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,25 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,22 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,8 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,26 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,36 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,26 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;86,21 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,26 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;9.058 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8.142 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.546 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.683 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;8.165 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7.390 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.869 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7.133 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.616 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.959 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,35 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,36 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,14 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,76 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,87 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,61 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,08 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,47 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;384 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;993 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;370 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;962 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;356 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;943 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;346 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;930 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;340 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;916 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,35 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,88 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,71 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,96 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,1 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,66 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,54 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,25 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;9.411 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;9.169 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.731 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;8.906 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;8.731 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;8.403 02 Albacete;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;8.516 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.371 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;8.128 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;8.214 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;8.129 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.893 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;7.850 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;7.646 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 02 Albacete;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,63 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,22 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,24 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,49 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,3 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,09 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,28 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,66 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,4 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,61 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,57 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;9.036 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;8.356 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.521 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;8.545 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.937 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6.219 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8.166 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7.587 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.989 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.872 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;7.361 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.816 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;7.105 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.630 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,57 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,99 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,37 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,37 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,8 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,84 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,12 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,09 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,19 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,03 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,34 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;375 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;813 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.210 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;361 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;794 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.184 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;350 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;784 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.139 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;342 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;768 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.077 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;745 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.016 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,27 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,66 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,82 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,33 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,43 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,79 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,2 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,46 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,98 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,64 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,22 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;9.415 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;9.356 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;9.171 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.836 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.791 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.679 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;8.466 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.472 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;8.314 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;8.152 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;8.011 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;7.933 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.828 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,85 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,96 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,64 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,92 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,55 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,66 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,13 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,35 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,79 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,36 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;9.314 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;9.045 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8.114 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.737 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8.490 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7.645 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;8.372 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8.179 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;7.306 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.866 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.031 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.652 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.861 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,81 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,86 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,22 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,89 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,43 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,04 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,97 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,65 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,6 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,56 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;101 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;311 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.057 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;99 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;301 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.034 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;94 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;293 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.008 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;286 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;980 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;281 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;967 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,02 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,78 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,82 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,07 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,21 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,36 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,96 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,72 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,35 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,49 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;9.272 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;9.303 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;9.171 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;8.780 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.862 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.674 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;8.476 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;8.313 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;8.191 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;8.077 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.931 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.865 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,69 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,26 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,58 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,11 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,64 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,05 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,07 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,25 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,76 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;9.186 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.894 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.978 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.699 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;8.465 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7.513 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;8.089 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7.181 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.815 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.965 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.569 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.770 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,7 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,18 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,17 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,95 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,01 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,87 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,3 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,1 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,86 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;86 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;409 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.193 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;81 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;397 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.161 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;387 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.132 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;376 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.112 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;362 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.095 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,19 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,07 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,32 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,62 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,89 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,93 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,21 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,51 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,79 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;7.144 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;7.026 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;7.195 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;6.646 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;6.558 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;6.092 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;6.292 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;6.279 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.855 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.008 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;6.020 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.654 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.771 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.851 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.482 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,03 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,34 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;84,67 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,07 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,37 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;81,38 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,1 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,68 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;78,58 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,78 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,28 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,19 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.909 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.478 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.423 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.036 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.079 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.772 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.804 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.525 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.571 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.366 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,97 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,18 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,99 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,1 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,01 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,29 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,63 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,83 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;235 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;548 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;223 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;522 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;213 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;507 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;204 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;495 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;200 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;485 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,89 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,26 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,64 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,52 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,81 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,33 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,11 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,5 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;7.121 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.046 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.732 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;6.656 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;6.643 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;6.427 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.297 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;6.306 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;6.177 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.023 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;6.086 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.960 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;5.828 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;5.733 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 02 Albacete;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,47 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,28 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,47 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,43 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,5 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,76 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,58 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,38 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,53 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,71 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,16 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.899 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.580 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.328 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6.446 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.191 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.045 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.096 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.864 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.834 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.828 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.654 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.674 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.417 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.495 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,43 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,09 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,69 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,36 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,12 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,73 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,48 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,93 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,73 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,33 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,37 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;222 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;466 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.404 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;210 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;452 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.382 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;201 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;442 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.343 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;195 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;432 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.286 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;411 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.238 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,59 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,43 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,54 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,85 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,66 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,84 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,7 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,6 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,2 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,18 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;7.055 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;7.119 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;7.035 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.517 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.583 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.572 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.182 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;6.288 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;6.243 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;5.997 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.969 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.796 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;5.807 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,37 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,47 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,42 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,63 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,33 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,74 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,24 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,85 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,42 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,54 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.989 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.936 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6.512 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.453 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.410 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.067 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6.122 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;6.121 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.758 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.837 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.502 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.641 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.349 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,33 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,42 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,17 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,59 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,25 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,42 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,16 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,49 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,33 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,14 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;66 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;183 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;523 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;64 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;173 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;505 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;60 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;167 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;485 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;160 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;467 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;155 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;458 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,97 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,54 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,56 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,91 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,26 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,73 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;87,43 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,29 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;84,7 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;87,57 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.961 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;7.063 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;7.039 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.499 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.646 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.569 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;6.289 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;6.235 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;6.032 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;6.024 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.789 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.822 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,36 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,1 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,32 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,04 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,58 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,4 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,58 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,96 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,71 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.911 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.801 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6.403 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;6.453 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.395 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.959 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.047 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.648 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.798 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.453 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.568 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5.267 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,37 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,03 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,07 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,91 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,21 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,25 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,16 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,87 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,26 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;50 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;262 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;636 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;46 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;251 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;610 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;242 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;587 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;234 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;571 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;221 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;555 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;92 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,8 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,91 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,37 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,3 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,31 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,78 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,35 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,26 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.017 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;922 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.008 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.001 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;910 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;963 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;981 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;891 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;954 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;968 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;884 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;938 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;958 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;870 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;922 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,43 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,7 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,54 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,46 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,64 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,64 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,18 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,88 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,06 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,2 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,36 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,47 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;955 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;744 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;940 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;734 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;924 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;718 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;911 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;712 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;901 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;700 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,43 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,66 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,75 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,51 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,39 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,7 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,35 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,09 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;62 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;178 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;61 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;176 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;57 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;173 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;57 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;172 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;57 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;170 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,39 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,88 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,94 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,19 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,94 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,63 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,94 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,51 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;976 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;933 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;871 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;954 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;914 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;861 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;935 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;902 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;848 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;921 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;887 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;838 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;876 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;827 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,75 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,96 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,85 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,8 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,68 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,36 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,36 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,07 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,21 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,89 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,95 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;923 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;789 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;520 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;901 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;773 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;513 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;884 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;761 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;502 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;871 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;750 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;493 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;740 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;489 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,62 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,97 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,65 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,77 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,45 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,54 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,37 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,06 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;94,81 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,79 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,04 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;53 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;144 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;351 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;53 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;141 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;348 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;51 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;141 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;346 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;50 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;137 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;345 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;136 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;338 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,92 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,15 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,23 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,92 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,58 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,34 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,14 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,29 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,44 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,3 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.034 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;984 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;943 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.011 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;970 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;931 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;993 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;959 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;904 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;942 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;889 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;931 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;873 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,78 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,58 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,73 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,03 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,46 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,86 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,73 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,27 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,61 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,58 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.022 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;932 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;754 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;999 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;918 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;744 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;982 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;908 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;719 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;891 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;708 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;880 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;694 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,75 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,5 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,67 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,09 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,42 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,36 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,6 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,9 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,42 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,04 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;12 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;52 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;189 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;12 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;52 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;187 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;11 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;51 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;185 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;51 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;181 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;51 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;179 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,94 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,67 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,08 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,88 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,08 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,77 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,08 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,71 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.007 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;969 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;922 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;992 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;955 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;903 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;939 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;887 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;923 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;873 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;914 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;867 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,51 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,56 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,94 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,9 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,2 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,25 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,69 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,32 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,03 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;995 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;905 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;710 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;981 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;891 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;695 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;875 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;682 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;861 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;671 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;853 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;666 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,59 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,45 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,89 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,69 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,06 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,14 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,51 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,25 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,8 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;12 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;64 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;212 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;64 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;208 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;64 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;205 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;62 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;202 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;61 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;201 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;91,67 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,11 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,7 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,88 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,28 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,31 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,81 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.223 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.134 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.217 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.211 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.125 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.189 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.190 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.111 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.171 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.181 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.107 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.157 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.169 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.102 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.146 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,02 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,21 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,7 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,3 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,97 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,22 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,57 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,62 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,07 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,58 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,18 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,17 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.141 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;880 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.130 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;874 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.109 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;861 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.101 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;857 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.091 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;854 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,04 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,32 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,2 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,84 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,49 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,39 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,62 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,05 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;82 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;254 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;81 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;251 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;81 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;250 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;80 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;250 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;78 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;248 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,78 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,82 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,78 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,43 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,56 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,43 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,12 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,64 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.256 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.139 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.076 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.238 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.123 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.063 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.226 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.112 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.052 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.212 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.105 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.044 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.095 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.035 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 02 Albacete;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,57 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,6 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,79 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,61 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,63 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,77 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,5 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,01 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,03 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,14 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,19 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.159 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;947 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;636 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.143 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;933 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;624 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.131 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;922 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;617 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.118 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;917 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;613 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;908 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;610 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,62 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,52 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,11 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,58 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,36 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,01 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,46 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,83 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,38 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,88 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,91 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;97 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;192 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;440 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;95 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;190 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;439 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;95 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;190 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;435 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;94 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;188 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;431 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;187 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;425 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,94 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,96 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,77 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,94 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,96 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,86 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,91 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,92 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,95 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,4 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,59 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.264 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.198 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.138 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.246 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.183 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.122 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.229 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.170 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.113 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.159 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.099 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.152 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.094 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,58 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,75 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,59 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,23 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,66 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,8 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,74 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,57 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,16 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,13 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.241 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.124 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;808 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.223 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.109 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;795 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.206 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.097 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;790 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.086 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;782 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.079 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;779 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,55 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,67 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,39 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,18 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,6 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,77 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,62 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,78 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,41 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;23 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;74 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;330 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;23 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;74 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;327 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;23 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;73 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;323 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;73 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;317 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;73 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;315 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,09 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,65 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,88 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,65 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,06 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,65 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,45 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.246 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.210 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.155 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.231 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.200 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.147 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.188 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.136 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.176 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.125 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.168 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.121 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,8 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,17 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,31 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,18 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,35 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,19 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,4 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,53 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,06 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.223 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.133 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;828 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.208 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.124 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;822 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.113 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;814 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.102 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;804 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.094 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;800 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,77 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,21 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,28 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,23 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,31 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,26 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,1 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,56 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,62 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;23 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;77 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;327 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;23 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;76 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;325 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;75 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;322 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;74 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;321 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;74 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;321 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,7 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,39 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,4 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,47 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,1 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,17 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,1 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,17 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;34 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;33 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;33 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;33 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;37 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;38 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;33 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;37 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,06 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,06 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,06 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,37 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,06 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,37 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;36 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;25 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;36 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;24 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;36 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;24 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;36 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;24 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;36 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;24 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;9 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;9 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;9 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;9 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;9 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;37 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;31 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;34 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;37 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;31 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;34 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;37 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;31 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;33 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;37 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;31 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;33 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;31 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;33 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,06 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,06 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,06 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;34 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;34 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;34 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;24 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;34 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;24 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;25 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;24 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;9 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;44 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;35 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;34 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;44 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;35 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;33 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;44 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;35 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;33 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;35 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;33 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;35 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;33 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,06 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,06 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,06 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,06 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;44 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;33 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;26 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;44 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;33 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;25 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;44 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;33 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;25 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;33 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;25 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;33 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;25 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,15 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,15 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,15 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,15 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;8 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;8 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;8 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;8 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;8 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;38 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;41 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;36 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;38 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;41 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;36 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;41 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;36 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;41 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;36 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;41 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;36 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;24 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;24 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;24 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;24 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;37 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;24 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;4 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;12 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;12 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;12 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;12 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;12 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;20 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;19 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;18 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;20 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;19 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;18 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;20 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;19 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;18 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;20 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;19 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;18 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;20 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;19 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;18 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;17 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;15 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;17 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;17 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;15 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;17 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;15 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;21 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;20 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;18 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;21 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;20 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;18 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;21 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;20 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;18 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;21 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;20 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;18 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;20 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;18 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;21 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;15 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;12 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;21 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;15 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;12 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;21 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;12 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;21 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;15 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;15 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;5 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;5 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;5 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;5 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;5 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;20 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;21 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;18 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;20 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;21 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;18 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;20 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;21 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;19 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;21 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;19 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;21 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;18 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;20 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;14 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;18 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;20 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;14 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;18 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;20 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;19 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;19 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;14 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;7 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;20 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;20 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;19 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;20 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;20 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;19 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;20 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;20 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;18 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;13 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;17 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;13 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;17 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;17 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;94,44 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,44 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,44 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 02 Albacete;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;51.511 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;49.912 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;52.882 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;48.503 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;46.277 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;45.511 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;46.343 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;44.486 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;43.752 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;44.583 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;42.941 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;42.152 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;43.144 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;41.654 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;40.568 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,16 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,72 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,06 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,97 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,13 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,74 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,55 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,03 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,71 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,76 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,45 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,71 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;48.727 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;42.724 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;45.833 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;39.404 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;43.760 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;37.790 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;42.065 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;36.382 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;40.680 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;35.268 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,06 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,23 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,81 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,45 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,33 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,16 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,49 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,55 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2.784 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7.188 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2.670 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6.873 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2.583 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;6.696 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2.518 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;6.559 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2.464 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;6.386 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,91 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,62 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,78 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,16 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,45 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,25 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,51 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,84 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;52.209 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;49.218 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;48.159 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;49.451 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;46.956 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;46.026 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;47.213 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;45.046 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;44.107 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;45.252 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;43.391 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;42.226 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;41.781 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;40.164 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,72 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,4 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,57 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,43 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,52 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,59 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,67 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,16 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,68 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,89 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,4 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;49.437 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;41.587 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;36.711 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;46.760 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;39.534 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;34.719 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;44.599 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;37.782 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;33.112 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;42.709 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;36.343 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;31.688 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;34.939 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;30.112 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,59 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,06 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,57 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,21 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,85 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,2 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,39 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,39 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,32 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,01 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,02 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2.772 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;7.631 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;11.448 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2.691 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;7.422 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;11.307 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2.614 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;7.264 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;10.995 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2.543 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;7.048 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;10.538 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6.842 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;10.052 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,08 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,26 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,77 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,3 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,19 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,04 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,74 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,36 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,05 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,66 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,81 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;53.507 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;51.544 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;50.230 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;50.218 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;48.536 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;47.303 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;47.556 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;46.075 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;44.733 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;44.118 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;42.285 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;42.700 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;41.115 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,85 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,16 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,17 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,88 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,39 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,06 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,59 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,18 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,84 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,85 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;51.704 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;49.183 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;42.779 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;48.470 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;46.242 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;40.024 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;45.860 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;43.862 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;37.709 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;41.988 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;35.564 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;40.623 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;34.572 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,75 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,02 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,56 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,7 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,18 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,15 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,37 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,13 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,6 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,82 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.803 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2.361 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7.451 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.748 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2.294 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7.279 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.696 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2.213 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7.024 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2.130 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6.721 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2.077 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6.543 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,95 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,16 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,69 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,07 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,73 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,27 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,22 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,2 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,97 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;87,81 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;52.801 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;51.528 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;50.527 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;49.611 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;48.323 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;47.057 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;46.001 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;44.112 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;44.302 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;42.717 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;42.862 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;41.464 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,96 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,78 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,13 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,27 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,3 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,98 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,54 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,18 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,06 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;51.305 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;48.523 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;41.945 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;48.156 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;45.432 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;38.790 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;43.219 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;36.202 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;41.611 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;35.009 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;40.255 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;33.919 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,86 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,63 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,48 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,07 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,31 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,76 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,46 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,96 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,87 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1.496 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3.005 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;8.582 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1.455 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2.891 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;8.267 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2.782 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;7.910 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2.691 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;7.708 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2.607 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;7.545 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,26 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,21 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,33 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,58 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,17 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,55 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,82 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,76 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,92 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;39.113 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;38.439 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;40.097 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;36.280 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;34.991 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;33.356 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;34.324 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;33.375 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;31.777 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;32.723 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;31.965 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;30.372 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;31.404 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;30.796 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;28.995 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,76 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;91,03 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,19 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,76 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;86,83 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;79,25 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,66 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;83,16 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;75,75 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,29 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,12 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;72,31 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;37.311 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;34.444 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;34.577 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;31.273 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;32.695 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;29.792 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;31.151 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;28.493 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;29.881 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;27.469 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,67 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;90,79 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,63 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;86,49 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,49 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;82,72 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,09 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;79,75 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.802 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.995 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.703 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.718 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.629 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3.583 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.572 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3.472 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.523 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.327 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,51 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;93,07 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,4 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;89,69 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,24 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;86,91 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,52 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;83,28 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;39.472 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;37.888 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;37.107 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;36.917 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;35.778 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;35.104 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;34.840 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;34.016 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;33.317 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;33.090 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;32.509 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;31.605 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;31.049 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;29.728 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,53 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,43 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,6 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,27 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,78 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;89,79 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,83 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,8 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;85,17 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,95 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;80,11 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;37.670 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;33.362 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;29.877 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;35.187 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;31.427 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;27.987 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;33.179 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;29.800 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;26.472 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;31.491 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;28.474 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;25.138 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;27.182 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;23.667 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,41 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,2 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,67 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,08 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,32 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;88,6 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,6 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,35 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;84,14 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,48 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;79,21 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.802 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4.526 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;7.230 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.730 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4.351 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;7.117 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.661 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4.216 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6.845 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.599 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4.035 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6.467 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.867 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6.061 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,13 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,44 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,18 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,15 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,67 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,73 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,15 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;89,45 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;85,44 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;83,83 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;39.892 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;39.071 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;38.350 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;36.810 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;36.243 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;35.610 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;34.537 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;34.086 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;33.320 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;32.333 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;31.105 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;31.062 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;30.064 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,27 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,76 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,86 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,58 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,24 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;86,88 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,75 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;81,11 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,5 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;78,39 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;38.781 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;37.685 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;34.314 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;35.748 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;34.915 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;31.719 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;33.514 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;32.826 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;29.629 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;31.143 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;27.653 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;29.916 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;26.743 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,18 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,65 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,44 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,42 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,11 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,35 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,64 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;80,59 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,38 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;77,94 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.111 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.386 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4.036 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.062 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.328 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.891 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.023 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.260 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.691 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.190 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.452 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.146 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.321 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,59 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,82 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,41 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,08 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,91 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,45 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;85,86 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;85,53 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;82,68 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;82,28 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;39.595 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;39.077 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;38.667 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;36.713 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;36.117 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;35.421 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;33.993 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;32.722 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;32.463 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;31.483 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;31.151 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;30.342 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,72 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,43 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,61 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,99 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;84,63 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,07 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;81,42 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;79,72 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;78,47 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;38.714 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;37.056 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;33.955 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;35.866 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;34.195 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;30.974 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;32.157 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;28.566 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;30.708 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;27.479 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;29.472 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;26.469 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,64 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,28 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,22 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;86,78 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;84,13 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;82,87 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;80,93 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,53 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;77,95 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;881 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2.021 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4.712 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;847 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.922 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;4.447 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.836 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4.156 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.755 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;4.004 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.679 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3.873 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,14 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,1 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,38 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,85 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;88,2 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,84 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;84,97 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,08 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;82,19 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;5.427 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;5.132 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;5.562 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;5.322 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;5.008 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;5.201 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;5.220 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;4.918 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;5.117 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.133 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.848 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.003 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.069 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.775 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.879 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,07 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,58 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;93,51 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,19 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,83 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;92 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,58 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,47 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;89,95 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,4 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,04 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;87,72 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5.042 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.925 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.946 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.825 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.851 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.757 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.767 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.699 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.707 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.645 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,1 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,45 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,21 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,72 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,55 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,24 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,36 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,87 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;385 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.207 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;376 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.183 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;369 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.161 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;366 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.149 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;362 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.130 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,66 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,01 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,84 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,19 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,06 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,19 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,03 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,62 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;5.493 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.981 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.879 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;5.394 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;4.905 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;4.824 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.302 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.829 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.748 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.176 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.734 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.641 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;4.648 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;4.525 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,2 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,47 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,87 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,52 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,95 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,32 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,23 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,04 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,12 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,31 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;92,74 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.126 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.770 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.126 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.033 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.711 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.084 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.945 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.648 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.031 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.825 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.576 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.974 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.512 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.908 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,19 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,44 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,66 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,47 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,76 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,96 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,13 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,85 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,14 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,16 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,03 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;367 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.211 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.753 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;361 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.194 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.740 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;357 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.181 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.717 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;351 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.158 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.667 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.136 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.617 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,37 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,6 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,26 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,28 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,52 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,95 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,64 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,62 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,09 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,81 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,24 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5.871 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.474 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5.303 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;5.748 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.373 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.189 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.539 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.201 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.022 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;5.083 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;4.879 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;4.995 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;4.813 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,9 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,15 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,85 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,35 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,01 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,7 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92,86 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;92 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;91,25 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;90,76 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5.608 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5.129 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4.046 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.486 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.033 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.946 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.285 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.864 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.817 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.755 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.711 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.671 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.668 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,82 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,13 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,53 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,24 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,83 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;94,34 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;92,71 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;91,72 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;91,07 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;90,66 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;263 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;345 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.257 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;262 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;340 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.243 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;254 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;337 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.205 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;328 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.168 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;324 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.145 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,62 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,55 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,89 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,58 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,68 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,86 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,07 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,92 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,91 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,09 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5.731 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.453 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5.314 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.549 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.307 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.168 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;5.196 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;5.004 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;5.104 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;4.917 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.022 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.854 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,82 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,32 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,25 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,29 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;94,17 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;93,6 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;92,53 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,1 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;91,34 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5.502 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5.052 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.868 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.323 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.915 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.754 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.819 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.633 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.734 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.571 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.657 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.523 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,75 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,29 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,05 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,39 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;93,92 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,71 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;92,32 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,18 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;91,08 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;229 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;401 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.446 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;226 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;392 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.414 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;377 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.371 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;370 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.346 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;365 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.331 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,69 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,76 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,79 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,01 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,81 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,27 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,08 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,02 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,05 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.647 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.051 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.915 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;6.579 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;5.990 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;6.648 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;6.480 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;5.907 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;6.554 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.409 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.843 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.473 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.355 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.800 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.390 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,98 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,99 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,14 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,49 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,62 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,78 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,42 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,56 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,61 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,61 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,85 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,41 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.079 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4.176 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.017 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4.128 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.924 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;4.065 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.858 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4.015 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.804 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.980 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,98 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,85 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,45 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,34 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,36 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,14 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,48 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,31 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;568 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.875 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;562 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.862 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;556 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.842 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;551 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.828 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;551 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.820 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,94 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,31 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,89 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,24 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,01 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,49 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,01 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,07 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.905 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.059 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;5.898 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;6.804 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;5.985 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;5.825 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.736 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.914 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;5.769 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.653 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.863 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.707 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;5.800 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;5.639 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,54 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,78 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,76 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,55 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,61 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,81 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,35 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,77 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,76 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,73 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,61 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.336 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.261 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.528 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6.238 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4.204 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.470 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.174 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.143 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.431 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.093 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.103 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.398 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.056 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.360 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,45 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,66 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,36 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,44 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,23 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,25 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,16 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,29 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,32 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,19 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,24 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;569 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.798 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.370 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;566 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.781 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.355 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;562 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.771 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.338 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;560 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.760 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.309 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.744 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.279 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,47 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,05 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,37 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,77 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,5 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,65 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,42 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,89 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,43 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,16 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;7.394 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.687 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.300 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;7.310 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.609 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.227 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.132 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;6.478 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;6.114 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;6.393 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;6.025 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;6.336 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;5.962 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,86 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,83 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,84 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,46 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,87 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,05 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,6 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,63 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,75 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,63 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.987 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.092 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4.267 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.908 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.018 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.207 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6.734 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.897 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4.111 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.816 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.048 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.764 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.009 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,87 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,79 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,59 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,38 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,8 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,34 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,47 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,87 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,62 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,95 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;407 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;595 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.033 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;402 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;591 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.020 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;398 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;581 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.003 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;577 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.977 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;572 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.953 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,77 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,33 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,36 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,79 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,65 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,52 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,97 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,25 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,13 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,06 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7.121 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.674 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.264 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.997 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.576 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.187 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;6.491 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;6.106 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;6.417 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;6.038 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.372 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.990 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,26 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,53 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,77 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,26 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,48 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,15 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,39 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,47 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,63 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.757 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.127 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.969 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;6.636 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.035 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.910 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.958 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.851 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.887 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.808 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.845 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.777 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,21 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,5 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,51 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,24 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,03 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,08 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,94 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,4 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,16 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;364 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;547 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.295 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;361 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;541 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.277 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;533 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.255 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;530 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.230 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;527 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.213 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,18 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,9 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,22 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,44 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,26 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,89 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,17 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,34 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,43 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;226 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;199 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;217 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;224 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;198 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;215 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;223 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;197 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;214 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;223 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;196 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;214 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;221 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;195 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;214 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,12 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,5 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,08 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,67 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,99 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,62 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,67 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,49 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,62 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,79 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,99 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,62 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;205 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;123 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;203 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;122 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;202 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;121 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;202 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;120 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;201 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;120 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,02 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,19 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,54 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,37 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,54 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,56 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,05 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,56 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;21 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;76 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;21 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;76 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;21 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;76 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;21 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;76 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;20 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;75 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,24 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,68 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;237 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;199 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;190 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;235 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;198 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;188 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;235 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;197 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;188 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;233 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;196 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;188 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;195 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;187 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,16 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,5 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,95 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,16 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,99 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,95 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,31 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,49 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,95 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,99 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,42 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;208 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;132 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;122 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;206 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;131 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;120 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;206 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;130 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;120 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;205 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;130 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;120 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;129 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;119 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,04 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,24 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,36 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,04 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,48 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,36 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,56 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,48 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,36 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,73 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,54 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;29 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;67 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;68 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;29 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;67 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;68 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;29 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;67 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;68 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;28 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;66 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;68 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;66 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;68 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,55 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,51 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,51 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;245 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;216 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;190 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;245 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;215 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;190 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;243 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;215 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;190 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;214 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;189 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;214 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;189 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,54 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,18 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,54 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,07 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;99,47 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,07 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;99,47 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;226 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;191 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;104 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;226 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;190 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;104 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;225 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;190 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;104 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;189 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;104 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;189 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;104 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,48 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,56 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,48 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,95 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,95 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;19 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;25 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;86 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;19 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;25 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;86 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;18 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;25 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;86 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;25 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;85 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;25 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;85 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,74 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,84 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,84 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;247 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;223 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;187 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;245 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;223 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;186 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;221 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;185 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;220 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;185 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;220 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;184 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,19 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,47 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,1 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,93 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,65 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,93 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,65 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,4 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;229 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;198 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;97 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;228 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;198 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;96 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;196 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;96 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;195 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;96 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;195 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;95 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,56 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,97 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,99 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,97 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,48 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,97 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,48 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,94 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;18 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;25 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;90 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;17 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;25 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;90 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;25 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;89 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;25 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;89 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;25 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;89 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,44 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,89 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,89 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,89 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;98 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;91 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;91 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;98 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;90 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;91 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;96 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;89 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;90 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;95 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;89 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;90 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;95 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;88 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;90 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,9 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,96 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,9 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,94 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,9 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,94 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,7 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,9 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;90 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;56 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;90 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;56 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;88 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;55 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;87 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;55 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;87 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;54 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,78 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,21 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,67 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,21 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,67 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,43 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;35 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;34 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;34 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;34 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;34 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,14 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,14 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,14 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,14 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;102 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;91 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;85 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;101 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;90 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;85 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;90 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;85 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;89 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;85 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;89 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;85 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,02 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,9 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,04 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,9 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,04 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,8 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,8 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;97 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;62 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;58 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;96 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;61 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;58 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;95 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;61 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;58 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;95 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;60 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;58 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;60 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;58 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,97 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,39 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,94 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,39 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,94 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,77 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,77 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;5 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;29 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;27 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;5 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;29 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;27 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;5 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;29 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;27 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;5 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;29 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;27 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;29 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;27 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;105 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;96 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;87 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;105 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;96 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;87 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;105 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;95 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;87 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;95 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;87 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;93 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;87 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,96 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,96 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,88 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;102 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;86 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;48 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;102 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;86 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;48 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;102 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;85 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;48 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;85 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;48 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;83 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;48 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,84 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,84 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,51 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;10 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;39 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;10 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;39 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;10 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;39 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;10 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;39 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;10 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;39 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;107 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;101 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;95 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;107 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;95 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;95 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;98 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;94 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;97 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;94 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,01 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,01 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,03 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,95 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,04 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,95 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;103 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;90 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;56 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;103 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;89 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;56 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;89 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;56 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;87 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;55 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;86 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;55 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,89 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,89 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,67 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,21 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,56 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,21 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;11 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;39 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;11 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;39 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;11 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;39 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;11 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;39 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;11 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;39 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 03 Alicante/Alacant;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;16.455 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;15.931 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;16.540 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;15.431 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;14.874 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;14.170 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;14.656 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;14.202 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;13.621 04 Almería;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;13.983 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;13.640 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;13.028 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;13.507 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;13.242 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;12.578 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,78 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,37 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,67 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,07 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,15 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,35 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,98 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,62 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;78,77 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,08 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,12 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,05 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;15.854 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;14.694 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;14.854 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;13.671 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;14.102 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;13.026 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;13.453 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;12.497 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12.989 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;12.129 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,69 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,04 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,95 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,65 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,86 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,05 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,93 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,54 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;601 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.237 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;577 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.203 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;554 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.176 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;530 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.143 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;518 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.113 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,01 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,25 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,18 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,07 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,19 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,4 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,19 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,98 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;16.534 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;15.956 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;15.020 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;15.536 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;15.092 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;14.334 04 Almería;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;14.718 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;14.376 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;13.646 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;14.085 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;13.813 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;13.105 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;13.265 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;12.573 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 04 Almería;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,96 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,59 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,43 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,02 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,1 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,85 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,19 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,57 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,25 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,13 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,71 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;15.985 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;14.647 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;13.261 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;15.003 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;13.815 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;12.601 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;14.202 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;13.142 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;11.970 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;13.589 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;12.611 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;11.493 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;12.095 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11.008 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 04 Almería;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,86 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,32 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,02 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,85 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,72 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,26 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,01 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,1 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,67 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,58 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,01 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;549 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.309 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.759 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;533 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.277 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.733 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;516 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.234 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.676 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;496 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.202 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.612 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.170 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.565 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 04 Almería;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,09 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,56 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,52 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,99 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,27 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,28 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,35 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,83 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,64 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,38 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,97 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;16.907 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;16.545 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;15.959 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;15.666 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;15.407 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;14.838 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;14.748 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;14.565 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;14.007 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;13.910 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;13.366 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;13.443 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;12.953 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,66 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,12 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,98 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,23 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,03 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,77 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,07 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,75 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,25 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,16 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;16.492 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;16.113 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;14.810 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;15.263 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14.990 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;13.724 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14.358 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;14.166 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;12.932 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;13.523 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;12.318 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;13.065 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11.924 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,55 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,03 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,67 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,06 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,92 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,32 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,93 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,17 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,08 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,51 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;415 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;432 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.149 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;403 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;417 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.114 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;390 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;399 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.075 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;387 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.048 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;378 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.029 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,11 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,53 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,95 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,98 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,36 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,56 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,58 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,21 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,5 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,56 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;16.625 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16.400 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;15.980 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;15.465 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;15.312 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;14.808 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;14.538 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;14.019 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;13.969 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;13.512 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;13.419 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;13.080 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,02 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,37 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,67 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,65 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,73 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,18 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,56 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,82 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,85 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;16.255 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;15.764 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;14.830 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;15.103 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;14.697 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;13.696 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;13.945 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;12.938 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;13.393 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;12.450 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;12.871 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;12.045 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,91 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,23 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,35 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,46 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,24 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,96 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,95 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,65 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,22 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;370 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;636 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.150 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;362 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;615 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.112 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;593 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.081 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;576 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.062 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;548 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.035 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,84 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,7 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,7 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,24 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,57 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,35 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,16 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;12.720 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;12.459 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;12.835 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;11.746 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;11.451 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;10.626 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;11.046 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;10.844 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;10.135 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;10.425 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;10.338 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.595 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;10.001 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;9.973 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;9.198 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,34 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;91,91 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;82,79 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;86,84 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,04 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;78,96 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;81,96 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;82,98 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;74,76 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;78,62 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,05 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;71,66 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12.290 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;11.796 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11.335 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10.818 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;10.655 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10.236 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10.058 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9.758 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;9.646 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9.416 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,23 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,71 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,7 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;86,78 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;81,84 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;82,72 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;78,49 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;79,82 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;430 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;663 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;411 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;633 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;391 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;608 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;367 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;580 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;355 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;557 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,58 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,48 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,93 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,7 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;85,35 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;87,48 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;82,56 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;84,01 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;12.739 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;12.450 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;11.713 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;11.810 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;11.651 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;11.075 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;11.045 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;10.988 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;10.432 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.480 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;10.475 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.935 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;9.976 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;9.455 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 04 Almería;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,71 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,58 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,55 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;86,7 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,26 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;89,06 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;82,27 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,14 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;84,82 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;80,13 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;80,72 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;12.357 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;11.668 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10.695 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11.443 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10.898 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.077 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;10.694 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;10.274 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.481 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;10.147 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9.788 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.035 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;9.318 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;8.591 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,6 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,4 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,22 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;86,54 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,05 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;88,65 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;82,12 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;83,89 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;84,48 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;79,86 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;80,33 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;382 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;782 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.018 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;367 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;753 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;998 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;351 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;714 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;951 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;333 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;687 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;900 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;658 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;864 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,07 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,29 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,04 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,88 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;91,3 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;93,42 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,17 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;87,85 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;88,41 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;84,14 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;84,87 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;12.942 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;12.740 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12.411 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;11.773 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;11.676 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;11.360 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;10.979 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;10.941 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;10.619 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;10.347 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;10.035 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;9.920 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;9.662 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;90,97 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;91,65 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;91,53 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;84,83 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;85,88 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;85,56 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;81,22 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;80,86 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;77,86 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;77,85 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;12.662 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12.475 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11.873 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;11.505 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;11.426 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;10.850 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.723 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10.702 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10.136 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10.118 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9.569 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;9.699 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9.209 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;90,86 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;91,59 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;91,38 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;84,69 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;85,79 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;85,37 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;81,11 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;80,59 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;77,75 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;77,56 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;280 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;265 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;538 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;268 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;250 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;510 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;256 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;239 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;483 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;229 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;466 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;221 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;453 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,71 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,34 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;94,8 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,43 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,19 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;89,78 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,42 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;86,62 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;83,4 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;84,2 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;12.801 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;12.716 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;12.495 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.737 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;11.709 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;11.405 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;10.992 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;10.667 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;10.473 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;10.213 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;9.960 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;9.819 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;91,69 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,08 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,28 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,44 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;85,37 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;82,36 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;81,74 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;78,33 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;78,58 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;12.555 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12.269 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;11.928 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;11.498 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11.281 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10.870 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10.583 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10.156 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10.079 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9.717 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;9.591 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9.346 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;91,58 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,95 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,13 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;86,26 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,14 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;82,15 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;81,46 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;78,17 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;78,35 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;246 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;447 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;567 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;239 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;428 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;535 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;409 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;511 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;394 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;496 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;369 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;473 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,15 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,75 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,36 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,5 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,12 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,14 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,48 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,55 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;83,42 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.658 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.551 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.650 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.628 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.514 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.552 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.592 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.488 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.530 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.565 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.459 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.502 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.533 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.440 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.467 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,19 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,61 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;94,06 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,02 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,94 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;92,73 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,39 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,07 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;91,03 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,46 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,84 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,91 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.585 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.349 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.558 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.315 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.524 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.290 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.497 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.264 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.465 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.248 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,3 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,48 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,15 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,63 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,45 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,7 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,43 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,51 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;73 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;202 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;70 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;199 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;68 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;198 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;68 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;195 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;68 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;192 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,89 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,51 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,15 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,02 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,15 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,53 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,15 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,05 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.691 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.584 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.468 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.660 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.560 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.455 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.632 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.532 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.431 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.590 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.502 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.403 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.470 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.368 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,17 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,48 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,11 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,51 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,72 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,48 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,03 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,82 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,57 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,8 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,19 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.620 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.370 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.188 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.589 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.347 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.175 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.562 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.321 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.157 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.522 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.292 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.136 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.263 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.109 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,09 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,32 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,91 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,42 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,42 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,39 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;93,95 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,31 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,62 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,19 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,35 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;71 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;214 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;280 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;71 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;213 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;280 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;70 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;211 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;274 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;68 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;210 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;267 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;207 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;259 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,53 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,59 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,6 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,86 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,77 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,13 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,36 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,73 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,5 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.738 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.714 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.631 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.694 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.676 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.589 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.627 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.613 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.529 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.579 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.495 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.551 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.473 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,47 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,78 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,42 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;93,61 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;94,11 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;93,75 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92,12 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;91,66 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90,49 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;90,31 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.683 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.647 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.430 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.639 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.609 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.391 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.572 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.549 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.336 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.517 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.308 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.490 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.290 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,39 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,69 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,27 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;93,4 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,05 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;93,43 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;92,11 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;91,47 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,47 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;90,21 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;55 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;67 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;201 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;55 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;67 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;198 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;55 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;64 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;193 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;62 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;187 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;61 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;183 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,51 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,52 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,02 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,54 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,03 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,04 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,04 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.728 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.662 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.602 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.677 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.607 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.543 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.571 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.507 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.540 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.484 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.521 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.462 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,05 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,69 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,32 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;94,52 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;94,07 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;92,66 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;92,63 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;91,52 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;91,26 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.673 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.578 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.407 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.622 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.524 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.353 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.490 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.323 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.461 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.303 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.444 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.282 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,95 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,58 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;96,16 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;94,42 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;94,03 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;92,59 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;92,61 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;91,51 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;91,12 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;55 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;84 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;195 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;55 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;83 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;190 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;81 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;184 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;79 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;181 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;77 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;180 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,81 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,44 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,43 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,36 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,05 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,82 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,67 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,31 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.922 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.774 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.907 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.903 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.762 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.845 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.866 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.729 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.813 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.844 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.706 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.790 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.824 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.692 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.772 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,01 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,32 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,75 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,09 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,46 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,07 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,94 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,17 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,86 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,9 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,38 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,92 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.830 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.420 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.813 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.409 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.777 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.376 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.755 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.355 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.735 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.345 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,07 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,23 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,1 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,9 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,9 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,42 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,81 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,72 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;92 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;354 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;90 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;353 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;89 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;353 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;89 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;351 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;89 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;347 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,83 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,72 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,74 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,72 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,74 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,15 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,74 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,02 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.949 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.778 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.694 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.914 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.742 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.666 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.891 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.721 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.647 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.865 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.701 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.631 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.685 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.614 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 04 Almería;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,2 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,98 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,35 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,02 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,79 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,23 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,69 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,67 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,28 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,77 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,28 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.859 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.478 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.249 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.825 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.443 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.226 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.802 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.424 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.211 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.776 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.408 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.201 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.392 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.187 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,17 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,63 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,16 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,93 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,35 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,96 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,54 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,26 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,16 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,18 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,04 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;90 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;300 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;445 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;89 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;299 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;440 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;89 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;297 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;436 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;89 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;293 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;430 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;293 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;427 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,89 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,67 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,88 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,89 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,98 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,89 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,67 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,63 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,67 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,96 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.085 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.966 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.805 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.058 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.933 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.781 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.002 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.889 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.751 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.863 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.728 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.851 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.712 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,71 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,32 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,67 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,02 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,08 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,01 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,76 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,73 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,15 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,85 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.009 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.870 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.416 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.982 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.837 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.396 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.927 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.797 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.373 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.771 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.354 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.759 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.340 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,66 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,24 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,59 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,92 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,1 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,96 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,71 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,62 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,06 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,63 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;76 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;96 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;389 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;76 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;96 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;385 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;75 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;92 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;378 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;92 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;374 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;92 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;372 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,97 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,68 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,83 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,17 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,83 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,14 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,83 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,63 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.952 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.889 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.761 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.908 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.864 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.738 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.844 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.723 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.825 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.695 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.808 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.680 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,75 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,68 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,69 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,62 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,84 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,61 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,25 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,71 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,4 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.888 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.791 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.395 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.845 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.767 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.373 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.748 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.359 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.729 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.331 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.713 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.319 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,72 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,66 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,42 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,6 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,42 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,54 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,41 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,64 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,55 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;64 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;98 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;366 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;63 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;97 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;365 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;96 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;364 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;96 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;364 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;95 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;361 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,44 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,98 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,73 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,96 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,45 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,96 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,45 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,94 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,63 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;90 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;89 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;94 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;90 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;89 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;93 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;88 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;85 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;90 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;87 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;82 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;89 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;87 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;82 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;89 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,94 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,78 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,51 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,74 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,67 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;92,13 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,68 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,67 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,13 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,68 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;88 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;80 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;88 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;80 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;86 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;77 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;85 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;74 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;85 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;74 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,73 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,25 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,59 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;92,5 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,59 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,5 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;9 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;9 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;8 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;8 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;8 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;88,89 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,89 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,89 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;91 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;88 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;87 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;89 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;84 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;89 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;89 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;81 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 04 Almería;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,8 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,45 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;93,1 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,8 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,05 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,1 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,8 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;92,05 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;93,1 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,05 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,1 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;89 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;83 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;79 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;87 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;80 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;74 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;87 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;77 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;74 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;87 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;77 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;74 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;77 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;74 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,75 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,39 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,67 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,75 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,77 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,67 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,75 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;92,77 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;93,67 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,77 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,67 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;5 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;7 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;7 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;7 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;4 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;7 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;80 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;87,5 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;80 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;87,5 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;80 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;87,5 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;80 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,5 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;88 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;80 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;75 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;87 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;77 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;71 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;86 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;77 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;71 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;77 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;71 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;77 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;69 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,86 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;96,25 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,67 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,73 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,25 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,67 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,25 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,67 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,25 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;86 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;79 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;62 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;85 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;76 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;58 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;84 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;76 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;58 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;76 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;58 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;76 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;56 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,84 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;96,2 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,55 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,67 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,2 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;93,55 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,2 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,55 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,2 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;90,32 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;13 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;13 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;13 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;13 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;13 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;94 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;85 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;76 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;94 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;84 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;76 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;84 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;76 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;84 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;74 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;83 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;73 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,82 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,82 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,82 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,37 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,65 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,05 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;91 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;82 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;64 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;91 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;81 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;64 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;81 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;64 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;81 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;63 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;80 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;62 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,78 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,78 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,78 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,44 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,56 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,88 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;12 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;12 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;12 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;11 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;11 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,67 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,67 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;65 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;58 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;54 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;64 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;58 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;54 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;64 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;56 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;53 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;62 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;55 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;52 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;62 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;55 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;52 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,46 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,46 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,55 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,15 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,38 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,83 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,3 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,38 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,83 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,3 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;61 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;49 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;60 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;49 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;60 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;47 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;58 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;46 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;58 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;46 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,36 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,36 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,92 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,08 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,88 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,08 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,88 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;4 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;9 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;4 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;9 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;4 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;9 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;4 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;9 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;4 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;9 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;64 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;56 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;58 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;63 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;55 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;57 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;61 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;54 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;55 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;61 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;54 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;55 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;53 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;55 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 04 Almería;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,44 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,21 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,28 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,31 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,43 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,83 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,31 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,43 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,83 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,64 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,83 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;60 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;48 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;50 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;59 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;47 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;49 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;57 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;46 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;47 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;57 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;46 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;47 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;45 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;47 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,33 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,92 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;95,83 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;94 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,83 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;94 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,75 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;8 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;54 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;45 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;37 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;54 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;45 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;37 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;54 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;45 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;37 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;44 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;37 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;44 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;37 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,78 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,78 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;52 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;42 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;29 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;52 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;42 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;29 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;52 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;42 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;29 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;41 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;29 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;41 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;29 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,62 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,62 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;8 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;8 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;8 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;8 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;8 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;50 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;48 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;46 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;49 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;48 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;46 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;47 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;46 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;47 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;46 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;47 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;46 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,92 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,92 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,92 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;48 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;44 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;36 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;47 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;44 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;36 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;43 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;36 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;43 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;36 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;43 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;36 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,92 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,73 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,73 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,73 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;4 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;10 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;10 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;10 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;10 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;10 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 04 Almería;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;7.691 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;7.644 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;7.944 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;7.346 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;7.311 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;7.307 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;7.019 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;7.067 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;7.055 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.785 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;6.887 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.863 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.601 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;6.708 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.705 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,51 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,64 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,98 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,26 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,45 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,81 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,22 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,1 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;86,39 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,83 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,76 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;84,4 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.278 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.403 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.940 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.095 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.619 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.874 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.398 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.715 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.221 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.558 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,36 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,19 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,95 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,74 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,91 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,26 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,48 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,8 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;413 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.241 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;406 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.216 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;400 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.193 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;387 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.172 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;380 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.150 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,31 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,99 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,85 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,13 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,7 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,44 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,01 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,67 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;7.651 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.619 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.585 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;7.257 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;7.302 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;7.293 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.980 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.084 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.072 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.767 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;6.883 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;6.891 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;6.673 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;6.678 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 01 Araba/Álava;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,85 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,84 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,15 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,23 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,98 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,24 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,45 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,34 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,85 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,58 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,04 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7.266 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.389 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.637 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6.883 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.097 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.383 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.613 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.898 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.210 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.408 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.718 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.067 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.523 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.900 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,73 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,43 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,49 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,01 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,31 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,43 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,19 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,5 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,89 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,45 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,93 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;385 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.230 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.948 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;374 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.205 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.910 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;367 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.186 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.862 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;359 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.165 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.824 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.150 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.778 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,14 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,97 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,05 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,32 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,42 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,59 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,25 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,72 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,63 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,5 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,27 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;7.610 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;7.662 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;7.619 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;7.233 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;7.332 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.314 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.974 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.088 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.083 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;6.853 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;6.853 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;6.644 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;6.708 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,05 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,69 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,64 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,51 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,96 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,44 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,95 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,71 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;88,04 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;7.468 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.310 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6.267 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.094 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.990 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.992 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6.839 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;6.749 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.779 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.517 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.579 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;6.311 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.457 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,99 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,62 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,61 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,58 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,33 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,21 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,15 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;89,02 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,33 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;87,08 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;142 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;352 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.352 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;139 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;342 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.322 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;135 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;339 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.304 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;336 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.274 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;333 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.251 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,89 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,16 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,78 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,07 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,31 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,45 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,45 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,23 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,6 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,53 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7.552 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;7.631 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;7.619 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.240 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;7.328 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;7.315 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;7.059 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;7.057 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;6.796 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;6.873 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.603 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;6.719 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,87 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,03 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,01 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,5 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,62 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,06 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;90,21 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,53 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;88,19 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7.452 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.236 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6.212 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.143 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.940 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.930 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.675 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.701 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.421 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.540 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.240 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5.406 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,85 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,91 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,46 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,25 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,77 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,74 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;89,18 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,24 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;87,03 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;395 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.407 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;97 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;388 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.385 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;384 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.356 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;375 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.333 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;363 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.313 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,23 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,44 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,22 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,38 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,94 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,74 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,9 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,32 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;5.328 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;5.358 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;5.452 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;5.007 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;5.046 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;4.869 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;4.726 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;4.830 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;4.642 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.521 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.669 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.480 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.365 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.509 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.337 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,98 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,18 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,31 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,7 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,15 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,14 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,85 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,14 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,17 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,93 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,15 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,55 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5.111 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4.733 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.797 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4.444 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.521 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;4.248 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.323 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4.104 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.171 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.958 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,86 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,89 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,46 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,75 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,58 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,71 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,61 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,63 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;217 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;625 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;210 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;602 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;205 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;582 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;198 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;565 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;194 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;551 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,77 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,32 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,47 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,12 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,24 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,4 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,4 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,16 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;5.271 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;5.340 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;5.263 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;4.919 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;5.051 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;4.997 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.672 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.851 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.803 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.486 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.669 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.632 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;4.481 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;4.440 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,32 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,59 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,95 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,64 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,84 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,26 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,11 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,43 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,01 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,91 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,36 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.074 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.733 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;4.111 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.732 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4.466 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.876 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.491 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.282 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.720 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.312 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.113 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.584 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.936 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.432 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,26 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,36 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,28 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,51 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,47 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,49 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,98 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,9 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,18 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,16 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,48 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;197 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;607 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.152 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;187 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;585 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.121 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;181 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;569 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.083 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;174 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;556 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.048 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;545 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.008 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,92 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,38 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,31 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,88 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,74 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,01 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,32 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,6 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,97 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,79 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,5 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5.199 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.344 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5.298 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.847 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.033 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.017 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.622 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.813 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.798 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;4.604 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;4.592 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;4.424 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;4.464 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,23 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,18 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,7 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,9 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,06 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,56 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,15 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,67 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,78 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,26 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5.125 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5.183 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4.638 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.776 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.881 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.382 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.555 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.662 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4.178 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.456 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.999 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.278 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.893 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,19 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,17 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,48 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,88 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,95 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,08 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,97 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,22 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,54 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,94 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;74 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;161 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;660 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;71 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;152 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;635 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;67 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;151 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;620 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;148 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;593 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;146 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;571 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,95 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,41 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,21 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,54 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,79 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,94 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,93 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,85 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,68 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,52 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5.172 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.317 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5.315 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.887 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.035 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.024 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;4.791 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;4.792 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;4.568 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;4.629 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.394 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.490 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,49 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,7 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,52 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,11 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,16 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,91 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,09 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,64 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,48 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5.128 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5.113 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4.653 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.846 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.837 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4.381 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.595 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4.176 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.381 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.034 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.214 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.911 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,5 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,6 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,15 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,87 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,75 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,68 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,7 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,42 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,05 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;44 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;204 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;662 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;41 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;198 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;643 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;196 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;616 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;187 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;595 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;180 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;579 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;93,18 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,06 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,13 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,08 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,05 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,67 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,88 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,24 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,46 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;868 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;847 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;933 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;859 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;836 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;903 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;840 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;820 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;892 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;824 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;810 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;876 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;807 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;799 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;867 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,96 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,7 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,78 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,77 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,81 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,61 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,93 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,63 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,89 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,97 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,33 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,93 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;798 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;641 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;789 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;631 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;770 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;617 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;757 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;608 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;741 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;601 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,87 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,44 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,49 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,26 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,86 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,85 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,86 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,76 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;70 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;206 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;70 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;205 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;70 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;203 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;67 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;202 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;66 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;198 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,51 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,54 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,71 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,06 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,29 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,12 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;888 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;842 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;855 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;865 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;827 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;844 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;847 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;818 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;832 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;828 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;807 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;828 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;802 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;816 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,41 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,22 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,71 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,38 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,15 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,31 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;93,24 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,84 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,84 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,25 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,44 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;824 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;626 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;541 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;801 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;612 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;530 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;784 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;603 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;525 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;766 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;596 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;523 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;592 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;515 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,21 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,76 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,97 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,15 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,33 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,04 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,96 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,21 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,67 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,57 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,19 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;64 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;216 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;314 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;64 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;215 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;314 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;63 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;215 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;307 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;62 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;211 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;305 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;210 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;301 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,54 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,44 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,54 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,77 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,88 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,69 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,13 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,22 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,86 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;898 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;875 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;884 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;885 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;867 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;874 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;864 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;853 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;868 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;843 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;853 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;827 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;844 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,55 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,09 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,87 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,21 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,49 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,19 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,34 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,49 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,51 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,48 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;875 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;819 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;645 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;862 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;811 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;637 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;841 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;799 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;634 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;789 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;620 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;773 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;611 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,51 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,02 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,76 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,11 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,56 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,29 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,34 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,12 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,38 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,73 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;23 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;56 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;239 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;23 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;56 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;237 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;23 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;54 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;234 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;54 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;233 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;54 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;233 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,16 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,43 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,91 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,43 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,49 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,43 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,49 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;878 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;861 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;871 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;860 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;849 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;864 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;839 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;847 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;819 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;834 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;807 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;826 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,95 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,61 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,2 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,44 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,24 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,12 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,75 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,73 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,83 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;867 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;801 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;639 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;849 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;790 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;634 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;782 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;618 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;762 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;606 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;753 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;599 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,92 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,63 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,22 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,63 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,71 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,13 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,84 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,01 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,74 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;60 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;232 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;59 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;230 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;57 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;229 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;57 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;228 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;54 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;227 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,33 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,14 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,71 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,28 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,84 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.377 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.325 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.445 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.363 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.315 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.421 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.337 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.304 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.408 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.325 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.295 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.395 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.315 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.288 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.389 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,98 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,25 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,34 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,1 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,42 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,44 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,22 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,74 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,54 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,5 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,21 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,12 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.268 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;959 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.254 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;950 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.229 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;940 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.220 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;934 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.211 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;931 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,9 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,06 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,92 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,02 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,21 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,39 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,5 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,08 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;109 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;366 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;109 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;365 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;108 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;364 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;105 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;361 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;104 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;357 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,73 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,08 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,45 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,33 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,63 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,41 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,54 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.371 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.324 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.356 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.353 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.312 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.342 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.342 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.303 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.328 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.334 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.296 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.322 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.280 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.313 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,69 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,09 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,97 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,88 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,41 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,94 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,3 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,89 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,49 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,68 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,83 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.261 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;960 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;907 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.244 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;950 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;900 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.233 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;944 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;889 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.225 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;941 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;884 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;928 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;877 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,65 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,96 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,23 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,78 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,33 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,02 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,15 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,02 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,46 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,67 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,69 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;110 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;364 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;449 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;109 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;362 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;442 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;109 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;359 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;439 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;109 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;355 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;438 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;352 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;436 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,09 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,45 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,44 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,09 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,63 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,77 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;99,09 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,53 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,55 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,7 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,1 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.393 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.330 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.332 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.382 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.319 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.319 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.369 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.310 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.313 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.295 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.304 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.283 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.296 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,21 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,17 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,02 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,28 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,5 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,57 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,37 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,9 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,47 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,3 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.357 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.214 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;918 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.346 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.204 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;908 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.333 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.195 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;902 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.180 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;895 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.169 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;888 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,19 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,18 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,91 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,23 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,43 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,26 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,2 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,49 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,29 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,73 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;36 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;116 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;414 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;36 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;115 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;411 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;36 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;115 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;411 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;115 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;409 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;114 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;408 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,14 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,28 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,14 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,28 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,14 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,79 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,28 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,55 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.383 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.338 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.321 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.374 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.330 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.315 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.316 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.306 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.297 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.298 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.290 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.291 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,35 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,4 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,55 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,36 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,86 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,94 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,26 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,41 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,73 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.347 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.224 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;856 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.338 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.216 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;851 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.202 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;843 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.183 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;836 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.178 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;832 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,33 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,35 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,42 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,2 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,48 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,65 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,66 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,24 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,2 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;36 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;114 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;465 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;36 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;114 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;464 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;114 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;463 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;114 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;462 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;112 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;459 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,78 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,57 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,35 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,25 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,71 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;93 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;89 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;85 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;92 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;89 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;85 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;91 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;88 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;84 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;90 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;88 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;83 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;89 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;88 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;83 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,92 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,85 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,88 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,82 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,77 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,88 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,65 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,7 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,88 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,65 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;79 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;60 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;78 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;60 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;77 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;59 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;76 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;59 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;76 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;59 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,73 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,47 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,33 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,2 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,33 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,2 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,33 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;14 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;29 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;14 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;29 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;14 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;29 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;14 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;29 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;13 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;29 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,86 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;94 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;87 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;84 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;93 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;86 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;83 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;92 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;86 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;82 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;92 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;86 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;82 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;85 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;82 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,94 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,85 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,81 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,87 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,85 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,62 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,87 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,85 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,62 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,7 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,62 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;87 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;58 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;63 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;86 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;57 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;62 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;85 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;57 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;61 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;85 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;57 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;61 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;56 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;61 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,85 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,28 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,41 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,7 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,28 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,83 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,7 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,28 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,83 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,55 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,83 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;29 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;21 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;29 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;21 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;29 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;21 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;29 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;21 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;29 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;21 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;95 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;86 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;80 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;94 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;86 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;79 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;94 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;86 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;79 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;85 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;79 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;84 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;79 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,95 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,75 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,95 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,75 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,84 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,75 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,67 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,75 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;90 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;73 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;55 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;89 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;73 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;54 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;89 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;73 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;54 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;72 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;54 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;71 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;54 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,89 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,18 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,89 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,18 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,63 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,18 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,26 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,18 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;5 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;25 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;5 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;25 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;5 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;13 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;25 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;13 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;25 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;13 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;25 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;93 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;90 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;86 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;93 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;90 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;86 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;89 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;86 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;88 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;86 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;88 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;86 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,89 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,78 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,78 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;88 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;76 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;52 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;88 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;76 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;52 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;75 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;52 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;74 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;52 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;74 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;52 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,68 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,37 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,37 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;34 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;14 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;34 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;14 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;34 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;14 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;34 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;14 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;34 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;29 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;29 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;29 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;29 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;25 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;24 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;29 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;22 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;22 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;22 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;22 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;10 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;22 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;90 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;15 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;15 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;15 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;15 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;15 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;26 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;26 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;26 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;25 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;25 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;27 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,15 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,15 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;20 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;15 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;20 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;15 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;20 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;15 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;20 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;15 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;15 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;91,67 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;91,67 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;14 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;12 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;14 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;12 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;14 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;12 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;14 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;12 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;14 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;12 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;27 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;27 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;26 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;26 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;26 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;25 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,3 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,3 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,3 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;21 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;21 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;21 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;21 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;21 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;20 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;20 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;20 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,24 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,24 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,24 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;14 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;14 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;14 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;14 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;14 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;25 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;24 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;24 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;24 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;24 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;26 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;22 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;22 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;12 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;22 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;21 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;21 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;12 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;21 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;12 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;21 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;12 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,45 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,45 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,45 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,45 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;14 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;14 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;14 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;14 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;14 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 01 Araba/Álava;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;24.026 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;23.402 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;24.500 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;22.763 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;22.239 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;22.090 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;21.761 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;21.463 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;21.448 33 Asturias;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;21.033 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;20.878 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;20.840 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;20.386 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;20.309 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;20.228 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,74 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,03 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,16 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,57 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,71 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,54 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,54 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,21 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,06 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,85 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;86,78 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,56 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;22.873 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;20.307 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;21.649 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;19.229 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;20.696 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18.508 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;19.997 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;17.981 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;19.380 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;17.480 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,65 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,69 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,48 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,14 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,43 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,55 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,73 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,08 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.153 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.095 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.114 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.010 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.065 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.955 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.036 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.897 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.006 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.829 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,62 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,25 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,37 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,48 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,85 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,6 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,25 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,41 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;23.955 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;23.336 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;22.988 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;22.724 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;22.342 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;22.216 33 Asturias;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;21.869 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;21.636 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;21.523 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;21.052 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;20.948 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;20.826 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;20.214 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;20.109 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 33 Asturias;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,86 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,74 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,64 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,29 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,72 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,63 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,88 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,77 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,6 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,62 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,48 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;22.824 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;20.233 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;18.009 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;21.629 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;19.291 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;17.316 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;20.806 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;18.645 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;16.729 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;20.021 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;18.029 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;16.154 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;17.372 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;15.577 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,76 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,34 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,15 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,16 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,15 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,89 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,72 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,11 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,7 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,86 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,5 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.131 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.103 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4.979 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.095 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.051 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4.900 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.063 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.991 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4.794 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.031 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.919 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4.672 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.842 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4.532 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,82 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,32 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,41 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,99 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,39 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,28 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,16 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,07 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,83 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,59 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,02 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;24.276 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;24.075 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;23.579 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;22.946 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;22.894 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;22.528 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;21.779 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;21.832 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;21.530 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;20.986 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;20.733 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;20.359 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;20.238 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,52 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,09 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,54 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,71 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,68 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,31 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,17 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,93 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,56 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,83 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;23.538 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;23.209 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;20.656 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;22.229 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;22.044 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;19.664 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;21.086 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;21.008 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;18.730 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;20.191 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;18.014 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;19.586 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;17.563 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,44 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,98 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,2 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,58 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,52 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,68 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,21 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,39 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,03 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;738 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;866 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.923 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;717 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;850 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.864 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;693 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;824 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.800 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;795 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.719 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;773 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.675 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,15 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,15 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,98 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,9 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,15 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,79 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,8 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,02 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,26 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,52 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;24.015 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;24.078 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;23.870 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;22.595 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;22.721 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;22.416 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;21.732 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;21.488 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;20.957 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;20.868 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;20.344 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;20.368 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,09 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,36 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,91 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,26 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,02 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,04 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,42 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,49 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,33 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;23.341 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;22.849 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;20.721 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;21.943 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;21.542 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;19.342 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;20.606 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;18.494 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;19.868 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17.927 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;19.276 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17.483 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,01 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,28 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,34 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,18 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,25 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,95 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,52 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,36 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,37 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;674 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.229 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.149 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;652 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.179 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.074 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.126 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.994 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.089 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.941 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.068 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.885 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,74 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,93 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,62 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,62 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,08 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,61 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,39 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,9 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,62 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;18.671 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;18.410 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;19.043 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;17.485 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;17.295 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;16.755 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;16.560 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;16.582 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;16.162 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;15.893 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.045 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;15.597 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;15.290 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;15.513 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.029 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,65 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,94 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,99 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,69 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,07 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,87 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,12 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,15 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,9 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,89 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,26 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,92 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;17.874 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16.628 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;16.725 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15.587 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;15.841 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14.922 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.200 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.432 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14.623 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13.955 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,57 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,74 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,63 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,74 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,04 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,79 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,81 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,92 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;797 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.782 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;760 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.708 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;719 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.660 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;693 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.613 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;667 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.558 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,36 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,85 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,21 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,15 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,95 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,52 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,69 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,43 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;18.561 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;18.319 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;17.995 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;17.411 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;17.395 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;17.266 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;16.618 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;16.733 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;16.608 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;15.861 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.084 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;15.948 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;15.424 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;15.277 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 33 Asturias;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,8 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,96 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,95 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,53 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,34 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,29 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,45 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,8 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,62 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,2 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,9 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;17.765 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16.528 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14.857 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;16.648 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;15.652 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14.191 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;15.885 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.043 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.628 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;15.158 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;14.455 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13.073 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;13.859 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12.520 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,71 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,7 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,52 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,42 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,02 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,73 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,33 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,46 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,99 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,85 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,27 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;796 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.791 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.138 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;763 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.743 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.075 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;733 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.690 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.980 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;703 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.629 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.875 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.565 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.757 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,85 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,32 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,99 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,09 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,36 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,96 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,32 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,95 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,62 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,38 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,86 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18.646 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;18.737 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;18.439 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;17.381 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;17.608 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;17.433 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;16.325 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;16.641 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;16.499 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;15.879 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;15.754 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;15.291 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;15.303 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,22 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,97 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,54 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,55 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,81 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,48 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,75 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,44 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,61 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,99 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;18.121 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;18.213 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16.881 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;16.876 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17.100 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.927 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;15.843 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.154 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;15.046 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.417 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14.368 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14.849 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.952 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,13 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,89 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,35 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,43 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,69 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,13 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,65 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,11 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,53 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,65 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;525 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;524 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.558 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;505 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;508 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.506 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;482 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;487 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.453 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;462 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.386 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;442 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.351 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,19 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,95 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,66 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,81 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,94 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,26 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,17 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,96 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;84,35 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,71 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;18.491 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;18.705 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;18.644 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;17.137 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;17.402 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;17.240 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;16.490 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;16.366 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;15.773 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;15.802 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.215 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;15.346 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,68 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,03 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,47 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,16 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,78 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,33 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,76 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,34 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,31 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;18.027 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;17.857 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;16.948 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16.695 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;16.600 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.610 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15.735 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.801 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.051 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;14.279 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14.512 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.869 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,61 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,96 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,11 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,12 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,33 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,29 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,25 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,27 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,83 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;464 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;848 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.696 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;442 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;802 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.630 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;755 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.565 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;722 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.523 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;703 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.477 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,26 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,58 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,11 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,03 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,28 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;85,14 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,8 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,9 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,09 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.285 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.133 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.390 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.238 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.103 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.309 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.193 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.068 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.283 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.163 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.038 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.258 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.137 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.015 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.229 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,94 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,59 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,61 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,97 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,95 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,52 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,66 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,55 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,48 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,52 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,47 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,26 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.146 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.601 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.576 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.058 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.545 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.030 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.523 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.005 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.508 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,86 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,44 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,9 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,5 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,59 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,13 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,43 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,19 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;139 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;532 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;138 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;527 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;135 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;523 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;133 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;515 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;132 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;507 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,28 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,06 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,12 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,31 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,68 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,8 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,96 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,3 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.288 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.156 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.139 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.239 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.114 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.114 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.210 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.084 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.092 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.173 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.058 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.069 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.007 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.045 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,86 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,05 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,83 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,59 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,66 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,8 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,97 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,45 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,73 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,09 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,61 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.159 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.636 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.325 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.110 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.595 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.309 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.081 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.570 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.292 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.045 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.550 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.278 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.505 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.264 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,73 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,49 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,79 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,39 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;95,97 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,51 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,72 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,74 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,45 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;91,99 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,4 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;129 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;520 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;814 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;129 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;519 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;805 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;129 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;514 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;800 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;128 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;508 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;791 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;502 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;781 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,81 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,89 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,85 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,28 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;99,22 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,69 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,17 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,54 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,95 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.412 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.321 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.252 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.372 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.287 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.219 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.304 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.218 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.172 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.162 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.140 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.138 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.114 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,34 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,54 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,53 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,52 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,56 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,45 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,15 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,03 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,12 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,87 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.318 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.189 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.707 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.278 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.155 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.678 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.211 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.090 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.637 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.038 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.612 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.014 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.591 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,27 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,45 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,3 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,38 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,48 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,9 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,1 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,43 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,01 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,2 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;94 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;132 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;545 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;94 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;132 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;541 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;93 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;128 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;535 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;124 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;528 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;124 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;523 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,27 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,94 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,97 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,17 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,94 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,88 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,94 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,96 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.315 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.299 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.268 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.275 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.261 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.237 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.214 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.206 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.182 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.172 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.156 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.145 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,27 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,35 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,63 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,3 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,27 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,91 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,77 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,78 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,58 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.219 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.133 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.720 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.179 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.098 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.693 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.055 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.668 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.023 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.640 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.998 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.617 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,2 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,36 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,43 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,34 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,98 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,84 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,35 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,67 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,01 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;96 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;166 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;548 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;96 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;163 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;544 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;159 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;538 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;159 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;532 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;158 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;528 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,19 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,27 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,78 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,18 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,78 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,08 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,18 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,35 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.874 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.669 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.874 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.844 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.651 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.834 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.812 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.623 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;2.812 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.782 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.607 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.794 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.765 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.593 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.779 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,96 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,33 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,61 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,84 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,28 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,84 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,8 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,68 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,22 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,21 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,15 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,69 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.675 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.953 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.646 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.941 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.619 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.916 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.590 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.903 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.576 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.894 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,92 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,39 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,91 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,11 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,82 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,44 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,3 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,98 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;199 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;716 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;198 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;710 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;193 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;707 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;192 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;704 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;189 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;699 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,5 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,16 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,98 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,74 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,48 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,32 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,97 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,63 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.900 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.665 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.669 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.868 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.637 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;2.651 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.836 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.625 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.638 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.814 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.612 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.624 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.589 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.602 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 33 Asturias;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,9 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,95 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,33 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,79 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,5 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,84 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,03 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,01 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,31 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,15 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,49 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.714 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.935 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.693 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.685 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.910 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.682 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.655 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.900 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.675 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.634 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.892 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.669 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.876 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.659 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,93 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,71 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,35 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,83 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,19 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,94 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,05 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,78 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,58 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,95 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,99 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;186 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;730 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;976 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;183 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;727 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;969 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;181 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;725 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;963 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;180 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;720 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;955 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;713 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;943 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,39 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,59 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,28 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,31 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,32 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,67 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,77 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,63 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,85 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,67 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,62 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.009 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.823 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.701 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.985 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.807 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.689 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.943 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.781 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.672 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;2.753 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.652 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;2.738 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.634 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,2 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,43 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,56 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,81 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,51 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,93 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,52 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,19 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,99 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,52 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.903 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.627 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.940 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.880 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.611 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.931 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.838 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.586 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.919 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.558 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.906 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.545 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.892 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,21 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,39 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,54 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,76 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,44 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,92 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,37 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,25 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,88 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,53 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;106 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;196 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;761 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;105 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;196 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;758 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;105 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;195 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;753 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;195 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;746 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;193 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;742 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,06 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,61 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;99,06 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,49 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,95 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,49 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,03 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,47 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,5 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.003 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.881 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.767 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.978 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.865 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.748 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;2.835 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;2.725 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;2.809 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.703 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.781 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.688 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,17 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,44 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,31 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,4 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,48 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,5 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,69 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,53 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,14 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.901 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.681 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.930 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.876 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.666 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.916 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.638 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.902 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.616 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.885 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.589 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.876 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,14 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,44 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,27 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,4 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,55 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,58 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,67 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,57 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,2 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;102 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;200 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;837 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;102 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;199 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;832 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;197 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;823 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;193 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;818 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;192 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;812 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,5 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,4 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,5 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,33 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,5 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,73 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,01 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;134 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;128 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;127 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;134 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;128 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;127 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;134 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;128 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;126 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;133 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;127 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;126 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;133 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;127 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;126 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,21 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,25 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;99,22 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;99,21 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,25 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;99,22 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;99,21 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;120 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;89 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;120 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;89 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;120 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;89 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;119 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;88 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;119 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;88 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,17 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,88 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,17 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,88 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;14 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;39 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;14 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;39 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;14 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;39 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;14 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;39 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;14 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;39 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;142 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;134 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;123 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;142 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;134 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;123 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;141 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;133 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;123 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;141 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;133 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;123 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;133 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;123 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,3 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,25 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,3 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;99,25 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,25 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;127 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;95 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;90 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;127 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;95 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;90 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;126 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;94 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;90 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;126 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;94 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;90 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;94 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;90 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,21 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,95 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,21 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,95 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,95 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;39 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;33 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;39 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;33 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;39 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;33 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;39 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;33 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;39 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;33 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;147 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;133 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;130 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;146 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;132 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;130 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;146 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;132 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;130 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;132 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;130 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;132 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;130 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,32 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,25 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,32 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,25 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,25 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,25 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;138 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;125 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;87 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;137 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;124 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;87 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;137 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;124 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;87 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;124 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;87 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;124 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;87 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,28 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,2 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,28 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,2 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,2 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,2 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;9 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;8 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;43 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;9 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;8 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;43 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;9 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;8 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;43 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;8 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;43 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;8 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;43 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;139 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;131 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;130 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;139 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;131 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;130 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;131 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;130 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;131 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;130 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;130 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;129 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,24 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;99,23 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;131 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;122 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;88 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;131 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;122 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;88 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;122 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;88 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;122 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;88 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;121 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;87 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;99,18 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,86 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;9 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;42 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;9 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;42 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;9 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;42 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;9 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;42 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;9 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;42 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;62 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;62 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;66 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;62 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;62 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;65 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;62 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;62 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;65 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;62 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;61 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;65 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;61 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;61 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;65 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,48 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,48 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,39 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,48 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,39 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,39 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,48 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;58 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;36 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;58 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;36 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;58 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;36 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;58 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;35 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;57 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;35 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,22 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,28 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,22 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;4 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;26 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;4 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;26 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;4 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;26 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;4 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;26 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;4 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;26 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;64 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;62 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;62 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;64 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;62 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;62 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;64 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;61 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;62 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;63 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;61 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;62 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;61 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;62 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,39 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,44 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,39 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,39 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;59 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;39 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;59 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;39 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;59 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;38 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;58 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;38 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;38 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,31 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,44 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;5 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;23 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;18 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;5 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;23 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;18 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;5 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;23 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;18 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;5 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;23 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;18 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;23 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;18 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;62 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;61 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;57 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;62 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;60 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;57 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;61 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;60 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;57 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;60 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;57 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;60 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;57 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,36 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,39 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,36 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,36 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,36 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;58 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;55 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;41 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;58 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;54 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;41 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;57 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;54 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;41 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;54 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;41 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;54 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;41 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,18 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,28 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,18 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,18 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,18 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;16 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;16 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;16 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;16 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;16 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;67 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;62 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;61 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;66 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;62 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;61 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;62 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;61 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;62 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;61 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;62 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;60 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,51 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,36 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;63 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;56 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;35 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;62 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;56 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;35 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;56 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;35 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;56 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;35 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;56 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;34 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,41 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,14 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;6 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;26 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;6 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;26 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;26 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;26 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;26 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 33 Asturias;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.691 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.578 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.807 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.531 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.408 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.379 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.410 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.317 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.278 05 Ávila;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.317 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.236 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.183 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.239 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.146 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.096 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,67 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,25 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,76 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;92,39 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,71 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,1 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,87 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,44 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,61 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,75 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,93 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,32 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.561 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.240 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.405 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.077 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.287 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.996 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.201 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.920 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.123 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.835 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,62 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,97 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;92,31 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,47 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,89 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;90,12 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;87,7 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,5 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;130 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;338 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;126 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;331 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;123 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;321 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;116 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;316 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;116 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;311 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,92 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,93 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,62 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,97 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,23 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,49 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,23 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,01 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.708 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.595 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.517 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.557 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.478 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.396 05 Ávila;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.433 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.362 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.287 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.337 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.254 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.188 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.166 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.076 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 05 Ávila;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,93 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,75 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,56 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,58 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,52 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,46 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,99 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,51 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,65 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,07 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,46 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.589 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.241 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.828 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.443 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.134 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.713 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.324 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.023 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.615 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.229 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.922 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.532 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.838 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.437 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,93 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,7 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,93 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,62 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,27 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,47 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,97 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,16 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,53 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,57 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,17 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;119 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;354 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;689 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;114 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;344 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;683 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;109 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;339 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;672 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;108 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;332 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;656 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;328 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;639 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,8 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,18 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,13 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,6 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,76 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,53 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,76 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,79 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,21 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,66 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,74 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.836 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.782 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.646 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.612 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.545 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.467 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.476 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.393 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.323 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.288 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.195 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.204 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.137 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,16 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,73 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,09 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,62 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,71 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,14 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,94 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,63 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,72 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,04 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.740 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.694 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.114 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.520 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.460 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.944 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.385 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.311 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.815 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.208 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.701 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.126 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.653 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,12 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,67 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,54 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,51 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,63 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,4 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,84 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,74 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,62 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,2 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;96 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;88 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;532 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;92 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;85 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;523 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;91 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;82 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;508 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;80 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;494 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;78 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;484 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,83 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,59 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,31 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,79 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,18 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,49 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,91 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,86 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,64 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,98 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.747 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.718 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.666 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.587 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.514 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.456 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.386 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.317 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.291 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.240 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.210 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.167 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,73 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,51 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,27 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,07 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,48 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,52 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,38 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,34 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,39 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.661 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.576 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.296 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.502 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.377 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.098 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.256 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.966 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.168 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.898 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.091 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.830 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,66 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,44 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,99 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,05 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,99 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,59 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,92 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,44 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,86 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;86 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;142 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;370 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;85 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;137 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;358 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;130 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;351 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;123 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;342 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;119 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;337 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,84 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,48 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,76 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,55 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,86 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,62 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,43 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,8 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,08 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.965 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.925 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.063 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;2.811 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;2.763 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;2.656 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;2.697 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;2.677 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;2.564 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.609 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.598 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.479 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.534 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.514 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.400 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,81 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,46 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,71 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,96 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,52 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,71 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,99 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,82 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;80,93 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,46 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,95 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,35 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.865 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.717 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.715 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.560 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.604 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.484 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.522 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.410 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.447 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.330 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,76 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,22 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,89 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,42 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,03 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,7 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,41 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,76 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;208 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;96 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;203 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;93 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;193 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;87 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;188 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;87 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;184 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,6 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,79 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,38 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,46 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.966 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.938 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.852 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;2.823 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;2.826 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;2.737 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.702 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.714 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.637 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.611 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.612 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.544 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;2.530 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;2.440 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 05 Ávila;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,18 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,19 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,97 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,1 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,38 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,46 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,03 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,9 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,2 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,11 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,55 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.876 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.721 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.390 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.737 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.619 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.279 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.620 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.512 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.188 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.530 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.417 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.109 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.339 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.019 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,17 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,25 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,36 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,1 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,32 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,55 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,97 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,83 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,24 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,96 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,48 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;90 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;217 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;462 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;86 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;207 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;458 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;82 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;202 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;449 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;81 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;195 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;435 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;191 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;421 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,56 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,39 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,13 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,11 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,09 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,19 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,86 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,16 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,02 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,13 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.045 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.037 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.954 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.829 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.810 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.786 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.703 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.669 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.650 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;2.570 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;2.533 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;2.491 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;2.478 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,91 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,53 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,31 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,77 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,88 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,71 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,62 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,75 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,02 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,89 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.972 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.977 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.617 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.759 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.753 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.457 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.634 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.615 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.335 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.518 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.230 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.440 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.184 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,83 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,48 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,89 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,63 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,84 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,22 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,58 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,21 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,96 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,45 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;73 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;60 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;337 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;70 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;57 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;329 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;69 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;54 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;315 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;52 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;303 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;51 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;294 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,89 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,63 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,52 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,47 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,67 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,91 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;87,24 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.970 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.002 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.983 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.819 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.808 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.780 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;2.685 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;2.651 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;2.597 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;2.580 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.520 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.511 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,92 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,54 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,19 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,44 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,87 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,51 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,49 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,94 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,18 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.903 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.887 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.756 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.753 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.698 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.565 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.582 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.440 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.501 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.377 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.427 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.313 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,83 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,45 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,07 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,44 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,53 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,63 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,25 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,07 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,93 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;67 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;115 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;227 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;66 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;110 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;215 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;103 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;211 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;96 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;203 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;93 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;198 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,51 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,65 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,71 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,57 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,95 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;83,48 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,43 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;80,87 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,22 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;348 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;306 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;375 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;346 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;304 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;359 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;342 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;300 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;353 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;337 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;300 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;347 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;336 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;298 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;342 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,43 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,35 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,73 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,28 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,13 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,84 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,53 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,55 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,39 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,2 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;333 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;255 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;331 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;254 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;327 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;250 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;323 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;250 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;322 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;248 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,4 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,61 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,2 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,7 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,25 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;15 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;51 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;15 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;50 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;15 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;50 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;14 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;50 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;14 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;50 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,33 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,33 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,04 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;367 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;325 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;325 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;363 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;322 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;321 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;360 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;320 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;316 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;356 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;318 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;311 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;315 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;307 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,91 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,08 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,77 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,09 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,46 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,23 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,85 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,69 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,92 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,46 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;351 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;267 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;222 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;347 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;264 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;220 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;345 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;262 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;216 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;341 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;260 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;213 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;257 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;212 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,86 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,88 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,1 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,29 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,13 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,3 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,15 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,38 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,95 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,25 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,5 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;16 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;58 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;103 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;16 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;58 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;101 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;58 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;58 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;98 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;58 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;95 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,06 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,75 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,09 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,75 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,15 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,23 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;401 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;367 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;338 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;394 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;359 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;331 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;389 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;353 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;325 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;350 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;318 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;347 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;315 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,25 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,82 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,93 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,01 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,19 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,15 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,37 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,08 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,55 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,2 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;392 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;356 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;255 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;386 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;348 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;249 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;381 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;342 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;244 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;339 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;239 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;336 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;237 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,47 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,75 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,65 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,19 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,07 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,69 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,22 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,73 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,38 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,94 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;9 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;11 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;83 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;8 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;11 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;82 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;8 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;11 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;81 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;11 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;79 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;11 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;78 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;88,89 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,8 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;88,89 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,59 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,18 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,98 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;391 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;344 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;325 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;389 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;340 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;319 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;338 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;313 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;334 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;308 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;330 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;307 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,49 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,84 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,15 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,26 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,31 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,09 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,77 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,93 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,46 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;384 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;331 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;269 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;382 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;327 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;263 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;325 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;259 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;321 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;255 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;318 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;254 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,48 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,79 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,77 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,19 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,28 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,98 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,8 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,07 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,42 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;7 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;13 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;56 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;7 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;13 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;56 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;13 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;54 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;13 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;53 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;53 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,43 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,64 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,31 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,64 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;363 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;333 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;355 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;359 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;327 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;350 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;356 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;326 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;347 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;356 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;324 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;343 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;354 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;320 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;340 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,9 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,2 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,59 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,07 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,9 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,75 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,07 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,3 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,62 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,52 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,1 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,77 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;349 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;258 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;345 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;253 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;342 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;252 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;342 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;250 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;340 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;247 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,85 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,06 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,99 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,67 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,99 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,9 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,42 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,74 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;14 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;75 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;14 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;74 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;14 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;74 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;14 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;74 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;14 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;73 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,67 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,67 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,67 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,33 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;363 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;320 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;327 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;359 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;318 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;325 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;359 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;316 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;321 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;358 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;312 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;320 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;309 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;316 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 05 Ávila;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,9 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,38 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,39 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,9 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,75 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,17 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,62 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,5 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,86 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,56 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,64 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;351 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;244 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;208 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;348 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;242 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;206 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;348 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;240 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;203 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;347 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;236 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;202 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;233 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;198 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,15 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,18 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,04 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,15 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,36 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,6 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,86 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,72 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,12 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,49 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,19 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;12 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;76 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;119 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;11 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;76 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;119 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;11 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;76 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;118 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;11 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;76 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;118 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;76 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;118 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;91,67 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,67 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,16 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,67 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,16 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;99,16 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;377 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;365 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;342 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;376 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;363 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;338 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;371 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;358 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;336 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;355 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;332 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;353 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;332 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,73 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,45 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,83 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,41 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,08 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,25 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,26 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,08 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,71 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,08 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;364 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;348 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;233 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;363 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;346 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;229 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;358 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;341 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;227 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;338 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;223 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;337 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;223 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,73 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,43 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,28 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,35 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,99 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,42 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,13 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,71 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,84 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,71 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;13 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;17 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;109 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;13 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;17 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;109 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;13 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;17 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;109 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;17 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;109 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;16 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;109 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,12 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;371 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;359 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;346 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;364 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;353 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;345 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;350 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;341 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;347 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;340 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;347 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;337 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,11 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,33 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,71 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,49 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,55 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,66 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,27 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,66 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,4 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;360 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;345 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;262 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;353 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;339 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;261 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;336 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;258 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;333 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;257 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;333 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;254 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,06 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,26 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,62 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,39 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,47 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,52 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,09 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,52 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,95 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;84 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;14 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;84 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;14 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;83 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;14 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;83 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;14 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;83 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,81 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,81 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,81 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;10 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;10 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;10 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;10 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;10 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;11 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;10 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;10 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;10 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;10 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;10 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;10 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;10 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;8 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;10 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;9 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;9 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;9 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;10 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;10 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;8 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;7 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;7 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;12 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;10 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;9 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;12 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;10 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;9 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;10 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;9 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;10 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;9 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;10 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;9 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;11 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;10 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;4 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;4 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;3 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;3 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;3 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;3 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;4 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;3 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;4 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;4 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;3 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;3 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;3 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;3 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;4 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;3 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;4 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;3 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;2 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;4 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;3 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;2 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;3 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;2 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;3 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;2 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;.. 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;3 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 05 Ávila;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;14.795 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;14.290 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;14.865 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;13.768 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;13.301 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;12.562 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;13.120 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;12.765 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;12.124 06 Badajoz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;12.637 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;12.320 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;11.789 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;12.282 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;11.982 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;11.438 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,06 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,08 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;84,51 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,68 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,33 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;81,56 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,41 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,21 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,31 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,01 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,85 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,95 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14.327 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;13.260 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;13.318 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12.296 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;12.683 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11.779 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12.214 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.354 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;11.864 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.032 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,96 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,73 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,53 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,83 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,25 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,63 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,81 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,2 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;468 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.030 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;450 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.005 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;437 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;986 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;423 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;966 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;418 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;950 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,15 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,57 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,38 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,73 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,38 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,79 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,32 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,23 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;14.699 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;14.201 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;13.258 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;13.866 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;13.464 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;12.694 06 Badajoz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;13.272 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;12.882 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;12.280 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;12.844 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;12.460 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;11.867 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;11.925 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;11.393 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 06 Badajoz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,33 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,81 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,75 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,29 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,71 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,62 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,38 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,74 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,51 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,97 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,93 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14.258 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;13.391 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11.078 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;13.441 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.678 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.544 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;12.868 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12.115 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10.170 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;12.448 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.705 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.807 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.192 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.391 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,27 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,68 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,18 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,25 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,47 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,8 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,31 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,41 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,53 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,58 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,77 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;441 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;810 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.180 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;425 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;786 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.150 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;404 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;767 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.110 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;396 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;755 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.060 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;733 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.002 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,37 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,04 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,62 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,61 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,69 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,79 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,8 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,21 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,5 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,49 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,83 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;14.999 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;14.562 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14.137 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;14.099 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;13.619 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;13.395 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;13.497 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;13.030 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;12.772 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;12.432 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;12.176 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;12.051 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;11.847 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,52 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,75 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,99 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,48 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,34 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,37 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,13 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,76 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,8 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;14.613 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14.245 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12.820 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;13.733 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;13.312 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.105 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;13.137 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12.727 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.508 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12.138 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;10.945 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;11.763 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10.633 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,98 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,45 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,42 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,9 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,34 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,77 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,21 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,37 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,58 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,94 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;386 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;317 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.317 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;366 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;307 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.290 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;360 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;303 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.264 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;294 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.231 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;288 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.214 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,82 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,85 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,95 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,26 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,58 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,98 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,74 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,47 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,85 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,18 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;15.173 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;14.536 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14.377 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;14.342 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;13.705 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;13.474 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;12.972 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;12.752 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;12.493 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;12.327 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;12.101 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;11.946 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,52 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,28 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,72 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,24 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,7 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,95 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,74 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,25 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,09 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;14.817 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14.048 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13.069 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;13.992 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13.226 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12.192 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;12.512 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.501 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12.047 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;11.099 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;11.675 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.738 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,43 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,15 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,29 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,07 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,76 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,93 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,11 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,16 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;356 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;488 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.308 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;350 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;479 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.282 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;460 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.251 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;446 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.228 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;426 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.208 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,31 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,16 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,01 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,26 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,64 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,39 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,88 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,3 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,35 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;11.547 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;11.297 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;11.687 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;10.570 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;10.368 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;9.502 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;9.983 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;9.871 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;9.100 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;9.538 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;9.457 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;8.795 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;9.214 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;9.139 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.478 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,54 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;91,78 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;81,3 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;86,46 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,38 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;77,86 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;82,6 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;83,71 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;75,25 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;79,8 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,9 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;72,54 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;11.241 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10.753 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10.280 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9.842 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;9.703 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9.360 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;9.271 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8.957 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;8.951 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8.652 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,45 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,53 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,32 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,05 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,47 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,3 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,63 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;80,46 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;306 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;544 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;290 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;526 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;280 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;511 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;267 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;500 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;263 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;487 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,77 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,69 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,5 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,93 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,25 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,91 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,95 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,52 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;11.491 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;11.193 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;10.485 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;10.721 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;10.496 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;9.950 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;10.163 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;9.948 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;9.559 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;9.768 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;9.549 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.169 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;9.063 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;8.737 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,3 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,77 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,9 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,44 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,88 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,17 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,01 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,31 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,45 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;80,97 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,33 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11.191 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10.742 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9.107 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;10.436 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10.067 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8.597 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;9.894 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9.531 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;8.241 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;9.506 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9.142 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7.897 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8.673 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7.507 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,25 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,72 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,4 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,41 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,73 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,49 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,94 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,11 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,71 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;80,74 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,43 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;300 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;451 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.378 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;285 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;429 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.353 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;269 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;417 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.318 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;262 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;407 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.272 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;390 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.230 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,12 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,19 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;89,67 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,46 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,65 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,33 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,24 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,31 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,47 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,26 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11.644 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;11.369 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;11.158 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;10.792 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;10.468 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;10.453 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;10.242 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;9.910 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;9.867 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;9.365 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;9.323 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;9.021 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;9.020 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,68 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,07 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,68 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,96 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,17 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,43 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,37 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,55 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,35 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;80,84 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.379 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11.192 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10.420 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;10.544 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10.297 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9.737 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.000 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;9.743 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9.174 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;9.204 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8.650 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8.863 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8.363 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,66 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,45 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,88 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,05 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,04 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,24 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,01 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,19 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,26 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;265 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;177 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;738 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;248 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;171 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;716 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;242 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;167 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;693 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;161 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;673 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;158 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;657 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,58 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,61 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,02 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,32 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,35 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,9 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,96 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,19 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,27 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,02 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;11.788 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.336 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.346 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.024 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;10.534 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;10.487 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;9.856 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;9.816 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;9.431 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;9.425 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;9.074 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;9.073 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,52 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,93 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,43 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,94 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,52 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,2 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,07 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,05 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;79,97 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.556 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10.989 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10.640 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;10.797 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10.195 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9.805 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9.535 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.153 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9.121 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.781 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;8.780 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8.441 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,43 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,77 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,15 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;86,77 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,02 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;82,53 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,9 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;79,33 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;232 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;347 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;706 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;227 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;339 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;682 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;321 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;663 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;310 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;644 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;294 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;632 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,84 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,69 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,6 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,51 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,91 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,34 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,22 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,73 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,52 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.501 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.390 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.472 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.470 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.351 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.402 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.437 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.326 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.380 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.416 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.309 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.363 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.395 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.297 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.340 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,93 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,19 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,24 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,74 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,4 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,75 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,34 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,17 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,6 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,94 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,31 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,03 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.436 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.201 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.406 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.165 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.375 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.141 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.355 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.130 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.335 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.120 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,91 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,75 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,36 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,09 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,97 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,26 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;65 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;189 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;64 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;186 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;62 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;185 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;61 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;179 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;60 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;177 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,46 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,41 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,38 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,88 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,85 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,71 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,31 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,65 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.457 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.390 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.301 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.423 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.368 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.283 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.406 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.351 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.269 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.385 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.336 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.255 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.301 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.231 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,67 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,42 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,62 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,5 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,19 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,54 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,06 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,12 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,46 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,6 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,62 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.400 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.256 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;964 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.367 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.235 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;947 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.354 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.222 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;936 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.333 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.208 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;926 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.175 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;912 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,64 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,33 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,24 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,71 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,29 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,1 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,21 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,18 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,06 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,55 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,61 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;57 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;134 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;337 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;56 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;133 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;336 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;52 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;129 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;333 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;52 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;128 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;329 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;126 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;319 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,25 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,25 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,7 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,23 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,27 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,81 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,23 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,52 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,63 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,03 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,66 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.539 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.481 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.390 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.517 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.461 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.367 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.485 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.441 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.344 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.408 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.314 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.391 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.297 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,57 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,65 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,35 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,49 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,3 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,69 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,07 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,53 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,92 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,31 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.500 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.426 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.171 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.480 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.407 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.152 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.448 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.387 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.130 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.355 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.106 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.341 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.089 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,67 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,67 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,38 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,53 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,27 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,5 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,02 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,45 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,04 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;39 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;55 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;219 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;37 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;54 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;215 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;37 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;54 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;214 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;53 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;208 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;50 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;208 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,87 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,18 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,17 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,87 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,18 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,72 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,36 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,98 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,91 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,98 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.564 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.457 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.375 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.525 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.440 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.346 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.402 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.316 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.370 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.296 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.351 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.281 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,51 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,83 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,89 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,23 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,71 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,03 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,25 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,72 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,16 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.515 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.398 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.153 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.477 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.381 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.125 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.344 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.313 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.081 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.296 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.072 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,49 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,78 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,57 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,14 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,4 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,92 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,76 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,7 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;92,97 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;49 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;59 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;222 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;48 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;59 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;221 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;58 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;216 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;57 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;215 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;55 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;209 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,96 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,55 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,31 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,3 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,61 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,85 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,22 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,14 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.645 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.508 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.596 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.626 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.488 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.548 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.598 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.474 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.534 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.581 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.460 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.521 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.571 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.452 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.512 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,84 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,67 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,99 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,14 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,75 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,12 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,11 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,82 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,3 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,5 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,29 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,74 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.561 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.234 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.543 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.218 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.516 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.207 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.499 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.196 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.489 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.189 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,85 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,7 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,12 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,81 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,03 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,92 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,39 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,35 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;84 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;274 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;83 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;270 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;82 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;267 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;82 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;264 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;82 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;263 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,81 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,54 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,62 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,45 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,62 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,35 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,62 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,99 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.647 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.526 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.379 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.618 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.508 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.368 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.599 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.491 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.359 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.587 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.483 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.350 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.469 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.333 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,24 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,82 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,2 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,09 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,71 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,55 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,36 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,18 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,9 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,26 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,66 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.572 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.321 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;941 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.543 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.304 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;934 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.525 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.290 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;927 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.514 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.283 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;918 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.272 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;907 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,16 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,71 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,26 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,01 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,65 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,51 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,31 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,12 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,56 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,29 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,39 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;75 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;205 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;438 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;75 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;204 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;434 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;74 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;201 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;432 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;73 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;200 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;432 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;197 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;426 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,51 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,09 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,67 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,05 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,63 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,33 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,56 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,63 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,1 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,26 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.705 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.616 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.501 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.679 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.595 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.487 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.659 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.584 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.473 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.564 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.452 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.544 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.443 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,48 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,7 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,07 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,3 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,02 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,13 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,78 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,74 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,54 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,14 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.632 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.540 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.165 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.607 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.522 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.152 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.587 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.511 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.140 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.493 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.126 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.473 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.118 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,47 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,83 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,88 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,24 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,12 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,85 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,95 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,65 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,65 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,97 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;73 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;76 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;336 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;72 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;73 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;335 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;72 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;73 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;333 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;71 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;326 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;71 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;325 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,63 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,05 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,7 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,63 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,05 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,11 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,42 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,02 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,42 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,73 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.707 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.640 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.561 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.679 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.628 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.546 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.611 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.526 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.589 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.512 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.573 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.498 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,36 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,27 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,04 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,23 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,76 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,89 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,86 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,91 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,96 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.643 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.565 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.206 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.615 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.554 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.192 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.537 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.179 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.517 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.168 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.503 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.156 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,3 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,3 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,84 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,21 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,76 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,93 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,85 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,04 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,85 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;64 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;75 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;355 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;64 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;74 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;354 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;74 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;347 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;72 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;344 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;70 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;342 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,67 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,72 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,67 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,75 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,9 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,33 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,34 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;79 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;73 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;89 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;79 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;72 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;89 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;79 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;72 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;89 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;79 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;72 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;89 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;79 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;72 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;87 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,63 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,63 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,63 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,63 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,75 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;70 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;56 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;70 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;55 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;70 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;55 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;70 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;55 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;70 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;55 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,21 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,21 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,21 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,21 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;9 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;17 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;9 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;17 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;9 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;17 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;9 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;17 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;9 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;17 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;80 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;69 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;73 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;80 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;69 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;73 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;80 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;69 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;73 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;80 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;69 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;73 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;69 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;72 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,63 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;73 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;55 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;51 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;73 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;55 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;51 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;73 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;55 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;51 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;73 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;55 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;51 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;55 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;50 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,04 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;14 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;22 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;14 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;22 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;14 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;22 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;14 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;22 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;14 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;22 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;88 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;73 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;67 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;88 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;72 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;67 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;88 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;72 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;67 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;72 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;66 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;72 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;66 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,63 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,63 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,63 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,51 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,63 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,51 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;81 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;67 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;50 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;81 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;66 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;50 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;81 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;66 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;50 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;66 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;49 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;66 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;49 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,51 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,51 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,51 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,51 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;17 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;17 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;7 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;17 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;17 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;17 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;89 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;76 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;72 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;89 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;76 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;72 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;76 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;71 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;76 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;71 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;76 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;71 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,61 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,61 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,61 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;80 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;72 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;53 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;80 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;72 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;53 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;72 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;52 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;72 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;52 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;72 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;52 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,11 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,11 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,11 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;9 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;4 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;19 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;9 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;19 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;19 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;19 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;19 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;23 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;22 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;21 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;23 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;22 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;21 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;23 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;22 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;21 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;23 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;22 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;21 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;23 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;22 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;21 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;19 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;19 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;19 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;16 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;19 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;16 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;19 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;16 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;4 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;6 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;4 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;4 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;6 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;4 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;6 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;4 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;6 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;24 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;23 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;20 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;24 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;23 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;20 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;24 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;23 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;20 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;24 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;23 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;20 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;23 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;20 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;22 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;17 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;15 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;22 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;17 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;15 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;22 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;17 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;15 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;22 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;17 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;15 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;17 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;15 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;21 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;21 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;21 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;21 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;23 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;21 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;21 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;20 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;14 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;21 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;20 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;14 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;21 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;20 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;20 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;20 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;14 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;7 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;25 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;27 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;23 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;25 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;27 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;23 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;27 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;23 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;27 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;23 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;27 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;23 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;23 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;24 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;17 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;23 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;24 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;17 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;24 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;17 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;24 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;24 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 06 Badajoz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;33.288 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;32.023 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;34.322 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;31.182 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;29.995 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;30.573 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;29.863 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;28.916 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;29.544 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;28.832 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;28.086 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;28.523 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;27.653 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;27.084 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;26.886 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,67 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,67 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,08 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,71 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,3 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,08 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,61 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,71 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,1 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,07 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,58 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,33 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;31.816 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;25.693 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;29.774 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;23.922 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;28.499 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;22.965 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;27.501 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;22.227 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;26.375 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;21.438 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,58 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,11 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,57 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,38 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,44 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,51 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,9 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,44 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.472 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;6.330 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.408 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6.073 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.364 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;5.951 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.331 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;5.859 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.278 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;5.646 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,65 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,94 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,66 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,01 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,42 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,56 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,82 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,19 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;35.038 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;32.278 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;33.451 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;33.330 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;30.906 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;32.101 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;31.994 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;29.829 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;30.758 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;29.161 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;28.166 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;28.059 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;27.037 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;26.834 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 07 Balears, Illes;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,13 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,75 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,96 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,31 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,41 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,95 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,23 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,26 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;83,88 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,76 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;80,22 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;33.535 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;25.544 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;24.206 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;31.868 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;24.307 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;23.005 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;30.569 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;23.343 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;21.931 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;27.887 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;22.050 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;20.290 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;21.098 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;19.372 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,03 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,16 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,04 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,16 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,38 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,6 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,16 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,32 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;83,82 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,59 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;80,03 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.503 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6.734 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9.245 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.462 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6.599 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9.096 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.425 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6.486 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8.827 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.274 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6.116 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;7.769 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;5.939 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;7.462 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,27 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,39 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,81 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,32 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,48 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;84,76 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,82 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;84,03 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,19 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;80,71 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;40.810 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;38.501 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;36.918 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;38.310 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;36.338 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;34.742 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;30.997 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;30.207 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;29.248 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;28.680 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;27.807 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;27.816 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;27.078 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,87 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,38 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,11 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;75,95 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;78,46 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;79,22 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;74,49 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;75,32 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;72,25 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;73,35 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;40.203 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;36.567 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;27.196 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;37.721 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;34.465 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;25.322 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;30.470 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;28.833 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;21.749 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;27.356 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;20.608 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;26.515 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;20.012 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,83 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,25 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,11 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;75,79 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;78,85 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;79,97 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;74,81 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;75,78 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;72,51 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;73,58 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;607 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.934 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;9.722 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;589 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.873 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;9.420 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;527 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.374 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7.499 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.324 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7.199 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.301 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;7.066 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,03 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,85 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,89 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;86,82 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;71,04 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;77,13 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;68,46 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;74,05 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;67,27 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;72,68 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;40.038 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;38.595 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;36.940 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;32.235 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;31.600 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;30.588 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;29.856 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;28.879 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;28.793 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;28.001 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;27.917 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;27.299 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;80,51 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;81,88 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;82,8 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;77,36 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;78,18 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;74,6 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;75,8 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;72,33 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;73,9 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;39.560 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;36.755 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;28.303 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;31.805 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;30.098 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;23.825 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;28.421 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;22.399 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;27.392 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;21.639 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;26.547 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;21.032 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;80,4 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;81,89 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;84,18 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;77,33 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;79,14 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;74,53 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;76,45 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;72,23 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;74,31 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;478 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.840 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;8.637 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;430 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.502 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6.763 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.435 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6.480 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.401 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6.362 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.370 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6.267 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;89,96 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;81,63 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;78,3 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;77,99 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;75,03 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;76,14 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;73,66 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;74,46 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;72,56 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;25.327 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;24.640 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;25.805 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;23.334 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;22.715 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;22.292 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;22.117 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;21.717 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;21.357 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;21.166 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;20.960 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;20.428 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;20.080 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;20.037 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;18.957 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,13 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,19 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,39 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,33 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,14 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,76 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,57 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,06 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,16 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;79,28 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;81,32 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;73,46 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;24.362 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;20.938 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;22.423 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;19.235 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;21.243 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18.332 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;20.319 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;17.649 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;19.278 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;16.910 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,04 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,87 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,2 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,55 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,4 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,29 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,13 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;80,76 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;965 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.702 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;911 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.480 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;874 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3.385 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;847 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3.311 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;802 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.127 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,4 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;94 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,57 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,44 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,77 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,44 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,11 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;84,47 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;25.945 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;24.661 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;25.034 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;24.351 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;23.373 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;23.760 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;23.107 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;22.370 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;22.509 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;20.689 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;20.851 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;20.136 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;19.817 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;19.044 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,86 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,78 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,91 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,06 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,71 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;89,91 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;79,74 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,55 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;80,43 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;80,36 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;76,07 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;25.018 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;20.668 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;19.546 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23.460 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;19.490 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;18.398 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;22.246 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;18.583 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17.384 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;19.948 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;17.387 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;15.846 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;16.503 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;14.996 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,77 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,3 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,13 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,92 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,91 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;88,94 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;79,73 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;84,13 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;81,07 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;79,85 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;76,72 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;927 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.993 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.488 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;891 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.883 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5.362 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;861 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.787 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.125 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;741 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.464 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4.290 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.314 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4.048 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,12 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,25 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,7 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,88 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,84 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;93,39 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;79,94 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;86,75 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;78,17 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;83 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;73,76 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;29.272 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;28.195 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;27.189 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;26.911 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;26.169 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;25.133 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;21.374 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;21.266 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;20.633 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;19.906 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;19.359 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;19.123 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;18.730 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,93 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,81 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,44 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;73,02 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;75,42 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;75,89 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;70,6 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;71,2 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;67,82 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;68,89 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;28.926 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;27.174 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;22.277 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;26.580 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;25.202 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;20.475 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;21.082 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;20.602 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;17.219 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;19.282 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;16.162 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;18.517 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;15.616 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,89 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,74 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;91,91 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;72,88 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;75,82 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;77,29 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;70,96 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;72,55 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;68,14 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;70,1 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;346 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.021 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4.912 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;331 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;967 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4.658 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;292 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;664 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.414 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;624 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.197 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;606 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.114 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,66 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,71 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;94,83 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;84,39 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;65,03 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;69,5 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;61,12 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;65,09 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;59,35 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;63,4 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;28.950 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;28.385 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;27.501 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;22.691 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;22.581 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;22.073 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;21.009 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;20.528 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;20.040 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;19.752 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;19.250 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;19.123 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;78,38 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;79,55 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;80,26 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;74,01 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;74,64 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;70,6 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;71,82 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;67,82 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;69,54 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;28.686 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;27.256 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;23.160 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;22.456 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;21.697 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;18.996 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;20.179 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;17.653 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;19.238 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;16.951 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;18.475 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;16.394 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;78,28 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;79,6 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;82,02 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;74,04 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;76,22 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;70,58 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;73,19 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;67,78 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;70,79 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;264 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.129 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4.341 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;235 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;884 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.077 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;830 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.875 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;802 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.801 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;775 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.729 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;89,02 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;78,3 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;70,88 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;73,52 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;66,23 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;71,04 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;64,52 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;68,64 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;62,87 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.450 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.291 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.760 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.379 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.222 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.605 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.330 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.191 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.554 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.288 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.149 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.494 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.234 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.105 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.391 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,94 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,9 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,88 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,52 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,96 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,52 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,3 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,69 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,93 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,74 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,35 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,19 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.256 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.329 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.192 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.281 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.147 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.259 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.107 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.226 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.056 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.198 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,03 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,94 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,65 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,99 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,42 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,58 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,86 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,38 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;194 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;962 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;187 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;941 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;183 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;932 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;181 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;923 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;178 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;907 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,39 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,82 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,33 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,88 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,3 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,95 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,75 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,28 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.887 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.355 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.663 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.826 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.312 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.623 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.776 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.274 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.563 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.514 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.177 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.360 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.123 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.278 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,43 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,72 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,91 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,14 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,59 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,27 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;90,4 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,69 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;91,73 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,08 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;89,49 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.681 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.352 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.264 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.621 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.319 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.233 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.574 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.290 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.191 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.330 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.223 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.122 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.183 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.079 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,37 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,6 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,63 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,09 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,36 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,78 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;90,46 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,52 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;93,73 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,81 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;91,83 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;206 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.003 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.399 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;205 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;993 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.390 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;202 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;984 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.372 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;184 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;954 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.238 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;940 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.199 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,51 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,36 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,06 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,11 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,07 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,32 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,11 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;88,49 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,72 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;85,7 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.657 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.298 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.164 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.577 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.221 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.083 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.749 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.572 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.517 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.480 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.424 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.433 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.379 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,28 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,21 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,05 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;80,5 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;83,11 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;84,46 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;80,97 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;82,23 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,87 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,15 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.570 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.986 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.505 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.490 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.911 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.453 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.673 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.355 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.226 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.266 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.174 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.222 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.149 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,25 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,12 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,92 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;80,37 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;84,17 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,86 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;81,94 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,79 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,83 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,79 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;87 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;312 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.659 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;87 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;310 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.630 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;76 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;217 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.291 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;214 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.250 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;211 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.230 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,36 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,25 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;87,36 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;69,55 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;77,82 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;68,59 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;75,35 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;67,63 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;74,14 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.487 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.248 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.009 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.746 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.622 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.483 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.525 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.385 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.476 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.338 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.427 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.301 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;83,49 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;85,26 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;86,88 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;82,98 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;84,44 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;81,83 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,26 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,67 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,34 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.426 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.991 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.581 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.691 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.411 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.373 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.321 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.317 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.274 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.288 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.226 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.259 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;83,39 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;85,47 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,94 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;83,21 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,77 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;82,03 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,65 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,83 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;87,52 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;61 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;257 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.428 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;55 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;211 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.110 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;204 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.068 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;202 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.050 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;201 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.042 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;90,16 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;82,1 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;77,73 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;79,38 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;74,79 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;78,6 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;73,53 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;78,21 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;72,97 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.252 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.854 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.492 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;4.211 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;3.821 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;4.412 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;4.159 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;3.771 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;4.369 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.124 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.743 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.338 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.089 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.708 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.276 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,04 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,14 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,22 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,81 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,85 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,26 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,99 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,12 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,57 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,17 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,21 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,19 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.963 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.331 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.925 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.311 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.876 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.279 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.845 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.257 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.814 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.235 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,04 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,14 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,8 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,77 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,02 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,83 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,24 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,88 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;289 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.523 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;286 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.510 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;283 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.492 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;279 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.486 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;275 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.473 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,96 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,15 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,92 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,96 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,54 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,57 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,16 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,72 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.907 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.020 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.480 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;4.854 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;3.979 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;4.444 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.815 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.946 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.413 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.667 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.899 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.291 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;3.859 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;4.241 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,92 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,98 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,2 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,13 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,16 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,5 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,11 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,99 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,78 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,67 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.561 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.419 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.280 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.512 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.393 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.258 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.476 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.365 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.241 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.341 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.335 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.208 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.308 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.183 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,93 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,93 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,04 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,14 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,77 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,29 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,18 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,53 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,84 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,41 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,75 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;346 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.601 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.200 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;342 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.586 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.186 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;339 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.581 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.172 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;326 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.564 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.083 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.551 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.058 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,84 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,06 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,36 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,98 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,75 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,73 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,22 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,69 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,68 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,88 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,55 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.444 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.656 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5.228 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.387 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.600 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.190 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.447 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.024 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.765 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;4.950 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;4.692 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;4.917 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;4.637 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,12 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,01 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,27 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;84,53 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,83 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,14 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,52 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,75 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,93 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;88,7 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.292 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5.101 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.329 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.237 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.050 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.310 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.309 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.576 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.220 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.509 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.188 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.478 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.163 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,13 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,18 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;84,38 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,71 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,32 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,39 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,95 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,79 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,87 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;152 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;555 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.899 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;150 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;550 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.880 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;138 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;448 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.545 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;441 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.504 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;439 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.474 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,68 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,1 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,34 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,79 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;80,72 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;87,79 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;79,46 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;86,37 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;79,1 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,34 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.174 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.597 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5.108 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.376 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.034 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.713 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;4.960 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;4.648 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;4.916 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;4.593 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.881 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.560 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;87,07 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;89,94 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,27 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,62 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,99 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,83 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,92 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,21 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;89,27 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.039 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5.169 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.469 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.254 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.653 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.363 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.585 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.336 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.545 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.307 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.512 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.286 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;87 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;90,02 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,71 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,7 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;94,61 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,93 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,44 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;87,29 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;92,59 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;135 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;428 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.639 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;122 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;381 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.350 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;375 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.312 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;371 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.286 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;369 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.274 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;90,37 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;89,02 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;89,05 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;87,62 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;87,61 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,68 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;86,62 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,21 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,17 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;188 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;171 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;184 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;188 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;170 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;183 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;187 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;170 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;183 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;184 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;167 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;182 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;180 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;167 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;181 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,42 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,46 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,47 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,42 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,46 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,87 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,66 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,91 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,74 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,66 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,37 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;171 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;69 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;171 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;69 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;170 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;69 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;167 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;69 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;164 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;69 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,42 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,66 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,91 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;17 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;102 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;17 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;101 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;17 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;101 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;17 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;98 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;16 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;98 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,02 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,02 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,08 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,12 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,08 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;213 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;175 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;194 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;213 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;175 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;194 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;210 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;172 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;193 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;206 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;172 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;192 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;172 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;191 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,59 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,29 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,48 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,71 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,29 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,97 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,29 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,45 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;198 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;75 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;85 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;198 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;75 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;85 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;196 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;75 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;84 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;192 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;75 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;83 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;75 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;83 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,99 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,82 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,97 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,65 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,65 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;109 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;109 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;14 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;97 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;109 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;14 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;97 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;109 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;97 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;108 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,33 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,33 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;99,08 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;303 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;249 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;234 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;301 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;246 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;233 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;293 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;243 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;230 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;243 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;229 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;242 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;229 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,34 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,8 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,57 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,7 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,59 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,29 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,59 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,86 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,19 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,86 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;288 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;225 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;59 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;287 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;222 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;58 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;279 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;220 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;58 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;220 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;58 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;219 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;58 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,65 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,67 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,31 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,88 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,78 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,31 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,78 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,31 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,33 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,31 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;15 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;24 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;175 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;14 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;24 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;175 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;14 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;23 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;172 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;23 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;171 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;23 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;171 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,33 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,33 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,83 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,29 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,83 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,71 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,83 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,71 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;296 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;261 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;223 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;292 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;260 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;220 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;260 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;219 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;259 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;219 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;257 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;217 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,65 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,62 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,65 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,62 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,21 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,23 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,21 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,47 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,31 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;284 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;247 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;68 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;280 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;246 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;68 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;246 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;68 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;245 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;68 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;244 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;68 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,59 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,6 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,6 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;99,19 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,79 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;12 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;155 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;12 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;14 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;152 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;14 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;151 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;14 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;151 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;13 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;149 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,06 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,42 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,42 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,86 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,13 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;71 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;67 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;81 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;70 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;67 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;81 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;70 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;67 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;81 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;70 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;67 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;81 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;70 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;67 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;81 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,59 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,59 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,59 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,59 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;64 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;26 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;63 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;26 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;63 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;26 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;63 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;26 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;63 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;26 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,44 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,44 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,44 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,44 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;41 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;41 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;41 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;41 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;41 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;86 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;67 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;80 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;86 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;67 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;80 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;86 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;67 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;80 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;85 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;67 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;80 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;66 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;80 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,84 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,51 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;77 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;30 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;31 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;77 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;30 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;31 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;77 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;30 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;31 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;76 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;30 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;31 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;29 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;31 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,7 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,67 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;9 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;37 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;49 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;9 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;37 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;49 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;9 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;37 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;49 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;9 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;37 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;49 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;37 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;49 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;134 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;103 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;103 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;134 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;102 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;103 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;134 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;102 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;103 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;101 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;103 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;101 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;103 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,03 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,03 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,06 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,06 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;127 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;81 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;26 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;127 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;80 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;26 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;127 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;80 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;26 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;79 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;26 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;79 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;26 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,77 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,77 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,53 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,53 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;22 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;77 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;22 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;77 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;7 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;22 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;77 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;22 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;77 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;22 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;77 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;131 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;104 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;99 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;130 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;103 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;99 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;102 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;99 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;102 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;99 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;102 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;98 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,24 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,04 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,08 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,08 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,08 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,99 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;125 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;92 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;25 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;124 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;91 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;25 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;90 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;25 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;90 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;25 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;90 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;25 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,2 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,91 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,83 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,83 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,83 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;74 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;12 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;74 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;12 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;74 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;12 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;74 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;73 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,65 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 07 Balears, Illes;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;156.161 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;151.735 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;157.466 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;148.033 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;144.660 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;142.756 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;142.132 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;139.848 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;138.227 08 Barcelona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;137.442 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;135.683 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;134.149 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;133.579 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;132.195 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;130.358 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,8 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,34 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,66 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,02 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,17 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,78 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,01 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,42 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,19 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,54 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,12 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,78 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;147.867 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;125.638 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;140.047 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;119.302 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;134.375 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;115.098 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;129.879 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;111.418 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;126.174 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;108.412 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,71 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,96 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,88 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,61 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,84 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,68 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,33 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,29 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8.294 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;26.097 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7.986 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;25.358 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7.757 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;24.750 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7.563 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;24.265 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7.405 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;23.783 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,29 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,17 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,53 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,84 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,19 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,98 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,28 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,13 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;156.279 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;151.968 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;149.494 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;149.119 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;146.045 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;144.128 08 Barcelona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;143.603 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;141.084 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;139.395 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;139.116 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;137.091 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;135.168 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;131.943 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;130.495 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 08 Barcelona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,42 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,1 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,41 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,89 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,84 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,24 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,02 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,21 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,42 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,82 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,29 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;148.307 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;128.939 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;111.903 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;141.387 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;123.587 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;106.943 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;136.058 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;119.065 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;103.110 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;131.727 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;115.513 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;99.822 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;110.979 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;96.165 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,33 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,85 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,57 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,74 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,34 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,14 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,82 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,59 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,2 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,07 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,94 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7.972 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;23.029 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;37.591 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7.732 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;22.458 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;37.185 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7.545 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;22.019 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;36.285 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7.389 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;21.578 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;35.346 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;20.964 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;34.330 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,99 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,52 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,92 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,64 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,61 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,53 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,69 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,7 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,03 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,03 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,33 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;157.317 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;154.736 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;150.936 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;150.020 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;147.772 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;144.797 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;144.444 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;142.785 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;139.590 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;136.977 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;134.475 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;132.768 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;131.060 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,36 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,5 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,93 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,82 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,28 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,48 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,52 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,09 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,8 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,83 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;152.731 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;147.211 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;128.412 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;145.560 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;140.423 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;122.797 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;140.081 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;135.608 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;118.178 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;129.991 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;113.658 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;125.953 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;110.713 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,3 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,39 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,63 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,72 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,12 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,03 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,3 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,51 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,56 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,22 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4.586 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;7.525 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;22.524 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4.460 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;7.349 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;22.000 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4.363 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;7.177 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;21.412 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6.986 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;20.817 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6.815 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;20.347 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,25 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,66 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,67 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,14 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,38 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,06 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,84 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,42 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,56 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,33 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;156.465 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;154.574 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;151.732 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;149.850 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;148.432 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;145.051 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;141.873 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;139.249 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;137.003 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;135.196 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;132.916 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;131.560 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,77 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,03 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,6 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,78 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,77 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,63 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,1 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,99 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,71 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;152.697 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;145.822 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;119.702 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;146.162 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;139.893 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;113.841 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;133.616 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;108.930 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;129.001 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;105.558 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;125.118 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;102.510 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,72 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,93 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,1 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,63 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,46 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,18 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,8 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,64 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3.768 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8.752 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;32.030 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3.688 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8.539 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;31.210 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8.257 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;30.319 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8.002 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;29.638 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7.798 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;29.050 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,88 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,57 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,44 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,34 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,66 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,43 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,53 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,1 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,7 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;112.367 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;110.049 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;113.139 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;104.758 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;103.418 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;99.502 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;99.366 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;99.092 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;95.399 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;95.135 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;95.306 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;91.792 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;91.699 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;92.237 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;88.451 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,23 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,97 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,95 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,43 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,04 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,32 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,66 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,6 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,13 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,61 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,81 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,18 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;107.637 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;96.950 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;100.296 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;90.924 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;95.097 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;87.057 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;91.026 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;83.645 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;87.720 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;80.924 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,18 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,78 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,35 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,8 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,57 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,28 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,5 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,47 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;4.730 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;13.099 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;4.462 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;12.494 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;4.269 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;12.035 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;4.109 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;11.661 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3.979 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;11.313 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,33 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,38 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,25 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,88 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,87 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,02 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,12 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;86,37 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;111.933 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;110.083 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;107.651 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;105.241 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;104.578 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;102.597 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;100.159 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;99.996 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;98.252 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;96.121 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;96.431 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;94.423 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;91.848 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;90.279 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,02 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,31 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,48 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,84 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,27 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,87 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,6 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,71 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,44 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,86 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;107.437 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;98.461 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;86.632 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;100.951 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;93.418 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;81.896 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;96.025 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;89.189 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;78.291 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;92.110 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;85.954 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;75.210 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;81.846 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;71.872 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,96 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,88 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,53 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,38 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,58 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,37 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,73 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,3 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,82 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,13 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,96 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4.496 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;11.622 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;21.019 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4.290 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;11.160 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;20.701 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4.134 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;10.807 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;19.961 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4.011 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;10.477 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;19.213 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;10.002 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;18.407 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,42 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,02 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,49 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,95 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,99 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,97 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,21 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,15 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,41 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,06 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,57 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;112.164 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;111.604 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;109.070 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;105.329 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;105.090 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;103.344 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;100.315 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;100.604 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;98.597 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;95.405 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;94.011 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;91.621 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;91.008 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,91 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,16 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,75 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,44 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,14 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,4 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,49 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,19 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,09 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,44 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;109.472 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;107.766 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;97.559 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;102.748 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;101.401 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;92.266 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;97.807 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;97.045 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;87.982 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;91.993 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;83.851 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;88.351 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;81.200 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,86 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,09 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,57 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,34 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,05 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,18 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,36 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,95 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,98 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,23 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2.692 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3.838 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;11.511 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2.581 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3.689 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;11.078 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2.508 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3.559 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;10.615 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3.412 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;10.160 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3.270 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;9.808 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,88 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,12 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,24 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,16 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,73 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,22 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,9 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,26 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85,2 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,21 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;111.823 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;111.455 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;109.908 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;105.619 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;105.701 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;103.593 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;99.719 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;98.301 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;95.333 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;94.715 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;91.664 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;91.452 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,45 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,84 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,25 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,47 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,44 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,53 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,18 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,24 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,21 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;109.709 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;106.290 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;93.752 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;103.571 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;100.728 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;88.115 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;94.990 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;83.517 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;90.829 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;80.431 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;87.335 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;77.602 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,41 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,77 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,99 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,37 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,08 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,45 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,79 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,17 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,77 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2.114 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;5.165 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;16.156 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2.048 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4.973 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;15.478 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4.729 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;14.784 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4.504 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;14.284 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4.329 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;13.850 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,88 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,28 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,8 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,56 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,51 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,2 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,41 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,81 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85,73 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;16.894 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;16.189 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;16.998 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;16.613 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;15.950 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;16.397 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;16.348 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;15.697 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;16.186 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.116 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;15.513 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;15.939 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;15.893 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;15.309 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.722 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,34 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,52 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,46 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,77 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,96 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,22 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,39 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,82 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,77 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,07 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,56 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,49 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;15.723 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;12.004 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;15.467 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;11.824 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;15.214 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11.638 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;14.998 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.499 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14.785 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.352 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,37 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,5 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,76 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,95 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,39 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,79 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,03 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,57 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.171 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4.185 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.146 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4.126 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.134 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4.059 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.118 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4.014 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.108 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.957 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,87 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,59 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,84 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,99 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,47 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,91 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,62 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,55 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;17.040 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;16.240 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;16.122 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;16.762 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;16.022 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;15.969 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;16.549 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;15.845 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;15.751 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.321 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;15.626 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;15.526 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;15.323 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;15.242 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,37 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,66 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,05 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,12 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,57 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,7 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,78 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,22 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,3 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,35 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,54 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;15.909 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12.575 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9.911 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;15.646 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.405 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9.790 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;15.444 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12.263 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.658 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;15.230 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;12.100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.539 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.864 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.354 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,35 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,65 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,78 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,08 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,52 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,45 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,73 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,22 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,25 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,35 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,38 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.131 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.665 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6.211 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.116 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.617 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6.179 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.105 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.582 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6.093 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.091 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.526 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.987 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.459 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.888 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,67 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,69 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,48 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,7 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,74 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,1 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,46 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,21 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,39 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,38 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,8 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;17.353 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;16.811 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;16.259 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;17.120 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;16.572 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;16.030 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;16.842 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;16.306 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;15.765 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;15.975 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;15.473 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;15.750 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;15.280 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,66 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,58 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,59 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,06 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,96 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,03 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,17 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,69 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,98 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;16.686 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;15.642 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12.704 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;16.457 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;15.416 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.521 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16.188 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;15.171 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;12.322 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;14.856 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;12.099 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14.648 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11.949 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,63 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,56 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,56 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,02 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,99 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,99 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,98 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,24 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,65 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,06 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;667 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.169 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.555 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;663 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.156 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.509 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;654 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.135 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.443 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.119 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.374 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.102 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.331 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,4 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,89 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,71 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,05 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,09 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,85 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,72 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,91 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,27 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,7 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;17.003 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16.714 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;16.235 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;16.791 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;16.507 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;16.020 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;16.198 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;15.742 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;15.947 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;15.510 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.758 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;15.330 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,75 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,76 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,68 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,91 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,96 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,41 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,53 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,28 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,43 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;16.419 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;15.526 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10.989 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16.213 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15.330 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10.843 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15.038 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10.654 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;14.797 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10.499 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14.625 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.382 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,75 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,74 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,67 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,86 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,95 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,3 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,54 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,2 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,48 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;584 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.188 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5.246 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;578 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.177 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5.177 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.160 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5.088 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.150 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5.011 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.133 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;4.948 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,97 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,07 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,68 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,64 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,99 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,8 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,52 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,37 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,32 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;24.471 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;23.160 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;24.857 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;24.242 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;22.964 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;24.398 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;24.006 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;22.739 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;24.195 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;23.789 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;22.552 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;23.979 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;23.593 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;22.347 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;23.758 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,06 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,15 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,15 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,1 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,18 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,34 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,21 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,37 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,47 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,41 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,49 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,58 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;22.348 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;15.372 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;22.134 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15.248 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;21.919 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15.102 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;21.718 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.977 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;21.538 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;14.845 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,04 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,19 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,08 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,24 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,18 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,43 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,38 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,57 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2.123 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7.788 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2.108 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7.716 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2.087 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7.637 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2.071 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7.575 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2.055 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7.502 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,29 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,08 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,3 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,06 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,55 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,27 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,8 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,33 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;24.835 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;23.322 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;23.348 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;24.650 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;23.127 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;23.196 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;24.438 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;22.933 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;23.032 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;24.223 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;22.734 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;22.869 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;22.482 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;22.638 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,26 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,16 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,35 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,4 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,33 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,65 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,54 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,48 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,95 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,4 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,96 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;22.760 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16.493 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;13.916 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;22.594 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.357 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.817 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;22.400 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;16.210 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.725 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;22.203 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;16.063 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13.644 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;15.880 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;13.517 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,27 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,18 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,29 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,42 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,28 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,63 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,55 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,39 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,05 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,28 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,13 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2.075 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6.829 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9.432 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2.056 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6.770 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9.379 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2.038 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6.723 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;9.307 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2.020 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6.671 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9.225 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6.602 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9.121 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,08 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,14 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,44 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,22 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,45 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,67 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,35 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,69 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,81 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,68 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,7 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;25.273 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;23.984 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;23.315 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;25.049 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;23.777 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;23.134 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;24.771 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;23.551 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;22.948 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;23.280 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;22.723 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;23.089 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;22.511 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,11 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,14 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,22 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,01 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,19 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,43 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,06 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,46 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,27 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,55 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;24.200 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;21.783 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16.802 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;23.987 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;21.589 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;16.665 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;23.723 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;21.381 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;16.535 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;21.138 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;16.375 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;20.959 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;16.236 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,12 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,11 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,18 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,03 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,15 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,41 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,04 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,46 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,22 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,63 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.073 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2.201 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6.513 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.062 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2.188 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6.469 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.048 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2.170 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6.413 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2.142 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6.348 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2.130 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6.275 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,97 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,41 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,32 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,67 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,59 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,46 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,32 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,47 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,77 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,35 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;25.077 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;24.019 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;23.257 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;24.883 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;23.846 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;23.113 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;23.588 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;22.894 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;23.362 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;22.667 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;23.142 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;22.483 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,23 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,28 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,38 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,21 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,44 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,26 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,46 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,35 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,67 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;24.135 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;21.912 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13.765 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;23.948 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;21.748 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;13.691 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;21.510 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;13.575 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;21.304 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13.449 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;21.094 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.351 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,23 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,25 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,46 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,17 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,62 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,23 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,7 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,27 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,99 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;942 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2.107 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;9.492 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;935 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2.098 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9.422 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2.078 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;9.319 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2.058 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;9.218 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2.048 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;9.132 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,26 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,57 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,26 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,62 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,18 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,67 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,11 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,2 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,21 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.592 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.539 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.635 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;1.585 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;1.530 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;1.625 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;1.577 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;1.524 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;1.617 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.568 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.519 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.611 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.563 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.512 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.599 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,56 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,42 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,39 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,06 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,03 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,9 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,49 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,7 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,53 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,18 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,25 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,8 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.413 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;885 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.406 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;879 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.401 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;876 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.394 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;874 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.390 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;869 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,5 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,32 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,15 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,98 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,66 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,76 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,37 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,19 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;179 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;654 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;179 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;651 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;176 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;648 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;174 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;645 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;173 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;643 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,54 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,32 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,08 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,21 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,62 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,65 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,32 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.615 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.518 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.562 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;1.611 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;1.516 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;1.558 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.603 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.510 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.554 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.598 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.502 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.544 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;1.493 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;1.532 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,75 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,87 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,74 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,26 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,47 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,49 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,95 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,95 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,85 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,35 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,08 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.442 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;959 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;947 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.438 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;958 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;944 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.432 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;955 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;942 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.427 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;948 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;935 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;942 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;929 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,72 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,9 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,68 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,31 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,58 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,47 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,96 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,85 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,73 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,23 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,1 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;173 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;559 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;615 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;173 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;558 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;614 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;171 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;555 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;612 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;171 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;554 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;609 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;551 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;603 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,82 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,84 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,84 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,28 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,51 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,84 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,11 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,02 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,57 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,05 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.664 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.531 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.513 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.661 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.528 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.512 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.656 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.521 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.503 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;1.515 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;1.493 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;1.506 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;1.487 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,82 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,8 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,93 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,52 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,35 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,34 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,95 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,68 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,37 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,28 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.560 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.331 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;911 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.557 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.328 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;911 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.552 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.322 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;905 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.316 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;900 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.307 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;896 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,81 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,77 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,49 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,32 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,34 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,87 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,79 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,2 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,35 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;104 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;200 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;602 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;104 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;200 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;601 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;104 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;199 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;598 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;199 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;593 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;199 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;591 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,83 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,5 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,34 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,5 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,5 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;99,5 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,17 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.683 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.554 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.529 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.680 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.548 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.522 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;1.540 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;1.511 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;1.533 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;1.505 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.527 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.499 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,82 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,61 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,54 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,1 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,82 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,65 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,43 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,26 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,04 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.597 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.365 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;789 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.594 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.359 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;785 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.351 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;778 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.344 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;774 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.339 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;771 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,81 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,56 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,49 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,97 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,61 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,46 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,1 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,1 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,72 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;86 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;189 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;740 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;86 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;189 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;737 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;189 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;733 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;189 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;731 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;188 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;728 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,59 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,05 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,78 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;99,47 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,38 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;837 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;798 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;837 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;835 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;798 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;834 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;835 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;796 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;830 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;834 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;793 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;828 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;831 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;790 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;828 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,76 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,64 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,76 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,75 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,16 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,64 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;99,37 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,92 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,28 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;99 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,92 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;746 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;427 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;744 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;427 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;744 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;425 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;743 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;423 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;741 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;422 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,73 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,73 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,53 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,6 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;99,06 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,33 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,83 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;91 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;371 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;91 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;371 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;91 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;371 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;91 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;370 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;90 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;368 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,73 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,9 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;99,19 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;856 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;805 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;811 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;855 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;802 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;808 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;854 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;800 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;806 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;853 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;798 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;806 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;797 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;804 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 08 Barcelona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,88 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,63 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,63 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,77 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,38 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,38 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,65 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;99,13 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,38 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,01 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;99,14 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;759 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;451 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;497 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;758 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;449 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;496 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;757 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;448 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;494 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;757 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;448 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;494 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;447 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;493 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,87 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,56 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,8 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,74 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,33 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,4 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,74 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;99,33 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;99,4 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;99,11 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;99,2 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;97 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;354 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;314 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;97 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;353 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;312 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;97 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;352 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;312 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;96 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;350 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;312 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;350 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;311 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,72 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,36 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,44 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,36 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,97 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,87 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,36 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,87 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;99,04 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;863 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;806 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;779 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;861 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;805 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;777 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;860 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;803 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;777 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;802 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;775 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;802 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;774 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,77 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,88 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,74 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,65 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,63 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,74 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,5 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;99,49 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,5 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;99,36 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;813 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;689 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;436 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;811 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;689 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;434 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;811 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;689 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;434 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;688 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;433 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;688 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;432 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,75 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,54 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,75 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,54 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,85 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;99,31 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,85 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;99,08 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;50 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;117 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;343 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;50 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;116 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;343 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;49 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;114 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;343 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;114 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;342 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;114 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;342 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,15 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,44 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,44 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,71 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,44 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;99,71 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;879 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;832 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;803 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;877 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;830 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;803 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;828 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;801 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;828 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;799 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;825 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;796 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,77 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,76 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,52 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,75 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,52 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,5 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,16 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;99,13 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;837 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;729 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;407 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;836 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;728 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;407 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;727 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;406 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;727 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;405 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;725 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;404 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,88 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,86 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,73 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,75 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;99,73 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;99,51 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;99,45 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;99,26 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;42 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;103 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;396 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;41 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;102 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;396 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;101 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;395 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;101 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;394 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;100 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;392 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,62 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,03 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,06 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,75 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,06 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,49 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,09 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,99 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 08 Barcelona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;26.609 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;26.281 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;27.072 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;25.312 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;25.107 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;24.999 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;24.191 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;24.172 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;24.205 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;23.432 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;23.479 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;23.534 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;22.855 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;22.926 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;22.920 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,13 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,53 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;92,34 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,91 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,98 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;89,41 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,06 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,34 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;86,93 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,89 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,23 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;84,66 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;25.411 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;22.473 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;24.157 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;21.409 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;23.076 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;20.562 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;22.344 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;19.949 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;21.786 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;19.479 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,07 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,27 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,81 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,5 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,93 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,77 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,73 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,68 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.198 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.808 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.155 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.698 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.115 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3.610 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.088 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3.530 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.069 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.447 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,41 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,11 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,07 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,8 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,82 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,7 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,23 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,52 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;26.402 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;26.244 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;26.011 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;25.060 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;25.094 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;25.101 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;24.184 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;24.271 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;24.329 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;23.522 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;23.624 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;23.634 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;22.799 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;22.865 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 48 Bizkaia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,92 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,62 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,5 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,6 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,48 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,53 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,09 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,02 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,86 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,87 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,91 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;25.256 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;22.396 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;19.794 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23.952 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;21.342 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;18.990 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;23.104 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;20.600 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;18.383 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;22.461 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;20.042 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;17.825 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;19.311 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;17.221 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,84 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,29 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,94 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,48 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,98 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,87 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,93 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,49 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,05 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,23 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.146 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.848 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6.217 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.108 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.752 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6.111 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.080 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.671 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.946 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.061 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.582 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.809 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.488 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.644 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,68 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,51 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,29 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,24 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,4 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,64 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,58 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,09 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,44 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,64 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,78 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;26.258 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;26.308 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;26.100 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;25.095 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;25.184 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;25.103 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;24.297 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;24.392 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;24.271 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;23.478 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;23.444 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;22.781 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;22.852 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,57 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,73 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,18 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,53 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,72 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,99 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,24 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,82 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,59 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,56 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;25.666 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;25.283 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;22.472 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;24.521 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;24.174 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;21.564 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;23.737 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;23.407 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;20.802 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;22.519 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;20.070 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;21.841 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;19.549 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,54 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,61 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,96 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;92,48 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,58 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,57 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,07 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;89,31 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,39 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,99 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;592 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.025 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.628 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;574 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.010 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.539 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;560 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;985 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.469 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;959 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.374 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;940 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.303 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,96 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,54 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,55 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,59 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,1 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,62 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,56 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,71 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,04 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;26.129 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;26.296 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;26.156 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;25.155 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;25.297 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;25.116 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;24.255 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;24.163 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;23.375 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;23.445 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;22.737 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;22.855 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,27 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,2 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,02 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,24 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,38 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,89 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,64 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,47 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,38 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;25.653 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;25.039 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;21.920 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;24.691 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;24.082 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;20.968 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;23.082 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;20.129 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;22.243 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;19.493 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;21.625 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;18.988 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,25 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,18 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,66 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,18 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,83 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,83 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,93 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,37 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,62 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;476 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.257 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4.236 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;464 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.215 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;4.148 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.173 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4.034 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.132 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3.952 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.112 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3.867 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,48 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,66 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,92 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,32 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,23 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,06 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,3 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,46 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,29 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;19.212 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;19.127 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;19.562 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;17.997 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;18.039 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;17.648 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;16.986 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;17.198 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;16.945 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.297 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.574 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;16.358 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;15.775 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;16.086 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.805 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,68 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,31 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,22 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,41 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,91 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,62 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,83 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,65 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,62 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,11 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,1 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,79 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;18.485 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;17.139 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17.310 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16.142 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.333 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15.375 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.669 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.812 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15.161 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;14.389 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,64 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,18 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,36 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,71 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,77 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,42 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,02 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,95 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;727 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.988 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;687 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.897 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;653 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.823 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;628 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.762 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;614 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.697 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,5 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,42 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;89,82 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,7 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,38 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,63 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,46 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,36 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;18.958 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;19.067 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;18.842 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;17.729 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;18.006 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;18.009 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;16.921 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;17.247 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;17.310 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.315 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.672 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.671 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;15.937 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;15.999 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,52 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,44 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,58 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,26 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,45 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,87 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,06 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,44 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,48 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,58 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,91 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18.284 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;17.068 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14.976 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;17.088 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.089 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14.222 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.306 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.394 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.652 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;15.716 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;14.891 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13.132 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;14.227 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12.590 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,46 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,26 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,97 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,18 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,19 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,16 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,95 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,25 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,69 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,35 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,07 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;674 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.999 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.866 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;641 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.917 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.787 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;615 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.853 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.658 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;599 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.781 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.539 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.710 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.409 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,1 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,9 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,96 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,25 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,7 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,62 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,87 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,09 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,54 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;85,54 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,18 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18.823 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;19.016 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;18.968 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;17.725 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;17.969 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;18.042 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;16.992 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.248 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;17.272 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;16.426 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;16.542 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;15.783 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;16.013 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,17 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,49 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,12 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,27 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,7 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,06 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,38 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,21 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,42 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;18.417 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;18.483 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;17.103 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;17.337 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17.446 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;16.242 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16.616 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.746 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;15.531 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.940 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14.870 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15.313 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;14.396 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,14 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,39 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,97 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,22 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,6 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,81 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,24 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,94 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,85 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,17 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;406 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;533 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.865 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;388 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;523 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.800 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;376 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;502 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.741 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;486 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.672 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;470 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.617 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,57 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,12 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,51 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,61 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,18 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,35 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,18 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,65 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,18 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,7 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;18.687 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;19.027 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;19.004 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;17.763 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;18.096 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;18.019 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;17.140 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;17.160 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;16.342 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;16.511 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.766 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;15.990 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,06 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,11 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,82 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,08 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,3 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,89 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,88 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,86 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,14 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;18.370 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18.239 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;16.811 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;17.457 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17.348 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.901 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;16.431 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;15.132 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.669 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;14.549 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15.110 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;14.090 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,03 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,11 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,59 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,09 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,01 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,91 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,54 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,84 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,81 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;317 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;788 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.193 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;306 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;748 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.118 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;709 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.028 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;673 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.962 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;656 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.900 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,53 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,92 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,58 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,97 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,48 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;85,41 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,47 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,25 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,64 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.751 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.721 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.823 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.712 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.681 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.722 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.658 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.631 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.675 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.619 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.601 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.632 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.591 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.565 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.603 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,58 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,53 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,42 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,62 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,69 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,76 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,2 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,59 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,23 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,18 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,27 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,21 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.614 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.111 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.575 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.077 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.521 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.034 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.482 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.012 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.458 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.986 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,51 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,39 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,44 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,35 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,95 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,31 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,03 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,08 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;137 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;610 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;137 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;604 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;137 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;597 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;137 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;589 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;133 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;579 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,02 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,87 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,56 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,08 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,92 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.781 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.736 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.690 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.723 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.689 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.651 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.685 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.662 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.615 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.654 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.621 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.592 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.572 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.549 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,91 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,28 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,55 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,55 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,3 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,21 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,43 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,8 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,36 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,01 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,76 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.643 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.114 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.769 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.589 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.075 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.745 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.551 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.054 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.728 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.521 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.022 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.713 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.984 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.682 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,96 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,16 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,64 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,52 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,16 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,68 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,38 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,65 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,83 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,85 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,08 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;138 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;622 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;921 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;134 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;614 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;906 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;134 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;608 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;887 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;133 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;599 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;879 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;588 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;867 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,1 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,71 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,37 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,1 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,75 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,31 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,38 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,3 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,44 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,53 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,14 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.789 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.772 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.724 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.755 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.736 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.685 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.719 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.704 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.654 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.656 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.610 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.634 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.576 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,78 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,7 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,57 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,49 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,55 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,43 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,82 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,81 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,02 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,57 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.724 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.636 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.139 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.690 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.600 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.113 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.655 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.569 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.085 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.523 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.049 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.501 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.022 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,75 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,63 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,78 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,47 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,46 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,48 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,71 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,79 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,88 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,53 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;65 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;136 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;585 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;65 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;136 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;572 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;64 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;135 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;569 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;133 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;561 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;133 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;554 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,78 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,46 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,26 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,26 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,79 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,9 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,79 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,7 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.788 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.734 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.710 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.765 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.699 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.683 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.653 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.645 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.613 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.612 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.576 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.574 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,18 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,72 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,04 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,6 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,57 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,38 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,22 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,98 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.731 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.590 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.021 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.708 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.555 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.999 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.510 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.967 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.471 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.941 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.436 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.914 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,16 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,65 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,91 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,91 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,33 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,41 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,04 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,05 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,71 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;57 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;144 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;689 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;57 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;144 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;684 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;143 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;678 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;142 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;671 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;140 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;660 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,27 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,31 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,4 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,61 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,39 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,22 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,79 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.229 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.034 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.252 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;4.189 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;3.989 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;4.197 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;4.133 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;3.948 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;4.153 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.103 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.911 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.117 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.078 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.885 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.089 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,05 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,88 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,71 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,73 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,87 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,67 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,02 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,95 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,83 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,43 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,31 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,17 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.930 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.962 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.893 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.930 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.843 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.896 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.814 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.869 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.790 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.850 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,06 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,92 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,79 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,77 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,05 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,86 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,44 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,22 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;299 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.072 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;296 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.059 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;290 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.052 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;289 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.042 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;288 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.035 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,79 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,99 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,13 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,66 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,2 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,32 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,55 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.249 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.052 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.063 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;4.194 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;4.012 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;4.025 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.165 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.977 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.993 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.141 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.949 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.964 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;3.911 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;3.911 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,71 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,01 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,06 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,02 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,15 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,28 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,46 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,46 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,56 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,52 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,26 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.950 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.961 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.752 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.896 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.927 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.726 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.868 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.902 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.709 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.846 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.881 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.690 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.855 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.660 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,63 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,85 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,06 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,92 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,01 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,44 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,37 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,3 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,75 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,42 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,66 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;299 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.091 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.311 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;298 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.085 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.299 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;297 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.075 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.284 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;295 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.068 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.274 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.056 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.251 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,67 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,45 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,08 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,33 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,53 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,94 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,66 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,89 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,18 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,79 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,42 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.237 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.120 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.018 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.207 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.080 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.990 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.179 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.045 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.963 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;4.004 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;3.911 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.972 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;3.886 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,29 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,03 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,3 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,63 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,18 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,63 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,18 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,34 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,41 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,71 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.128 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.804 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.968 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.098 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.769 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.949 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.071 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.737 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.930 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.704 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.896 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.675 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.880 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,27 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,08 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,36 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,62 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,24 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,72 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,37 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,57 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,61 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,04 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;109 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;316 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.050 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;109 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;311 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.041 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;108 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;308 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.033 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;300 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.015 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;297 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.006 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,42 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,14 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;99,08 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,47 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,38 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,94 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,67 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,99 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,81 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.235 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.132 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.048 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.209 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.101 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.023 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;4.064 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.968 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;4.022 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;3.935 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.998 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.905 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,39 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,25 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,38 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,35 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,02 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,34 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,21 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,76 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,47 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.142 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.852 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.850 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.117 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.823 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.833 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.788 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.796 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.750 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.772 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.727 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.753 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,4 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,25 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,4 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,34 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,11 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,35 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,26 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,75 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,6 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;93 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;280 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.198 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;92 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;278 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.190 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;276 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.172 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;272 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.163 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;271 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.152 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,92 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,29 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,33 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,57 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,83 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,14 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,08 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,79 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,16 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;277 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;257 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;278 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;276 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;256 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;276 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;276 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;254 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;276 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;275 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;252 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;274 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;273 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;250 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;273 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,64 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,61 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,28 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,64 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,83 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,28 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,28 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,05 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,56 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,56 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,28 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,2 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;254 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;174 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;253 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;173 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;253 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;171 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;253 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;170 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;251 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;168 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,61 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,43 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,61 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,28 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,61 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,7 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,82 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,55 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;23 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;83 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;23 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;83 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;23 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;83 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;22 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;82 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;22 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;82 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,65 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,8 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,65 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,8 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;277 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;253 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;270 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;277 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;251 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;270 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;276 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;249 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;268 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;275 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;246 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;267 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;245 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;266 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,21 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,64 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,42 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,26 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,28 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,23 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,89 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,84 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,52 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;255 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;168 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;194 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;255 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;166 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;194 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;255 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;165 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;193 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;254 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;163 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;192 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;162 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;191 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,81 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,21 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,48 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,61 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,02 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,97 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,43 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,45 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;22 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;85 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;76 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;22 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;85 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;76 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;21 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;84 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;75 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;21 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;83 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;75 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;83 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;75 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,45 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,82 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,68 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,45 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,65 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,68 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,65 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,68 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;274 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;262 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;247 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;273 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;261 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;244 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;272 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;257 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;243 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;256 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;242 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;256 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;239 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,64 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,62 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,79 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,27 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,09 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,38 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,71 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,98 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,71 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,76 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;265 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;234 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;169 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;264 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;233 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;167 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;263 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;229 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;166 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;228 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;165 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;228 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;162 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,62 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,57 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,82 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,25 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,86 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,22 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,44 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,63 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,44 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,86 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;9 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;28 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;78 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;9 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;28 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;77 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;9 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;28 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;77 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;28 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;77 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;28 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;77 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,72 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,72 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,72 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,72 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;276 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;264 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;251 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;275 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;262 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;251 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;261 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;250 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;261 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;248 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;260 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;247 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,64 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,24 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,86 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,6 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,86 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,8 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,48 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,41 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;268 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;231 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;153 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;267 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;229 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;153 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;228 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;152 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;228 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;150 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;227 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;150 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,63 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,13 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,7 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,35 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,7 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,04 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,27 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,04 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;33 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;98 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;33 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;98 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;33 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;98 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;33 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;98 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;33 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;97 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,98 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;140 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;142 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;157 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;138 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;142 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;156 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;138 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;141 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;156 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;138 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;141 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;153 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;138 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;140 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;150 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,57 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,36 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,57 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,3 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,36 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,57 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;99,3 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,45 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,57 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,59 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,54 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;128 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;87 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;126 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;87 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;126 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;86 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;126 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;86 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;126 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;86 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,44 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,44 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,85 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,44 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,85 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,44 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,85 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;12 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;55 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;12 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;55 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;12 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;55 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;12 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;55 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;12 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;54 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,18 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;137 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;136 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;146 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;137 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;136 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;146 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;137 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;136 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;143 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;137 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;136 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;140 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;134 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;140 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,95 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,89 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,53 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,89 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;124 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;85 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;103 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;124 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;85 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;103 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;124 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;85 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;101 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;124 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;85 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;98 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;83 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;98 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,06 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,15 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,65 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,15 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;13 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;51 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;43 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;13 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;51 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;43 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;13 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;51 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;42 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;13 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;51 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;42 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;51 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;42 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,67 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,67 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,67 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;135 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;138 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;143 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;135 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;138 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;142 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;135 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;138 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;139 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;136 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;139 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;136 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;138 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,3 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,2 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,55 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,2 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,55 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,5 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;132 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;126 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;93 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;132 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;126 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;93 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;132 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;126 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;90 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;124 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;90 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;124 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;89 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,77 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,41 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,77 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,41 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,7 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;12 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;50 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;12 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;49 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;49 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;49 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;49 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;143 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;139 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;143 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;143 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;139 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;140 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;137 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;140 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;137 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;139 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;137 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;139 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,9 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,56 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,9 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,56 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,2 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,56 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,2 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;142 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;127 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;85 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;142 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;127 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;82 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;125 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;82 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;125 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;81 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;125 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;81 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;96,47 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,43 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,47 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,43 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,29 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,43 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,29 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;58 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;12 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;58 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;12 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;58 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;12 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;58 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;58 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 48 Bizkaia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.534 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.392 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.821 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;8.153 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;8.039 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;8.117 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;7.896 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;7.816 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;7.901 09 Burgos;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.664 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.602 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.693 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.469 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.409 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.521 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,54 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,79 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;92,02 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;92,52 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;93,14 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;89,57 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,81 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,59 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;87,21 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,52 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,29 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;85,26 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.177 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.345 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.812 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.006 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.557 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.800 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.333 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.603 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.148 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.428 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,54 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,38 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;92,42 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,58 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,68 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,9 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;87,42 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,52 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;357 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.047 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;341 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.033 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;339 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.016 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;331 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;999 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;321 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;981 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,52 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,66 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,96 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,04 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,72 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,42 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,92 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,7 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.534 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.400 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.374 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;8.199 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;8.109 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;8.126 09 Burgos;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.929 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.845 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.885 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.690 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.616 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.683 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;7.388 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;7.453 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 09 Burgos;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,07 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,54 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;97,04 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,91 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,39 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,16 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;90,11 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,67 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;91,75 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,95 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;89 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.198 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.341 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.381 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.869 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.067 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6.159 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.610 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.821 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.965 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.381 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.613 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.799 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.401 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.598 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,99 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,27 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,52 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,83 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,92 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,48 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;90,03 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,08 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,88 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,2 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87,73 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;336 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.059 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.993 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;330 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.042 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.967 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;319 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.024 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.920 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;309 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.003 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.884 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;987 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.855 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,21 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,39 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,7 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,94 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,69 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,34 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,96 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,71 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,53 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,2 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,08 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.652 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.606 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.498 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.232 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.219 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.150 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.904 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.888 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.868 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;7.622 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;7.607 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;7.459 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.460 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,15 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,5 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,9 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,35 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,66 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,59 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,57 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,52 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,67 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,79 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.520 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.334 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.225 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.106 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.953 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.909 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.784 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.625 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.648 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.362 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.405 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.203 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.277 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,14 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,43 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,63 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,36 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,49 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,01 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,34 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,65 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,43 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,88 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;132 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;272 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.273 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;126 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;266 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.241 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;120 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;263 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.220 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;260 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.202 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;256 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.183 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,45 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,79 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,49 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,91 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,69 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,84 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,59 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,42 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,12 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,93 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.536 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.578 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.503 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;8.116 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.152 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.097 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;7.859 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;7.810 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;7.657 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;7.629 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.471 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.447 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,08 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,03 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,23 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,62 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,85 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,26 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,72 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,09 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,58 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.432 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.210 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.217 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.017 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.789 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.834 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.511 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.559 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.314 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.399 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.138 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.240 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,08 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,87 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,69 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,49 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,88 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,09 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,67 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,94 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,46 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;104 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;368 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.286 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;99 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;363 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.263 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;348 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.251 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;343 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.230 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;333 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.207 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,19 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,64 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,21 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,57 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,28 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;93,21 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,65 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90,49 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,86 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.321 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.273 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.509 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;5.967 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;5.941 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;5.845 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;5.733 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;5.734 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.653 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.524 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.540 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.466 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.342 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.358 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.312 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,4 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,71 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,8 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,7 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,41 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,85 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,39 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,32 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,98 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,51 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,41 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,61 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.101 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5.737 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5.759 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.419 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.527 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.226 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.325 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.045 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.153 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4.880 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,39 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,46 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,59 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,09 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,28 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,94 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,46 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,06 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;220 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;536 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;208 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;522 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;206 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;508 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;199 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;495 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;189 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;478 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,55 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,39 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,64 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,78 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,45 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,35 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,91 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,18 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.292 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.263 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.238 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;5.981 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;5.988 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;6.010 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.730 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.742 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;5.784 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.509 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.524 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.597 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;5.325 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;5.391 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 09 Burgos;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,06 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,61 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,34 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,07 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,68 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,72 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,56 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,2 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,72 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,02 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,42 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.102 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.726 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.072 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.795 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.465 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.864 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.554 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.233 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.677 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.341 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.035 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.520 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.844 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.337 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,97 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,44 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,9 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,02 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,39 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,21 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,53 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,93 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,12 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,6 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,51 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;190 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;537 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.166 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;186 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;523 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.146 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;176 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;509 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.107 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;168 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;489 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.077 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;481 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.054 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,89 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,39 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,28 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,63 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,79 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,94 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,42 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,06 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,37 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,57 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,39 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.360 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.394 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.357 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;5.962 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.024 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.024 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.663 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.711 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.760 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;5.475 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.526 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.327 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;5.390 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,74 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,21 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,76 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,04 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,32 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,61 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,63 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,93 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,31 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,79 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.268 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.266 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.700 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.875 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.902 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.395 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.581 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.591 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.147 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.356 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.926 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.211 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.807 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,73 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,19 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,65 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,04 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,23 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,3 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,48 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,42 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,16 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,33 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;92 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;128 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;657 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;87 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;122 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;629 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;82 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;120 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;613 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;119 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;600 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;116 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;583 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,57 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,31 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95,74 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;89,13 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,75 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,3 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,97 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,32 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,63 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,74 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.258 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.362 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.322 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.859 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.951 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.930 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;5.691 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;5.669 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;5.507 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;5.503 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.343 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.337 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,62 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,54 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,8 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,45 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,67 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,56 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,05 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,98 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,42 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.192 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.139 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5.682 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.797 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5.732 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.310 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.483 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.059 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.304 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.912 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.148 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.765 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,62 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,37 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,45 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,31 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,04 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,4 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,45 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,86 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,86 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;66 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;223 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;640 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;62 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;219 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;620 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;208 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;610 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;203 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;591 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;195 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;572 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;93,94 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,21 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,88 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,27 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,31 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,03 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,34 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,44 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,38 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;894 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;876 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;963 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;884 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;861 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;940 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;872 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;856 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;927 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;858 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;844 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;914 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;851 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;840 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;905 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,88 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,29 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,61 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,54 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,72 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,26 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,97 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,35 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,91 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,19 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,89 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,98 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;836 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;678 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;828 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;663 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;816 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;658 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;803 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;649 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;796 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;646 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,04 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,79 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,61 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,05 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,05 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,72 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,22 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,28 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;58 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;198 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;56 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;198 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;56 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;198 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;55 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;195 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;55 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;194 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,55 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,55 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,83 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,48 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,83 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,98 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;918 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;875 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;874 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;903 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;871 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;861 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;891 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;861 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;852 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;879 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;857 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;842 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;840 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;826 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,37 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,54 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,51 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,06 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,4 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,48 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,75 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,94 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,34 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,51 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;859 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;668 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;554 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;845 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;664 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;544 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;833 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;657 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;540 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;822 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;654 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;534 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;641 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;523 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,37 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,4 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,19 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,97 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,35 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,47 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,69 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,9 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,39 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,96 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,4 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;59 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;207 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;320 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;58 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;207 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;317 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;58 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;204 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;312 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;57 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;203 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;308 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;199 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;303 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,31 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,06 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,31 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,55 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,5 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,61 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,07 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,25 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,14 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,69 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;942 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;913 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;871 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;931 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;901 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;864 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;911 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;894 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;854 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;880 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;833 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;874 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;829 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,83 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,69 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,2 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,71 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,92 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,05 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,39 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,64 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,73 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,18 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;929 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;862 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;658 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;918 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;850 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;654 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;898 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;843 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;648 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;831 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;632 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;825 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;628 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,82 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,61 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,39 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,66 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,8 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,48 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,4 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,05 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,71 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,44 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;13 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;51 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;213 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;13 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;51 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;210 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;13 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;51 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;206 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;49 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;201 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;49 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;201 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,59 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,71 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,08 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,37 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,08 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,37 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;936 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;904 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;900 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;926 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;899 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;893 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;882 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;874 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;872 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;869 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;859 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;862 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,93 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,45 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,22 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,57 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,11 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,46 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,56 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,02 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,78 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;924 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;844 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;659 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;914 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;840 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;653 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;826 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;636 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;816 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;631 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;805 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;626 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,92 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,53 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,09 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,87 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,51 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,68 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,75 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,38 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,99 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;12 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;60 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;241 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;12 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;59 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;240 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;56 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;238 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;56 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;238 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;54 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;236 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,33 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,59 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,33 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,76 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;93,33 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,76 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,93 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.228 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.156 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.256 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.211 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.151 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.241 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.200 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.140 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.230 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.191 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.132 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.222 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.186 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.125 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.213 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,62 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,57 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,81 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,72 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,62 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,93 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,99 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,92 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,29 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,58 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,32 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,58 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.153 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;865 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.138 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;860 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.127 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;852 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.118 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;845 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.113 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;838 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,7 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,42 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,75 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,5 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,96 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,69 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,53 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,88 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;75 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;291 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;73 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;291 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;73 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;288 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;73 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;287 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;73 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;287 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,33 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,33 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,97 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,33 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,63 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,33 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,63 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.229 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.175 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.176 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.220 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.163 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.169 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.213 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.155 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.163 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.208 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.148 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.158 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.136 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.151 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 09 Burgos;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,27 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,98 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,4 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,7 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,3 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,89 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,29 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,7 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,47 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,68 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,87 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.148 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;879 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;703 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.140 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;870 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;699 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.134 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;863 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;696 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.129 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;856 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;693 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;848 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;687 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,3 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,98 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,43 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,78 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,18 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,34 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,38 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,58 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,47 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,72 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;81 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;296 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;473 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;80 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;293 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;470 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;79 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;292 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;467 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;79 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;292 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;465 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;288 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;464 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,77 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,99 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,37 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,53 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,65 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,73 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,53 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,65 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,31 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,3 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,1 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.254 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.210 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.183 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.243 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.205 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.175 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.235 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.194 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.167 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.178 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.162 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.169 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.155 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,12 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,59 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,32 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,48 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,68 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,65 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,36 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,22 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,61 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,63 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.230 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.122 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;808 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.220 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.117 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;801 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.212 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.107 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;794 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.091 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;789 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.083 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;784 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,19 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,55 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,13 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,54 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,66 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,27 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,24 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,65 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,52 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,03 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;24 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;88 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;375 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;23 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;88 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;374 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;23 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;87 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;373 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;87 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;373 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;86 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;371 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,83 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,73 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,83 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,86 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,47 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,86 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,47 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,73 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,93 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.246 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.223 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.195 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.236 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.213 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.188 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.197 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.182 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.189 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.172 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.180 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.163 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,2 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,18 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,41 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,87 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,91 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,22 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,08 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,48 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,32 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.222 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.143 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;820 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.212 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.133 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;815 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.118 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;809 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.110 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;801 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.101 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;794 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,18 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,13 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,39 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,81 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,66 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,11 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,68 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,33 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,83 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;24 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;80 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;375 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;24 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;80 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;373 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;79 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;373 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;79 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;371 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;79 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;369 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,47 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,75 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,47 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,75 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,93 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,75 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,4 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;56 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;55 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;61 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;56 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;54 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;59 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;56 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;54 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;59 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;56 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;54 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;59 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;56 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;54 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;59 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,18 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,72 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,18 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,72 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,18 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,72 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,18 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,72 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;54 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;45 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;54 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;44 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;54 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;44 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;54 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;44 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;54 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;44 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,78 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,78 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,78 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,78 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;10 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;10 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;10 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;10 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;10 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;59 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;56 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;54 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;59 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;56 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;54 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;59 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;56 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;54 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;59 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;56 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;54 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;56 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;53 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,15 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;57 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;47 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;31 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;57 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;47 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;31 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;57 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;47 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;31 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;57 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;47 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;31 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;47 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;30 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,77 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;9 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;9 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;9 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;23 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;9 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;23 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;9 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;23 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;62 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;59 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;56 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;62 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;59 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;56 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;62 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;59 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;56 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;59 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;55 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;59 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;55 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,21 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,21 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;61 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;57 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;40 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;61 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;57 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;40 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;61 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;57 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;40 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;57 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;39 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;57 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;39 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,5 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,5 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;16 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;16 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;16 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;16 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;16 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;62 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;58 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;53 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;61 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;58 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;53 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;58 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;52 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;58 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;52 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;58 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;52 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,39 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,11 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,11 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,11 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;61 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;57 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;38 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;61 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;57 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;38 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;57 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;37 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;57 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;37 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;57 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;37 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,37 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,37 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,37 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;15 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;15 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;15 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;15 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;15 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;35 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;32 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;35 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;35 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;35 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;34 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;32 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,14 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;33 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;20 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;33 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;20 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;33 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;20 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;33 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;20 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;32 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;20 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,97 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;12 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;12 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;12 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;12 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;12 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;36 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;31 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;32 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;36 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;31 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;32 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;36 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;31 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;32 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;35 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;31 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;32 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;31 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;32 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,22 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;32 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;32 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;32 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;32 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;21 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;10 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;11 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;10 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;11 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;10 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;11 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;10 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;11 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;10 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;11 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;75 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;34 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;30 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;31 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;34 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;30 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;31 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;33 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;30 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;31 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;30 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;31 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;30 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;31 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,06 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;32 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;27 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;32 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;27 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;19 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;32 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;27 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;19 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;27 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;19 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;27 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;19 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;12 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;12 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;12 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;12 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;12 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;50 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;34 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;31 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;33 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;34 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;31 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;33 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;31 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;33 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;31 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;33 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;31 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;33 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;33 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;27 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;18 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;33 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;27 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;18 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;27 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;18 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;27 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;18 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;27 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;18 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;4 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;15 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;15 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;15 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;15 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;15 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 09 Burgos;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.776 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.494 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.831 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;8.233 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;7.989 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;7.598 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;7.818 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;7.642 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;7.303 10 Cáceres;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.508 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.402 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.087 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.273 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.197 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.887 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,81 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,05 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,04 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,08 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,97 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,7 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,55 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,14 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;80,25 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,87 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,73 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;77,99 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.499 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.673 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.964 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.195 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.560 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.863 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.258 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.638 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.028 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.454 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,71 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,77 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,95 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,44 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,4 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,51 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,69 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,11 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;277 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;821 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;269 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;794 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;258 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;779 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;250 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;764 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;245 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;743 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,11 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,71 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,14 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,88 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,25 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,06 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,45 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,5 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.784 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.485 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.931 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;8.250 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;8.017 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;7.574 10 Cáceres;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.860 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.713 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.321 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.571 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.459 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.098 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;7.199 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;6.846 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 10 Cáceres;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,92 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,48 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,5 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,48 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,9 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,31 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,19 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,91 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,5 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,84 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,32 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.500 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.805 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.309 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.980 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.352 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.973 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.603 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7.060 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.758 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.323 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.824 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.574 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.580 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.366 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,88 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,2 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,67 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,45 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,45 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,27 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,15 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,43 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,35 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,3 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,05 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;284 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;680 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.622 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;270 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;665 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.601 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;257 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;653 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.563 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;248 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;635 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.524 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;619 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.480 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,07 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,79 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,71 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,49 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,03 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,36 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,32 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,38 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,96 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,03 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,25 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.915 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.678 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.347 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.281 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.132 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.907 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.887 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.792 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.563 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;7.487 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;7.246 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;7.250 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.050 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,89 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,71 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,73 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,47 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,79 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,61 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,28 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,81 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,54 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,46 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.795 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.468 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.319 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.167 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.928 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.900 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.780 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.592 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.583 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.291 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.291 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.059 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.111 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,86 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,62 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,28 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,46 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,66 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,94 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,1 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,95 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,36 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,5 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;120 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;210 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.028 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;114 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;204 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.007 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;107 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;200 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;980 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;196 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;955 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;191 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;939 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,14 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,96 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;89,17 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,24 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,33 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,33 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,9 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,95 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,34 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.882 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.699 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.549 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;8.350 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.212 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.013 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;7.845 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;7.639 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;7.521 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;7.370 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.265 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.176 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,01 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,4 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,73 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,18 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,36 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,46 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,21 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,52 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,94 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.777 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.383 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.549 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.252 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.912 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7.042 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.552 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.696 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.237 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.443 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.990 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.266 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,02 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,38 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,28 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,09 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,7 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,33 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,35 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,38 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;105 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;316 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.000 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;98 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;300 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;971 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;293 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;943 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;284 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;927 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;275 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;910 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;93,33 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,94 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,1 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,72 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,3 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,87 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,7 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,03 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.903 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.792 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.986 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;6.373 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;6.306 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;5.814 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;5.988 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;5.983 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.542 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.704 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.762 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.343 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.489 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.569 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.161 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,32 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,84 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,22 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;86,74 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,09 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;79,33 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;82,63 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,84 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;76,48 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;79,52 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;81,99 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;73,88 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.721 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.304 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.199 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.842 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.825 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.531 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.549 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.321 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.339 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.146 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,23 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,67 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,67 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,74 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,56 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,41 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,44 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,63 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;182 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;488 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;174 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;464 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;163 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;452 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;155 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;441 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;150 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;423 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,6 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,08 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;89,56 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,62 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;85,16 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,37 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;82,42 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;86,68 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.874 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.753 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.343 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;6.373 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;6.305 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;6.001 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.008 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;6.019 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;5.762 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.742 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.780 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.555 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;5.531 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;5.321 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,71 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,37 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,61 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,4 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,13 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,84 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,53 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,59 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,58 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,9 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,89 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.676 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.349 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.301 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6.188 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.914 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.977 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.836 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.638 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.771 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.579 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.414 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.596 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.178 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.397 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,69 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,15 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,89 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,42 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,8 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,57 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,27 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,7 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,56 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,95 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;198 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;404 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.042 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;185 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;391 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.024 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;172 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;381 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;991 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;163 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;366 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;959 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;353 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;924 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;93,43 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,78 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,27 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;86,87 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,31 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,11 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;82,32 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,59 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,03 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,38 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,68 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.939 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.844 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.611 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.348 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.330 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.189 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.984 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;6.011 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.878 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;5.720 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.579 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.503 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;5.401 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,48 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,49 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,62 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,24 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,83 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,91 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,58 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,39 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,41 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,7 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.847 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.711 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6.008 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.262 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.202 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.603 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.904 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.887 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.312 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.600 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.033 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.386 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.869 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,46 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,42 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,26 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,23 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,72 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,42 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,45 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,77 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,26 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,04 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;92 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;133 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;603 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;86 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;128 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;586 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;80 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;124 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;566 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;120 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;546 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;117 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;532 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,48 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,24 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,18 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;86,96 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,23 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,86 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,23 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,55 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,97 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,23 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.952 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.842 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.768 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.447 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.377 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.261 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;6.022 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;5.907 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;5.728 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;5.659 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.487 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.481 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,74 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,2 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,51 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,02 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,28 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,72 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,61 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,2 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;80,98 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.870 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.609 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6.182 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;6.372 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.160 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.697 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.812 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.366 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.526 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.132 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.294 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.967 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,75 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,21 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,15 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,94 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,8 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,61 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,02 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,1 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,35 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;82 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;233 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;586 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;75 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;217 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;564 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;210 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;541 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;202 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;527 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;193 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;514 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;91,46 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;93,13 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,25 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,13 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,32 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,7 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,93 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,83 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,71 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;850 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;784 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;864 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;842 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;777 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;825 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;824 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;759 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;810 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;817 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;753 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;802 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;808 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;749 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;794 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,06 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,11 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,49 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,94 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,81 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,75 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,12 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,05 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,82 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,06 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,54 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,9 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;797 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;651 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;789 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;645 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;771 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;629 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;764 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;625 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;755 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;622 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,08 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,74 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,62 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,86 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,01 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,73 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,55 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;53 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;133 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;53 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;132 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;53 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;130 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;53 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;128 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;53 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;127 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,25 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,74 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,24 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,49 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;872 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;817 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;718 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;854 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;804 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;709 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;847 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;796 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;703 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;834 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;787 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;697 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;780 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;687 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,94 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,41 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,75 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,13 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,43 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,91 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,64 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,33 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,08 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,47 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,68 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;834 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;700 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;461 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;817 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;688 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;454 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;810 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;681 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;450 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;797 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;674 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;448 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;668 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;445 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,96 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,29 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,48 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,12 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,29 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,61 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,56 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,29 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,18 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,43 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,53 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;38 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;117 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;257 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;37 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;116 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;255 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;37 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;115 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;253 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;37 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;113 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;249 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;112 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;242 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,37 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,15 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,22 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,37 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,29 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,44 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,37 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,58 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,89 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,73 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,16 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;923 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;852 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;806 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;903 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;836 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;798 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;888 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;825 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;780 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;818 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;772 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;805 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;760 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,83 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,12 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,01 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,21 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,83 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,77 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,01 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,78 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,48 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,29 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;906 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;818 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;629 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;886 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;802 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;622 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;872 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;791 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;607 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;784 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;603 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;773 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;592 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,79 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,04 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,89 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,25 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,7 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,5 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,84 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,87 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,5 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,12 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;17 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;34 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;177 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;17 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;34 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;176 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;16 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;34 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;173 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;34 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;169 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;32 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;168 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,44 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,12 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,74 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,48 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,12 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,92 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;873 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;850 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;833 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;856 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;838 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;819 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;830 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;810 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;814 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;797 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;809 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;789 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,05 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,59 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,32 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,65 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,24 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,76 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,68 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,18 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,72 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;862 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;810 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;660 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;845 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;798 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;652 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;790 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;646 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;774 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;634 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;769 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;627 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,03 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,52 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,79 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,53 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,88 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,56 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,06 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,94 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;40 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;173 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;40 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;167 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;40 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;164 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;40 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;163 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;40 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;162 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,53 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,8 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,22 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,64 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;971 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;875 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;939 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;966 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;864 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;917 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;955 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;858 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;909 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;936 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;845 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;901 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;925 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;837 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;891 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,49 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,74 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,66 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,35 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,06 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,81 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,4 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,57 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,95 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,26 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,66 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,89 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;931 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;687 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;926 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;678 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;915 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;673 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;896 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;662 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;885 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;656 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,46 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,69 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,28 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,96 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,24 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,36 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,06 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,49 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;40 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;188 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;40 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;186 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;40 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;185 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;40 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;183 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;40 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;181 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,94 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,4 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,34 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,28 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;990 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;874 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;828 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;976 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;867 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;822 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;958 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;857 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;815 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;948 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;851 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;805 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;847 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;798 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,59 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,2 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,28 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,77 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,05 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,43 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,76 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,37 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,22 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,91 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,38 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;943 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;726 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;518 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;929 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;720 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;513 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;911 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;711 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;509 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;901 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;706 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;502 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;704 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;497 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,52 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,17 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,03 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,61 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,93 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,26 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,55 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,25 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,91 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,97 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,95 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;47 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;148 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;310 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;47 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;147 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;309 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;47 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;146 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;306 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;47 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;145 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;303 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;143 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;301 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,32 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,68 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,65 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,71 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,97 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,74 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,62 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,1 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.004 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;938 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;887 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;982 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;922 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;878 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;967 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;912 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;863 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;905 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;854 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;898 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;848 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,81 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,29 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,99 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,31 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,23 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,29 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,48 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,28 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,74 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,6 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;993 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;899 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;650 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;971 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;884 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;644 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;956 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;874 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;633 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;867 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;625 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;860 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;620 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,78 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,33 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,08 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,27 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,22 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,38 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,44 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,15 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,66 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,38 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;11 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;39 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;237 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;11 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;38 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;234 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;11 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;38 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;230 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;38 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;229 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;38 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;228 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,44 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,73 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,44 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,05 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,44 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,62 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,44 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,2 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.007 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;959 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;903 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;997 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;949 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;889 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;945 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;879 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;931 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;871 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;921 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;863 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,01 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,96 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,45 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,54 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,34 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,08 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,46 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,04 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,57 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;995 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;920 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;673 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;985 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;910 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;660 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;906 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;652 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;893 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;645 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;883 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;640 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,99 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,91 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,07 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,48 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,88 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,07 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,84 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,98 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,1 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;12 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;39 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;230 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;12 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;39 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;229 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;39 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;227 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;38 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;226 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;38 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;223 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,57 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,7 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,44 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,26 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,44 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,96 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;36 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;30 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;28 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;36 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;29 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;28 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;35 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;29 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;28 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;35 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;29 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;27 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;35 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;29 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;27 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;96,67 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,22 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,67 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,22 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,67 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,43 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,22 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,67 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,43 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;36 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;24 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;36 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;23 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;35 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;23 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;35 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;23 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;35 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;23 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,83 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,22 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,83 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,22 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,83 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,22 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,83 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;6 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;6 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;6 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;6 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;33 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;27 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;29 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;32 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;27 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;29 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;32 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;27 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;28 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;32 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;27 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;28 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;27 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;27 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,97 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,97 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,55 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,97 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,55 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,1 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;33 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;32 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;32 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;21 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;32 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;21 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;22 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;20 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,97 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,97 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,45 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,97 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,45 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;90,91 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;5 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;7 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;5 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;7 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;5 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;7 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;5 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;7 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;5 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;7 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;34 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;29 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;29 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;33 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;29 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;28 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;33 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;29 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;28 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;29 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;27 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;29 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;27 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,06 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,55 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,06 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,55 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,1 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,1 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;34 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;26 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;24 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;33 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;26 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;23 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;33 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;26 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;23 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;26 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;22 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;26 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;22 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,06 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,83 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,06 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,83 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;91,67 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;91,67 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;5 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;5 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;5 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;5 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;5 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;37 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;33 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;31 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;37 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;33 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;30 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;33 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;29 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;33 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;29 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;33 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;29 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,77 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;93,55 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;93,55 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,55 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;37 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;30 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;26 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;37 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;30 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;25 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;30 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;24 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;30 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;24 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;30 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;24 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;96,15 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;92,31 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;92,31 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;92,31 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;16 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;13 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;14 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;16 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;13 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;14 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;16 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;13 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;14 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;16 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;13 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;14 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;16 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;13 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;14 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;14 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;14 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;14 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;6 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;6 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;6 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;6 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;15 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;14 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;13 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;15 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;14 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;13 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;15 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;14 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;13 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;15 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;14 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;13 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;14 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;13 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;8 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;14 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;8 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;14 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;8 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;14 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;14 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;14 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;14 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;15 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;14 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;15 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;15 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;15 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;14 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;14 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;13 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;15 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;13 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;15 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;14 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;15 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;14 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;15 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;14 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;15 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;14 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;13 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;8 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;13 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;14 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;14 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;8 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;14 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 10 Cáceres;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;25.690 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;24.440 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;25.879 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;23.778 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;22.566 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;21.182 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;22.587 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;21.620 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;20.374 11 Cádiz;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;21.712 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;20.830 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;19.733 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;20.930 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;20.191 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;18.995 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,56 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,33 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;81,85 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,92 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,46 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;78,73 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,52 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,23 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;76,25 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,47 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,61 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;73,4 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;24.497 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;21.976 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;22.633 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;20.171 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;21.484 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;19.280 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;20.641 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;18.541 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;19.881 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;17.957 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,39 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,79 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,7 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,73 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,26 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,37 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,16 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,71 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.193 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.464 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.145 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.395 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.103 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.340 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.071 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.289 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.049 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.234 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,98 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,2 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,46 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,97 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,77 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,9 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,93 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,67 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;25.802 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;24.422 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;22.457 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;24.216 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;23.159 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;21.471 11 Cádiz;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;23.080 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;22.156 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;20.666 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;21.937 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;21.187 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;19.766 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;20.254 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;18.856 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 11 Cádiz;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,85 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,83 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,61 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,45 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,72 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,02 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,02 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,75 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,02 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,93 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,96 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;24.650 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;21.989 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;17.413 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23.115 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;20.779 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;16.487 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;22.011 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;19.825 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;15.784 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;20.904 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;18.908 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;15.059 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;18.040 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;14.318 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,77 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,5 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,68 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,29 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,16 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,64 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,8 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,99 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,48 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,04 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,23 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.152 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.433 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.044 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.101 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.380 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4.984 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.069 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.331 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4.882 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.033 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.279 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4.707 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.214 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4.538 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,57 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,82 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,81 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,8 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,81 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,79 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,67 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,67 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,32 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,97 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;26.978 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;26.251 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;24.988 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;24.977 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;24.331 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;23.308 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;23.126 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;22.614 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;21.690 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;21.449 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;20.541 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;20.709 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;19.925 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,58 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,69 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,28 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;85,72 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;86,15 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;86,8 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;81,71 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;82,2 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;78,89 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;79,74 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;26.353 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;25.462 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;22.148 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;24.369 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;23.558 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;20.532 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;22.539 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;21.854 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;19.001 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;20.709 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;17.933 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;19.990 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;17.367 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,47 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,52 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,7 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;85,53 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;85,83 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;85,79 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;81,33 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;80,97 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;78,51 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;78,41 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;625 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;789 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.840 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;608 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;773 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.776 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;587 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;760 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.689 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;740 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.608 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;719 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.558 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,28 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,97 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,75 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,92 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,32 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,68 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,79 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,83 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,13 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,07 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;26.540 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;26.067 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;25.230 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;24.291 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;23.875 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;23.005 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;22.485 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;21.591 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;21.559 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;20.837 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;20.844 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;20.174 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;91,53 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,59 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,18 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,26 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;85,58 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;82,71 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;82,59 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;79,96 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;79,96 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;25.995 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;24.760 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;22.553 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;23.765 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;22.606 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;20.417 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;21.265 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;19.079 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;20.382 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;18.381 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;19.698 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17.772 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;91,42 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,3 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,53 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;85,88 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;84,6 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;82,32 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;81,5 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,56 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;78,8 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;545 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.307 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.677 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;526 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.269 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.588 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.220 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.512 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.177 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.456 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.146 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.402 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,51 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,09 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,68 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,34 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,84 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,05 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,74 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,68 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,73 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;19.706 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;19.133 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;19.978 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;17.895 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;17.358 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;15.679 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;16.809 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;16.483 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;14.949 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.018 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;15.752 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;14.377 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;15.307 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;15.167 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;13.728 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;90,81 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;90,72 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;78,48 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;85,3 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;86,15 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;74,83 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;81,28 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;82,33 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;71,96 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;77,68 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;79,27 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;68,72 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;18.919 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;17.830 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17.151 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16.114 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.102 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15.282 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.337 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.592 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14.645 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;14.050 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;90,65 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;90,38 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;85,11 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;85,71 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;81,07 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;81,84 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;77,41 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;78,8 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;787 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.303 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;744 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.244 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;707 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.201 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;681 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.160 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;662 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.117 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,54 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,47 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;89,83 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,17 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,53 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,03 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,12 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,73 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;19.708 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;18.990 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;17.616 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;18.215 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;17.790 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;16.677 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;17.161 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;16.845 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;15.925 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.147 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;15.993 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;15.097 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;15.161 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;14.281 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,42 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,68 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,67 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,08 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,7 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,4 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;81,93 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,22 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;85,7 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;79,84 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;81,07 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18.946 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;17.641 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14.529 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;17.494 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.483 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.634 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.465 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.577 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;12.964 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;15.481 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;14.762 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12.274 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;13.982 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11.596 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,34 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,44 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,84 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;86,9 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,3 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,23 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;81,71 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;83,68 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;84,48 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;79,26 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;79,81 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;762 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.349 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.087 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;721 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.307 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.043 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;696 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.268 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.961 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;666 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.231 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.823 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.179 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.685 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,62 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,89 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,57 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,34 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,92 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,4 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,25 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,45 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,4 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,98 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;20.089 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;19.862 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19.152 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;18.279 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;18.067 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;17.640 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;16.780 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;16.659 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;16.247 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;15.632 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;15.234 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;14.975 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;14.678 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;90,99 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;90,96 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,11 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;83,53 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;83,87 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;84,83 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;78,7 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;79,54 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;75,4 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;76,64 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19.676 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;19.406 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;17.710 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;17.879 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17.626 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;16.250 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16.390 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.228 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.920 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.217 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.969 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14.578 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.452 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;90,87 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;90,83 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;91,76 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;83,3 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;83,62 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;84,25 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;78,41 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;78,88 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;75,12 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;75,96 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;413 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;456 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.442 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;400 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;441 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.390 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;390 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;431 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.327 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;415 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.265 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;397 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.226 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,85 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,71 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,39 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,43 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,52 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,02 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,01 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;87,73 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,06 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,02 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;20.003 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;19.897 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;19.499 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;18.010 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;17.936 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;17.467 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;16.667 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;16.182 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;15.825 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;15.497 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.190 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;14.892 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;90,04 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;90,14 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;89,58 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;83,77 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;82,99 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;79,53 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;79,48 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;76,34 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;76,37 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;19.645 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;19.013 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;18.101 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;17.666 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17.083 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;16.142 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15.857 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.921 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.056 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;14.279 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14.444 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.717 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;89,93 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;89,85 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;89,18 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;83,4 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;82,43 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;79,19 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;78,89 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;75,97 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;75,78 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;358 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;884 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.398 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;344 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;853 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.325 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;810 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.261 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;769 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.218 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;746 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.175 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,09 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,49 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,78 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,63 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,2 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,99 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,12 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,39 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;84,05 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.793 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.529 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.717 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.738 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.464 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.475 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.670 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.418 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.430 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.612 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.384 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.388 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.570 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.351 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.333 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,03 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,43 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,09 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,6 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,61 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;89,44 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;93,52 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,27 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;87,89 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,02 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,96 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;85,87 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.617 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.085 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.564 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.028 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.499 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.984 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.445 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.952 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.405 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.928 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,97 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,27 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,49 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,16 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;93,43 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,62 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;91,9 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,47 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;176 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;444 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;174 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;436 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;171 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;434 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;167 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;432 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;165 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;423 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,86 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,2 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,16 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,75 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,89 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,3 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,75 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,27 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.816 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.549 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.265 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.759 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.509 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.235 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.703 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.480 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.201 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.620 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.399 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.159 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.327 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,98 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,43 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,68 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,99 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,29 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,17 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;93,04 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,12 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,32 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;91,29 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;92,72 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.652 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.117 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.433 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.601 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.081 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.412 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.551 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.056 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.390 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.470 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.985 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.364 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.921 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.326 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,08 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,3 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,53 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,19 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,12 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;93,14 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,76 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,18 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;90,74 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;92,53 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;164 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;432 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;832 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;158 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;428 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;823 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;152 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;424 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;811 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;150 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;414 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;795 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;406 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;774 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,34 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,07 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,92 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,68 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,15 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,48 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,46 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,83 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,55 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,98 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,03 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.150 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.917 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.710 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.039 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.855 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.607 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.857 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.695 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.492 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.612 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.404 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.564 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.372 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;96,48 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,87 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,2 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,7 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,39 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,96 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,54 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,71 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,9 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,53 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.046 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.784 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.205 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.939 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.722 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.110 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.762 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.562 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.007 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.480 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.932 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.434 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.904 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;96,49 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,77 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,69 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,68 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,03 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,02 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,08 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,62 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,43 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,35 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;104 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;133 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;505 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;133 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;497 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;95 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;133 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;485 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;132 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;472 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;130 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;468 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,15 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,42 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,35 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,04 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,25 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,47 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,74 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,67 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.053 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.869 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.707 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.896 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.729 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.580 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.661 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.494 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.615 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.460 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.559 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.429 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,86 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,12 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,31 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,75 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,13 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;91,15 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;90,88 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;89,19 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;89,73 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.970 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.688 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.229 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.814 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.553 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.108 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.488 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.031 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.444 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.002 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.394 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.973 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,75 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,98 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,57 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,56 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,12 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;90,92 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;89,82 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;89,06 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;88,52 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;83 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;181 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;478 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;82 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;176 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;472 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;173 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;463 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;171 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;458 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;165 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;456 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,8 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,24 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,74 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,58 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,86 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,48 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,82 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,16 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,4 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.044 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.649 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.041 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.998 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.615 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.887 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.961 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.590 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;2.855 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.935 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.565 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.828 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.906 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.544 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.794 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,49 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,72 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;94,94 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,27 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,77 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,88 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,42 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,83 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,47 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,04 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,88 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.824 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.969 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.781 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.937 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.746 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.922 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.722 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.905 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.694 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.887 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,48 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,37 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,24 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,61 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,39 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,75 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,4 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,84 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;220 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;680 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;217 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;678 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;215 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;668 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;213 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;660 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;212 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;657 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,64 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,71 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,73 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,24 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,82 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,06 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,36 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,62 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.130 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.752 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.444 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.094 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.729 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;2.427 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.068 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.700 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.408 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.022 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.664 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.378 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.635 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.344 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,85 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,16 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,3 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,02 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,11 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,53 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,55 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,8 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,3 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,75 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,91 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.912 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.137 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.360 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.880 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.121 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.350 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.855 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.098 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.339 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.813 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.067 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.330 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.043 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.306 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,9 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,25 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,26 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,04 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,18 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,46 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,6 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,72 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,79 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,6 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,03 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;218 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;615 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.084 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;214 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;608 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.077 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;213 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;602 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.069 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;209 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;597 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.048 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;592 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.038 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,17 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,86 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,35 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,71 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,89 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,62 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,87 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,07 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,68 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,26 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,76 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.573 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.328 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.990 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.493 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.265 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.925 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.323 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.116 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.815 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.061 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.767 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.026 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.739 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,76 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,11 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,83 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;93 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;93,63 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,15 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;91,98 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;92,54 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90,93 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;91,61 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.470 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.142 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.139 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.390 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.080 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.078 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.226 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.934 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.980 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.882 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.938 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.848 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.917 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,69 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,03 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,15 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;92,97 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;93,38 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,57 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;91,73 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;90,6 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,64 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;89,62 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;103 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;186 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;851 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;103 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;185 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;847 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;97 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;182 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;835 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;179 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;829 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;178 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;822 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,46 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,53 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,17 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,85 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,12 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,24 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,41 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,7 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,59 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.325 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.155 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.884 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.226 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.064 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.818 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.011 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;2.775 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;2.973 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.740 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.949 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.713 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,02 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,12 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,71 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,44 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,22 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,23 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,01 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,47 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,07 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.226 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.924 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.121 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.131 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.835 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.065 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.785 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.025 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.747 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.998 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.725 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.980 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,06 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,96 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,36 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,25 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,47 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,95 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,2 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,19 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,35 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;99 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;231 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;763 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;95 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;229 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;753 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;226 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;750 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;226 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;742 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;224 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;733 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,96 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,13 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,69 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,84 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,3 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,84 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,25 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,97 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,07 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;112 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;98 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;108 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;112 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;98 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;106 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;112 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;98 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;106 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;112 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;98 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;106 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;112 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;98 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;106 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,15 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,15 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,15 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,15 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;104 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;67 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;104 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;67 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;104 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;67 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;104 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;67 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;104 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;67 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;31 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;31 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;31 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;31 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;31 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;109 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;109 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;109 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;109 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;97 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,98 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;103 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;69 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;66 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;103 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;69 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;66 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;103 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;69 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;66 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;103 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;69 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;66 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;69 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;65 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,48 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;29 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;32 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;29 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;32 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;29 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;32 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;29 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;32 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;29 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;32 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;122 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;106 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;102 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;122 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;106 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;102 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;122 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;106 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;102 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;106 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;102 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;106 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;102 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;119 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;96 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;70 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;119 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;96 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;70 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;119 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;96 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;70 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;96 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;70 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;96 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;70 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;10 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;32 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;10 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;32 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;10 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;32 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;10 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;32 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;10 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;32 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;119 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;107 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;101 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;119 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;107 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;101 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;107 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;101 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;107 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;101 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;107 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;101 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;116 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;98 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;73 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;116 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;98 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;73 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;98 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;73 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;98 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;73 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;98 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;73 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;9 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;28 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;9 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;28 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;9 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;28 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;9 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;28 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;9 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;28 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;31 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;31 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;31 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;34 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;31 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;34 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;35 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;31 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;34 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,14 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,14 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,14 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;33 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;25 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;33 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;25 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;33 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;25 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;33 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;25 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;33 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;25 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;6 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;6 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;6 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;6 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;39 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;33 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;34 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;39 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;33 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;34 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;39 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;33 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;34 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;39 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;33 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;34 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;33 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;34 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;37 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;37 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;37 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;37 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;25 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;8 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;8 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;9 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;8 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;8 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;44 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;38 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;34 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;44 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;38 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;34 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;44 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;38 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;34 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;38 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;34 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;38 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;34 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;42 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;34 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;24 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;42 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;34 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;24 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;42 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;34 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;24 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;34 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;24 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;34 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;24 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;10 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;10 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;10 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;10 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;10 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;40 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;40 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;39 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;38 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;37 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;29 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;38 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;37 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;29 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;37 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;29 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;37 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;29 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;37 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;29 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;10 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;10 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;10 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;10 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;10 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 11 Cádiz;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;14.388 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;13.790 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;14.505 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;13.710 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;13.171 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;13.081 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;13.152 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;12.767 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;12.713 39 Cantabria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;12.771 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;12.442 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;12.360 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;12.441 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;12.152 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;11.979 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,29 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,51 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,18 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,41 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,58 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,65 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,76 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,22 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,21 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,47 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,12 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,59 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;13.915 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;12.529 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;13.252 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;11.940 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;12.701 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11.550 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12.329 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.249 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12.003 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;10.985 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,24 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,3 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,28 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,19 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,6 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,78 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,26 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,68 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;473 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.261 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;458 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.231 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;451 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.217 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;442 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.193 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;438 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.167 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,83 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,62 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,35 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,51 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,45 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,61 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,6 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,55 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;14.469 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;13.963 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;13.608 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;13.796 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;13.422 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;13.172 39 Cantabria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;13.321 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;13.008 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;12.761 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;12.855 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;12.615 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;12.305 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;12.236 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;11.939 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 39 Cantabria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,35 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,13 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,8 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,07 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,16 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,78 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,85 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,35 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,42 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,63 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,74 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;13.987 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12.643 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11.340 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;13.323 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.117 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.936 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;12.857 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11.726 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10.578 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;12.402 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.359 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10.186 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.008 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.870 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,25 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,84 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,44 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,92 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,75 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,28 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,67 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,84 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,82 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,07 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87,04 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;482 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.320 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.268 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;473 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.305 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.236 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;464 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.282 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.183 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;453 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.256 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.119 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.228 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.069 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,13 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,86 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,59 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,27 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,12 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,25 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,98 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,15 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,43 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,03 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,23 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;14.857 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;14.635 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14.192 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;14.036 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;13.845 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;13.494 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;13.341 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;13.165 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;12.787 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;12.714 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;12.371 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;12.378 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;12.125 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,47 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,6 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,08 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,8 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,96 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,1 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,87 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,17 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,58 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,44 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;14.691 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14.282 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12.831 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;13.875 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;13.500 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.164 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;13.186 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12.830 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.487 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12.386 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11.100 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12.053 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10.870 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,45 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,52 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,8 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,76 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,83 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,53 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,72 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,51 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,39 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,72 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;166 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;353 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.361 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;161 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;345 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.330 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;155 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;335 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.300 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;328 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.271 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;325 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.255 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,99 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,73 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,72 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,37 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,9 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,52 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,92 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,39 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,07 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,21 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;14.642 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;14.554 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14.226 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;13.774 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;13.682 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;13.253 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;13.159 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;12.767 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;12.738 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;12.460 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;12.428 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;12.168 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,07 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,01 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,16 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,42 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,74 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,52 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,59 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,39 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,53 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;14.524 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14.030 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;12.884 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;13.659 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13.171 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;11.944 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;12.669 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.490 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12.259 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;11.196 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;11.957 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.923 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,04 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,88 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,7 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,3 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,18 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,38 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,9 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,22 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,78 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;118 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;524 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.342 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;115 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;511 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.309 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;490 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.277 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;479 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.264 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;471 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.245 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,46 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,52 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,54 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,51 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,16 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,41 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,19 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,89 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,77 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;11.091 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;10.731 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;11.173 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;10.449 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;10.131 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;9.834 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;9.950 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;9.768 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;9.499 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;9.592 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;9.468 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.176 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;9.283 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;9.197 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.829 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,21 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,41 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,02 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,71 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,03 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,02 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,48 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,23 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,13 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,7 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,7 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,02 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;10.777 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10.043 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10.149 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9.467 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;9.655 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9.115 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;9.306 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8.833 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;9.001 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8.587 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,17 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,26 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,59 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,76 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,35 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,95 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,52 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,5 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;314 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;688 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;300 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;664 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;295 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;653 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;286 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;635 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;282 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;610 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,54 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,51 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,95 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,91 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,08 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,3 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,81 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,66 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;11.123 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;10.864 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;10.570 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;10.505 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;10.366 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;10.163 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;10.052 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;9.972 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;9.779 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;9.622 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;9.598 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.351 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;9.257 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;9.005 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,44 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,42 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,15 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,37 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,79 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,52 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,51 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,35 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,47 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,21 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,19 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;10.797 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10.147 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9.202 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;10.187 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9.661 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8.819 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;9.742 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9.287 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;8.482 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;9.323 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8.938 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;8.110 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8.618 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7.808 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,35 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,21 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,84 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,23 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,52 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,18 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,35 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,09 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,13 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,93 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,85 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;326 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;717 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.368 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;318 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;705 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.344 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;310 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;685 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.297 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;299 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;660 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.241 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;639 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.197 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,55 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,33 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,25 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,09 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,54 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,81 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,72 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,05 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,72 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,12 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,5 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11.244 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;11.191 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;10.938 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;10.459 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;10.444 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;10.274 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;9.862 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;9.835 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;9.636 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;9.436 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;9.247 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;9.134 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;9.027 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,02 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,32 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,93 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,71 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,88 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,1 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,32 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,54 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,62 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,53 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.112 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11.015 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10.254 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;10.331 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10.276 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9.617 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;9.739 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;9.676 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9.003 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;9.282 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8.639 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8.983 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8.431 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,97 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,29 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,79 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,64 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,84 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,8 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,27 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,25 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,55 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,22 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;132 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;176 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;684 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;128 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;168 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;657 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;123 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;159 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;633 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;154 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;608 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;151 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;596 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,97 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,45 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,05 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,18 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,34 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,54 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;87,5 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,89 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85,8 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;87,13 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;11.122 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.150 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.006 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;10.327 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;10.333 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;10.087 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;9.859 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;9.626 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;9.476 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;9.346 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;9.187 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;9.081 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,85 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,67 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,65 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,42 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,46 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,99 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,92 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,39 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,51 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.018 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10.796 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10.354 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;10.226 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;9.991 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9.462 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9.536 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.027 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9.164 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.757 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;8.881 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8.504 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,81 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,54 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,38 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,33 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,18 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,88 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,58 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,26 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,13 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;104 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;354 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;652 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;101 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;342 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;625 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;323 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;599 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;312 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;589 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;306 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;577 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,12 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,61 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,86 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,24 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,87 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,14 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,34 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,44 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,5 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.391 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.310 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.363 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.366 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.298 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.318 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.339 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.272 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.294 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.326 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.260 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.275 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.310 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.249 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.254 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,2 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,08 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,7 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,26 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,1 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,94 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,33 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,18 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,54 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,18 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,34 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.321 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.094 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.297 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.086 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.271 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.061 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.258 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.053 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.242 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.042 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,18 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,27 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,21 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,98 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,23 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,25 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,02 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,25 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;70 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;216 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;69 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;212 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;68 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;211 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;68 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;207 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;68 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;207 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,57 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,15 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,14 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,69 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,14 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,83 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,14 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,83 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.374 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.299 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.246 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.352 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.276 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.227 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.336 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.270 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.208 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.314 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.258 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.194 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.231 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.181 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,4 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,23 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,48 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,23 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,77 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,95 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,63 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,84 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,83 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,77 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,78 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.314 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.078 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;887 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.292 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.056 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;873 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.276 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.051 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;858 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.254 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.039 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;848 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.016 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;839 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,33 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,96 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,42 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,11 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,5 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,73 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,43 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,38 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,6 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,25 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,59 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;60 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;221 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;359 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;60 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;220 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;354 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;60 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;219 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;350 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;60 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;219 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;346 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;215 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;342 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,55 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,61 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,1 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,49 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,1 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,38 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,29 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,26 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.485 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.448 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.360 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.464 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.426 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.337 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.407 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.381 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.296 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.348 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.277 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.333 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.264 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,59 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,48 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,31 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,75 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,37 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,29 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,09 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,9 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,06 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,94 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.470 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.384 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.122 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.450 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.362 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.102 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.394 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.318 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.063 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.287 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.047 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.272 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.036 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,64 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,41 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,22 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,83 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,23 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;94,74 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;92,99 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,32 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;91,91 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,34 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;15 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;64 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;238 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;14 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;64 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;235 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;13 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;63 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;233 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;61 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;230 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;61 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;228 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,33 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,74 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;86,67 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,44 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,9 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,31 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,64 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,31 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,8 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.464 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.452 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.339 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.419 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.415 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.305 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.384 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.289 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.366 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.274 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.357 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.262 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,93 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,45 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,46 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,32 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,27 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,08 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,15 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,46 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,25 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.455 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.387 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.093 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.410 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.350 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.065 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.321 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.053 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.303 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.039 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.295 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.031 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,91 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,33 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,44 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,24 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,34 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,94 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,06 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,37 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,33 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;9 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;65 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;246 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;9 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;65 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;240 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;63 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;236 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;63 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;235 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;62 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;231 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,56 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,92 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,93 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,92 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,53 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,38 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,9 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.781 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.629 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.837 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.770 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.622 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.798 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.738 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.607 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.789 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.728 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.594 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.781 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.723 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.587 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.769 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,38 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,57 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,88 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,59 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,65 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,39 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,02 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,85 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,95 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,74 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,42 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,3 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.701 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.305 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.690 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.300 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.659 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.287 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.649 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.276 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.644 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.270 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,35 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,62 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,53 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,62 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,94 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,78 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,65 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,32 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;80 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;324 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;80 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;322 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;79 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;320 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;79 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;318 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;79 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;317 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,38 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,75 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,77 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,75 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,15 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,75 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,84 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.840 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.679 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.673 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.807 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.659 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.663 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.801 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.645 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.657 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.787 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.639 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.644 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.628 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.637 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,21 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,81 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,4 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,88 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,97 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,04 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,12 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,62 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,27 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,96 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,85 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.752 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.328 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.163 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.720 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.310 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.156 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.715 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.298 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.151 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.701 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.293 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.142 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.285 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.137 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,17 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,64 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,4 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,89 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,74 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,97 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,09 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,36 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,19 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,76 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,76 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;88 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;351 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;510 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;87 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;349 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;507 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;86 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;347 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;506 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;86 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;346 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;502 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;343 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;500 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,86 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,43 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,41 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,73 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,86 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,22 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,73 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,58 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,43 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,72 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,04 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.005 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.874 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.776 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.990 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.853 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.766 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.949 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.828 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.739 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.809 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.731 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.790 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.718 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,25 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,88 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,44 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,21 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,55 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,92 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,53 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,47 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,52 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,73 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.986 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.772 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.371 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.971 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.751 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.362 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.930 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.726 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.339 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.707 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.332 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.688 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.321 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,24 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,81 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,34 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,18 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,4 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,67 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,33 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,16 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,26 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,35 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;19 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;102 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;405 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;19 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;102 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;404 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;19 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;102 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;400 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;102 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;399 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;102 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;397 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,75 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,77 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,52 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,02 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.925 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.827 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.759 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.897 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.810 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.740 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.792 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.731 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.772 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.719 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.760 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.704 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,55 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,07 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,92 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,08 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,41 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,99 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,73 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,33 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,87 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.920 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.734 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.354 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.892 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.718 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.335 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.700 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.328 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.680 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.318 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.669 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.306 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,54 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,08 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,6 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,04 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,08 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,89 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,34 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,25 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,45 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;93 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;405 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;92 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;405 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;92 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;403 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;92 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;401 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;91 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;398 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,92 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,92 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,51 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,92 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,01 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,85 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,27 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;82 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;78 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;84 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;82 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;78 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;84 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;82 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;78 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;84 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;82 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;78 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;82 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;82 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;78 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;81 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,62 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,43 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;76 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;55 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;76 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;55 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;76 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;55 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;76 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;55 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;76 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;55 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;6 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;23 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;23 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;23 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;23 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;23 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;89 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;79 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;77 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;89 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;79 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;77 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;89 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;79 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;76 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;89 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;79 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;75 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;79 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;75 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,7 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,4 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,4 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;84 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;84 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;84 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;56 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;84 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;55 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;57 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;55 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,25 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,49 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,49 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;5 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;22 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;20 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;5 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;22 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;20 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;5 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;22 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;20 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;5 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;22 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;20 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;22 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;20 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;79 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;80 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;78 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;79 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;80 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;77 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;79 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;80 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;76 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;80 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;76 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;80 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;76 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,72 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,44 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,44 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,44 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;79 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;74 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;56 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;79 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;74 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;55 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;79 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;74 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;54 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;74 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;54 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;74 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;54 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,21 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,43 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,43 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,43 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;22 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;22 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;22 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;22 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;22 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;88 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;82 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;78 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;88 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;82 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;77 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;82 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;77 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;82 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;77 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;82 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;77 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,72 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,72 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,72 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,72 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;88 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;75 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;54 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;88 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;75 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;53 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;75 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;53 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;75 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;53 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;75 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;53 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,15 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,15 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,15 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,15 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;7 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;24 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;7 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;24 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;7 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;24 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;7 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;24 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;24 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;43 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;42 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;48 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;43 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;42 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;47 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;43 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;42 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;47 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;43 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;42 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;46 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;43 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;41 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;46 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,92 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,92 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,83 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,62 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,83 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;40 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;32 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;40 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;32 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;40 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;32 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;40 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;32 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;40 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;31 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,88 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;10 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;10 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;10 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;10 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;10 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;43 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;42 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;42 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;43 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;42 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;42 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;43 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;42 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;41 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;43 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;41 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;41 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;41 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;41 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,62 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,62 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,62 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,62 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,62 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;40 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;33 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;31 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;40 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;33 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;31 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;40 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;33 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;31 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;40 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;32 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;31 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;32 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;31 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,97 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,97 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;9 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;11 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;9 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;11 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;9 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;10 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;9 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;10 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;9 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;10 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;90,91 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,91 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,91 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;44 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;42 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;40 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;44 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;42 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;40 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;44 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;41 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;40 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;41 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;40 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;41 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;40 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,62 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,62 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,62 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;44 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;37 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;28 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;44 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;37 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;28 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;44 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;36 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;28 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;36 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;28 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;36 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;28 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,3 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,3 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,3 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;5 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;12 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;5 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;12 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;5 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;12 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;5 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;12 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;5 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;12 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;43 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;43 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;44 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;43 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;42 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;44 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;42 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;44 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;42 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;44 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;42 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;44 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,67 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,67 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,67 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,67 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;43 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;38 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;29 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;43 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;29 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;29 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;29 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;29 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,37 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;5 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;15 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;5 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;15 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;5 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;15 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;5 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;15 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;5 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;15 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 39 Cantabria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;15.812 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;15.456 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;15.980 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;14.947 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;14.514 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;14.202 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;14.255 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;13.958 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;13.723 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;13.765 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;13.504 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;13.260 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;13.393 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;13.163 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;12.902 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,53 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,91 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,87 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,15 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,31 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,88 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,05 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,37 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,98 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,7 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,16 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,74 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14.906 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;13.627 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;14.077 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12.740 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;13.411 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;12.224 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12.950 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.804 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12.589 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.504 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,44 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,49 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,97 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,7 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,88 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,62 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,46 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,42 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;906 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.829 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;870 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.774 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;844 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.734 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;815 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.700 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;804 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.659 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,03 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,99 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,16 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,81 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,96 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,95 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,74 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,71 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;15.886 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;15.372 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;14.945 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;15.043 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;14.699 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;14.378 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;14.435 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;14.116 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;13.835 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;13.914 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;13.630 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;13.382 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;13.163 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;12.865 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,69 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,62 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,21 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,87 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,83 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,57 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,59 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,67 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,54 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,63 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,08 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;15.016 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;13.492 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11.442 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;14.204 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.863 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.920 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;13.621 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12.329 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10.468 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;13.123 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.890 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10.149 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.480 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.742 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,59 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,34 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,44 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,71 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,38 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,49 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,39 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,13 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,7 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,09 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,14 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;870 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.880 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.503 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;839 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.836 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.458 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;814 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.787 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.367 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;791 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.740 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.233 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.683 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.123 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,44 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,66 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,72 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,56 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,05 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,12 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,92 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,55 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,29 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,52 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,15 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;16.277 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;16.054 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;15.588 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;15.226 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;15.014 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;14.669 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;14.419 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;14.273 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;13.997 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;13.726 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;13.381 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;13.342 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;13.053 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,54 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,52 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,1 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,59 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,91 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,79 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,5 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,84 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,11 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,74 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;15.951 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;15.340 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;13.474 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;14.912 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14.323 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.606 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14.118 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;13.602 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.999 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;13.073 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11.449 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12.697 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11.164 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,49 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,37 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,56 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,51 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,67 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,05 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,22 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,97 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,77 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,86 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;326 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;714 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.114 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;314 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;691 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.063 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;301 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;671 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.998 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;653 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.932 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;645 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.889 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,32 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,78 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,59 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,33 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,98 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,51 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,46 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,39 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,34 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,36 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;15.965 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;15.782 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;15.545 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;15.011 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;14.888 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;14.643 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;14.247 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;13.932 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;13.743 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;13.509 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;13.335 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;13.128 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,02 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,34 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,2 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,27 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,62 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,08 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,9 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,49 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,45 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15.714 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14.852 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13.267 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;14.771 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13.985 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12.434 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;13.388 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.789 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12.905 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;11.413 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;12.530 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;11.075 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,16 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,72 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,14 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,86 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,89 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,03 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,37 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,48 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;251 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;930 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.278 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;240 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;903 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.209 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;859 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.143 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;838 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.096 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;805 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.053 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,62 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,1 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,97 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,37 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,07 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,11 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,01 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,56 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,12 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;11.923 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;11.797 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;12.110 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;11.109 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;10.914 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;10.461 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;10.480 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;10.397 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;10.034 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;10.023 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;9.986 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.617 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;9.683 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;9.674 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;9.287 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,17 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,52 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,38 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,9 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,13 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,86 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,06 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,65 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,41 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,21 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,69 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;11.326 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10.763 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10.545 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9.922 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;9.940 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9.436 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;9.509 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9.050 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;9.178 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8.771 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,1 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,19 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,76 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,67 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,96 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,08 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,03 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,49 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;597 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.034 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;564 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;992 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;540 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;961 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;514 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;936 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;505 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;903 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,47 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,94 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,45 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,94 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,1 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,52 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,59 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,33 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;11.929 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;11.727 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;11.388 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;11.145 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;11.097 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;10.870 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;10.581 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;10.564 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;10.368 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.115 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;10.131 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.950 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;9.708 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;9.480 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,43 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,63 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,45 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,7 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,08 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,04 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,79 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,39 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,37 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,78 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,25 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11.362 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10.566 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9.029 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;10.606 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9.974 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8.545 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;10.065 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9.481 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;8.122 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;9.619 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9.088 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7.814 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8.714 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7.436 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,35 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,4 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,64 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,58 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,73 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,95 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,66 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,01 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,54 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,47 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,36 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;567 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.161 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.359 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;539 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.123 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.325 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;516 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.083 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.246 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;496 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.043 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.136 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;994 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.044 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,06 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,73 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,56 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,01 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,28 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,21 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,48 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,84 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,55 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;85,62 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,65 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;12.010 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;12.018 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;11.851 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;11.069 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;11.064 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;11.007 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;10.406 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;10.450 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;10.411 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;9.967 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;9.853 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;9.615 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;9.558 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,16 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,06 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,88 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,64 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;86,95 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,85 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,93 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,14 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;80,65 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.764 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11.612 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10.632 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;10.835 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10.677 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9.831 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.183 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10.076 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9.287 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;9.606 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8.778 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;9.261 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8.516 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,1 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;91,95 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,47 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,56 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;86,77 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,35 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,72 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;82,56 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,75 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,1 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;246 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;406 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.219 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;234 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;387 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.176 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;223 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;374 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.124 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;361 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.075 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;354 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.042 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,12 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,32 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,47 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,65 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,12 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,21 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,92 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,19 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,19 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,48 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;11.956 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.918 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.874 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.102 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;11.101 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;11.027 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;10.512 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;10.376 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;10.052 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;9.986 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;9.670 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;9.643 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,86 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,14 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,87 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,2 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,38 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,34 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,1 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,14 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,21 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.768 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;11.302 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10.608 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;10.925 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10.507 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9.820 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9.956 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.221 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9.516 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.867 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;9.164 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8.553 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,84 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,97 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,57 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,09 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,92 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,2 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,59 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,08 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,63 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;188 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;616 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.266 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;177 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;594 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.207 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;556 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.155 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;536 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.119 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;506 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.090 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,15 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,43 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,34 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,26 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,23 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,01 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,39 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,14 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,1 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.640 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.538 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.665 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.615 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.510 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.584 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.579 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.488 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.550 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.558 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.468 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.520 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.538 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.454 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.502 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,48 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,18 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,14 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,28 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,75 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,09 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,45 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;91,29 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,78 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,54 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,21 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.515 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.261 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.491 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.242 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.455 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.224 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.437 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.206 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.417 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.196 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,42 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,49 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,04 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,07 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,85 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,64 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,53 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,85 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;125 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;277 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;124 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;268 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;124 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;264 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;121 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;262 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;121 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;258 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,2 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,75 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,2 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,31 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,58 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,14 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.688 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.535 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.527 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.658 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.507 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.498 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.633 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.482 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.470 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.597 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.452 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.445 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.432 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.420 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,22 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,18 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,1 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,74 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,55 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,27 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,61 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,59 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,63 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,29 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;92,99 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.572 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.262 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.009 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.543 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.239 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;986 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.520 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.217 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;968 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.485 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.190 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;961 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.173 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;946 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,16 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,18 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,72 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,69 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,43 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,94 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,47 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,29 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,24 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,95 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,76 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;116 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;273 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;518 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;115 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;268 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;512 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;113 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;265 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;502 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;112 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;262 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;484 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;259 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;474 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,14 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,17 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,84 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,41 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,07 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,91 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,55 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,97 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,44 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,87 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,51 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.843 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.728 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.658 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.785 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.687 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.614 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.711 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.615 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.567 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.580 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.535 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.562 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.517 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;96,85 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,63 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,35 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,84 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;93,46 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,51 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;91,44 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;92,58 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90,39 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;91,5 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.810 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.612 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.310 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.752 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.573 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.272 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.680 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.504 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.231 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.472 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.210 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.454 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.198 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;96,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,58 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,1 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;92,82 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;93,3 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;93,97 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;91,32 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;92,37 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,2 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;91,45 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;33 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;116 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;348 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;33 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;114 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;342 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;31 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;111 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;336 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;108 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;325 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;108 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;319 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,28 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,28 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,94 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,69 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,55 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,1 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,39 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,1 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,67 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.715 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.682 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.596 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.652 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.636 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.558 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.607 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.530 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.578 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.513 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.560 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.497 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,33 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,27 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,62 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,54 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,86 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;93,82 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,75 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.695 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.557 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.235 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.632 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.515 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.202 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.491 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.182 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.462 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.170 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.447 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.159 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,28 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,3 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,33 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,76 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,71 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,9 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,74 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,94 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,85 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;20 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;125 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;361 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;20 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;121 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;356 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;116 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;348 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;116 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;343 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;113 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;338 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,61 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,4 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,8 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,01 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90,4 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,63 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.071 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.956 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.031 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.047 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.929 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.984 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.020 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.913 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.966 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.009 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.894 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.953 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.997 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.880 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.943 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,84 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,62 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,69 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,54 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,8 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,8 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,01 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,83 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,16 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,43 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,11 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,67 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.904 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.495 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.882 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.471 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.857 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.460 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.846 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.447 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.836 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.437 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,84 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,39 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,53 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,66 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,95 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,79 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,43 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,12 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;167 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;461 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;165 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;458 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;163 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;453 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;163 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;447 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;161 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;443 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,8 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,35 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,6 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,26 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,6 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,96 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,41 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,1 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.089 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.943 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.868 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.062 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.930 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.850 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.047 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.911 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.839 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.029 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.889 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.829 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.865 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.811 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,71 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,33 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,04 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,99 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,35 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,45 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,13 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,22 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,91 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,99 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,95 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.929 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.550 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.276 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.904 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.538 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.263 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.889 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.524 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.253 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.873 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.506 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.249 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.487 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.239 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,7 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,23 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,98 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,93 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,32 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,2 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,1 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,16 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,88 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,94 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,1 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;160 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;393 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;592 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;158 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;392 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;587 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;158 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;387 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;586 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;156 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;383 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;580 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;378 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;572 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,75 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,75 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,16 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,75 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,47 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,99 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,5 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,46 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,97 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,18 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,62 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.250 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.146 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.920 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.200 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.102 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.891 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.131 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.048 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.863 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;2.019 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.841 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;2.005 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.826 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,78 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,95 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,49 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,71 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,43 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,03 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,08 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,89 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,43 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,1 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.215 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.977 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.437 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.165 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.934 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.410 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.096 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.884 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.389 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.857 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.372 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.844 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.361 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,74 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,82 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,12 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,63 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,3 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,66 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,93 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,48 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,27 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,71 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;35 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;169 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;483 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;35 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;168 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;481 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;35 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;164 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;474 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;162 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;469 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;161 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;465 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,41 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,59 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,04 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,14 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,86 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,1 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,27 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,27 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.123 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.013 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.912 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.087 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.985 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.899 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.962 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.872 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.947 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.856 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.939 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.837 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,3 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,61 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,32 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,47 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,91 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,72 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,07 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,32 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,08 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.090 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.853 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.325 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.054 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.826 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.317 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.804 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.295 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.790 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.285 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.782 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.274 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,28 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,54 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,4 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,36 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,74 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,6 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,98 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,17 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,15 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;33 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;160 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;587 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;33 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;159 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;582 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;158 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;577 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;157 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;571 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;157 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;563 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,38 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,15 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,75 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,3 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,13 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,27 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,13 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,91 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;115 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;106 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;111 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;114 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;103 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;111 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;114 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;102 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;111 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;114 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;101 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;109 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;114 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;109 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,13 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,17 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,13 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,23 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,13 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,28 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,2 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,13 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,34 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,2 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;108 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;66 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;107 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;64 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;107 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;63 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;107 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;63 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;107 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;62 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,07 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,97 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,07 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,45 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,07 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,45 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,07 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,94 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;40 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;39 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;39 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;38 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;38 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,5 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,5 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;114 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;111 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;104 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;113 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;109 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;102 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;112 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;104 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;101 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;111 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;103 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;101 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;103 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;99 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,12 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,2 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,08 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,25 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,69 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,12 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,37 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;92,79 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,12 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,79 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,19 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;99 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;75 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;78 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;98 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;73 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;76 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;97 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;69 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;76 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;96 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;68 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;76 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;68 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;74 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,99 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,33 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,44 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,98 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,44 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,97 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,67 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,44 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;90,67 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,87 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;36 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;26 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;36 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;26 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;35 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;25 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;35 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;25 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;35 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;25 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,22 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,22 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,22 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,15 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;115 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;106 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;107 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;114 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;105 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;105 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;113 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;104 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;105 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;104 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;102 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;104 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;102 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,13 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,06 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,13 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,26 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,11 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,13 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,11 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,33 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,11 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,33 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;108 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;91 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;62 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;107 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;91 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;60 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;106 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;90 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;60 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;90 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;58 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;90 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;58 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,07 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,77 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,15 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,9 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,77 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,9 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,55 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,9 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,55 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;15 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;45 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;14 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;45 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;7 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;14 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;45 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;14 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;44 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;14 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;44 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;93,33 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,33 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,33 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,78 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,33 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,78 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;109 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;110 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;105 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;108 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;108 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;104 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;108 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;108 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;108 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;98 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,08 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,18 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,05 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,18 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,24 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,18 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,24 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,18 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,33 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;104 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;93 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;61 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;103 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;91 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;60 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;91 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;57 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;91 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;57 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;91 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;56 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,04 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,85 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,36 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,85 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;93,44 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,85 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,44 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,85 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;91,8 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;17 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;44 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;17 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;44 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;17 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;43 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;17 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;43 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;17 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;42 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,73 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,73 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,45 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;63 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;59 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;63 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;62 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;58 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;62 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;62 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;58 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;62 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;61 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;55 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;61 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;61 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;55 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;61 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,41 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,31 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,41 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,41 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,31 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,41 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,83 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;93,22 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,83 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,83 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,22 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,83 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;53 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;42 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;52 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;41 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;52 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;41 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;51 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;38 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;51 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;38 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,11 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,62 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,11 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,62 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,23 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;90,48 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,23 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;90,48 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;10 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;17 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;10 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;17 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;10 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;17 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;10 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;17 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;10 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;17 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;66 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;56 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;58 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;65 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;56 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;58 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;62 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;55 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;57 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;62 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;55 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;57 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;55 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;55 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,48 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;93,94 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,21 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,28 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;93,94 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,21 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,28 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,21 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,83 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;54 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;39 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;50 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;53 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;39 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;50 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;50 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;38 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;49 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;50 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;38 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;49 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;38 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;47 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,15 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,59 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,44 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,59 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,44 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,44 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;12 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;17 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;12 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;17 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;12 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;17 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;12 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;17 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;17 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;8 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;59 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;56 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;52 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;58 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;56 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;52 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;58 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;56 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;51 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;56 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;50 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;56 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;50 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,31 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,31 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,08 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,15 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,15 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;54 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;48 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;33 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;53 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;48 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;33 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;53 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;48 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;32 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;48 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;31 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;48 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;31 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,15 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,15 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,97 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,94 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,94 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;5 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;8 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;19 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;5 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;8 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;19 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;5 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;8 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;19 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;8 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;19 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;8 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;19 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;62 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;59 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;58 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;62 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;58 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;55 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;58 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;54 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;58 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;54 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;58 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;53 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,31 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,83 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,31 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;93,1 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,31 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;93,1 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,31 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;91,38 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;57 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;47 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;38 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;57 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;46 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;35 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;46 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;34 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;46 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;34 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;46 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;33 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,87 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,11 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,87 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,47 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,87 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;89,47 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,87 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,84 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;20 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;12 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;20 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;12 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;20 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;12 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;20 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;20 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 12 Castellón/Castelló;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;11.300 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;10.895 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;11.450 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;10.632 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;10.240 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;9.639 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;10.121 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;9.857 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;9.371 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;9.766 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;9.529 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.103 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;9.503 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;9.281 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.844 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,09 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,99 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;84,18 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,57 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,47 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;81,84 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,42 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,46 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,5 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,1 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,19 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;77,24 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;10.571 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9.447 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;9.923 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;8.821 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;9.442 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;8.462 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;9.107 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8.165 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;8.854 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7.937 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,87 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,37 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,32 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,57 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,15 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,43 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,76 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,02 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;729 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.448 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;709 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.419 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;679 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.395 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;659 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.364 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;649 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.344 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,26 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,14 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,34 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,4 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,2 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,03 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,82 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;11.331 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;11.001 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;10.073 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;10.683 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;10.474 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;9.738 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;10.231 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;10.042 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;9.427 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;9.898 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;9.677 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.124 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;9.321 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;8.812 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 13 Ciudad Real;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,28 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,21 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,67 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,29 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,28 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,59 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,35 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,96 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,58 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,73 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,48 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;10.615 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9.634 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7.776 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;10.001 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9.136 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7.458 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;9.565 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;8.732 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7.190 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;9.245 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8.390 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6.936 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8.062 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.672 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,22 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,83 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,91 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,11 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,64 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,46 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,09 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,09 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,2 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,68 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,8 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;716 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.367 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.297 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;682 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.338 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.280 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;666 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.310 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.237 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;653 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.287 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.188 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.259 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.140 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,25 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,88 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,26 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,02 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,83 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,39 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,2 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,15 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,25 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,1 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,16 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11.416 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;11.391 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;10.885 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;10.716 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;10.667 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;10.322 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;10.250 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;10.142 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;9.769 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;9.719 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;9.393 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;9.411 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;9.171 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,87 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,64 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,83 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,79 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,04 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,75 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,32 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,29 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,62 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,25 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.168 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;10.883 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9.187 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;10.478 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10.168 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8.655 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.015 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;9.651 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8.141 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;9.236 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.798 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8.941 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;7.601 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,82 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,43 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,21 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,68 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,68 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,61 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,87 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,88 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,16 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,74 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;248 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;508 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.698 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;238 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;499 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.667 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;235 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;491 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.628 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;483 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.595 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;470 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.570 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,97 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,23 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,17 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,76 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,65 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,88 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,08 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,93 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,52 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,46 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;11.271 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.267 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.018 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;10.652 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;10.580 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;10.244 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;10.096 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;9.771 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;9.718 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;9.489 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;9.420 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;9.206 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,51 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,9 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,98 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,61 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,68 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,25 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,12 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,61 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,55 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.053 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10.505 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9.462 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;10.435 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;9.842 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8.723 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9.381 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;8.284 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9.032 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.025 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;8.750 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7.773 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,41 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,69 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,19 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,3 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,55 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,98 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,81 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,29 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,15 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;218 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;762 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.556 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;217 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;738 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.521 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;715 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.487 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;686 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.464 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;670 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.433 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,54 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,85 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,75 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,83 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,57 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,03 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,09 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,93 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,1 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.691 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.504 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.881 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;8.060 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;7.879 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;7.203 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;7.597 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;7.529 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;6.965 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.266 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.233 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.722 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.015 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.004 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.487 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,74 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,65 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;81,11 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,41 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,53 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;78,43 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,6 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,05 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;75,69 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,72 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,36 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;73,04 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.181 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.674 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.569 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.073 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.133 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.742 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.821 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.466 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.579 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.253 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,52 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,17 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,19 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,86 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,38 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,26 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,42 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,48 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;510 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;830 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;491 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;806 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;464 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;787 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;445 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;767 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;436 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;751 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,27 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,11 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,98 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,82 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,25 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,41 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,49 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,48 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.715 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.558 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.911 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;8.109 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;8.066 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;7.591 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.684 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.664 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.295 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.367 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.327 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.009 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;7.003 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;6.725 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,05 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,25 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,95 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,17 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,55 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,21 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,53 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,62 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,6 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,83 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,01 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.236 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.760 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.471 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.661 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.292 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6.163 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.251 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.909 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.901 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.943 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.591 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.659 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.291 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.411 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,02 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,97 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,24 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,04 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,03 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,19 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,3 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;84,94 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,45 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,07 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,62 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;479 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;798 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.440 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;448 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;774 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.428 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;433 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;755 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.394 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;424 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;736 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.350 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;712 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.314 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;93,53 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,99 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,17 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,4 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,61 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,81 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,52 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,23 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,75 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,22 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,25 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.722 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.791 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.477 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.065 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.110 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.940 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.629 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.630 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.420 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;7.240 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;7.085 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;6.957 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;6.881 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,47 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,25 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,67 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,47 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;86,79 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,53 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,36 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,58 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,14 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,17 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.526 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.488 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.524 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.877 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.814 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7.011 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.443 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.341 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.524 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.958 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.211 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;6.687 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.027 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,39 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,06 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,18 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,3 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;86,49 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,71 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;81,97 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;82,55 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;78,78 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,1 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;196 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;303 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;953 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;188 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;296 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;929 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;186 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;289 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;896 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;282 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;874 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;270 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;854 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,92 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,69 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,48 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,9 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,38 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,02 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,07 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,71 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,11 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,61 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.574 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.672 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.553 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.985 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.028 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;7.815 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;7.581 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;7.379 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;7.240 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;7.121 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.959 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;6.865 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,13 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,57 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,37 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,42 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,27 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,49 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,26 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,25 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;80,26 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.404 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.133 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.677 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.816 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.511 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.970 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.085 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.559 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.770 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.319 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.504 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.084 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,35 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,79 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,11 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,44 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,24 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;82,31 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,97 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;79,25 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;170 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;539 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;876 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;169 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;517 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;845 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;496 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;820 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;470 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;802 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;455 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;781 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,41 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,92 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,46 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,02 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,61 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,2 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,55 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,42 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,16 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.165 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.077 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.160 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.143 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.064 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.075 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.117 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.046 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.062 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.104 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.025 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.047 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.096 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.014 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.030 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,11 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,79 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;92,67 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,88 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,12 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;91,55 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,76 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,17 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;90,26 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,08 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,15 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,79 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.065 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;832 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.044 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;820 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.020 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;804 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.007 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;789 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.000 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;780 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,03 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,56 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,77 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,63 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,55 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,83 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,9 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,75 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;245 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;99 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;244 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;97 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;242 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;97 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;236 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;96 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;234 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,59 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,78 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,33 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,51 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.150 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.097 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;963 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.129 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.080 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;960 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.115 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.059 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;951 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.105 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.041 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;939 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.023 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;926 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,17 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,45 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,69 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,96 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,54 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,75 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,09 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,9 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,51 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,25 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,16 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.050 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;875 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;564 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.031 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;859 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;561 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.017 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;843 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;558 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.010 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;827 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;550 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;811 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;542 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,19 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,17 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,47 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,86 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,34 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,94 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,19 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,51 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,52 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,69 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,1 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;222 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;399 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;98 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;221 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;399 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;98 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;216 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;393 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;95 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;214 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;389 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;212 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;384 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,55 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,3 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,5 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,4 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,49 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,5 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,24 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.190 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.161 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.087 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.167 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.137 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.074 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.146 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.110 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.051 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.095 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.028 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.085 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.018 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,07 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,93 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,8 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,3 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,61 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,69 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,32 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,57 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,45 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,65 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.164 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.071 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;789 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.142 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.048 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;780 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.122 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.021 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;762 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.007 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;745 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;997 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;736 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,11 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,85 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,86 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,39 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,33 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,58 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,02 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,42 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,09 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,28 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;26 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;90 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;298 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;25 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;89 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;294 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;24 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;89 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;289 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;88 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;283 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;88 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;282 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,15 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,89 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,66 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,31 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,89 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,98 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,78 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,97 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,78 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,63 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.211 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.150 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.088 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.191 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.125 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.065 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.105 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.044 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.087 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.030 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.078 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.017 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,35 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,83 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,89 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,09 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,96 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,52 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,67 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,74 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,47 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.186 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.052 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;807 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.166 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.029 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;786 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.010 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;770 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;993 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;758 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;984 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;751 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,31 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,81 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,4 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,01 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,42 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,39 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,93 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,54 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,06 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;25 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;98 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;281 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;25 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;96 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;279 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;95 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;274 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;94 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;272 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;94 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;266 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,96 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,29 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,94 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,51 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,92 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,8 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,92 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,66 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.384 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.258 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.350 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.369 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.241 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.303 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.347 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.226 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.286 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.336 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.215 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.276 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.332 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.207 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.269 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,92 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,65 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,52 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,33 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,46 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,26 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,53 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,58 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,52 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,24 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,95 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.272 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;903 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.257 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;890 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.236 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;878 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.226 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;872 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.222 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;866 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,82 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,56 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,17 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,23 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,38 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,57 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,07 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,9 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;112 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;355 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;112 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;351 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;111 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;348 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;110 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;343 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;110 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;341 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,87 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,11 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,03 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,21 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,62 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,21 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,06 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.404 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.290 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.144 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.383 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.272 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.132 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.370 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.263 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.126 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.364 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.253 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.121 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.239 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.106 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,5 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,6 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,95 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,58 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,91 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,43 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,15 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,13 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,99 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,05 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,68 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.276 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;958 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;698 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.256 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;944 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;691 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.244 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;939 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;688 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.239 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;931 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;684 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;919 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;676 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,43 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,54 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,49 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,02 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,57 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,1 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,18 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,99 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,93 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,85 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;128 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;332 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;446 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;127 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;328 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;441 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;126 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;324 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;438 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;125 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;322 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;437 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;320 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;430 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,22 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,8 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,88 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,44 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,59 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,21 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,66 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,99 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,98 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,39 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,41 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.440 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.381 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.267 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.421 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.362 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.254 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.412 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.344 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.244 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.326 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.226 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.311 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.218 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,68 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,62 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,97 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,06 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,32 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,18 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,02 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,76 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,93 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,13 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.416 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.272 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;840 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.398 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.254 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;830 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.389 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.237 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;821 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.219 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;808 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.205 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;804 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,73 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,58 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,81 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,09 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,25 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,74 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,83 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,19 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,73 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,71 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;24 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;109 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;427 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;23 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;108 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;424 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;23 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;107 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;423 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;107 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;418 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;106 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;414 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,83 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,08 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,3 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,83 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,17 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,06 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,17 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,89 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,25 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,96 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.418 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.383 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.322 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.408 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.365 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.309 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.348 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.293 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.329 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.283 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.321 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.269 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,29 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,7 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,02 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,47 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,81 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,1 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,05 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,52 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,99 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.397 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.267 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;940 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.387 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.249 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;929 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.233 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;917 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.216 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;910 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.209 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;900 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,28 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,58 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,83 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,32 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,55 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,97 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,81 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,42 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,74 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;21 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;116 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;382 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;21 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;116 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;380 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;115 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;376 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;113 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;373 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;112 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;369 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,48 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,14 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,43 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,41 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,64 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,55 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,6 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;45 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;43 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;45 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;45 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;43 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;44 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;45 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;43 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;44 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;45 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;43 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;44 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;45 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;43 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;44 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,78 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,78 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,78 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,78 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;39 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;29 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;39 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;29 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;39 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;29 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;39 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;29 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;39 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;29 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;6 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;14 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;14 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;14 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;14 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;14 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;49 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;43 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;41 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;49 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;43 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;41 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;49 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;43 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;41 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;49 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;43 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;41 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;43 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;41 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;42 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;31 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;32 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;42 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;31 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;32 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;42 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;31 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;32 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;42 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;31 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;32 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;31 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;32 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;12 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;12 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;12 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;9 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;12 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;12 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;49 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;45 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;48 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;45 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;48 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;45 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;45 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;45 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,96 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,96 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;48 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;25 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;47 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;25 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;47 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;25 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;25 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;40 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;25 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,92 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,92 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;5 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;15 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;5 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;15 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;5 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;15 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;5 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;15 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;5 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;15 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;52 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;47 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;41 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;52 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;47 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;41 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;47 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;41 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;47 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;41 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;47 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;41 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;51 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;40 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;28 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;51 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;40 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;28 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;40 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;28 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;40 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;28 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;40 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;28 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;7 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;13 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;7 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;13 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;7 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;13 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;7 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;13 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;13 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;15 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;13 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;14 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;15 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;13 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;14 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;15 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;13 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;14 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;15 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;13 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;14 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;15 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;13 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;14 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;14 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;14 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;14 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;14 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;14 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;14 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;14 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;13 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;14 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;10 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;10 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;10 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;15 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;13 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;15 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;13 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;14 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;15 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;13 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;14 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;13 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;14 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;13 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;14 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;14 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;14 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;12 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;5 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;5 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;5 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;5 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;5 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;16 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;15 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;16 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;15 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;14 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;15 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;14 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;15 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;14 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;15 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;14 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;13 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;15 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;13 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;13 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;13 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;4 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;4 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;4 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 13 Ciudad Real;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;17.117 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;16.422 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;17.499 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;16.036 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;15.374 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;14.558 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;15.302 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;14.779 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;14.017 14 Córdoba;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;14.721 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;14.287 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;13.548 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;14.256 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;13.898 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;13.121 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,68 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,62 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,19 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,4 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;80,1 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;77,42 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,29 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,63 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;74,98 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;16.942 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;15.841 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;15.867 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;14.807 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;15.141 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14.220 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;14.565 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;13.740 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14.103 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13.364 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,65 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,47 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,37 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,77 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,97 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,74 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,24 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,36 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;175 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;581 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;169 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;567 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;161 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;559 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;156 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;547 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;153 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;534 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,57 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,59 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,21 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,14 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,15 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,43 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,91 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;17.216 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;16.484 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;15.279 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;16.197 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;15.620 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;14.616 14 Córdoba;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;15.434 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;14.988 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;14.057 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;14.846 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;14.478 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;13.559 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;13.976 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;13.062 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 14 Córdoba;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,08 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,76 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,66 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,65 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,92 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,23 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,83 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,74 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,79 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,49 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;17.053 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;15.933 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;15.097 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;16.038 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;15.077 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14.435 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;15.282 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;14.456 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.885 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;14.699 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;13.960 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13.391 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;13.474 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12.898 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,05 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,63 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,62 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,61 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,73 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,97 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,2 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,62 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,7 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,57 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,43 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;163 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;551 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;182 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;159 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;543 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;181 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;152 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;532 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;172 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;147 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;518 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;168 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;502 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;164 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,55 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,55 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,45 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,25 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,55 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,51 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,18 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,01 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,31 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,11 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,11 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;17.434 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;17.036 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;16.515 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;16.277 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;15.988 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;15.503 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;15.443 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;15.249 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;14.641 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;14.634 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;14.026 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;14.186 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;13.671 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,36 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,85 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,87 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,58 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,51 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,65 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,9 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,93 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,27 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,78 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;17.371 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;16.878 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16.348 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;16.216 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;15.836 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.345 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;15.385 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;15.098 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.488 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;14.487 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.875 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14.045 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.521 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,35 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,83 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,86 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,57 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,45 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,62 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,83 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,87 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,21 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,71 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;63 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;158 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;167 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;61 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;152 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;158 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;58 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;151 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;153 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;147 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;151 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;141 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;150 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,83 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,2 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;94,61 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,06 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,57 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,62 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,04 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,42 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,24 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,82 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;17.243 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16.989 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;16.632 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;16.121 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;15.938 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;15.381 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;15.183 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;14.635 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;14.642 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;14.193 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;14.164 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;13.795 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,49 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,81 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,48 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,37 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,99 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,19 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,34 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,37 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,94 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;17.185 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;16.781 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;16.468 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16.066 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15.738 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.223 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;14.987 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.479 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;14.454 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;14.037 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;13.980 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.642 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,49 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,78 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,44 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,31 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,92 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,13 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,24 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,31 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,84 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;58 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;208 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;164 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;55 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;200 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;158 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;196 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;156 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;188 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;156 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;184 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;153 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,83 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,15 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,34 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,23 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,12 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,38 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,12 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,46 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,29 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;13.074 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;12.678 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;13.467 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;12.054 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;11.682 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;10.705 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;11.378 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;11.132 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;10.221 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;10.845 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;10.670 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.799 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;10.432 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;10.311 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;9.417 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,2 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,14 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;79,49 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,03 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,81 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;75,9 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;82,95 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,16 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;72,76 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;79,79 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;81,33 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;69,93 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12.968 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;12.403 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11.952 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;11.418 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;11.282 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10.874 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10.752 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;10.419 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;10.341 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;10.068 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,17 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,06 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,67 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,91 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,74 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,17 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;106 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;275 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;102 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;264 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;96 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;258 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;93 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;251 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;91 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;243 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,23 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,57 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,82 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,74 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,27 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,85 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,36 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;13.146 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;12.723 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;11.817 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;12.190 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;11.906 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;11.193 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;11.476 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;11.308 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;10.666 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.953 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;10.833 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;10.198 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;10.382 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;9.740 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,73 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,58 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,72 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,3 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,88 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,26 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,32 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,15 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,3 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,6 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,42 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;13.049 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12.453 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11.748 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;12.096 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;11.644 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11.125 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11.385 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11.053 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10.602 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;10.865 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;10.587 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10.136 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;10.147 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.680 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,7 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,5 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,7 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,25 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,76 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,25 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,26 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,02 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,28 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,48 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,4 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;97 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;270 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;69 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;94 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;262 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;68 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;91 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;255 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;64 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;88 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;246 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;62 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;235 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;60 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,91 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,04 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,55 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,81 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,44 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;92,75 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,72 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,11 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;89,86 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,04 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,96 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;13.284 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;13.088 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12.792 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;12.186 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;12.087 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;11.821 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;11.433 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;11.387 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;11.011 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;10.832 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;10.449 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;10.426 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;10.125 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,73 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,35 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,41 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,07 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;86,08 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,76 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;81,68 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,66 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;79,15 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;13.238 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;13.004 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12.737 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;12.142 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;12.007 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11.771 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;11.390 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;11.308 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10.965 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10.756 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;10.404 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10.353 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10.080 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,72 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,33 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,42 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,04 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;86,96 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,09 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,71 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;81,68 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,61 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;79,14 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;46 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;84 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;55 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;44 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;80 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;50 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;43 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;79 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;46 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;76 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;45 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;73 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;45 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,65 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,24 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;90,91 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,48 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,05 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;83,64 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,48 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;81,82 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,9 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;81,82 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;13.166 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;13.039 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;12.802 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;12.133 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;12.044 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;11.611 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;11.348 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;10.921 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;10.859 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;10.517 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;10.423 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;10.148 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,15 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,37 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;90,7 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,03 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;85,31 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,28 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;82,15 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;79,94 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;79,27 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;13.125 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12.897 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;12.755 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;12.093 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11.910 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;11.569 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;11.218 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10.880 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10.735 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10.476 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;10.301 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.108 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,14 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,35 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,7 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;86,98 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,3 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,24 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;82,13 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,87 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;79,25 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;41 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;142 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;47 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;40 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;134 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;42 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;130 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;41 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;124 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;41 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;122 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;40 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,56 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,37 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;89,36 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,55 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;87,23 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,32 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,23 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,92 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85,11 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.762 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.632 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.713 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.720 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.603 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.594 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.693 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.578 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.568 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.668 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.563 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.541 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.639 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.548 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.516 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,62 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,22 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;93,05 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,08 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,69 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;91,54 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,67 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,77 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;89,96 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,02 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,85 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,5 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.740 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.535 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.699 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.506 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.672 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.482 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.647 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.469 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.619 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.455 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,64 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,11 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,09 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,55 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,66 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,7 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,05 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,79 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;22 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;97 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;21 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;97 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;21 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;96 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;21 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;94 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;20 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;93 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,45 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,45 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,97 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,45 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,91 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,91 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,88 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.774 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.659 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.487 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.748 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.628 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.474 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.722 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.610 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.457 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.685 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.589 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.441 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.559 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.424 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,53 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,13 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,13 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,07 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,05 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,98 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,98 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,78 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,91 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,97 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,76 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.752 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.564 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.457 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.726 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.533 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.444 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.701 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.517 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.429 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.666 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.499 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.415 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.473 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.398 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,52 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,02 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,11 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,09 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,99 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,08 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,09 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,84 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,12 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,18 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,95 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;22 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;95 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;30 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;22 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;95 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;30 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;21 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;93 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;28 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;19 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;90 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;26 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;86 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;26 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,45 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,89 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;93,33 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;86,36 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,74 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;86,67 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,53 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,67 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.831 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.738 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.644 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.796 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.711 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.621 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.750 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.693 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.588 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.654 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.556 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.632 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.539 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,09 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,45 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,6 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,58 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,41 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,59 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,17 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,65 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,9 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,61 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.822 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.714 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.626 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.787 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.687 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.604 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.742 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.669 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.572 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.630 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.540 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.610 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.523 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,08 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,42 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,65 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,61 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,37 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,68 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,1 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,71 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,93 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,67 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;9 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;24 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;18 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;9 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;24 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;17 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;8 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;24 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;16 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;24 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;16 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;22 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;16 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;94,44 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;88,89 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;88,89 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,89 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,67 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,89 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.782 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.760 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.702 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.731 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.725 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.662 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.683 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.627 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.656 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.605 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.637 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.592 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,14 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,01 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,65 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,63 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,59 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,09 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,3 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,01 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,54 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.775 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.735 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.682 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.725 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.700 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.642 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.658 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.607 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.631 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.585 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.613 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.573 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,18 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,98 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,62 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,56 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,54 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,01 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,23 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,97 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,52 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;7 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;25 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;20 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;25 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;20 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;25 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;20 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;25 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;20 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;24 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;19 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;85,71 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.156 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.008 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.205 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.137 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.985 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.145 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.106 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.965 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;2.114 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.084 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.950 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.096 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.063 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.935 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.076 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,12 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,85 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,28 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,68 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,86 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,87 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,66 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,11 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,06 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,69 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,36 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,15 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.113 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.810 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.095 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.790 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.066 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.771 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.046 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.759 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.025 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.748 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,15 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,9 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,78 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,85 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,83 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,18 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,84 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,57 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;43 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;198 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;42 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;195 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;40 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;194 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;38 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;191 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;38 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;187 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,67 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,48 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,02 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,98 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,37 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,46 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,37 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,44 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.171 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.994 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.878 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.134 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.978 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.852 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.112 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.962 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.838 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.086 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.948 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.824 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.927 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.802 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,3 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,2 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,62 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,28 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,4 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,87 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,08 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,69 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,12 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,64 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,95 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.131 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.818 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.801 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.095 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.802 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.775 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.076 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.788 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.764 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.050 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.776 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.750 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.756 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.730 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,31 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,12 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,56 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,42 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,35 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,95 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,2 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,69 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,17 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,59 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,06 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;40 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;176 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;77 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;39 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;176 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;77 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;36 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;174 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;74 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;36 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;172 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;74 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;171 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;72 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,5 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,86 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,1 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,73 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,1 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,16 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,51 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.196 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.102 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.984 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.173 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.082 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.966 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.139 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.061 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.947 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;2.040 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.926 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;2.020 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.913 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,95 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,05 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,09 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,4 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,05 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,14 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,05 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,08 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,1 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,42 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.189 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.056 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.900 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.166 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.038 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.885 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.133 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.017 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.866 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.997 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.846 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.978 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.833 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,95 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,12 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,21 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,44 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,1 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,21 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,13 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,16 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,21 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,47 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;46 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;84 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;44 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;81 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;44 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;81 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;43 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;80 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;42 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;80 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,65 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,43 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;85,71 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,65 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,43 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,48 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,24 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,3 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,24 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.169 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.074 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.026 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.132 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.053 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.006 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;2.036 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.985 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;2.011 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.969 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.989 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.954 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,29 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,99 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,01 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,17 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,98 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,96 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,19 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,9 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,45 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.160 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.036 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.938 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.124 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.015 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.919 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.998 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.899 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.975 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.883 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.954 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.869 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,33 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,97 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,02 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,13 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,99 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,16 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,97 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,44 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;9 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;38 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;88 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;38 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;87 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;38 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;86 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;36 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;86 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;35 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;85 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;88,89 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,86 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,73 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,74 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,73 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,11 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,59 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;80 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;63 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;70 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;80 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;63 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;70 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;80 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;63 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;70 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;80 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;63 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;69 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;78 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;63 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;69 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,57 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,5 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,57 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;77 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;56 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;77 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;56 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;77 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;56 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;77 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;56 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;75 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;56 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,4 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;77 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;69 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;54 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;77 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;69 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;54 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;77 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;69 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;54 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;75 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;69 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;54 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;69 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;54 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,4 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;73 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;62 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;50 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;73 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;62 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;50 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;73 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;62 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;50 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;71 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;62 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;50 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;62 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;50 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,26 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;7 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;7 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;7 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;7 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;7 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;80 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;69 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;58 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;79 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;69 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;58 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;78 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;69 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;58 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;69 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;58 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;69 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;57 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,75 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,5 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,28 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;79 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;66 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;51 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;78 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;66 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;51 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;77 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;66 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;51 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;66 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;51 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;66 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;51 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,73 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,47 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,71 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;83 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;75 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;63 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;82 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;75 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;63 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;75 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;63 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;75 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;63 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;75 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;62 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,8 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,41 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;82 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;73 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;57 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;81 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;73 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;57 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;73 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;57 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;73 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;57 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;73 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;56 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,78 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,25 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;45 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;41 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;44 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;45 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;41 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;44 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;45 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;41 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;44 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;44 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;41 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;43 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;44 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;41 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;43 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,78 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,73 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,78 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,73 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;44 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;37 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;44 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;37 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;44 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;37 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;43 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;37 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;43 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;37 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,73 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,73 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;48 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;39 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;43 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;48 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;39 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;43 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;47 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;39 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;42 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;47 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;39 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;42 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;39 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;42 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,92 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,67 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,92 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,67 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,67 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;48 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;36 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;41 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;48 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;36 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;41 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;47 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;36 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;40 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;47 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;36 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;40 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;36 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;40 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,92 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,56 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,92 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,56 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,56 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;43 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;39 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;37 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;43 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;39 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;37 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;43 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;39 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;37 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;39 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;37 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;39 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;37 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;43 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;38 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;34 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;43 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;38 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;34 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;43 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;38 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;34 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;38 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;34 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;38 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;34 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;43 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;41 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;39 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;43 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;41 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;39 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;41 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;39 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;41 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;39 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;40 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;39 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,56 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;43 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;40 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;36 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;43 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;40 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;36 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;40 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;36 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;40 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;36 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;39 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;36 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,5 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 14 Córdoba;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;28.969 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;28.228 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;29.483 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;27.605 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;26.902 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;26.869 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;26.565 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;26.115 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;26.011 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;25.716 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;25.403 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;25.252 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;25.010 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;24.826 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;24.563 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,29 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,3 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,13 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,7 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,51 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,22 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,77 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,99 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,65 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,33 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,95 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;83,31 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;27.553 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;24.498 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;26.235 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;23.246 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;25.241 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;22.521 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;24.418 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;21.871 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;23.745 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;21.352 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,22 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,89 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,61 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,93 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,62 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,28 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,18 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,16 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.416 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.730 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.370 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.656 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.324 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3.594 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.298 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3.532 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.265 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.474 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,75 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,02 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,5 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,35 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,67 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,69 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,34 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,14 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;28.871 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;28.075 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;27.929 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;27.616 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;27.107 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;26.936 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;26.649 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;26.271 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;26.058 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;25.792 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;25.565 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;25.286 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;24.769 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;24.461 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 15 Coruña, A;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,65 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,55 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,44 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,3 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,57 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,3 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,34 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,06 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,54 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,22 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,58 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;27.482 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;24.396 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;22.319 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;26.272 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;23.495 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;21.397 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;25.338 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;22.733 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;20.653 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;24.511 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;22.092 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;20.014 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;21.390 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;19.334 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,6 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,31 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,87 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,2 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,18 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,54 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,19 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,56 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,67 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,68 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,63 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.389 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.679 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.610 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.344 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.612 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5.539 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.311 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.538 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.405 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.281 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.473 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.272 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.379 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.127 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,76 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,18 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,73 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,38 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,17 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,35 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,22 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,4 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,98 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,85 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,39 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;29.259 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;28.865 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;28.203 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;27.904 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;27.595 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;27.014 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;26.680 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;26.582 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;26.018 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;25.658 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;25.106 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;24.960 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;24.569 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,37 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,6 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,78 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,19 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,09 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,25 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,89 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,02 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,47 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,11 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;28.398 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;27.866 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;24.216 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;27.063 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;26.617 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;23.117 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;25.856 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;25.623 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;22.203 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;24.729 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;21.383 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;24.042 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;20.900 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,3 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,52 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,46 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,05 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,95 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,69 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,74 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,3 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,28 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,31 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;861 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;999 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.987 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;841 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;978 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.897 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;824 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;959 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.815 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;929 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.723 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;918 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.669 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,68 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,9 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,74 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,7 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,69 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,99 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,38 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,89 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,02 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;29.016 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;28.968 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;28.460 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;27.525 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;27.622 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;27.074 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;26.539 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;26.006 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;25.687 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;25.363 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;24.953 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;24.759 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,86 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,35 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,13 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,61 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,38 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,67 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,12 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,14 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;28.257 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;27.469 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;24.879 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;26.781 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;26.167 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;23.566 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;25.143 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;22.573 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;24.332 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;21.975 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;23.621 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;21.427 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,78 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,26 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,72 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,53 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,73 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,58 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,33 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,99 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,12 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;759 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.499 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.581 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;744 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.455 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.508 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.396 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3.433 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.355 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3.388 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.332 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3.332 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,02 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,06 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,96 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,13 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,87 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,39 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,61 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,86 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,05 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;22.390 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;22.043 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;22.801 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;21.090 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;20.783 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;20.317 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;20.136 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;20.067 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;19.520 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;19.334 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;19.403 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;18.823 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;18.678 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;18.874 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;18.201 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,19 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,28 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,11 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,93 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,04 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,61 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,35 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,02 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,55 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,42 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,62 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,83 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;21.442 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;19.945 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;20.184 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;18.741 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;19.272 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18.075 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;18.493 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;17.465 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;17.868 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;16.979 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,13 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,96 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,88 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,62 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,25 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,57 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,33 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,13 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;948 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.098 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;906 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.042 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;864 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.992 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;841 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.938 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;810 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.895 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,57 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,33 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,14 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,95 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,71 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,37 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,44 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,32 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;22.247 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;21.916 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;21.724 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;21.071 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;21.019 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;20.781 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;20.151 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;20.232 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;19.951 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;19.344 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;19.574 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;19.232 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;18.837 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;18.475 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,71 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,91 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,66 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,58 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,32 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,84 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,95 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,31 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,53 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,95 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,04 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;21.290 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;19.718 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;18.248 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;20.152 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;18.874 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;17.366 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;19.261 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;18.154 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;16.650 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;18.481 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;17.552 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;16.037 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;16.894 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;15.398 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,65 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,72 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,17 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,47 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,07 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,24 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,81 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,02 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,88 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,68 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,38 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;957 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.198 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.476 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;919 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.145 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.415 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;890 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.078 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.301 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;863 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.022 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.195 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.943 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.077 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,03 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,59 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,25 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,54 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,97 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,18 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,99 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,92 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,4 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,52 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;22.423 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;22.393 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;21.907 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;21.123 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;21.182 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;20.779 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;19.979 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;20.235 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;19.844 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;19.389 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;19.007 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;18.752 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;18.516 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,2 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,59 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,85 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,1 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,36 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,58 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,59 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,76 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,74 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,52 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;21.823 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;21.854 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19.798 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;20.543 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;20.661 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;18.740 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;19.414 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;19.732 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;17.868 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;18.913 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;17.100 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;18.283 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;16.646 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,13 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,54 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,66 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,96 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,29 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,25 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,54 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,37 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,66 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,08 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;600 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;539 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.109 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;580 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;521 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.039 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;565 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;503 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.976 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;476 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.907 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;469 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.870 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,67 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,66 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,68 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,17 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,32 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,69 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,31 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,42 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,01 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,67 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;22.201 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;22.404 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;22.142 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;20.789 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;21.119 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;20.807 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;20.113 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;19.815 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;19.332 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;19.228 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;18.642 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;18.675 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,64 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,26 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,97 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,77 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,49 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,29 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,84 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,21 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,34 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;21.675 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;21.338 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;20.230 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;20.277 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;20.095 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;18.958 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;19.144 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;18.023 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;18.400 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17.468 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;17.730 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;16.962 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,55 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,17 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,71 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,72 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,09 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,23 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,35 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,09 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,85 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;526 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.066 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.912 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;512 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.024 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.849 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;969 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.792 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;932 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.760 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;912 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.713 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,34 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,06 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,71 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,9 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,72 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,43 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,05 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,55 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,59 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.894 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.713 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.960 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.855 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.687 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.879 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.809 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.646 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.843 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.780 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.623 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.807 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.748 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.592 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.766 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,65 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,04 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,26 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,06 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,53 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,05 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,06 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,68 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,83 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,96 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,54 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,45 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.713 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.094 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.676 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.071 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.631 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.036 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.603 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.018 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.573 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.997 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,64 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,9 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,98 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,23 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,95 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,37 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,84 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,37 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;181 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;619 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;179 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;616 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;178 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;610 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;177 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;605 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;175 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;595 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,9 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,52 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,34 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,55 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,79 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,74 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,69 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,12 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.867 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.656 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.696 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.825 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.613 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.667 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.801 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.587 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.641 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.774 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.556 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.606 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.526 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.579 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,54 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,38 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,92 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,7 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,4 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,96 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,76 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,23 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,66 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,11 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,66 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.695 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.105 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.814 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.658 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.071 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.792 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.637 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.048 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.777 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.613 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.023 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.760 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.999 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.741 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,63 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,38 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,79 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,85 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,29 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,96 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,96 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,1 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,02 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,96 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,98 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;172 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;551 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;882 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;167 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;542 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;875 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;164 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;539 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;864 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;161 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;533 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;846 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;527 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;838 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,09 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,37 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,21 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,35 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,82 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,96 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,6 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,73 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,92 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,64 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,01 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.991 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.857 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.794 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.959 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.828 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.757 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.911 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.785 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.714 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.738 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.683 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.701 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.660 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,93 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,98 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,68 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,33 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,48 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,14 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,83 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,03 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,54 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,2 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.872 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.697 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.102 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.840 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.669 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.079 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.794 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.626 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.048 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.580 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.026 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.546 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.011 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,89 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,96 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,91 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,28 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,37 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,43 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,66 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,38 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,4 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,67 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;119 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;160 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;692 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;119 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;159 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;678 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;117 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;159 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;666 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;158 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;657 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;155 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;649 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,38 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,98 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,32 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,38 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,24 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,75 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,94 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,88 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,79 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.964 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.876 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.768 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.917 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.837 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.734 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.791 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.704 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.753 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.678 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.726 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.656 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,41 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,64 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,77 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,04 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,69 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,72 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,75 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,78 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,95 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.868 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.697 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.191 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.822 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.659 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.161 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.615 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.135 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.579 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.116 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.554 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.098 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,4 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,59 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,63 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,96 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,44 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,62 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,58 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,7 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,76 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;96 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;179 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;577 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;95 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;178 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;573 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;176 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;569 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;174 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;562 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;172 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;558 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,96 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,44 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,31 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,32 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,61 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,21 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,4 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,09 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,71 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.408 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.220 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.433 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.385 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;3.183 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.385 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.345 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;3.153 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.360 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.330 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.128 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.336 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.312 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.111 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.313 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,33 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,85 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,6 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,15 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,92 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,87 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,71 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,14 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,17 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,18 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,61 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,5 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.147 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.282 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.126 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.258 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.089 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.234 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.075 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.212 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.057 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.200 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,33 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,95 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,16 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,9 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,71 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,93 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,14 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,41 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;261 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;938 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;259 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;925 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;256 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;919 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;255 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;916 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;255 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;911 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,23 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,61 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,08 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,97 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,7 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,65 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,7 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,12 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.468 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.241 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.236 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.431 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;3.213 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;3.215 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.411 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.190 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.195 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.388 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.173 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.179 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;3.146 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;3.140 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,93 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,14 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,35 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,36 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,43 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,73 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,69 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,9 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,24 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,07 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,03 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.229 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.378 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.074 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.194 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.355 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.056 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.175 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.336 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.044 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.152 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.322 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.036 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.304 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.014 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,92 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,03 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,13 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,33 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,23 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,55 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,62 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,65 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,17 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,89 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,11 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;239 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;863 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.162 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;237 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;858 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.159 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;236 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;854 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.151 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;236 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;851 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.143 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;842 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.126 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,16 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,42 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,74 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,74 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,96 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,05 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,74 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,61 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,36 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,57 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,9 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.548 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.348 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.240 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.528 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.318 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.218 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.496 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.295 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.202 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.266 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;3.160 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.243 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;3.137 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,44 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,1 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,32 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,53 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,42 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,83 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,55 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,53 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,86 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,82 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.422 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.071 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.149 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.402 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.043 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.131 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.370 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.021 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.121 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.994 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.091 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.972 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.077 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,42 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,09 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,16 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,48 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,37 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,7 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,49 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,3 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,78 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,65 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;126 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;277 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.091 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;126 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;275 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.087 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;126 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;274 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.081 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;272 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.069 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;271 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.060 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,28 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,63 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,92 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,08 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,19 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,98 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,83 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,16 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.562 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.418 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.283 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.530 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.396 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.268 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.367 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.224 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.335 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;3.194 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.320 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.165 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,1 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,36 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,54 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,51 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,2 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,57 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,29 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,13 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,41 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.439 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.186 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.280 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.407 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.165 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.271 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.138 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.239 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.108 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.215 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.094 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.191 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,07 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,34 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,61 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,49 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,2 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,55 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,15 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,11 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,1 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;123 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;232 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.003 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;123 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;231 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;997 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;229 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;985 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;227 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;979 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;226 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;974 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,57 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,4 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,71 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,21 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,84 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,61 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,41 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,11 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;165 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;149 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;179 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;164 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;146 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;178 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;164 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;146 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;178 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;161 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;146 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;176 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;161 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;146 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;174 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,39 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,99 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,44 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,39 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,99 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,44 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,58 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,99 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,32 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,58 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,99 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,21 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;147 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;146 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;95 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;146 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;95 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;144 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;95 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;144 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;95 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,32 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,32 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,96 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;18 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;53 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;18 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;51 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;18 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;51 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;17 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;51 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;17 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;51 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,23 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,23 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,44 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,23 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,44 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,23 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;180 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;157 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;168 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;180 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;157 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;168 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;177 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;157 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;166 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;177 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;157 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;165 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;155 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;163 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,33 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,81 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,33 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,21 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,73 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,02 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;165 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;113 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;101 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;165 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;113 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;101 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;162 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;113 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;162 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;113 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;111 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,18 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,01 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,18 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;99,01 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,23 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;99,01 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;44 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;67 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;44 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;67 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;44 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;66 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;44 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;65 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;44 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;63 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,51 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,01 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,03 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;188 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;160 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;155 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;185 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;160 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;153 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;185 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;160 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;152 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;159 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;150 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;158 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;150 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,4 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,71 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,4 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,06 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,38 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,77 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,75 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,77 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;176 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;143 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;88 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;173 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;143 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;88 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;173 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;143 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;88 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;142 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;88 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;141 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;88 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,3 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,3 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,3 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,6 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;12 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;17 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;67 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;12 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;17 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;65 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;12 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;17 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;64 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;17 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;62 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;17 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;62 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,01 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,52 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,54 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,54 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;180 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;159 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;160 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;180 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;159 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;159 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;158 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;157 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;157 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;157 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;155 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;157 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,38 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,37 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,13 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,74 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,13 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,48 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,13 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;169 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;144 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;95 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;169 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;144 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;94 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;143 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;94 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;142 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;94 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;140 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;94 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,95 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,31 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,95 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,61 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,95 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,22 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,95 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;15 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;65 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;15 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;65 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;15 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;63 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;15 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;63 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;15 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;63 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,92 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,92 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,92 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;112 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;103 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;110 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;111 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;103 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;110 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;111 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;103 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;110 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;111 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;103 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;110 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;111 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;103 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;109 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,11 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,11 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,11 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,11 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;99,09 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;104 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;81 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;103 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;81 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;103 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;81 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;103 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;81 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;103 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;81 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,04 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,04 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,04 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,04 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;22 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;22 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;22 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;22 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;22 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;109 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;109 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;109 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;109 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;104 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;105 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;104 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,05 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;99,05 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;103 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;103 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;103 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;103 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;81 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;82 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;81 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,78 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,78 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;23 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;109 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;107 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;107 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;109 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;107 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;107 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;109 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;107 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;106 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;106 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;106 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;106 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;106 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,07 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,07 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;99,07 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,07 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;99,07 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;105 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;101 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;79 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;105 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;101 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;79 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;105 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;101 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;78 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;78 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;78 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,73 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,01 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,73 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,01 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,73 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;28 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;28 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;28 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;28 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;28 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;109 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;111 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;107 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;109 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;111 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;106 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;110 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;106 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;110 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;106 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;110 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;106 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,07 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,1 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,07 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,1 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,07 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,1 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;99,07 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;106 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;104 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;83 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;106 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;104 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;82 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;103 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;82 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;103 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;82 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;103 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;82 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,8 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,04 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,8 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;99,04 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,8 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;99,04 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,8 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;7 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;24 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;7 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;24 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;7 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;24 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;7 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;24 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;24 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 15 Coruña, A;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.888 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.743 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.987 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;4.598 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;4.471 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;4.380 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;4.383 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;4.310 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;4.219 16 Cuenca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.229 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.167 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.090 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.107 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.072 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.971 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,07 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,27 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,83 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,67 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,87 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,6 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,52 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,86 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,01 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,02 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,85 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,63 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.789 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4.485 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.500 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4.217 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.293 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;4.063 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.139 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.924 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.020 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.830 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,97 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,02 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,64 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,59 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,43 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,49 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,94 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,4 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;99 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;258 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;98 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;254 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;90 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;247 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;90 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;243 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;87 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;242 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,99 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,45 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,91 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,74 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,91 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,19 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,88 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,8 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.860 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.731 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.569 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;4.585 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;4.502 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;4.378 16 Cuenca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.398 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.330 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.235 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.250 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.210 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.103 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;4.054 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.948 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 16 Cuenca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,34 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,16 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,82 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,49 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,52 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,69 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,45 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,99 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,8 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,69 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,41 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.754 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.507 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;4.189 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.490 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4.285 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.004 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.304 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.119 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.866 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.160 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.000 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.741 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.847 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.590 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,45 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,07 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,58 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,53 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,39 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,29 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,51 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,75 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,31 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,36 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,7 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;106 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;224 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;380 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;95 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;217 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;374 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;94 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;211 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;369 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;90 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;210 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;362 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;207 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;358 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;89,62 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,88 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,42 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;88,68 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,2 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,11 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;84,91 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,75 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,26 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,41 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,21 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.908 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.894 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.756 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.597 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.579 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.495 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.410 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.408 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.300 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;4.222 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;4.123 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;4.085 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;4.026 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,66 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,56 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,51 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,85 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,07 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,41 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,27 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,69 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,47 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,65 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.876 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.812 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4.500 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.566 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.499 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.244 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.380 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.328 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4.053 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.144 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.880 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.014 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.788 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,64 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,5 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,31 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,83 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,94 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,07 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,12 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,22 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,42 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,18 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;32 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;82 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;256 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;31 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;80 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;251 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;30 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;80 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;247 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;78 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;243 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;71 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;238 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,88 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,56 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,05 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,75 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,56 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,48 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,12 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,92 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,59 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,97 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.827 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.853 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.782 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.571 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.605 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.497 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;4.391 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;4.278 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;4.221 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;4.156 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.100 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.043 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,7 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,89 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,04 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,48 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,46 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,98 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,91 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,48 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,55 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.805 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.745 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4.545 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.550 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.497 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4.264 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.284 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4.050 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.123 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.932 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.004 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.819 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,69 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,77 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,82 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,28 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,11 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,89 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,51 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,38 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,03 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;22 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;108 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;237 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;21 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;108 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;233 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;107 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;228 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;98 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;224 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;96 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;224 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,45 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,31 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,07 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,2 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,74 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,51 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,89 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,51 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.826 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.773 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.940 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;3.546 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;3.511 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;3.364 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;3.350 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;3.361 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;3.220 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.201 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.228 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.102 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.087 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.141 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.988 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,68 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,06 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,38 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,56 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,08 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;81,73 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,66 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,56 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;78,73 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,68 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,25 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;75,84 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.764 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.641 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.485 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.382 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.297 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.236 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.148 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.106 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.037 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.019 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,59 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,89 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,59 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,88 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,63 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,31 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,69 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,92 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;62 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;132 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;61 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;129 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;53 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;125 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;53 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;122 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;50 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;122 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,39 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,73 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;85,48 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,7 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;85,48 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,42 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;80,65 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,42 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.779 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.741 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.620 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;3.521 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;3.526 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;3.444 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.337 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.364 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.312 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.199 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.254 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.184 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;3.105 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;3.039 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,17 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,25 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,14 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,3 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,92 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,49 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,65 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,98 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,96 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,95 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.713 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.608 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.439 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.466 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.397 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.269 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.283 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.240 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.139 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.149 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.130 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.017 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.984 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.875 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,35 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,15 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,06 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,42 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,8 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,28 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,81 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,75 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,73 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,71 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,6 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;66 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;133 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;181 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;55 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;129 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;175 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;54 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;124 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;173 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;50 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;124 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;167 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;121 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;164 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;83,33 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,99 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;96,69 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;81,82 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,23 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,58 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;75,76 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,23 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,27 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,98 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,61 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.810 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.862 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.776 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.507 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.561 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.527 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.333 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.403 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.340 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;3.226 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;3.174 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;3.095 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;3.085 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,05 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,21 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,41 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,48 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,11 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,45 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,53 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,06 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,14 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,7 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.788 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.807 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.667 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.486 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.508 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.420 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.313 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.350 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.236 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.175 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.074 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.051 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.988 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,03 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,15 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,26 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,46 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,25 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,4 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,83 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,14 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,48 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;22 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;55 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;109 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;21 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;53 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;107 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;20 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;53 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;104 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;51 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;100 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;44 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;97 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,45 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,36 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,17 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,91 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,36 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,41 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,73 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,74 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;80 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,99 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.733 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.821 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.770 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.491 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.585 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.498 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;3.384 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;3.289 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;3.226 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;3.174 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.109 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.069 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,52 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,82 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,79 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,56 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,24 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,43 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,19 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,37 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,41 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.719 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.746 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.662 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.478 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.510 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.393 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.310 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.188 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.161 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.076 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.046 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.971 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,52 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,7 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,65 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,36 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,06 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,38 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,31 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,13 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;14 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;75 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;108 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;13 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;75 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;105 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;74 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;101 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;65 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;98 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;63 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;98 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;92,86 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,22 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,67 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,52 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,67 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,74 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,74 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;454 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;418 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;439 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;448 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;412 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;428 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;441 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;408 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;419 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;439 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;403 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;415 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;434 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;401 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;413 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,68 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,56 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,49 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,14 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,61 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,44 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,7 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,41 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,53 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,59 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,93 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,08 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;446 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;370 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;440 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;365 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;433 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;362 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;431 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;357 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;426 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;355 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,65 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,65 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,09 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,84 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,64 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,49 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,52 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,95 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;48 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;47 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;46 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;46 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;46 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,92 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,83 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,83 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,83 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;463 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;423 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;409 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;458 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;420 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;402 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;457 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;415 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;396 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;450 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;413 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;393 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;410 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;387 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,92 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,29 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,29 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,7 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,11 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,82 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,19 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,64 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,09 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,93 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,62 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;448 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;393 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;337 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;443 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;390 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;330 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;442 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;386 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;324 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;435 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;384 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;322 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;381 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;316 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,88 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,24 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,92 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,66 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,22 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,14 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,1 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,71 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,55 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,95 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,77 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;30 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;72 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;30 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;72 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;29 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;72 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;29 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;71 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;29 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;71 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,67 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,67 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,61 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,67 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,61 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;462 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;443 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;423 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;457 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;434 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;417 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;450 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;430 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;412 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;425 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;405 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;423 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;400 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,92 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,97 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,58 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,4 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,07 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,4 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,94 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,74 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,49 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,56 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;458 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;431 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;370 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;453 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;422 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;364 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;446 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;418 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;360 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;413 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;353 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;411 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;349 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,91 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,91 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,38 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,38 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,98 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,3 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,82 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,41 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,36 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,32 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;12 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;53 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;12 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;53 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;52 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;52 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;51 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,11 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,11 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,23 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;450 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;429 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;442 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;444 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;424 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;435 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;417 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;430 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;413 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;428 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;411 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;425 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,67 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,83 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,42 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,2 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,29 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,27 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,83 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,8 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,15 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;447 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;414 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;397 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;441 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;409 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;391 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;402 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;387 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;398 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;385 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;396 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;382 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,66 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,79 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,49 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,1 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,48 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,14 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,98 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,65 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,22 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;15 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;45 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;15 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;44 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;15 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;43 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;15 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;43 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;15 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;43 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,78 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,56 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,56 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,56 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;580 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;524 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;580 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;576 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;520 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;560 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;564 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;513 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;552 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;561 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;508 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;545 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;558 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;502 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;542 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,31 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,24 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,55 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,24 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,9 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,17 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,72 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,95 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,97 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,21 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,8 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,45 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;554 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;454 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;550 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;450 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;538 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;445 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;535 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;441 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;532 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;436 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,28 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,12 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,11 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,02 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,57 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,14 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,03 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,04 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;26 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;70 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;26 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;70 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;26 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;68 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;26 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;67 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;26 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;66 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,14 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,71 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,29 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;591 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;539 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;514 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;579 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;528 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;506 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;577 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;523 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;501 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;574 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;515 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;500 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;511 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;496 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,97 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,96 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,44 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,63 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,03 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,47 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,12 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,55 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,28 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,81 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,5 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;569 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;486 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;391 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;557 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;478 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;383 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;555 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;473 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;381 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;552 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;466 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;380 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;462 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;377 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,89 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,35 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,95 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,54 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,33 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,44 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,01 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,88 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,19 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,06 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,42 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;22 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;53 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;123 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;22 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;50 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;123 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;22 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;50 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;120 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;22 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;49 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;120 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;49 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;119 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;94,34 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,34 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,56 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,45 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,56 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,45 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,75 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;607 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;561 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;532 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;604 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;556 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;526 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;598 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;547 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;523 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;543 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;519 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;539 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;516 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,51 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,11 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,87 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,52 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,5 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,31 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,79 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,56 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,08 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,99 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;601 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;548 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;443 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;598 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;543 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;440 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;592 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;534 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;437 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;530 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;433 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;526 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;431 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,5 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,09 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,32 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,5 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,45 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,65 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,72 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,74 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,99 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,29 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;89 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;86 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;13 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;86 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;13 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;86 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;13 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;85 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,63 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,63 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,63 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,51 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;615 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;575 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;541 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;607 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;568 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;535 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;562 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;530 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;554 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;525 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;552 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;520 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,7 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,78 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,89 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,74 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,97 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,35 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,04 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,12 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;610 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;558 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;464 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;602 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;551 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;458 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;545 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;453 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;537 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;449 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;535 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;444 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,69 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,75 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,71 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,67 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,63 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,24 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,77 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,88 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,69 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;17 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;77 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;17 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;77 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;17 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;77 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;17 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;76 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;17 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;76 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,7 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,7 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;22 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;22 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;22 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;22 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;22 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;21 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;20 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;20 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;20 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;16 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;20 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;16 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;20 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;16 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;6 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;6 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;6 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;6 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;6 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;20 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;22 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;19 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;20 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;22 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;19 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;20 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;22 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;19 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;20 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;22 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;19 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;22 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;19 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;19 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;17 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;19 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;17 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;19 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;16 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;19 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;16 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;17 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;16 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;17 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;19 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;19 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;19 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;23 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;19 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;23 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;21 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;23 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;21 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;23 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;21 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;15 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;21 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;15 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;21 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;15 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;4 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;4 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;4 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;21 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;21 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;21 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;21 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;21 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;22 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;22 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;21 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;17 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;22 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;21 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;17 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;21 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;17 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;21 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;21 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;6 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;6 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;6 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;6 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;6 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;7 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;4 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;6 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;6 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;6 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;6 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;6 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;7 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;5 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;5 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;5 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;5 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;6 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;7 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 16 Cuenca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;18.363 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;18.167 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;18.694 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;17.560 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;17.426 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;17.442 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;16.850 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;16.876 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;16.953 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.395 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.450 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;16.524 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;16.040 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;16.080 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;16.132 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,63 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,92 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;93,3 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,76 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,89 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;90,69 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,28 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,55 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;88,39 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,35 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,51 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;86,3 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;17.514 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;15.431 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;16.739 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;14.755 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.042 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14.253 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.597 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;13.865 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15.254 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13.535 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,57 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,62 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,6 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,37 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,05 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,85 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;87,1 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,71 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;849 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.736 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;821 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.671 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;808 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.623 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;798 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.585 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;786 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.545 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,7 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,62 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,17 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,87 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,99 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,48 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,58 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,02 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;18.309 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;18.076 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;18.087 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;17.462 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;17.428 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;17.518 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;16.915 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;16.923 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;17.030 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.494 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.486 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.592 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;15.975 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;16.081 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,37 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,42 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,85 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,39 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,62 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,16 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;90,09 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,2 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;91,73 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,38 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,91 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;17.473 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;15.283 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;13.865 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;16.643 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;14.685 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.358 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.108 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;14.221 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;12.957 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;15.703 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;13.827 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12.622 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;13.376 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12.230 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,25 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,09 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,34 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,19 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,05 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,45 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,87 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,47 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;91,03 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,52 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;88,21 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;836 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.793 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4.222 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;819 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.743 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4.160 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;807 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.702 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4.073 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;791 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.659 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.970 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.599 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.851 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,97 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,21 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,53 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,53 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,74 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,47 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,62 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,2 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,03 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,05 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,21 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18.249 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;18.263 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;18.122 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;17.494 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;17.549 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;17.477 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;16.960 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.016 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;16.944 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;16.439 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;16.396 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;16.015 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;16.061 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,86 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;96,09 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,44 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,94 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;93,17 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;93,5 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;90,01 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;90,48 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,69 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;88,63 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;17.506 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;17.501 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15.165 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;16.762 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;16.803 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;14.574 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16.242 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.284 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.106 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.724 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.636 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15.312 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.346 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,75 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;96,01 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,1 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;92,78 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;93,05 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;93,02 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,85 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;89,92 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,49 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;88,01 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;743 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;762 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.957 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;732 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;746 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.903 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;718 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;732 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.838 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;715 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.760 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;703 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.715 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,52 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,9 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,17 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,64 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,06 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,98 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,83 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,34 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,26 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,82 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;18.142 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;18.237 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;18.182 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;17.492 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;17.590 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;17.510 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;16.954 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;16.898 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;16.388 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;16.463 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.987 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;16.086 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,42 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,45 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,3 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,96 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,94 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,86 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;90,55 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,66 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;88,47 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;17.445 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;17.343 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;15.167 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16.808 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;16.711 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;14.556 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;16.095 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.015 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.546 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13.623 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15.167 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.291 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,35 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,36 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,97 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,8 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;92,4 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,64 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;89,82 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;87,45 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;87,63 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;697 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;894 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.015 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;684 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;879 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.954 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;859 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.883 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;842 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.840 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;820 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.795 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,13 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,32 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,98 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,09 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,62 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,18 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,2 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,72 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,7 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;12.918 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;12.941 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;13.145 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;12.175 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;12.246 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;11.975 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;11.529 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;11.752 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;11.536 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;11.108 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;11.366 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;11.145 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;10.788 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;11.033 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;10.800 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,25 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,63 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,1 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,25 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,81 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,76 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,99 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,83 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,79 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,51 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,26 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,16 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12.430 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;11.538 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11.714 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10.900 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;11.079 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10.443 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10.668 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;10.089 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;10.357 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9.788 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,24 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,47 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,13 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,51 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,82 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,44 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,32 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,83 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;488 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.403 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;461 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.346 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;450 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.309 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;440 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.277 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;431 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.245 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,47 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,94 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,21 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,3 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,16 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,02 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,32 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;88,74 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;12.812 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;12.824 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;12.753 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;12.021 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;12.230 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;12.225 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;11.504 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;11.763 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;11.770 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;11.122 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;11.375 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;11.380 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;10.923 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;10.932 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,83 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,37 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,86 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,79 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,73 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,29 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,81 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,7 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,23 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,18 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,72 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;12.353 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;11.428 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10.199 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11.576 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10.874 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9.720 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11.071 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;10.441 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.343 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;10.702 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;10.085 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.037 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;9.677 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;8.685 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,71 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,15 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,3 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,62 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,36 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,61 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,63 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,25 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,61 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,68 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,16 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;459 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.396 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.554 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;445 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.356 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.505 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;433 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.322 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.427 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;420 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.290 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.343 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.246 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.247 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,95 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,13 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,08 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,34 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,7 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,03 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,5 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,41 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,74 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,26 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,98 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;12.651 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;12.846 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12.822 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;11.940 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;12.168 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;12.220 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;11.460 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;11.699 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;11.735 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;11.189 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;11.246 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;10.790 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;10.952 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,38 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,72 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,3 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,59 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,07 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,52 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,1 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,71 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,42 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;12.265 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12.448 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11.232 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;11.565 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;11.785 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;10.679 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;11.096 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;11.327 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10.247 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10.829 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9.818 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10.442 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9.552 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,29 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,67 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,08 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,47 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,99 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,23 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,99 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,41 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,88 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,04 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;386 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;398 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.590 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;375 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;383 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.541 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;364 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;372 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.488 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;360 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.428 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;348 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.400 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,15 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,23 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,92 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,3 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,47 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,58 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,45 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,81 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,44 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,05 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;12.632 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;12.844 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;12.862 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;12.028 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;12.251 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;12.238 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;11.680 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;11.682 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;11.156 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;11.295 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;10.787 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;10.957 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,22 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,38 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,15 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,94 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,83 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,86 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,82 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,98 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,19 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;12.274 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12.324 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;11.384 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;11.680 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11.746 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10.812 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;11.192 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10.312 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10.684 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9.955 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;10.337 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9.653 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,16 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,31 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,98 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,81 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,58 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,69 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,45 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,88 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,79 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;358 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;520 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.478 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;348 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;505 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.426 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;488 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.370 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;472 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.340 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;450 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.304 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,21 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,12 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,48 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,85 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,69 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,77 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,66 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,54 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,23 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.090 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.997 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.108 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.058 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.973 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.061 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.018 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.942 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.034 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.001 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.916 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.013 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.984 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.904 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.993 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,47 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,8 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,77 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,56 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,25 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,49 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,74 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,94 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,49 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,93 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,34 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,54 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.978 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.575 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.946 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.554 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.907 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.528 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.890 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.506 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.874 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.495 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,38 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,67 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,41 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,02 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,55 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,62 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,74 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,92 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;112 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;422 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;112 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;419 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;111 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;414 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;111 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;410 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;110 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;409 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,29 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,11 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,1 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;99,11 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,16 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,21 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,92 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.080 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.005 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.007 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.049 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.977 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.984 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.035 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.960 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.968 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.015 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.936 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.945 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.900 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.912 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,51 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,6 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,85 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,84 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,76 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,06 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,88 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,56 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,91 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,76 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,27 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.974 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.549 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.356 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.944 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.525 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.339 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.930 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.512 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.329 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.911 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.493 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.317 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.466 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.298 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,48 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,45 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,75 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,77 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,61 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,01 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,81 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,38 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,12 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,64 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,72 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;106 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;456 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;651 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;105 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;452 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;645 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;105 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;448 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;639 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;104 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;443 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;628 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;434 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;614 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,06 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,12 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,08 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,06 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,25 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,16 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,11 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,15 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,47 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,18 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,32 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.074 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.091 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.008 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.050 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.071 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.987 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.022 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.039 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.964 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.995 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.933 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.980 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.912 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,84 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,04 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,95 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,49 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,51 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,81 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,41 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,26 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,69 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,22 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.976 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.989 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.554 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.952 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.969 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.535 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.925 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.939 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.518 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.898 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.496 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.883 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.486 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,79 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,99 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,78 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,42 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,49 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,68 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,42 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,27 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,67 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,62 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;98 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;102 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;454 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;98 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;102 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;452 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;97 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;446 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;97 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;437 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;97 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;426 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,56 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,98 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,04 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,24 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,1 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,26 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,1 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,83 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.050 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.072 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.029 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.023 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.039 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.003 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.000 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.976 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.977 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.955 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.959 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.934 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,68 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,41 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,72 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,53 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,39 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,42 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,35 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,55 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,32 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.961 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.954 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.559 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.936 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.921 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.538 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.883 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.520 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.860 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.504 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.842 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.487 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,73 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,31 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,65 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,37 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,5 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,19 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,47 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,27 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,38 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;89 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;118 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;470 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;87 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;118 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;465 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;117 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;456 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;117 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;451 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;117 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;447 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,75 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,94 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,15 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,02 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;99,15 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,96 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;99,15 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,11 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.105 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.988 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.183 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.077 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.967 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.150 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.053 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.942 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.128 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.036 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.929 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.113 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.019 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.907 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.087 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,1 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,3 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,96 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,33 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,46 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,27 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,78 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,03 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,8 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,23 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,29 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,98 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.886 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.157 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.859 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.141 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.836 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.122 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.819 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.111 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.804 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.096 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,06 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,26 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,27 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,38 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,68 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,87 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,16 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,17 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;219 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;831 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;218 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;826 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;217 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;820 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;217 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;818 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;215 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;811 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,54 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,4 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,09 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,68 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;99,09 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,44 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,17 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,59 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.162 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.008 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.082 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.137 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.982 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;3.065 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.121 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.962 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.050 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.103 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.939 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.026 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.916 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.997 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,21 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,14 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,45 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,7 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,47 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,96 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,13 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,71 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,18 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,94 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,24 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.920 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.149 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.132 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.897 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.129 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.121 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.881 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.112 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.108 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.864 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.095 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.092 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.079 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.072 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,21 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,07 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,48 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,66 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,28 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,87 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,08 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,49 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,12 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,74 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,19 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;242 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;859 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;950 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;240 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;853 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;944 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;240 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;850 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;942 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;239 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;844 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;934 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;837 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;925 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,17 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,3 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,37 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,17 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,95 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,16 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,76 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,25 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,32 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,44 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,37 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.277 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.087 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.057 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.257 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.072 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.037 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.231 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.043 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.013 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.020 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.986 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.010 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.966 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,39 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,51 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,35 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,6 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,57 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,56 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,83 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,68 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,51 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,02 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.044 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.851 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.221 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.024 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.837 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.203 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.000 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.809 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.185 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.788 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.167 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.778 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.153 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,34 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,51 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,19 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,55 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,53 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,38 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,79 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,57 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,44 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,94 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;233 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;236 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;836 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;233 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;235 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;834 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;231 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;234 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;828 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;232 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;819 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;232 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;813 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,58 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,76 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;99,14 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,15 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,04 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,31 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,97 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,31 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,25 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.210 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.073 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.053 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.192 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.055 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.032 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.030 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.004 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.011 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.977 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.997 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.960 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,44 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,41 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,31 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,6 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,4 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,98 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,51 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,53 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,95 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.986 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.842 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.071 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.968 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.824 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.054 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.801 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.032 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.783 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.013 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.769 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.001 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,4 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,37 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,18 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,56 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,12 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,92 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,2 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,43 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,62 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;224 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;231 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;982 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;224 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;231 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;978 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;229 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;972 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;228 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;964 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;228 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;959 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,59 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,13 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,98 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,7 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,17 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,7 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,66 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;181 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;172 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;185 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;181 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;171 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;183 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;181 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;171 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;182 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;181 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;171 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;180 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;180 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;168 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;180 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,42 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,92 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,42 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,38 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;99,42 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,3 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,45 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,67 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,3 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;158 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;116 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;158 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;115 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;158 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;115 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;158 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;115 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;157 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;112 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,14 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,14 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;99,14 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,37 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,55 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;23 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;56 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;23 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;56 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;23 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;56 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;23 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;56 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;23 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;56 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;182 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;173 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;176 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;182 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;173 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;175 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;182 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;173 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;173 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;181 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;171 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;173 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;171 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;172 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,43 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,3 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,45 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,84 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,3 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,84 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,73 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;160 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;114 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;132 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;160 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;114 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;132 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;160 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;114 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;131 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;160 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;112 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;131 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;112 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;130 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,24 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,25 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;99,24 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,25 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,48 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;22 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;59 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;44 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;22 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;59 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;43 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;22 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;59 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;42 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;21 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;59 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;42 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;59 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;42 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,73 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,45 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,45 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,45 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,45 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;173 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;171 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;167 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;171 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;167 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;167 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;170 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,84 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,24 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,84 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,24 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,27 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,24 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,27 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;151 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;151 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;118 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;151 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;151 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;117 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;151 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;148 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;117 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;148 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;116 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;148 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;116 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,15 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,01 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,15 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,01 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,31 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,01 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,31 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;55 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;54 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;54 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;54 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;19 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;54 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,18 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,18 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,18 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,18 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;175 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;180 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;172 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;174 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;177 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;172 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;176 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;171 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;176 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;171 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;176 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;170 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,43 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,33 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,78 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,42 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,78 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,42 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,78 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,84 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;156 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;161 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;110 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;156 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;158 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;110 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;157 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;109 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;157 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;109 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;157 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;108 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,14 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,52 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,09 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,52 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;99,09 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,52 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,18 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;19 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;19 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;62 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;18 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;19 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;62 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;19 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;62 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;19 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;62 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;19 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;62 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,74 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;73 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;73 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;73 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;68 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;73 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;69 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;68 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;72 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,55 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,55 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,63 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;62 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;45 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;62 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;45 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;62 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;45 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;62 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;44 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;62 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;44 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,78 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,78 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;24 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;24 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;24 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;24 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;24 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;73 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;66 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;69 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;73 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;66 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;69 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;73 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;65 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;69 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;73 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;65 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;68 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;65 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;68 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,48 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,48 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,55 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,48 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,55 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;66 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;43 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;46 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;66 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;43 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;46 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;66 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;42 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;46 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;66 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;42 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;45 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;42 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;45 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,67 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,67 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,83 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,67 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,83 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;23 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;77 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;69 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;62 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;77 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;68 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;62 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;77 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;68 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;68 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;68 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,55 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,55 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,55 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,55 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;70 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;62 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;40 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;70 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;40 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;70 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;61 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,5 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,5 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,39 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,5 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;22 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;22 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;22 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;22 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;7 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;22 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;75 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;66 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;75 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;65 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;65 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;65 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;65 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,48 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,48 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,48 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,48 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;62 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;43 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;68 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;62 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;42 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;62 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;42 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;62 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;42 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;62 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;42 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,67 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,67 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,67 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,67 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;7 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;6 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;23 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;7 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;6 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;23 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;23 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;23 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;23 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 20 Gipuzkoa;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;23.112 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;22.258 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;23.290 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;21.823 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;21.241 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;20.862 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;20.949 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;20.552 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;20.169 17 Girona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;20.256 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;19.969 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;19.574 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;19.676 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;19.405 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;18.959 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,42 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,43 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,57 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,64 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,34 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,6 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,64 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,72 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,04 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,13 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,18 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,4 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;21.847 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;18.683 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;20.600 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;17.743 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;19.764 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;17.128 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;19.093 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;16.600 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;18.532 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;16.110 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,29 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,97 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,47 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,68 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,39 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,85 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,83 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,23 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.265 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.575 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.223 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.498 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.185 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3.424 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.163 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3.369 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.144 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.295 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,68 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,85 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,68 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,78 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,94 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,24 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,43 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,17 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;23.471 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;22.732 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;21.990 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;22.392 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;21.839 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;21.174 17 Girona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;21.504 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;21.053 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;20.466 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;20.567 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;20.168 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;19.662 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;19.433 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;19.031 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 17 Girona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,4 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,07 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,29 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,62 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,61 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,07 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,63 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,72 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,41 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,49 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,54 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;22.208 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;18.998 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;16.396 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;21.164 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;18.187 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;15.649 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;20.301 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;17.460 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;15.073 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;19.396 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;16.672 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;14.472 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;16.014 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;13.968 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 17 Girona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,3 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,73 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,44 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,41 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,9 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,93 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,34 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,76 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,27 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,29 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,19 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.263 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.734 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.594 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.228 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.652 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5.525 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.203 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.593 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.393 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.171 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.496 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.190 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.419 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.063 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 17 Girona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,23 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,8 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,77 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,25 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,22 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,41 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,72 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,63 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,78 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,56 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,51 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;25.059 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;24.435 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;23.248 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;23.341 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;22.820 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;21.885 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;21.482 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;21.127 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;20.475 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;20.220 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;19.746 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;19.655 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;19.317 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,14 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,39 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,14 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;85,73 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;86,46 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,07 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,75 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,94 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,44 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,09 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;24.236 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;23.276 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19.251 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;22.534 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;21.681 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;17.983 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;20.697 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;20.043 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;16.735 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;19.161 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;16.086 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;18.615 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;15.733 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,98 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,15 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,41 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;85,4 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;86,11 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,93 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,32 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,56 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,98 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,73 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;823 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.159 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.997 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;807 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.139 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.902 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;785 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.084 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.740 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.059 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.660 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.040 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.584 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,06 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,27 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,62 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,38 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,53 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,57 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,37 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,57 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,73 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,67 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;24.357 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;23.907 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;23.224 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;22.297 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;21.950 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;21.344 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;20.910 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;20.497 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;20.226 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;19.965 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;19.637 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;19.468 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;91,54 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,81 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,9 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,46 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,26 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,6 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,97 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,14 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,83 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;23.657 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;22.575 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;19.179 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;21.615 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;20.674 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;17.448 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;19.668 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;16.691 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;19.018 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;16.234 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;18.447 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;15.794 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;91,37 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,58 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,97 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,12 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,03 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,24 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,64 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,71 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,35 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;700 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.332 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4.045 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;682 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.276 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.896 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.242 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3.806 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.208 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3.731 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.190 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3.674 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,43 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,8 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,32 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,24 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,09 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,69 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,24 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,34 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,83 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;17.222 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;16.766 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;17.353 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;16.002 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;15.808 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;15.063 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;15.222 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;15.181 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;14.412 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;14.576 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;14.636 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;13.882 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;14.049 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;14.120 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;13.337 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,92 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,29 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,8 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,39 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,55 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,05 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,64 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,3 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;80 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,58 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,22 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,86 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;16.497 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;14.867 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;15.314 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;13.977 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;14.560 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;13.404 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;13.932 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;12.905 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;13.421 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;12.449 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,83 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,01 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,26 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,16 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,45 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,8 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,35 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,74 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;725 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.899 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;688 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.831 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;662 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.777 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;644 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.731 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;628 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.671 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,9 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,42 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,31 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,58 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,83 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,15 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,62 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,99 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;17.307 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;17.023 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;16.430 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;16.317 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;16.189 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;15.648 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;15.482 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;15.452 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;14.995 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;14.663 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;14.681 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;14.265 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;14.014 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;13.693 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 17 Girona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,28 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,1 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,24 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,46 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,77 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,27 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,72 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,24 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,82 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,32 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,34 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;16.593 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;15.079 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;13.068 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;15.630 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;14.305 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;12.346 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;14.817 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;13.616 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;11.803 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;14.018 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;12.918 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;11.235 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;12.318 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;10.772 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,2 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,87 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,48 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,3 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,3 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,32 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,48 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,67 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,97 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,69 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,43 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;714 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.944 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.362 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;687 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.884 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.302 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;665 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.836 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.192 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;645 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.763 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.030 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.696 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.921 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,22 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,91 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,22 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,14 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,44 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,94 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,34 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,69 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,12 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,24 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,88 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;17.941 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;17.785 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;17.153 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;16.386 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;16.312 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;15.913 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;14.966 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;14.974 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;14.730 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;14.176 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;14.076 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;13.663 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;13.700 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,33 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;91,72 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,77 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;83,42 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;84,19 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;85,87 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;79,71 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;82,06 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;76,82 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;79,87 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;17.469 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;17.240 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15.055 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;15.927 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;15.781 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;13.888 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14.516 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;14.468 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;12.801 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;13.693 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;12.212 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;13.196 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11.889 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,17 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;91,54 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,25 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;83,1 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;83,92 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;85,03 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;79,43 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;81,12 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;76,54 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;78,97 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;472 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;545 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.098 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;459 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;531 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.025 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;450 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;506 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.929 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;483 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.864 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;467 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.811 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,25 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,43 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,52 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,34 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,84 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,94 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,62 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,85 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85,69 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,32 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;17.809 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;17.685 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;17.284 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;16.036 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;15.965 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;15.599 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;15.008 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;14.826 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;14.385 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;14.354 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;13.840 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;13.896 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;90,04 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;90,27 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;90,25 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;84,86 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;85,78 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;81,34 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,05 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;78,26 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;80,4 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;17.421 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;16.894 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;15.211 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;15.659 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15.213 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;13.622 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;14.288 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;12.924 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;13.692 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;12.508 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;13.163 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;12.096 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;89,89 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;90,05 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;89,55 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;84,57 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;84,96 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;81,05 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;82,23 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;77,92 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;79,52 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;388 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;791 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.073 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;377 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;752 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.977 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;720 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.902 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;693 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.846 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;677 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.800 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,16 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,07 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,37 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,02 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,75 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,61 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,05 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,59 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,83 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.469 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.348 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.571 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.429 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.312 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.489 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.381 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.279 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.463 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.355 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.259 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.420 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.327 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.236 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.380 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,38 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,47 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,81 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,44 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,06 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,8 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,38 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,21 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,13 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,25 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,23 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,57 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.279 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.760 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.244 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.729 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.201 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.705 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.177 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.689 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.152 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.670 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,46 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,24 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,58 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,88 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,52 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,97 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,43 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,89 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;190 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;588 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;185 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;583 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;180 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;574 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;178 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;570 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;175 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;566 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,37 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,15 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,74 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,62 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,68 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,94 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,11 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,26 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.546 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.403 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.349 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.507 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.373 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.328 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.477 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.348 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.294 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.416 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.280 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.256 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.238 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.219 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,47 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,75 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,11 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,29 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,71 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,66 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,89 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,88 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,04 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,13 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,47 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.353 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.791 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.480 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.316 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.772 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.466 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.287 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.752 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.445 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.231 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.693 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.426 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.659 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.401 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,43 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,94 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,05 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,2 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,82 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,64 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,82 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,53 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,35 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,63 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,66 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;193 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;612 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;869 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;191 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;601 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;862 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;190 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;596 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;849 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;185 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;587 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;830 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;579 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;818 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,96 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,2 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,19 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,45 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,39 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,7 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,85 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,92 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,51 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,61 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,13 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.963 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.760 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.593 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.876 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.682 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.514 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.651 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.484 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.395 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.415 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.350 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.393 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.320 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,06 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,17 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,95 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,47 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,36 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,5 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;90,63 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,7 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;89,47 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.824 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.573 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.938 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.738 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.498 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.872 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.520 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.312 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.777 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.245 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.740 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.224 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.720 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;96,95 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,09 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,59 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,24 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,86 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,69 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,25 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;89,78 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,44 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;88,75 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;139 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;187 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;655 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;138 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;184 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;642 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;131 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;172 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;618 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;170 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;610 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;169 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;600 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,28 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,4 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,02 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,24 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,98 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,35 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,91 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,13 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,37 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,6 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.731 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.586 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.536 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.575 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.448 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.428 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.395 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.381 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.364 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.345 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.338 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.321 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,29 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,66 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,74 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,61 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;93,89 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;91,42 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;92,47 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;90,41 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;91,52 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.614 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.410 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.876 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.461 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.282 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.787 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.230 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.747 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.202 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.721 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.176 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.702 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,15 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,69 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,26 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,53 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;93,12 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;91,37 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;91,74 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;90,29 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;90,72 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;117 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;176 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;660 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;114 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;166 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;641 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;165 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;634 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;162 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;624 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;162 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;619 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,44 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,32 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,12 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,75 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,06 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,05 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,55 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,05 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,79 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.218 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.959 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.168 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.189 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.938 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.114 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.144 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.909 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.098 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.123 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.891 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.077 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.099 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.866 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.049 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,1 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,29 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,3 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,7 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,31 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,79 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,05 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,7 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,13 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,3 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,86 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,24 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.889 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.948 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.860 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.930 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.822 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.912 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.803 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.899 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.779 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.884 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,08 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,68 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,15 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,02 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,48 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,19 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,71 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;329 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.011 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;329 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.008 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;322 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;997 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;320 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;992 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;320 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;982 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,7 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,87 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,62 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,26 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,12 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,26 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,13 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.407 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.119 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.017 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.357 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;3.090 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;3.004 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.334 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.066 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.983 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.278 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.020 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.947 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.994 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.927 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 17 Girona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,53 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,07 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,57 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,86 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,3 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,87 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,21 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,83 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,68 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,99 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,02 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.082 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.017 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.722 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.038 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.999 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.711 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.017 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.981 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.699 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.968 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.950 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.685 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.926 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.670 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,57 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,11 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,36 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,89 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,22 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,66 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,3 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,68 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,85 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,49 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,98 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;325 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.102 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.295 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;319 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.091 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.293 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;317 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.085 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.284 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;310 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.070 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.262 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.068 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.257 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,15 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,85 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,54 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,46 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,15 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,38 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,1 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,45 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,91 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,07 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.918 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.682 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.305 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.842 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.618 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.261 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.629 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.461 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.153 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.421 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;3.126 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.392 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;3.103 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,06 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,26 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,67 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,62 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;94 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,4 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92,91 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,58 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,12 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,89 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.725 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.297 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.144 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.651 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.236 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.109 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.444 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.097 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.043 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.057 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.022 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.029 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.012 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,01 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,15 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,37 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;92,46 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;93,93 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,29 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;92,72 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,31 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;91,87 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,84 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;193 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;385 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.161 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;191 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;382 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.152 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;185 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;364 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.110 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;364 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.104 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;363 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.091 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,96 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,22 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,22 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,85 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,55 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,61 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,55 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,09 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,29 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,97 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.597 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.435 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.210 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.466 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.336 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.123 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.306 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.098 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.277 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;3.074 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.259 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.059 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,36 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,12 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,29 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,24 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,51 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,4 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,76 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,88 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,3 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.420 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.096 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.988 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.293 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.004 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.935 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.975 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.917 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.949 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.902 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.933 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.893 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,29 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,03 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,33 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,09 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,43 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,25 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,67 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,74 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,22 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;177 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;339 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.222 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;173 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;332 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.188 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;331 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.181 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;328 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.172 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;326 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.166 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,74 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,94 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,22 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,64 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,64 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,76 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,91 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,17 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,42 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;139 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;128 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;143 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;139 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;126 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;141 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;138 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;126 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;141 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;138 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;126 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;140 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;137 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;126 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;138 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,44 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,6 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,28 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,44 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,6 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,28 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,44 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,9 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,56 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,44 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,5 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;123 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;73 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;123 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;72 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;122 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;72 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;122 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;72 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;121 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;72 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,63 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,19 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,63 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,19 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,63 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,37 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,63 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;16 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;55 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;16 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;54 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;16 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;54 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;16 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;54 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;16 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;54 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,18 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,18 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,18 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,18 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;146 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;131 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;142 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;146 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;131 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;142 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;146 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;131 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;142 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;145 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;131 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;142 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;131 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;140 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,32 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,59 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;126 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;73 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;89 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;126 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;73 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;89 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;126 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;73 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;89 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;125 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;73 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;89 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;73 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;88 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,21 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,88 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;20 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;58 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;53 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;20 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;58 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;53 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;20 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;58 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;53 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;20 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;58 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;53 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;58 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;52 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,11 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;171 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;148 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;142 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;171 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;148 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;142 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;170 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;148 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;142 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;148 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;139 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;147 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;139 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,42 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,89 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,32 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,89 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;158 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;115 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;79 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;158 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;115 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;79 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;157 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;115 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;79 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;115 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;77 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;115 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;77 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,37 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,47 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,47 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;13 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;33 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;63 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;13 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;33 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;63 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;13 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;33 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;63 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;33 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;62 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;32 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;62 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,41 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,97 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,41 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;155 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;140 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;140 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;155 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;140 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;140 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;140 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;138 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;139 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;138 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;139 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;138 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,57 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,29 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,57 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,29 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,57 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;142 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;119 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;72 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;142 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;119 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;72 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;119 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;71 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;119 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;71 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;119 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;71 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,61 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,61 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,61 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;13 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;21 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;68 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;13 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;21 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;68 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;21 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;67 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;20 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;67 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;20 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;67 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,53 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,24 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,53 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,24 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,53 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;64 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;57 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;55 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;64 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;57 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;55 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;64 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;57 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;55 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;64 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;57 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;55 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;64 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;57 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;55 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;59 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;35 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;59 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;35 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;59 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;35 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;59 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;35 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;59 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;35 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;5 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;22 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;5 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;22 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;5 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;22 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;5 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;22 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;5 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;22 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;65 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;56 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;52 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;65 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;56 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;52 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;65 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;56 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;52 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;65 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;56 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;52 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;56 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;52 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 17 Girona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;54 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;38 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;37 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;54 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;38 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;37 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;54 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;38 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;37 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;54 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;38 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;37 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;38 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;37 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;11 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;18 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;15 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;11 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;18 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;15 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;11 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;18 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;15 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;11 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;18 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;15 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;18 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;15 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;66 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;60 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;55 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;66 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;60 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;55 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;66 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;60 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;55 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;60 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;55 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;60 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;55 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;60 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;51 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;35 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;60 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;51 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;35 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;60 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;51 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;35 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;51 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;35 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;51 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;35 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;9 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;20 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;9 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;20 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;9 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;20 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;9 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;20 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;9 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;20 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;65 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;61 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;54 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;65 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;61 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;54 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;61 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;54 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;61 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;54 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;61 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;54 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;60 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;56 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;32 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;60 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;56 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;32 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;56 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;32 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;56 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;32 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;56 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;32 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;22 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;22 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;22 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;22 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;5 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;22 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 17 Girona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;20.922 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;19.724 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;21.330 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;19.499 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;18.495 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;17.525 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;18.396 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;17.602 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;16.777 18 Granada;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;17.572 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.909 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;16.138 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;17.013 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;16.361 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.498 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,2 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,77 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;82,16 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,93 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,24 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;78,65 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,99 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,73 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;75,66 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,32 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,95 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;72,66 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;20.140 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;17.303 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;18.746 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16.148 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;17.674 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15.328 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;16.879 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.686 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;16.331 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;14.204 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,08 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,32 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,76 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,59 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,81 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,88 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,09 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,09 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;782 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.421 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;753 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.347 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;722 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.274 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;693 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.223 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;682 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.157 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,29 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,94 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,33 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,93 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,62 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,82 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,21 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,1 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;21.067 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;20.052 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;18.592 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;19.637 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;18.849 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;17.668 18 Granada;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;18.596 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;17.924 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;16.918 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;17.839 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;17.174 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.136 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;16.450 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;15.534 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 18 Granada;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,21 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,03 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,27 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,39 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,68 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,65 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,79 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,04 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,55 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;20.280 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;18.256 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14.635 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;18.897 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;17.129 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.773 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;17.887 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;16.248 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.126 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;17.153 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;15.547 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12.483 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;14.877 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11.983 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 18 Granada;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,18 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,83 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,11 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,2 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,69 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,58 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,16 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,3 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,49 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,88 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;787 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.796 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.957 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;740 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.720 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.895 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;709 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.676 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.792 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;686 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.627 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.653 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.573 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.551 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 18 Granada;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,03 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,77 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,43 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,09 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,32 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,83 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,17 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,59 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,32 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,58 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,74 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;21.224 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;20.643 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19.846 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;19.715 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;19.175 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;18.549 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;18.688 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;18.143 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;17.349 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;17.295 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;16.613 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;16.709 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;16.137 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,89 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,89 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,46 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,05 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,89 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,42 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,78 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,71 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,94 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,31 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;20.635 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;20.048 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;17.132 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;19.147 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;18.606 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.906 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;18.140 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;17.588 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.786 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;16.758 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14.125 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;16.191 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.715 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,79 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,81 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,84 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,91 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,73 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,31 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,59 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;82,45 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,76 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,05 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;589 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;595 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.714 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;568 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;569 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.643 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;548 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;555 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.563 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;537 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.488 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;518 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.422 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,43 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,63 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,38 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,04 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,28 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,44 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,25 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,67 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,06 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,24 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;20.944 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;20.543 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;20.085 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;19.609 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;19.169 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;18.343 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;18.157 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;17.443 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;17.419 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;16.849 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;16.768 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;16.288 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,63 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,31 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,33 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,39 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,85 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,79 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,89 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,62 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,1 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;20.405 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;19.662 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;17.472 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;19.090 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;18.322 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.823 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;17.349 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.999 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;16.651 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;14.468 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;16.028 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.960 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,56 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,18 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,56 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,24 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,85 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,69 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;82,81 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,52 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;79,9 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;539 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;881 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.613 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;519 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;847 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.520 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;808 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.444 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;768 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.381 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;740 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.328 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,29 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,14 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,44 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,71 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,53 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,17 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,12 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,09 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;16.244 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;15.656 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;16.677 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;14.894 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;14.482 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;13.113 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;13.933 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;13.671 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;12.451 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;13.174 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;13.029 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;11.868 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;12.663 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;12.522 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;11.303 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,69 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,5 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;78,63 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;85,77 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,32 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;74,66 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;81,1 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;83,22 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;71,16 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;77,95 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;79,98 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;67,78 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;15.703 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;14.266 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;14.381 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;13.154 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;13.445 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;12.405 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12.713 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.803 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12.212 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.346 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,58 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,21 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;85,62 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;86,95 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;80,96 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;82,74 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;77,77 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;79,53 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;541 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.390 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;513 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.328 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;488 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.266 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;461 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.226 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;451 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.176 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,82 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,54 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,2 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,08 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;85,21 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,2 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,36 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;84,6 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;16.369 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;15.904 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;14.701 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;15.065 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;14.792 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;13.834 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;14.088 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;13.926 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;13.124 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;13.398 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;13.227 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;12.399 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;12.568 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;11.850 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 18 Granada;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,03 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,01 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,1 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;86,07 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;87,56 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;89,27 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;81,85 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;83,17 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;84,34 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;79,02 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;80,61 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;15.806 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;14.814 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;12.249 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;14.542 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;13.761 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11.433 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;13.595 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12.931 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10.817 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;12.927 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;12.273 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10.212 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.658 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.747 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;92,89 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,34 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;86,01 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;87,29 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;88,31 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;81,79 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;82,85 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;83,37 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;78,7 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;79,57 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;563 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.090 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.452 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;523 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.031 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.401 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;493 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;995 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.307 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;471 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;954 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.187 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;910 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.103 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;92,9 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;94,59 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,92 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;87,57 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;91,28 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,09 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;83,66 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;87,52 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;89,19 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;83,49 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;85,77 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;16.483 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;16.263 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;15.681 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;15.039 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;14.859 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;14.435 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;14.103 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;13.906 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;13.320 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;13.131 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;12.647 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;12.595 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;12.204 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,24 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;91,37 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,05 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;85,56 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;85,51 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;84,94 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;80,74 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;80,65 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;77,45 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;77,83 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;16.092 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;15.895 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;14.158 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;14.669 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14.512 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.976 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;13.750 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;13.571 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.927 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12.813 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11.316 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12.293 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10.927 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,16 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;91,3 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;91,65 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;85,45 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;85,38 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;84,24 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;80,61 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;79,93 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;77,34 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;77,18 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;391 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;368 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.523 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;370 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;347 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.459 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;353 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;335 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.393 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;318 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.331 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;302 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.277 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,63 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,29 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95,8 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,28 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,03 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,46 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,41 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;87,39 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;82,07 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;83,85 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;16.225 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16.097 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;15.879 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;14.969 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;14.785 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;14.209 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;13.851 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;13.373 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;13.187 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;12.826 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;12.578 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;12.311 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,26 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,85 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;89,48 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,05 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;84,22 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;81,92 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;80,77 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;78,14 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;77,53 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15.882 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;15.441 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;14.429 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;14.644 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;14.159 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12.837 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;13.261 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;12.063 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12.635 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;11.572 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;12.052 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;11.096 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,21 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,7 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;88,97 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;85,88 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;83,6 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;81,83 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;80,2 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;78,05 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;76,9 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;343 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;656 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.450 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;325 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;626 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.372 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;590 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.310 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;552 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.254 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;526 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.215 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,75 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,43 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,62 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,94 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,34 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;84,15 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;86,48 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;80,18 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;83,79 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.112 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.850 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.085 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.070 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.818 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.922 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.991 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.769 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.873 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.949 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.740 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.843 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.921 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.717 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.813 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,01 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,27 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;92,18 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;94,27 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,62 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;89,83 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;92,28 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,05 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;88,39 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;90,96 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,81 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;86,95 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.022 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.454 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.981 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.428 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.904 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.380 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.863 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.355 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.836 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.339 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,97 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,21 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;94,16 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;94,91 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;92,14 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,19 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;90,8 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,09 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;90 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;396 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;89 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;390 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;87 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;389 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;86 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;385 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;85 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;378 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,89 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,48 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,67 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,23 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,56 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,22 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,44 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,45 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.111 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.883 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.716 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.036 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.832 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.682 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.993 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.795 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.662 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.949 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.767 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.630 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.732 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.591 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,45 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,29 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,02 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;94,41 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;95,33 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,85 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;92,33 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;93,84 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,99 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;91,98 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;92,72 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.032 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.615 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.092 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.960 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.566 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.065 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.918 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.533 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.050 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.874 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.509 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.030 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.478 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.004 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,46 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,97 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,53 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;94,39 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;94,92 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,15 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,22 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,44 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;94,32 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;91,52 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;91,94 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;79 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;268 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;624 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;76 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;266 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;617 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;75 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;262 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;612 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;75 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;258 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;600 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;254 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;587 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,2 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,25 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,88 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,94 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,76 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,08 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,94 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,27 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,15 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,78 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,07 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.091 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.998 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.906 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.049 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.956 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.877 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.996 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.907 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.824 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.871 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.779 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.845 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.761 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,99 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,9 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,48 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,46 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,45 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,7 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,64 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,34 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,34 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,39 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.028 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.909 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.437 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.986 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.868 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.412 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.933 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.820 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.367 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.785 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.331 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.760 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.316 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,93 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,85 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,26 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,32 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,34 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,13 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,5 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;92,62 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,19 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;91,58 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;63 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;89 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;469 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;63 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;88 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;465 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;63 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;87 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;457 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;86 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;448 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;85 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;445 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,88 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,15 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,75 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,44 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,63 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,52 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,51 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,88 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.075 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.983 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.920 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.026 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.945 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.879 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.904 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.834 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.861 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.806 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.836 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.782 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,64 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,08 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,86 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,02 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,52 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;93,85 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,06 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,59 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;92,81 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.008 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.903 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.451 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.960 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.867 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.417 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.827 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.382 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.785 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.356 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.761 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.340 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,61 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,11 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,66 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,01 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,24 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,8 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,45 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,54 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;92,35 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;67 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;80 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;469 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;66 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;78 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;462 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;77 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;452 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;76 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;450 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;75 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;442 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,51 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,5 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,51 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,25 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,38 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,95 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,75 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,24 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.438 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.104 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.449 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.407 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.081 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.372 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.345 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.048 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;2.335 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.322 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.026 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.309 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.302 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.009 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.264 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,73 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,91 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,86 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,19 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,34 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,35 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,24 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,29 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,28 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,42 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,48 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,45 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.296 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.505 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.265 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.488 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.207 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.465 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.185 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.450 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.165 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.442 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,65 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,87 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,12 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,34 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,17 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,35 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,29 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,81 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;142 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;599 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;142 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;593 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;138 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;583 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;137 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;576 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;137 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;567 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,18 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,33 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,48 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,16 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,48 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,66 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.461 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.156 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.068 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.411 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.116 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;2.045 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.390 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.094 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.025 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.367 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.072 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.001 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.042 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.987 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 18 Granada;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,97 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,14 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,89 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,11 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,12 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,92 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,18 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,1 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,76 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,71 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,08 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.332 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.746 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.224 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.286 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.721 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.205 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.265 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.703 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.189 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.243 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.685 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.171 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.661 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.162 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,03 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,57 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,45 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,13 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,54 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,14 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,18 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,51 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,67 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,13 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,93 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;129 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;410 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;844 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;125 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;395 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;840 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;125 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;391 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;836 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;124 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;387 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;830 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;381 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;825 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,9 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,34 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,53 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,9 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,37 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,05 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,12 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,39 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,34 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,93 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,75 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.520 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.266 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.159 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.497 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.244 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.137 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.459 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.215 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.106 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;2.178 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.088 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;2.154 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.073 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,09 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,03 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,98 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,58 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,75 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,55 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,12 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,71 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,06 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,02 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.398 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.140 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.471 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.375 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.122 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.452 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.340 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.094 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.426 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.057 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.412 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.035 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.406 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,04 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,16 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,71 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,58 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,85 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,94 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,12 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,99 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,09 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,58 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;122 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;126 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;688 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;122 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;122 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;685 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;119 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;121 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;680 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;121 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;676 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;119 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;667 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,83 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,56 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,54 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,03 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,84 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,03 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,26 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,44 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,95 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.504 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.342 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.171 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.474 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.319 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.142 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;2.282 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;2.123 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;2.251 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.104 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.234 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.082 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,8 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,02 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,66 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,44 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,79 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,11 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,91 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,39 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,9 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.389 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.209 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.516 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.360 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.188 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.494 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.153 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.479 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.123 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.465 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.107 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.449 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,79 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,05 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,55 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,46 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,56 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,11 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,64 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,38 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,58 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;115 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;133 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;655 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;114 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;131 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;648 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;129 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;644 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;128 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;639 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;127 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;633 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,13 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,5 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,93 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,99 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,32 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,24 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,56 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,49 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,64 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;92 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;77 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;83 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;92 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;77 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;82 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;91 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;77 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;82 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;91 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;77 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;82 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;91 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;76 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;82 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,8 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,91 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,8 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,91 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,8 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,91 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,7 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,8 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;86 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;54 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;86 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;54 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;85 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;54 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;85 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;54 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;85 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;53 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,84 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,84 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,84 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,15 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;6 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;23 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;23 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;23 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;23 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;23 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;87 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;75 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;74 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;86 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;75 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;74 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;86 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;75 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;74 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;86 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;74 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;73 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;74 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;73 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,85 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,85 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,85 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,67 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,65 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,67 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,65 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;77 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;58 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;51 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;76 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;58 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;51 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;76 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;58 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;51 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;76 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;57 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;51 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;57 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;51 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,7 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,7 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,7 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,28 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,28 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;10 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;17 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;10 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;17 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;10 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;17 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;23 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;10 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;17 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;22 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;17 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;22 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,65 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,65 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;97 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;85 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;75 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;97 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;85 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;75 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;97 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;84 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;74 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;84 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;74 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;84 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;74 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,82 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,67 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,82 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,67 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,82 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,67 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;89 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;76 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;52 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;89 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;76 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;52 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;89 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;75 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;52 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;75 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;52 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;75 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;52 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,68 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,68 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,68 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;8 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;9 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;23 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;8 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;9 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;23 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;8 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;9 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;22 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;9 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;22 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;9 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;22 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,65 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,65 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,65 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;103 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;89 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;84 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;103 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;88 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;82 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;88 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;82 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;88 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;82 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;88 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;82 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,88 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,62 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,88 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,62 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,88 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,62 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,88 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,62 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;95 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;81 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;57 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;95 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;80 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;56 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;80 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;56 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;80 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;56 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;80 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;56 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,77 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,25 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,77 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,25 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,77 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,25 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,77 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,25 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;27 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;26 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;26 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;26 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;26 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,3 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,3 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,3 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,3 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;36 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;37 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;37 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;37 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;37 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;37 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;36 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;33 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;24 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;33 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;24 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;33 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;24 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;33 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;24 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;33 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;24 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;13 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;13 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;13 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;13 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;13 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;39 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;34 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;33 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;39 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;34 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;33 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;39 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;34 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;33 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;39 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;34 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;33 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;34 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;33 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 18 Granada;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;33 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;23 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;19 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;33 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;23 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;19 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;33 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;23 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;19 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;33 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;23 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;19 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;23 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;19 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;11 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;14 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;11 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;14 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;11 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;14 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;11 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;14 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;11 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;14 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;33 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;31 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;25 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;33 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;31 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;25 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;33 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;31 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;25 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;31 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;25 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;31 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;25 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;14 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;14 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;28 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;14 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;5 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;11 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;5 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;11 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;5 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;11 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;11 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;11 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;37 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;32 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;31 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;37 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;32 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;31 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;32 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;31 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;32 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;31 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;32 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;31 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;31 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;28 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;19 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;31 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;28 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;19 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;28 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;19 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;28 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;19 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;28 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;19 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;4 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;12 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;12 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;12 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;12 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;12 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 18 Granada;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.812 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.558 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.744 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;4.535 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;4.306 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;4.166 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;4.311 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;4.161 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;4.025 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.129 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.020 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.903 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.018 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.915 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.774 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,24 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,47 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,82 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,59 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,29 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,84 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,81 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,2 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,27 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,5 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,89 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,55 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.577 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4.033 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.305 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.796 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.088 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.657 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.912 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.532 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.803 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.435 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,06 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,12 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,32 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,68 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,47 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,58 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,09 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,17 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;235 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;525 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;230 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;510 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;223 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;504 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;217 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;488 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;215 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;480 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,87 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,14 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,89 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,34 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,95 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,49 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,43 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.812 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.573 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.361 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;4.538 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;4.367 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;4.190 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.320 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.180 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.043 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.182 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.049 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.894 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.919 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.764 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 19 Guadalajara;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,31 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,5 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,08 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,78 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,41 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,71 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,91 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,54 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,29 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,7 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,31 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.585 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.012 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.394 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.317 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.812 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.234 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.106 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.642 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.109 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.969 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.521 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.993 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.402 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.891 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,15 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,01 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,29 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,55 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,78 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,6 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,56 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,76 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,19 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,8 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,18 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;227 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;561 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;967 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;221 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;555 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;956 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;214 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;538 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;934 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;213 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;528 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;901 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;517 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;873 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,36 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,93 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,86 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,27 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,9 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,59 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,83 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,12 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,17 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,16 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,28 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.847 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.727 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.513 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.547 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.429 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.285 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.359 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.260 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.100 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;4.106 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.946 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.974 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.846 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,81 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,7 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,95 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,93 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,12 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,85 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,86 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,44 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,07 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,22 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.650 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.525 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.887 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.356 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.235 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.672 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.169 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.070 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.503 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.921 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.365 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.793 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.271 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,68 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,59 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,47 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,66 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,94 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,12 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,65 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,57 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,82 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,15 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;197 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;202 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;626 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;191 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;194 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;613 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;190 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;190 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;597 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;185 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;581 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;181 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;575 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,95 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,04 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,92 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,45 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,06 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,37 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,58 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,81 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,6 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,85 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.788 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.689 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.564 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.539 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.466 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.299 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;4.279 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;4.105 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;4.114 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.985 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.963 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.875 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,8 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,24 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,19 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,26 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,94 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,74 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,31 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,52 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,9 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.612 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.433 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.992 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.364 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.218 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.743 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.036 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.562 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.881 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.450 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.737 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.356 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,62 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,15 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,76 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,04 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,23 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,55 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,42 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,3 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,07 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;176 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;256 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;572 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;175 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;248 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;556 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;243 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;543 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;233 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;535 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;226 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;519 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,43 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,88 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,2 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,92 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,93 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,02 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,53 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,28 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,73 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.724 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.566 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.663 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;3.456 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;3.322 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;3.134 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;3.258 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;3.186 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;3.013 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.096 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.058 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.902 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.991 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.967 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.787 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,8 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,16 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,56 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,49 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,34 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,25 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,14 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,75 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,22 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,32 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,2 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,09 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.581 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.289 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.317 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.058 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.126 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.928 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.969 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.813 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.866 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.729 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,63 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,98 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,29 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,02 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,91 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,53 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,03 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,97 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;143 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;277 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;139 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;264 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;132 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;258 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;127 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;245 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;125 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;238 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,2 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,31 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,31 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,14 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,81 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,45 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,41 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,92 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.719 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.573 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.405 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;3.468 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;3.377 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;3.249 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.270 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.198 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.108 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.142 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.081 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.971 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;2.960 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;2.851 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,25 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,51 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,42 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,93 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,5 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,28 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,49 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,23 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,25 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,84 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,73 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.573 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.256 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.788 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.328 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.066 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.642 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.136 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.902 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.522 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.008 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.794 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.412 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.682 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.317 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,14 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,16 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,76 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,77 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,13 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,46 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,19 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,81 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,51 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,37 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,11 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;146 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;317 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;617 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;140 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;311 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;607 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;134 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;296 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;586 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;134 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;287 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;559 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;278 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;534 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,89 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,11 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,38 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,78 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,38 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,98 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,78 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,54 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,6 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,7 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,55 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.736 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.679 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.540 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.452 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.393 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.319 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.278 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.239 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.146 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;3.095 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;3.005 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;2.978 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;2.913 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,4 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,23 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,76 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,74 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,04 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,87 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,13 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,89 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,95 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,29 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.608 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.565 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.210 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.330 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.286 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.001 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.156 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.135 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.842 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.994 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.713 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.879 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.625 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,29 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,17 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,49 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,47 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,94 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,54 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,98 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,52 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,76 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,78 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;128 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;114 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;330 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;122 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;107 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;318 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;122 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;104 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;304 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;101 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;292 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;99 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;288 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,31 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;93,86 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,36 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,31 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,23 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,12 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,6 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,48 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,84 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;87,27 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.716 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.628 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.583 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.473 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.416 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.329 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;3.238 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;3.145 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;3.090 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;3.030 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.954 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.931 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,46 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,16 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,91 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,25 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,78 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,17 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,57 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,42 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,8 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.604 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.469 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.278 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.361 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.265 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.040 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.092 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.866 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.953 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.758 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.823 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.673 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,26 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,12 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,74 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,13 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,43 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,13 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,14 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,38 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,54 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;112 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;159 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;305 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;112 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;151 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;289 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;146 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;279 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;137 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;272 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;131 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;258 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,97 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,75 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,82 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,48 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,16 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,18 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,39 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;84,59 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;498 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;444 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;487 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;494 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;440 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;459 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;480 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;436 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;448 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;465 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;426 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;441 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;461 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;418 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;432 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,2 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,1 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;94,25 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,39 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,2 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;91,99 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;93,37 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,95 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;90,55 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,57 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,14 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,71 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;454 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;353 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;451 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;350 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;437 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;346 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;422 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;338 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;418 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;330 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,34 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,15 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,26 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,02 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;92,95 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,75 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,07 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,48 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;44 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;91 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;43 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;90 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;43 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;90 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;43 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;88 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;43 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;88 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,73 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,9 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,73 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,9 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,73 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,7 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,73 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,7 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;484 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;440 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;426 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;472 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;434 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;417 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;456 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;430 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;415 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;449 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;422 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;406 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;417 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;400 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,52 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,64 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;97,89 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;94,21 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,73 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,42 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;92,77 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,91 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,31 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,77 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,9 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;445 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;354 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;268 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;433 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;348 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;259 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;417 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;345 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;257 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;411 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;337 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;254 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;334 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;250 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,3 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,31 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,64 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;93,71 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,46 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,9 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,36 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,2 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;94,78 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,35 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,28 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;39 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;86 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;158 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;39 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;86 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;158 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;39 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;85 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;158 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;38 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;85 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;152 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;83 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;150 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,84 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,44 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,84 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,2 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,51 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,94 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;481 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;467 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;441 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;472 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;461 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;436 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;463 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;454 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;428 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;447 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;420 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;440 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;416 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,13 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,72 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,87 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,26 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,22 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,05 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,72 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,24 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,22 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,33 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;453 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;435 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;329 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;444 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;430 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;325 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;436 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;423 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;319 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;418 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;314 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;412 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;310 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,01 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,85 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,78 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,25 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,24 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,96 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,09 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,44 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,71 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,22 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;28 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;32 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;112 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;28 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;31 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;111 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;27 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;31 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;109 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;29 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;106 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;28 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;106 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,88 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,11 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,43 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,88 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,32 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,63 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,64 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,5 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,64 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;467 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;484 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;424 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;462 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;478 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;419 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;473 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;414 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;466 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;412 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;457 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;405 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,93 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,76 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,82 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,73 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,64 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,28 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,17 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,42 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,52 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;439 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;446 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;340 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;435 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;440 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;335 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;435 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;332 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;428 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;330 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;419 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;324 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,09 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,65 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,53 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,53 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,65 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,96 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,06 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,95 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,29 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;28 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;38 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;84 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;27 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;38 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;84 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;38 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;82 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;38 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;82 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;38 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;81 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,43 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,62 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,62 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,43 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;538 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;502 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;543 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;533 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;498 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;523 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;521 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;493 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;514 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;517 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;491 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;510 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;515 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;485 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;505 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,07 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,2 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,32 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,84 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,21 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,66 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,1 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,81 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,92 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,72 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,61 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;495 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;371 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;490 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;368 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;478 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;363 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;474 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;361 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;472 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;356 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,99 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,19 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,57 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,84 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,76 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,3 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,35 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,96 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;43 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;131 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;43 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;130 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;43 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;130 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;43 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;130 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;43 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;129 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,24 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,24 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,24 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,47 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;556 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;513 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;484 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;545 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;509 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;478 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;542 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;506 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;474 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;539 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;500 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;471 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;496 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;467 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,02 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,22 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,76 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,48 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,64 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,93 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,94 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,47 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,31 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,69 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,49 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;521 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;377 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;308 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;510 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;373 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;303 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;507 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;370 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;300 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;504 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;365 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;297 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;361 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;294 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,89 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,94 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,38 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,31 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,14 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,4 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,74 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,82 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,43 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,76 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,45 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;35 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;136 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;176 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;35 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;136 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;175 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;35 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;136 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;174 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;35 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;135 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;174 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;135 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;173 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,43 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,86 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,26 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,86 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;99,26 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,3 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;576 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;532 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;485 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;570 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;526 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;483 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;565 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;519 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;479 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;516 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;474 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;508 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;470 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,96 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,87 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,59 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,09 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,56 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,76 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,99 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,73 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,49 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,91 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;540 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;486 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;325 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;534 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;480 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;323 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;529 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;473 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;319 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;470 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;315 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;463 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;313 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,89 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,77 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,38 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,96 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,33 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,15 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,71 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,92 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,27 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,31 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;36 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;46 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;160 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;36 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;46 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;160 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;36 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;46 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;160 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;46 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;159 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;45 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;157 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,38 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,83 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,13 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;551 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;526 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;509 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;550 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;521 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;503 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;517 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;498 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;507 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;495 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;502 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;492 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,82 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,05 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,82 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,29 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,84 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,39 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,25 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,44 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,66 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;520 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;476 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;352 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;519 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;471 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;346 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;467 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;342 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;458 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;340 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;453 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;337 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,81 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,95 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,3 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,11 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,16 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,22 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,59 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,17 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,74 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;31 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;50 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;157 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;31 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;50 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;157 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;50 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;156 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;49 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;155 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;49 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;155 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,36 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,73 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,73 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;35 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;29 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;34 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;35 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;29 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;33 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;35 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;29 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;33 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;34 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;29 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;33 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;34 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;29 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;33 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,06 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,06 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,14 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,06 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,14 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,06 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;32 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;15 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;32 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;32 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;32 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;15 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;32 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;15 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;14 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;14 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;14 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;14 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;14 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;66,67 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;66,67 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;36 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;36 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;35 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;35 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;30 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,22 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,22 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;33 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;19 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;22 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;33 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;19 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;22 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;33 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;19 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;22 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;33 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;19 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;22 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;19 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;22 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;11 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;11 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;11 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;11 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;11 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;8 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;66,67 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;66,67 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;37 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;33 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;31 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;36 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;33 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;31 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;36 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;32 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;31 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;32 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;31 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;32 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;31 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,3 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,3 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,97 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,97 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,97 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;35 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;27 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;34 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;27 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;19 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;34 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;27 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;19 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;27 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;19 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;27 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;19 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,14 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,14 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;12 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;12 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;5 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;12 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;5 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;12 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;5 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;12 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;83,33 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;83,33 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;83,33 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;37 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;34 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;32 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;37 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;34 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;32 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;34 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;32 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;34 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;32 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;33 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;32 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,06 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;35 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;31 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;17 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;35 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;31 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;17 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;31 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;17 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;31 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;31 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;15 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;15 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;15 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;15 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;15 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;66,67 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;16 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;16 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;17 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,12 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,12 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;15 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;15 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;15 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;12 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;12 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;12 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;11 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;11 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,67 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,67 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;17 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;17 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;17 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;17 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;17 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;17 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;16 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;94,12 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,12 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,12 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;13 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;8 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;13 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;13 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;8 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;13 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;8 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;8 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;11 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;11 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;10 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;10 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;10 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;8 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;90,91 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,91 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,91 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;17 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;17 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;17 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;16 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;14 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;14 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;12 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;12 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;12 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;12 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;12 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;12 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;16 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;16 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;16 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;16 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;17 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;15 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,75 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;14 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;11 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;14 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;11 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;11 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;11 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;6 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;11 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;6 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;11 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;11 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;11 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;10 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,91 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 19 Guadalajara;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;10.057 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;9.440 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;9.975 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;9.355 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;8.740 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;7.978 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;8.876 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;8.368 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;7.707 21 Huelva;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;8.505 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;8.058 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.455 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;8.168 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.791 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.182 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,02 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,58 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;79,98 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,26 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,64 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;77,26 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,57 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,36 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;74,74 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,22 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,53 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;72 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;9.669 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8.569 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.982 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.891 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;8.517 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7.545 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;8.153 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7.250 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.824 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.995 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,89 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,09 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,09 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,05 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,32 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,61 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,92 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,63 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;388 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;871 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;373 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;849 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;359 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;823 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;352 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;808 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;344 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;796 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,13 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,47 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,53 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,49 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,72 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,77 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,66 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,39 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;10.227 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;9.660 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.526 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;9.560 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;9.120 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;8.163 21 Huelva;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;9.046 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.652 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.830 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;8.551 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;8.238 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.482 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;7.905 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;7.162 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 21 Huelva;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,48 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,41 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,74 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,45 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,57 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,84 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,61 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,28 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,76 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,83 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;9.852 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;8.767 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.842 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;9.200 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;8.256 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6.499 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8.693 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7.804 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;6.187 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8.208 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;7.405 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.902 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;7.094 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.634 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,38 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,17 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,99 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,24 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,02 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,43 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,31 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;84,46 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,26 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;80,92 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,34 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;375 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;893 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.684 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;360 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;864 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.664 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;353 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;848 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.643 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;343 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;833 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.580 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;811 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.528 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,75 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,81 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,13 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,96 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,57 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,47 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,28 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,82 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,82 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,74 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;10.618 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;10.378 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;9.873 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;9.685 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;9.418 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;9.050 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;8.944 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.784 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;8.347 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;8.371 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;7.906 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;8.110 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.681 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,21 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;90,75 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;91,66 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;84,23 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;84,64 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;84,54 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;80,66 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;80,08 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;78,15 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;77,8 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;10.321 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;10.090 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8.954 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;9.393 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;9.134 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8.141 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;8.658 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8.506 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;7.464 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8.102 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.048 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.848 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.842 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,01 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;90,53 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;90,92 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;83,89 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;84,3 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;83,36 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;80,3 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;78,71 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;77,78 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;76,41 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;297 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;288 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;919 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;292 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;284 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;909 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;286 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;278 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;883 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;269 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;858 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;262 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;839 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,32 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,61 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,91 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,3 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,53 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,08 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,4 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,36 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,97 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,29 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;10.343 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;10.089 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;9.839 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;9.411 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;9.262 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.834 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;8.755 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;8.300 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;8.424 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;8.024 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;8.134 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.771 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;90,99 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,8 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;89,79 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,78 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;84,36 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,5 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;81,55 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,62 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;78,98 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;10.059 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;9.659 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;8.988 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;9.133 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;8.841 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8.013 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;8.347 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7.501 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;8.031 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7.246 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.751 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7.008 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;90,79 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,53 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;89,15 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;86,42 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;83,46 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,15 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;80,62 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,25 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;77,97 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;284 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;430 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;851 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;278 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;421 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;821 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;408 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;799 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;393 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;778 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;383 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;763 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,89 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,91 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,47 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,88 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,89 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,4 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,42 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,07 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,66 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;7.877 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;7.515 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;7.836 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;7.216 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;6.857 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;6.003 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;6.773 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;6.522 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.763 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.433 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;6.227 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.526 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.128 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.986 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.279 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,61 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;91,24 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;76,61 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;85,98 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;86,79 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;73,55 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;81,67 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;82,86 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;70,52 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;77,8 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;79,65 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;67,37 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.620 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.022 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.973 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.384 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.542 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.069 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.207 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.787 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.910 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.554 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,51 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;90,91 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;85,85 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;86,43 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;81,46 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;82,41 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;77,56 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;79,09 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;257 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;493 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;243 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;473 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;231 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;453 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;226 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;440 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;218 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;432 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,55 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,94 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;89,88 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,89 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,94 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,25 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,82 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,63 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;7.984 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.651 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.797 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;7.350 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;7.146 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;6.453 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.873 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;6.701 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;6.137 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.426 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;6.340 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.818 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;6.036 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;5.519 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 21 Huelva;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,06 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,4 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,94 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;86,08 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;87,58 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,29 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;80,49 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;82,86 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;85,6 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;78,89 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;81,2 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7.739 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.117 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.691 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.119 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.638 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.364 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.647 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.207 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.066 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.209 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.857 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.801 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.571 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.548 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;91,99 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,27 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,25 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;85,89 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;87,21 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,02 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;80,23 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;82,3 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;84,36 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;78,28 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;79,92 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;245 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;534 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.106 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;231 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;508 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.089 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;226 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;494 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.071 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;217 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;483 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.017 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;465 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;971 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,29 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,13 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,46 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,24 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,51 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,84 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,57 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,45 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,95 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,08 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,79 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.078 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;7.994 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;7.713 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;7.237 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;7.118 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.971 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.632 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;6.604 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;6.374 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;6.240 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.981 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;6.003 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;5.785 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;89,59 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;89,04 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;90,38 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;82,1 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;82,61 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;82,64 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;78,06 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;77,54 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;75,09 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;75 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;7.898 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.834 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.217 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.061 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.962 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.482 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6.461 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;6.453 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.903 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.096 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.530 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.865 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.347 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;89,4 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;88,87 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;89,82 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;81,81 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;82,37 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;81,79 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;77,81 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;76,62 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;74,87 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;74,09 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;180 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;160 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;496 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;176 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;156 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;489 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;171 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;151 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;471 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;144 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;451 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;138 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;438 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,78 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,5 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,59 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,38 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,96 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,93 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,25 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,31 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.011 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;7.859 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;7.764 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.172 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;7.118 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.831 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;6.649 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;6.346 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;6.347 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;6.102 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.085 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.863 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;89,53 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;90,57 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;87,98 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;84,6 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;81,74 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;80,76 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;78,59 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;77,43 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;75,52 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7.841 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.569 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.298 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.007 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.834 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.386 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.376 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.920 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.088 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.691 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.835 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5.465 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;89,36 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;90,29 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;87,5 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;84,24 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;81,12 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;80,43 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;77,98 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;77,09 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;74,88 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;170 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;290 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;466 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;165 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;284 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;445 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;273 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;426 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;259 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;411 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;250 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;398 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,06 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,93 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,49 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,14 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,42 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,31 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,2 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,21 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85,41 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.021 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;897 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.025 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;996 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;871 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;911 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;970 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;846 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;891 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;949 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;833 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;878 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;929 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;821 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;862 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,55 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,1 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,88 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;94,31 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,93 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;92,95 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;92,87 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,66 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;90,99 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;91,53 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;84,1 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;964 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;768 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;939 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;743 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;915 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;722 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;895 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;710 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;875 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;699 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,41 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,74 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;94,92 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;94,01 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;92,84 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;92,45 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;90,77 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;91,02 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;57 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;129 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;57 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;128 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;55 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;124 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;54 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;123 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;54 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;122 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,22 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,49 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,12 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,74 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,35 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,74 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,57 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.052 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;949 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;772 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.026 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;927 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;761 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;998 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;910 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;748 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;972 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;874 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;729 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;855 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;719 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,53 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,68 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,58 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;94,87 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;95,89 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,89 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;92,4 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;92,1 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,43 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;90,09 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,13 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.003 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;819 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;531 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;978 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;800 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;522 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;951 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;784 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;511 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;925 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;749 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;496 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;732 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;489 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,51 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,68 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,31 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;94,82 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;95,73 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,23 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,22 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;91,45 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;93,41 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;89,38 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;92,09 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;49 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;130 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;241 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;48 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;127 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;239 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;47 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;126 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;237 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;47 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;125 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;233 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;123 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;230 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,96 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,69 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,17 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,92 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,92 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,34 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,92 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,15 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,68 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,62 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,44 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.187 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.110 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.013 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.131 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.054 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;960 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.061 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.000 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;900 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;967 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;870 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;951 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;850 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,28 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,95 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,77 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,39 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,09 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,85 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,12 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,88 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,68 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,91 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.141 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.068 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;869 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.085 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.012 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;817 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.015 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;959 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;761 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;927 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;733 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;912 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;717 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,09 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,76 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,02 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,96 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,79 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,57 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,8 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,35 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,39 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,51 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;46 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;42 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;144 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;46 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;42 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;143 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;46 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;41 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;139 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;40 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;137 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;39 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;133 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,31 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,62 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,53 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,24 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,14 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,86 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,36 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.093 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.062 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;989 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.037 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.012 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;938 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;987 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;911 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;962 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;889 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;941 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;880 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,88 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,29 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,84 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,94 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,11 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;90,58 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,89 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;88,61 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;88,98 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.048 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.004 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;853 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;992 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;956 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;808 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;931 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;782 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;907 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;762 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;886 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;754 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,66 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,22 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,72 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,73 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,68 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;90,34 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;89,33 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;88,25 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;88,39 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;45 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;58 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;136 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;45 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;56 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;130 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;56 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;129 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;55 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;127 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;55 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;126 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,55 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,59 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,55 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,85 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,83 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,38 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,83 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,65 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.102 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;976 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.053 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.088 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;964 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.004 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.078 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;952 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;993 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.068 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;950 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;991 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.056 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;936 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;981 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,73 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,77 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,35 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,82 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,54 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,3 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,91 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,34 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,11 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,83 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,9 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,16 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.033 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;737 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.020 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;726 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.010 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;716 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.001 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;715 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;989 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;704 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,74 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,51 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,77 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,15 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,9 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,01 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,74 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,52 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;69 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;239 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;68 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;238 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;68 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;236 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;67 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;235 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;67 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;232 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,55 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,58 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,55 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,74 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,1 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,33 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,1 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,07 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.135 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.008 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;903 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.128 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;995 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;895 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.119 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;989 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;891 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.097 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;973 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;881 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;963 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;871 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 21 Huelva;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,38 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,71 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,11 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,59 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,12 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,67 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,65 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,53 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,56 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,54 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,46 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.058 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;788 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;580 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.051 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;775 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;573 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.043 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;770 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;570 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.022 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;757 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;565 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;749 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;558 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,34 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,35 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,79 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,58 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,72 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,28 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,6 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,07 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,41 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,05 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,21 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;77 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;220 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;323 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;77 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;220 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;322 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;76 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;219 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;321 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;75 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;216 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;316 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;214 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;313 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,69 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,7 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,55 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,38 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,4 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,18 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,83 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,27 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,9 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.293 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.218 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.096 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.258 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.191 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.068 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.192 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.125 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.022 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.110 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.006 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.102 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;997 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,29 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,78 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,45 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,19 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,36 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;93,25 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;91,13 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;91,79 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90,48 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;90,97 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.227 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.140 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;831 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.193 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.113 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;805 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.128 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.047 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;763 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.033 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;750 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.025 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;743 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,23 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,63 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,87 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,93 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,84 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,82 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;90,61 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;90,25 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;89,91 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;89,41 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;66 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;78 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;265 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;65 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;78 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;263 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;64 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;78 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;259 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;77 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;256 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;77 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;254 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,48 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,25 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,97 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,74 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,72 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,6 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,72 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,85 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.178 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.106 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.028 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.142 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.071 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.008 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.059 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;990 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.055 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;980 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.048 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;975 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;96,94 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,84 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,05 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,75 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,3 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,39 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,33 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,76 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,84 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.113 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.028 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;793 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.078 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;994 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;776 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;984 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;760 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;980 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;754 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;974 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;750 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;96,86 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,69 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,86 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,72 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,84 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,33 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,08 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,75 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,58 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;65 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;78 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;235 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;64 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;77 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;232 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;75 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;230 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;75 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;226 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;74 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;225 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,46 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,72 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,72 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,15 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,87 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,15 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,17 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,87 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,74 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;39 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;37 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;40 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;37 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;33 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;39 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;37 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;33 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;39 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;37 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;33 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;39 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;37 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;33 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;39 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,87 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;89,19 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,5 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;94,87 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,19 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,5 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,87 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,19 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,5 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,87 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;89,19 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,5 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;35 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;30 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;33 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;26 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;33 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;26 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;33 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;26 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;33 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;26 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,29 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;86,67 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;94,29 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;86,67 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,29 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,67 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,29 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,67 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;4 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;4 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;4 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;4 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;4 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;36 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;38 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;39 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;36 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;38 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;39 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;36 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;38 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;39 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;36 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;37 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;39 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;37 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;38 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,37 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,37 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,44 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;34 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;32 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;29 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;34 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;32 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;29 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;34 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;32 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;29 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;34 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;31 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;29 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;31 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;28 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,88 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,88 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,55 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;10 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;10 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;10 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;10 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;10 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;41 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;42 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;39 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;40 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;41 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;39 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;40 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;41 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;39 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;40 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;37 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;40 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;37 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,56 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,62 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,56 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,62 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,24 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,87 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,24 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,87 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;38 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;36 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;28 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;37 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;35 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;28 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;37 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;35 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;28 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;34 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;26 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;34 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;26 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,37 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,22 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,37 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,22 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,44 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;92,86 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,44 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,86 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;11 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;11 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;11 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;11 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;11 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;42 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;44 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;44 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;41 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;43 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;43 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;42 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;39 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;42 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;39 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;42 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;39 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,62 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,73 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,73 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,45 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,64 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,45 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,64 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,45 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;88,64 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;40 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;41 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;34 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;39 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;40 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;33 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;39 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;29 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;39 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;29 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;39 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;29 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,5 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,56 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,06 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,12 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,29 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,12 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,29 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,12 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,29 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;10 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;10 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;10 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;10 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;10 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;18 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;15 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;21 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;18 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;15 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;21 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;18 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;15 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;21 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;18 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;15 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;21 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;18 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;15 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;21 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;17 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;12 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;17 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;12 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;17 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;12 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;17 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;12 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;20 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;14 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;15 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;20 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;14 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;15 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;20 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;14 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;15 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;20 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;14 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;15 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;14 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;15 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;18 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;18 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;18 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;19 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;14 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;19 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;14 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;12 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;19 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;14 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;12 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;14 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;12 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;14 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;12 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;17 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;17 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;12 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;17 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;19 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;18 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;19 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;18 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;14 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;18 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;14 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;18 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;14 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;18 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;14 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;17 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;4 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;4 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;4 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 21 Huelva;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.396 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.150 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.522 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;6.089 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;5.862 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;5.850 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;5.789 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;5.649 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;5.645 22 Huesca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.577 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.484 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.470 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.431 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.365 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.322 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,2 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,32 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,7 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,51 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,85 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,55 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,2 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,17 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,87 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,91 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,24 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,6 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.190 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5.502 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5.891 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.234 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.596 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.033 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.397 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4.883 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.252 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4.779 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,17 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,13 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,4 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,48 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,19 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,75 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,85 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,86 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;206 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;648 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;198 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;628 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;193 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;616 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;180 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;601 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;179 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;586 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,12 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,91 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,69 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,06 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,38 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,75 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,89 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,43 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.411 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.207 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.101 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;6.058 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;5.932 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;5.847 22 Huesca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.808 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.718 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;5.659 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.607 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.541 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.480 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;5.371 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;5.318 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 22 Huesca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,49 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,57 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,84 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,59 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,12 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,76 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,46 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,27 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,82 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,53 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,17 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.222 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.602 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;4.793 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.875 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.339 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.570 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.635 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.144 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.419 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.440 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.981 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.280 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.823 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.154 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,42 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,31 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,35 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,57 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,82 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,2 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,43 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,91 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,3 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,09 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,67 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;189 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;605 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.308 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;183 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;593 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.277 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;173 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;574 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.240 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;167 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;560 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.200 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;548 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.164 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,83 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,02 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,63 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,53 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,88 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,8 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,36 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,56 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,74 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,58 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,99 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.517 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.453 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.318 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.118 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.089 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.001 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.800 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.781 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.682 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;5.590 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;5.489 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;5.454 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;5.375 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,88 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,36 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,98 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,59 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,93 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,63 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,88 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,52 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,07 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.351 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.273 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.617 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.961 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.919 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.324 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.647 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.615 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.027 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.430 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.856 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.296 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.752 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,86 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,36 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,78 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,92 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,51 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,5 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,56 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,45 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,43 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,6 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;166 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;180 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;701 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;157 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;170 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;677 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;153 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;166 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;655 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;160 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;633 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;158 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;623 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,58 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,44 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,58 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,17 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,22 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,44 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,89 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,3 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,78 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,87 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.369 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.374 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.312 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.996 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.002 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.882 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;5.776 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;5.656 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;5.585 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;5.497 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.428 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.367 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,14 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,16 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,19 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,62 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,61 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,62 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,09 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,16 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,03 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.224 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.179 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5.631 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.854 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5.810 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.224 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.592 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.025 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.407 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.878 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.256 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.761 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,06 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,03 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,77 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,5 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,24 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,51 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,63 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,06 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,55 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;145 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;195 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;681 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;142 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;192 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;658 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;184 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;631 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;178 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;619 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;172 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;606 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,93 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,46 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,62 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,36 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,66 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,28 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,9 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,21 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,99 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.722 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.688 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.908 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;4.435 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;4.411 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;4.284 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;4.171 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;4.210 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;4.100 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.984 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.058 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.943 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.854 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.947 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.810 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,92 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,09 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,29 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,33 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,8 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,54 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,37 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,56 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;80,34 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,62 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,19 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;77,63 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.593 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4.315 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.311 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4.056 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.051 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.865 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.875 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.725 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.746 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.627 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,86 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,2 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,57 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,37 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,33 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,56 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,06 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;129 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;373 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;124 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;355 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;120 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;345 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;109 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;333 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;108 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;320 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,12 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,17 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,02 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,49 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;84,5 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,28 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,72 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,79 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.748 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.724 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.626 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;4.432 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;4.463 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;4.392 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.199 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.260 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.216 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.014 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.097 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.051 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;3.942 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;3.904 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 22 Huesca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,34 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,48 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,94 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,44 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,18 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,14 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,54 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,73 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,57 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,45 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,39 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.644 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.373 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.810 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.332 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4.120 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.602 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.108 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.933 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.459 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.928 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.784 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.329 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.638 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.212 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,28 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,21 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,54 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,46 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,94 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,79 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,58 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,53 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,38 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,19 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,3 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;104 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;351 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;816 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;100 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;343 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;790 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;91 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;327 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;757 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;86 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;313 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;722 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;304 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;692 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,15 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,72 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;96,81 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;87,5 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,16 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;92,77 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;82,69 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,17 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;88,48 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,61 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;84,8 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.773 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.806 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.747 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.396 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.461 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.449 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.130 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.184 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.161 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;4.013 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;3.985 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;3.885 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;3.876 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,1 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,82 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,72 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,53 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,06 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,66 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,5 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,95 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,84 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,65 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.678 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.702 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4.364 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.309 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.366 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.085 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.045 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.093 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.814 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.926 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.659 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.800 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.558 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,11 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,85 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,61 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,47 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,05 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,4 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,5 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,85 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,82 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,53 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;95 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;104 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;383 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;87 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;95 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;364 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;85 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;91 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;347 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;87 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;326 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;85 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;318 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;91,58 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;91,35 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95,04 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;89,47 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;87,5 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;90,6 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;83,65 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;85,12 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;81,73 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;83,03 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.715 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.760 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.754 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.375 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.414 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.350 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;4.207 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;4.142 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;4.024 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;3.993 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.879 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.877 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,79 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,73 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,5 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,38 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,13 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,54 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,99 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,49 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,55 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.638 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.634 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4.396 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.300 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.291 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4.011 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.091 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.825 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.914 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.685 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.774 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.578 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,71 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,6 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,24 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,28 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,01 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,46 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,83 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,44 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,39 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;77 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;126 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;358 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;75 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;123 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;339 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;116 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;317 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;110 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;308 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;105 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;299 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,4 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,62 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,69 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,06 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;88,55 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,3 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;86,03 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,33 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;83,52 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;782 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;659 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;720 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;770 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;653 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;691 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;750 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;646 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;679 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;738 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;640 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;668 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;727 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;637 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;662 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,47 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,09 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,97 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,91 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,03 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,31 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,37 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,12 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,78 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,97 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,66 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,94 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;742 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;547 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;732 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;542 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;713 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;535 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;702 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;529 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;691 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;527 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,65 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,09 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,09 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,81 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,61 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,71 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,13 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,34 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;40 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;112 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;38 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;111 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;37 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;111 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;36 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;111 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;36 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;110 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,11 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,5 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,11 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,11 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,21 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;767 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;655 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;662 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;747 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;648 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;649 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;739 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;643 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;641 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;727 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;634 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;634 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;629 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;626 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,39 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,93 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,04 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,35 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,17 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,83 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,78 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,79 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,77 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,03 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,56 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;733 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;563 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;447 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;714 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;557 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;437 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;706 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;553 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;430 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;694 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;544 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;426 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;539 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;421 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,41 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,93 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,76 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,32 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,22 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,2 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,68 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,63 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,3 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,74 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,18 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;34 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;92 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;215 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;33 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;91 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;212 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;33 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;90 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;211 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;33 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;90 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;208 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;90 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;205 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,06 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,91 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,6 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,06 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,83 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,14 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,06 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,83 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,74 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,83 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,35 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;776 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;729 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;710 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;764 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;718 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;697 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;730 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;702 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;678 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;694 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;667 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;687 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;665 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,45 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,49 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,17 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,07 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,3 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,49 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,2 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,94 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,24 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,66 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;758 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;702 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;586 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;746 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;691 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;575 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;712 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;675 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;558 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;667 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;548 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;660 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;546 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,42 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,43 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,12 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;93,93 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,15 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,22 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,01 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,52 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,02 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,17 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;18 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;27 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;124 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;18 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;27 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;122 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;18 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;27 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;120 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;27 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;119 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;27 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;119 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,39 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,77 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,97 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,97 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;739 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;729 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;713 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;718 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;717 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;695 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;707 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;682 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;704 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;677 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;699 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;672 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,16 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,35 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,48 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,98 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,65 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,57 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,95 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,88 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,25 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;717 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;696 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;589 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;696 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;684 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;573 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;675 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;564 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;672 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;560 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;668 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;557 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,07 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,28 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,28 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,98 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,76 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,55 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,08 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,98 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,57 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;22 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;33 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;124 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;22 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;33 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;122 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;32 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;118 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;32 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;117 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;31 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;115 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,39 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,97 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,16 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,97 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,35 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,94 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,74 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;852 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;765 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;859 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;845 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;760 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;840 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;830 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;755 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;831 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;818 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;748 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;824 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;813 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;744 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;815 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,18 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,35 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,79 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,42 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,69 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,74 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,01 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,78 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,93 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,42 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,25 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,88 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;817 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;613 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;811 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;609 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;796 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;606 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;785 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;602 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;780 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;598 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,27 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,35 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,43 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,86 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,08 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,21 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,47 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,55 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;35 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;152 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;34 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;151 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;34 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;149 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;33 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;146 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;33 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;146 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,14 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,34 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,14 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,03 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,29 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,05 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,29 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,05 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;856 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;792 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;783 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;840 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;785 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;776 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;832 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;779 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;772 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;828 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;776 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;765 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;767 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;758 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 22 Huesca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,13 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,12 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,11 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,2 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,36 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,6 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,73 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,98 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,7 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,84 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,81 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;808 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;640 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;516 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;793 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;636 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;511 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;786 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;632 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;510 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;783 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;629 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;505 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;623 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;501 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,14 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,38 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,03 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,28 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,75 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,84 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,91 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,28 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,87 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,34 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,09 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;48 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;152 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;267 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;47 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;149 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;265 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;46 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;147 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;262 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;45 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;147 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;260 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;144 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;257 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,92 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,03 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,25 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,83 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,71 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,13 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,75 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,71 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,38 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,74 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,25 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;925 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;879 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;821 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;916 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;871 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;815 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;898 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;858 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;804 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;847 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;798 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;846 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;795 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,03 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,09 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,27 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,08 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,61 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,93 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,36 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,2 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,25 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,83 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;876 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;832 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;636 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;868 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;825 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;633 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;852 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;812 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;625 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;803 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;619 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;802 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;618 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,09 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,16 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,53 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,26 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,6 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,27 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,51 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,33 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,39 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,17 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;49 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;47 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;185 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;48 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;46 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;182 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;46 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;46 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;179 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;44 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;179 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;44 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;177 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,96 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,87 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,38 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,88 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,87 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,76 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,62 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,76 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,62 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,68 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;874 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;848 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;806 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;862 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;836 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;798 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;828 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;793 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;823 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;788 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;817 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;779 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,63 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,58 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,01 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,64 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,39 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,05 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,77 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,34 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,65 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;832 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;813 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;618 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;821 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;801 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;612 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;793 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;608 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;788 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;605 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;782 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;598 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,68 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,52 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,03 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,54 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,38 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,92 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,9 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,19 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,76 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;42 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;35 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;188 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;41 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;35 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;186 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;35 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;185 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;35 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;183 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;35 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;181 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,62 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,94 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,4 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,34 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,28 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;28 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;27 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;23 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;28 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;27 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;23 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;27 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;27 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;23 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;26 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;27 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;23 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;26 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;27 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;23 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,43 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;92,86 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,86 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;26 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;18 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;26 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;18 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;25 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;24 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;18 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;24 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;18 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,15 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;92,31 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,31 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;9 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;9 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;9 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;9 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;9 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;29 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;26 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;19 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;28 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;26 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;19 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;27 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;26 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;19 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;27 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;25 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;19 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;25 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;19 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,55 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;93,1 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;93,1 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,15 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,15 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;26 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;25 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;24 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;16 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;11 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;24 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;15 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;11 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;15 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,15 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,31 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,31 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,75 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,75 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;10 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;10 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;10 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;10 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;10 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;8 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;33 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;27 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;28 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;32 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;27 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;28 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;32 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;26 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;27 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;26 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;27 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;26 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;27 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;96,97 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,97 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,3 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,43 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,3 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,43 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,3 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,43 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;29 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;25 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;21 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;28 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;25 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;21 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;28 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;24 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;20 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;24 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;20 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;24 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;20 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;96,55 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,55 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,24 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,24 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,24 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;7 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;31 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;25 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;28 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;31 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;24 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;28 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;24 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;28 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;24 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;28 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;23 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;28 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;27 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;24 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;19 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;27 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;23 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;19 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;23 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;19 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;23 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;19 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;22 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;19 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,83 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,83 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,83 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;91,67 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;9 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;9 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;9 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;9 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;12 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;11 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;12 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;12 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;12 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;12 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;11 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;10 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;12 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,67 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,67 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;91,67 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;91,67 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;90,91 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;11 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;11 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;11 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,67 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,67 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;91,67 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;91,67 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;50 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;11 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;10 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;11 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;10 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;10 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;9 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;8 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;11 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;80 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;10 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;11 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;80 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;.. 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;10 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;12 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;10 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;12 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;12 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;10 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;11 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;12 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;10 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;12 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;10 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;12 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,67 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,33 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,33 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;12 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;11 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,67 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,33 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,33 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;10 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;12 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;10 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;11 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;11 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;10 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;11 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;10 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;11 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;10 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;11 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,67 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;83,33 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;83,33 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,33 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;10 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;10 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;10 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,67 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;83,33 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,33 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,33 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 22 Huesca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;12.666 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;12.067 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;12.992 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;11.793 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;11.273 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;10.706 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;11.278 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;10.805 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;10.363 23 Jaén;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;10.840 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;10.455 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;10.035 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;10.464 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;10.095 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;9.587 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,11 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,42 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;82,4 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,04 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,54 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;79,76 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,58 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,64 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;77,24 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,61 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,66 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;73,79 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12.310 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;11.342 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11.445 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10.554 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;10.938 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10.097 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10.508 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9.755 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;10.139 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9.412 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,97 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,05 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,85 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,02 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,36 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,01 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,36 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,98 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;356 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;725 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;348 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;719 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;340 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;708 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;332 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;700 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;325 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;683 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,75 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,17 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,51 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,66 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,26 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,55 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,29 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,21 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;12.937 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;12.374 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;11.365 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;12.209 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;11.724 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;10.909 23 Jaén;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;11.618 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;11.222 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;10.516 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.964 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;10.589 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.930 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;10.205 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;9.561 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 23 Jaén;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,37 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,75 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,99 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,8 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,69 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,53 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,75 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,57 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,37 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,47 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,13 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;12.609 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;11.590 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10.252 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11.887 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10.951 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9.802 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11.306 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;10.456 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.420 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;10.662 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9.843 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;8.861 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;9.471 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;8.509 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,27 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,49 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,61 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,67 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,22 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,88 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,56 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;84,93 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,43 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,72 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;328 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;784 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.113 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;322 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;773 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.107 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;312 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;766 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.096 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;302 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;746 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.069 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;734 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.052 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,17 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,6 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,46 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,12 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,7 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,47 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,07 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,15 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,05 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,62 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,52 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;13.432 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;13.146 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12.615 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;12.425 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;12.213 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;11.797 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;11.443 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;11.184 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;10.717 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;10.719 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;10.242 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;10.426 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;9.960 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,5 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,9 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,52 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;85,19 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;85,08 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;84,95 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;81,54 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;81,19 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,31 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;78,95 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;13.143 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;12.890 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11.919 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;12.144 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;11.961 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11.108 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;11.170 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10.938 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10.039 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10.478 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9.570 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10.187 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9.295 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,4 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,79 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,2 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;84,99 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;84,86 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;84,23 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;81,29 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;80,29 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,03 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;77,98 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;289 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;256 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;696 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;281 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;252 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;689 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;273 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;246 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;678 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;241 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;672 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;239 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;665 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,23 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,44 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,99 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,46 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,09 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,41 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,14 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,55 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,36 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,55 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;13.227 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;13.089 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;12.774 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.943 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;11.758 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;11.278 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;11.178 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;10.714 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;10.799 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;10.366 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;10.445 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;10.100 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;90,29 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;89,83 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;88,29 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;85,4 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;83,87 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;82,5 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;81,15 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;79,8 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;79,07 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;12.947 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12.700 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;11.997 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;11.671 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11.377 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10.518 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10.804 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.958 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10.431 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9.619 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;10.088 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9.361 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;90,14 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;89,58 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;87,67 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;85,07 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;83 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;82,13 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;80,18 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,43 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;78,03 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;280 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;389 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;777 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;272 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;381 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;760 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;374 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;756 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;368 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;747 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;357 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;739 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,14 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,94 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,81 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,14 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,3 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,6 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,14 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,77 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,11 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;9.962 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;9.620 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;10.331 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;9.125 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;8.863 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;8.173 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;8.648 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;8.427 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;7.856 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;8.239 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;8.104 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.545 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.892 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.767 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.130 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,6 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,13 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;79,11 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;86,81 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,6 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;76,04 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;82,7 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,24 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;73,03 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;79,22 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,74 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;69,02 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;9.759 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9.299 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.929 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;8.547 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;8.458 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;8.119 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;8.056 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7.801 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.716 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7.476 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,5 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,91 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,67 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,31 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,55 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,89 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,07 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;80,4 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;203 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;321 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;196 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;316 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;190 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;308 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;183 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;303 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;176 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;291 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,55 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,44 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,6 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,95 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,15 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,39 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,7 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,65 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;10.294 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;9.913 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;9.151 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;9.597 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;9.293 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;8.712 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;9.035 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.823 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;8.329 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;8.422 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;8.237 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.774 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;7.878 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;7.434 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 23 Jaén;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,23 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,75 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,2 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,77 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,02 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;81,81 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;83,09 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;84,95 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;79,47 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;81,24 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;10.102 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9.549 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;8.665 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;9.410 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;8.937 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8.230 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8.858 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;8.472 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7.857 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8.255 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;7.901 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7.318 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;7.552 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.989 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,15 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,59 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,98 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,69 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,72 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,68 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;81,72 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;82,74 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;84,45 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;79,09 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;80,66 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;192 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;364 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;486 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;187 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;356 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;482 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;177 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;351 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;472 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;167 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;336 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;456 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;326 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;445 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,4 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,8 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,18 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,19 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,43 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,12 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;86,98 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,31 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,83 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,56 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,56 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;10.649 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;10.529 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;10.146 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;9.684 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;9.639 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;9.340 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;8.777 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.685 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;8.332 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;8.249 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;7.895 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;7.984 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;7.640 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;90,94 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;91,55 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,06 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;82,42 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;82,49 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;82,12 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;78,35 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;77,81 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;75,83 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;75,3 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;10.496 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;10.406 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9.898 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;9.539 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;9.520 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9.098 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;8.639 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8.570 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8.095 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8.137 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.661 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.874 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;7.410 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;90,88 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;91,49 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;91,92 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;82,31 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;82,36 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;81,78 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;78,2 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;77,4 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;75,67 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;74,86 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;153 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;123 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;248 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;145 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;119 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;242 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;138 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;115 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;237 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;112 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;234 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;110 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;230 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,77 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,75 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,58 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,2 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,5 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,56 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,06 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,35 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,43 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,74 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;10.451 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;10.444 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;10.236 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;9.244 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;9.197 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.813 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;8.647 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;8.293 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;8.301 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;7.970 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.972 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.732 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;88,45 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;88,06 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;86,1 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;82,79 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;81,02 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;79,48 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;77,86 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;76,33 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;75,54 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;10.311 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10.218 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9.924 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;9.111 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;8.979 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8.513 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;8.436 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7.994 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;8.095 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7.676 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.775 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7.443 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;88,36 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;87,87 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;85,78 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;82,56 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;80,55 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;79,22 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;77,35 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;76,09 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;75 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;140 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;226 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;312 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;133 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;218 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;300 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;211 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;299 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;206 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;294 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;197 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;289 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,46 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,15 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,36 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,83 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,15 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,23 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,17 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,63 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.188 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.050 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.229 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.167 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.027 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.137 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.147 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.004 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.116 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.129 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;994 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.105 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.115 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;982 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.083 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,23 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,81 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;92,51 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,55 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,62 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;90,81 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,03 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,67 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;89,91 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,86 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,52 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,12 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.135 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;914 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.115 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;892 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.097 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;870 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.080 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;860 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.066 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;852 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,24 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,59 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,65 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,19 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,15 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,09 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,92 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,22 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;53 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;136 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;52 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;135 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;50 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;134 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;49 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;134 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;49 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;130 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,11 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,26 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,34 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,53 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,45 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,53 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,45 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,59 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.199 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.106 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.010 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.181 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.087 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;998 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.165 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.073 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;993 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.142 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.039 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;969 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.023 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;956 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,5 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,28 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,81 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,16 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,02 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,32 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,25 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;93,94 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,94 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,5 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,65 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.156 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;960 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;769 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.139 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;943 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;758 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.123 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;929 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;753 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;898 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;736 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;884 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;725 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,53 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,23 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,57 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,15 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,77 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,92 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,16 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,54 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,71 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,08 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,28 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;43 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;146 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;241 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;42 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;144 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;240 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;42 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;144 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;240 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;42 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;141 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;233 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;139 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;231 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,67 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,63 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,59 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,67 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,63 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,59 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,67 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,58 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,68 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,21 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,85 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.271 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.187 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.151 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.240 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.162 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.147 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.190 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.107 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.092 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.092 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.074 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.077 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.056 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,56 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,89 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,65 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;93,63 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;93,26 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,87 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,31 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90,73 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;91,75 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.228 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.141 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.004 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.197 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.116 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.000 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.147 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.062 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;950 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.049 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;933 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.034 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;915 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,48 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,81 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,6 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;93,4 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;93,08 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;94,62 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;91,94 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;92,93 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,62 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;91,14 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;43 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;46 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;147 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;43 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;46 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;147 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;43 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;45 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;142 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;43 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;141 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;43 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;141 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,83 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,6 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,48 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,92 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,48 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,92 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.243 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.194 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.183 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.193 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.129 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.121 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.107 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.098 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.089 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.083 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.076 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.070 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,98 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,56 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,76 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,71 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,81 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;91,21 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;91,55 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;90,12 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;90,45 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.199 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.143 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.022 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.149 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.078 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;965 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.056 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;945 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.039 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;932 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.027 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;919 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,83 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,31 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,42 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,39 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;92,47 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;90,9 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;91,19 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;89,85 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;89,92 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;44 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;51 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;161 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;44 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;51 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;156 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;51 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;153 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;50 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;151 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;49 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;151 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,89 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,03 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,04 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,79 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,08 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,79 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.449 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.338 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.371 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.435 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.325 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.335 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.417 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.316 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.330 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.407 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.299 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.325 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.392 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.288 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.314 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,03 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,03 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,37 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,79 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,36 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,01 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,1 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,09 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,64 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,07 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,26 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,84 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.353 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.087 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.339 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.074 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.321 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.067 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.311 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.053 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.296 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.043 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,97 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,8 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,63 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,16 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,9 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,87 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,79 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,95 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;96 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;251 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;96 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;251 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;96 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;249 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;96 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;246 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;96 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;245 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,2 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,01 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,61 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.377 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.294 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.146 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.364 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.283 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.141 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.352 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.265 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.137 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.334 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.252 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.130 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.244 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.115 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 23 Jaén;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,06 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,15 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,56 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,18 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,76 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,21 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,88 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,75 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,6 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,14 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,29 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.286 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.038 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;780 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.273 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.028 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;776 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.261 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.012 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;773 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.243 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.001 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;770 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;993 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;759 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,99 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,04 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,49 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,06 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,5 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,1 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,66 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,44 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,72 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,66 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,31 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;91 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;256 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;366 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;91 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;255 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;365 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;91 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;253 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;364 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;91 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;251 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;360 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;251 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;356 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,61 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,73 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,83 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,45 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,05 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,36 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,05 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,27 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.444 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.368 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.259 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.434 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.350 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.251 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.409 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.330 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.234 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.317 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.215 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.304 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.206 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,31 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,68 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,36 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,58 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,22 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,01 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,27 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,51 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,32 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,79 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.353 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.286 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;976 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.343 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.268 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;969 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.319 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.249 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;953 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.236 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;936 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.223 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;930 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,26 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,6 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,28 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,49 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,12 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,64 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,11 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,9 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,1 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,29 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;91 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;82 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;283 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;91 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;82 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;282 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;90 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;81 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;281 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;81 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;279 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;81 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;276 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,65 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,9 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,78 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,29 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,78 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,59 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,78 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,53 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.465 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.391 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.293 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.438 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.372 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.282 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.365 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.262 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.350 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.252 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.339 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.237 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,16 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,63 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,15 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,13 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,6 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,05 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,83 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,26 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,67 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.371 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.284 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.010 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.345 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.265 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;999 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.258 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;979 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.243 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;971 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.233 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;959 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,1 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,52 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,91 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,98 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,93 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,81 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,14 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,03 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,95 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;94 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;107 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;283 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;93 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;107 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;283 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;107 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;283 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;107 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;281 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;106 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;278 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,94 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,29 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;99,07 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,23 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;47 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;42 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;45 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;47 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;41 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;45 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;47 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;41 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;45 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;47 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;41 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;45 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;47 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;41 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;45 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,62 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,62 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,62 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,62 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;44 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;29 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;44 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;28 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;44 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;28 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;44 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;28 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;44 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;28 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,55 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,55 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,55 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,55 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;13 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;13 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;13 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;13 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;13 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;49 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;44 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;41 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;49 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;44 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;41 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;49 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;44 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;41 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;49 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;44 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;41 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;44 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;40 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,56 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;47 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;30 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;24 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;47 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;30 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;24 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;47 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;30 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;24 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;47 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;30 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;24 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;30 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;23 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,83 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;14 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;17 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;14 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;17 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;14 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;17 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;14 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;17 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;14 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;17 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;49 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;43 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;42 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;49 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;43 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;42 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;49 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;43 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;42 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;43 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;41 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;43 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;41 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,62 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,62 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;47 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;40 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;30 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;47 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;40 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;30 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;47 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;40 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;30 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;40 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;29 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;40 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;29 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,67 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,67 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;12 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;12 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;12 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;12 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;12 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;52 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;40 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;45 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;52 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;40 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;45 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;40 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;44 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;40 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;44 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;40 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;44 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,78 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,78 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,78 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;50 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;35 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;31 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;50 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;35 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;31 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;35 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;30 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;35 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;30 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;35 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;30 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,77 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,77 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,77 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;5 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;14 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;5 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;14 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;5 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;14 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;5 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;14 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;5 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;14 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;20 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;17 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;16 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;19 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;17 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;16 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;19 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;17 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;16 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;18 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;17 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;15 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;18 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;17 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;15 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;90 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,75 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;90 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,75 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;19 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;13 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;18 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;13 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;18 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;13 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;17 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;13 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;17 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,74 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;94,74 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,47 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;89,47 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;18 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;17 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;17 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;18 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;17 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;17 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;17 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;17 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;16 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;17 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;17 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;16 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;16 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;16 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;94,44 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,12 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,44 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,12 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,12 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,12 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;18 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;17 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;17 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;12 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;13 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;94,44 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,86 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,44 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;92,86 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,31 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;92,86 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;4 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;19 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;19 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;17 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;18 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;19 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;17 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;18 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;19 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;17 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;18 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;17 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;18 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;17 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,74 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,74 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,74 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,74 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;17 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;18 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;18 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;17 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;16 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;16 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,74 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,74 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,12 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,12 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;16 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;20 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;17 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;16 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;20 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;17 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;19 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;17 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;19 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;17 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;18 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;17 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;90 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;16 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;20 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;20 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;19 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;19 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;18 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;90 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;7 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;7 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;7 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;7 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;7 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 23 Jaén;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;10.346 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;10.102 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;10.724 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;9.865 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;9.653 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;9.668 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;9.483 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;9.348 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;9.331 24 León;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;9.216 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;9.102 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.072 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;8.946 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;8.897 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.818 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,35 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,56 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,15 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,66 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,54 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,01 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,08 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,1 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,6 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,47 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,07 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,23 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;9.954 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8.840 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;9.488 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;8.425 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;9.117 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;8.153 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;8.861 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7.933 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;8.600 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7.748 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,32 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,31 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,59 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,23 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,02 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,74 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,4 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,65 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;392 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.262 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;377 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.228 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;366 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.195 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;355 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.169 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;346 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.149 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,17 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,31 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,37 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,69 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,56 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,63 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,27 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,05 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;10.353 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;10.140 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;10.007 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;9.866 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;9.744 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;9.626 24 León;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;9.540 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;9.438 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;9.335 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;9.218 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;9.157 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.054 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;8.889 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;8.788 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 24 León;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,3 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,09 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,19 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,15 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,08 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,28 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,04 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,31 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,48 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,66 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,82 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;9.994 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9.057 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7.607 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;9.517 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;8.693 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7.266 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;9.200 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;8.410 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7.041 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8.890 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8.147 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6.821 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;7.898 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.609 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 24 León;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,23 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,98 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,52 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,06 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,86 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,56 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,95 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,95 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,67 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,2 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,88 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;359 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.083 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.400 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;349 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.051 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.360 24 León;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;340 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.028 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.294 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;328 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.010 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.233 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;991 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.179 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 24 León;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,21 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,05 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,33 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,71 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,92 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,58 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,36 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,26 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,04 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,51 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,79 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;10.557 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;10.399 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;10.209 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;10.016 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;9.902 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;9.765 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;9.537 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;9.503 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;9.370 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;9.194 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;9.073 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;8.961 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;8.889 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,88 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,22 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,65 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,34 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,38 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,78 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,41 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,87 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,17 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,07 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;10.256 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;10.082 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8.856 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;9.722 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;9.595 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8.445 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;9.253 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;9.206 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8.080 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8.901 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.808 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8.678 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;7.650 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,79 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,17 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,36 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,22 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,31 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,24 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,29 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,17 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,07 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,38 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;301 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;317 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.353 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;294 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;307 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.320 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;284 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;297 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.290 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;293 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.265 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;283 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.239 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,67 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,85 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,56 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,35 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,69 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,34 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,43 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,5 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,27 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,57 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;10.411 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;10.390 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;10.328 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;9.818 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;9.849 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;9.750 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;9.486 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;9.393 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;9.205 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;9.156 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;8.977 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;8.937 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,3 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,79 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,4 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,3 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,95 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,59 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,65 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,4 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,53 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;10.124 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;9.971 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;8.895 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;9.540 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;9.438 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8.349 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9.087 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;8.023 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;8.818 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7.816 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;8.601 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7.622 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,23 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,65 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,86 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,13 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,2 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,44 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,87 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,26 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,69 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;287 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;419 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.433 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;278 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;411 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.401 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;399 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.370 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;387 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.340 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;376 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.315 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,86 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,09 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,77 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,23 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,6 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,36 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,51 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,74 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,77 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.044 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;7.986 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.400 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;7.591 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;7.554 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;7.393 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;7.238 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;7.270 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;7.086 24 León;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.989 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.034 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.844 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.737 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;6.839 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.604 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,37 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,59 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,01 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,98 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,03 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,36 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,88 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,08 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,48 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,75 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,64 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,62 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.756 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.218 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.317 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.815 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.971 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.558 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.732 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.343 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.488 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.167 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,34 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,42 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,88 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,86 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,8 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,88 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,65 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,44 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;288 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;768 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;274 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;739 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;267 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;712 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;257 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;691 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;249 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;672 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,14 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,22 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,71 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,71 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,24 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,97 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,46 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,5 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.037 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.996 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.866 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;7.574 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;7.620 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;7.506 24 León;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.267 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.324 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.227 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.963 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.053 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;6.956 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;6.809 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;6.715 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 24 León;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,24 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,3 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,42 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,42 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,6 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,88 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,64 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,21 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,43 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,16 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,37 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7.790 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.332 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.263 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.336 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.981 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.934 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.037 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.705 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.714 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.744 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.451 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.501 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.222 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.306 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,17 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,21 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,75 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,33 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,45 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,23 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,57 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,98 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,83 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,86 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,72 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;247 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;664 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.603 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;238 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;639 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.572 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;230 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;619 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.513 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;219 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;602 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.455 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;587 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.409 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 24 León;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,36 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,23 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,07 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,12 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,22 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,39 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,66 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,66 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,77 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,4 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,9 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.158 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.144 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.059 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;7.639 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;7.663 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.626 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.191 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.275 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.242 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;6.990 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;6.968 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;6.772 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;6.803 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,64 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,09 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,63 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,15 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,33 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,86 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,83 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,46 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,15 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,41 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;7.964 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.941 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.249 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.451 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.470 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.844 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.012 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.090 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.488 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.808 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.235 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;6.597 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.089 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,56 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,07 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,41 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,05 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,28 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,5 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,73 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,01 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,08 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;194 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;203 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;810 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;188 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;193 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;782 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;179 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;185 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;754 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;182 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;733 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;175 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;714 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,91 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,07 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,54 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,27 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,13 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,09 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,66 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,49 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,21 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,15 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.022 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.104 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.124 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.464 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;7.573 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;7.561 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;7.236 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;7.227 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;6.975 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;7.009 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.763 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;6.801 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,04 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,45 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,07 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,29 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,96 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,07 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,28 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,45 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,71 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7.837 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.806 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.286 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.287 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.283 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.752 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.955 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.445 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.703 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.250 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.501 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.062 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,98 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,3 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,67 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,1 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,46 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,87 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,78 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,28 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,2 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;185 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;298 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;838 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;177 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;290 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;809 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;281 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;782 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;272 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;759 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;262 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;739 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,68 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,32 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,54 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,3 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,32 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,28 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,57 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,92 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,19 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.016 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;969 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.040 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;999 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;960 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.009 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;981 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;946 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;989 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;971 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;940 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;977 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;959 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;933 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;970 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,33 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,07 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,02 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,56 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,63 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,1 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,57 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,01 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,94 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,39 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,28 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,27 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;975 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;779 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;959 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;773 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;943 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;763 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;934 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;760 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;923 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;753 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,36 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,23 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,72 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,95 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,79 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,56 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,67 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,66 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;41 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;190 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;40 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;187 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;38 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;183 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;37 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;180 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;36 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;180 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,56 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,42 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,68 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,32 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,24 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,74 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,8 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,74 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.023 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;967 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;975 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.010 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;951 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;959 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;998 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;943 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;950 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;986 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;938 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;945 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;925 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;925 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,73 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,35 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,36 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,56 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,52 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,44 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,38 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,92 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,66 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,87 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;987 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;818 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;634 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;974 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;807 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;626 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;962 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;801 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;624 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;950 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;796 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;621 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;784 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;608 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,68 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,66 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,74 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,47 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,92 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,42 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,25 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,31 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,95 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,84 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,9 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;36 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;149 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;341 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;36 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;144 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;333 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;36 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;142 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;326 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;36 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;142 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;324 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;141 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;317 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,64 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,65 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,3 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,6 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,3 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,01 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,63 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,96 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.039 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.010 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;975 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.024 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.001 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;967 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.006 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;994 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;963 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;981 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;946 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;971 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;934 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,56 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,11 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,18 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,82 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,42 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,77 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,13 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,03 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,14 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,79 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.004 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;967 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;771 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;989 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;958 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;768 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;971 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;952 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;765 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;939 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;751 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;931 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;743 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,51 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,07 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,61 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,71 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,45 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,22 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,1 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,41 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,28 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,37 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;35 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;43 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;204 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;35 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;43 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;199 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;35 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;42 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;198 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;42 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;195 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;40 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;191 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,55 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,67 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,06 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,67 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,59 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,02 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,63 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.043 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.022 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.011 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.019 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.017 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.003 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.002 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;990 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;990 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;976 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;981 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;970 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,7 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,51 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,21 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,04 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,92 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,87 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,54 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,99 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,94 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.011 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;970 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;780 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;987 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;965 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;772 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;952 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;760 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;942 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;751 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;933 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;746 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,63 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,48 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,97 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,14 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,44 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,11 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,28 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,19 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,64 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;32 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;52 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;231 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;32 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;52 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;231 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;50 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;230 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;48 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;225 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;48 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;224 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,15 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,57 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,31 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,4 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,31 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,97 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.208 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.074 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.210 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.197 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.066 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.194 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.186 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.059 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.184 24 León;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.178 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.055 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.179 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.173 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.052 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.172 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,09 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,26 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,68 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,18 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,6 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,85 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,52 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,23 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,44 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,1 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,95 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,86 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.152 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;798 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.141 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;792 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.132 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;787 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.124 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;785 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.119 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;783 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,05 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,25 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,26 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,62 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,57 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,37 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,14 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,12 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;56 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;276 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;56 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;274 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;54 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;272 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;54 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;270 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;54 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;269 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,28 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,43 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,55 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,43 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,83 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,43 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,46 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.209 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.106 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.098 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.198 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.102 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.093 24 León;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.191 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.100 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.090 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.186 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.095 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.085 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.084 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.080 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 24 León;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,09 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,64 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,54 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,51 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,46 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,27 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,1 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;99,01 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,82 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,01 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,36 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.139 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;862 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;667 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.129 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;860 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;663 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.123 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;859 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;660 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.119 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;855 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;656 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;847 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;652 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,12 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,77 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,4 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,6 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,65 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,95 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,24 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;99,19 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,35 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,26 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,75 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;70 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;244 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;431 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;69 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;242 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;430 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;68 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;241 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;430 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;67 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;240 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;429 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;237 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;428 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 24 León;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,57 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,18 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,77 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,14 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,77 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,77 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,71 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,36 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,54 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,13 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;99,3 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.283 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.172 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.105 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.276 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.165 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.102 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.264 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.161 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.095 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.150 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.089 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.145 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.082 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,45 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,4 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,73 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,52 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,06 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,1 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,12 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,55 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,7 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,92 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.215 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.109 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;790 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.209 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.102 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;787 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.198 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.099 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;781 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.089 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;776 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.085 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;772 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,51 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,37 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,62 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,6 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,1 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,86 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,2 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,23 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,84 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,72 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;68 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;63 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;315 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;67 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;63 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;315 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;66 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;62 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;314 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;61 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;313 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;60 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;310 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,53 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,06 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,41 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,68 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,83 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,37 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,24 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,41 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.264 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.188 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.122 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.254 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.183 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.115 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.172 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.105 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.164 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.100 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.157 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.095 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,21 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,58 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,38 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,65 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,48 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,98 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,04 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,39 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,59 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.200 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.126 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;785 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.191 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.121 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;781 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.111 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;774 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.104 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;771 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.098 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;770 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,25 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,56 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,49 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,67 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,6 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,05 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,22 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,51 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,09 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;64 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;62 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;337 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;63 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;62 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;334 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;61 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;331 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;60 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;329 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;59 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;325 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,44 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,11 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,39 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,22 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,77 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,63 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,16 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,44 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;55 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;52 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;54 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;55 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;55 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;55 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;55 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;52 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,3 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,3 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,3 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,3 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;49 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;34 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;49 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;34 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;49 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;34 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;49 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;34 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;49 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;34 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;6 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;18 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;18 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;18 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;18 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;18 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;61 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;49 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;49 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;61 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;61 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;61 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;49 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 24 León;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;59 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;33 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;30 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;59 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;33 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;30 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;59 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;33 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;30 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;59 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;33 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;30 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;33 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;30 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;16 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;19 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;16 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;19 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;16 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;19 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;16 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;19 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;16 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;19 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;55 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;52 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;51 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;55 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;52 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;51 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;55 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;52 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;51 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;52 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;51 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;52 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;51 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;54 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;48 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;33 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;54 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;48 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;33 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;54 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;48 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;33 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;48 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;33 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;48 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;33 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;18 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;18 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;18 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;18 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;18 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;59 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;53 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;49 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;59 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;53 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;49 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;53 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;49 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;53 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;49 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;53 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;49 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;57 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;47 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;31 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;57 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;47 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;31 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;47 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;31 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;47 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;31 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;47 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;31 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;6 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;18 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;6 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;18 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;18 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;18 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;18 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;23 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;21 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;20 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;23 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;21 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;20 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;23 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;21 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;20 24 León;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;23 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;21 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;20 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;22 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;21 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;20 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,65 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;22 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;11 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;22 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;11 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;22 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;22 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;21 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,45 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;10 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;10 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;10 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;10 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;10 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;23 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;22 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;19 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;23 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;22 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;19 24 León;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;23 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;22 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;19 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;22 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;22 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;19 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;22 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;19 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 24 León;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,65 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;19 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;13 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;19 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;19 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;18 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;12 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;12 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;13 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,74 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;10 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;10 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;10 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;10 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;10 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;22 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;21 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;22 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;21 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;19 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;21 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;21 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;19 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;21 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;19 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;21 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;19 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,45 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;17 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;13 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;19 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;13 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;18 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;17 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;13 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;17 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;17 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,74 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;23 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;23 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;22 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;22 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;23 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;22 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;23 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;22 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;23 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;22 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;23 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;22 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,65 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;19 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;22 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;18 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;22 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;13 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;22 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;13 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;22 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;22 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,74 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;9 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;9 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;9 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;9 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 24 León;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;12.101 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;11.688 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;12.218 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;11.524 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;11.172 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;11.101 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;11.004 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;10.773 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;10.715 25 Lleida;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;10.625 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;10.484 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;10.368 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;10.353 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;10.248 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;10.078 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,23 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,59 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,86 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,93 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,17 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,7 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,8 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,7 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,86 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,55 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,68 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,48 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;11.753 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10.619 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11.183 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10.127 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;10.676 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9.746 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10.305 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9.472 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;10.040 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9.255 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,15 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,37 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,84 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,78 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,68 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,2 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,42 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,16 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;348 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.069 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;341 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.045 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;328 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.027 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;320 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.012 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;313 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;993 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,99 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,75 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,25 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,07 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,95 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,67 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,94 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,89 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;12.085 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;11.736 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;11.581 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;11.500 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;11.253 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;11.116 25 Lleida;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;11.052 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;10.894 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;10.723 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.733 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;10.591 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;10.394 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;10.269 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;10.075 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 25 Lleida;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,16 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,88 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,98 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,45 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,83 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,59 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,81 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,24 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,75 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,5 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11.744 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10.756 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9.906 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11.169 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10.296 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9.475 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;10.731 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9.957 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.123 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;10.418 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9.673 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;8.828 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;9.370 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;8.542 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,1 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,72 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,65 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,37 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,57 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,1 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,71 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,93 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,12 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,11 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,23 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;341 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;980 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.675 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;331 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;957 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.641 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;321 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;937 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.600 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;315 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;918 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.566 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;899 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.533 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,07 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,65 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,97 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,13 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,61 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,52 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,38 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,67 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,49 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,73 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,52 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;12.156 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;11.999 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;11.706 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;11.489 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;11.407 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;11.156 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;11.073 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;10.996 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;10.710 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;10.626 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;10.366 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;10.354 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;10.160 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,51 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,07 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,3 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,09 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,64 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,49 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,56 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,55 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,29 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,79 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.867 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11.707 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10.843 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;11.208 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;11.120 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;10.312 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.798 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10.717 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9.890 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10.352 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9.564 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10.086 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9.368 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,45 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,99 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,1 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,99 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,54 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,21 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,43 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,2 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,15 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,4 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;289 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;292 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;863 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;281 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;287 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;844 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;275 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;279 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;820 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;274 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;802 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;268 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;792 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,23 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,29 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,8 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,16 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,55 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,02 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,84 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,93 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,78 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,77 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;12.002 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.921 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.746 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.483 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;11.401 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;11.150 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;10.976 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;10.749 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;10.618 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;10.459 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;10.308 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;10.219 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,68 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,64 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,93 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,07 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,51 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,07 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,04 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,47 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.749 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;11.537 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10.485 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;11.236 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11.025 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9.916 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10.613 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.537 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10.264 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9.264 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;9.965 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9.043 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,63 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,56 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,57 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,99 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,96 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,97 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,35 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,37 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,25 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;253 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;384 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.261 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;247 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;376 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.234 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;363 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.212 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;354 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.195 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;343 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.176 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,63 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,92 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,86 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,53 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,11 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,19 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,77 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,32 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,26 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.899 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.724 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;9.135 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;8.364 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;8.236 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;8.095 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;7.915 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;7.894 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;7.736 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.579 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.621 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.417 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.332 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.409 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.150 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,99 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,41 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,62 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,94 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,49 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,69 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,17 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,36 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,19 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,39 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,93 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,27 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.711 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8.138 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.183 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.671 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.743 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7.343 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.412 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7.081 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.170 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.884 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,94 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,26 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,89 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,23 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,09 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,01 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,31 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,59 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;188 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;586 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;181 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;565 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;172 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;551 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;167 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;540 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;162 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;525 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,28 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,42 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,49 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,03 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,83 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,15 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,17 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,59 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.871 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.756 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.687 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;8.347 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;8.328 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;8.251 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.937 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.983 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.880 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.642 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.702 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.574 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;7.406 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;7.280 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 25 Lleida;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,09 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,11 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,98 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,47 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,17 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,71 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,15 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,96 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,19 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,58 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,8 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.685 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;8.222 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7.699 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;8.169 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.813 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7.292 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.766 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7.484 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;6.954 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.475 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;7.218 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6.675 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.938 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.411 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,06 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,03 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,71 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,42 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,02 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,32 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,07 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,79 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,7 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,38 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,27 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;186 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;534 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;988 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;178 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;515 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;959 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;171 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;499 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;926 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;167 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;484 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;899 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;468 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;869 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,7 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,44 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,06 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,94 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,45 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;93,72 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,78 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,64 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,99 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,64 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,96 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.951 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.919 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.753 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.324 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.349 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.230 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.949 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.973 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.815 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;7.638 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;7.500 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;7.395 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;7.316 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,61 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,02 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,81 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,39 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,28 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,64 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,68 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,91 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,58 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.801 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.768 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8.301 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.181 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8.201 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7.796 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.809 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.833 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;7.402 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.502 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.102 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.264 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.925 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,96 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,53 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,92 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,73 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,34 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,17 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,56 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,56 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,85 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,42 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;150 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;151 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;452 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;143 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;148 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;434 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;140 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;140 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;413 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;136 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;398 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;131 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;391 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,33 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,01 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,02 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,33 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,72 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,37 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,07 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,05 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,75 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,5 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.857 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.854 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.772 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;8.364 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.361 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.205 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;7.965 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;7.839 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;7.648 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;7.583 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.371 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.355 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,43 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,43 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,54 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,96 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,36 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,38 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,45 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,25 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,85 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.729 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.613 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;8.099 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.241 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;8.127 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7.557 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.743 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7.210 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.434 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.968 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.164 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.754 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,41 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,36 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,31 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,9 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,02 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,31 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,04 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,18 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,39 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;128 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;241 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;673 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;123 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;234 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;648 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;222 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;629 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;214 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;615 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;207 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;601 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,09 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,1 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,29 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,12 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,46 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,8 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,38 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,89 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,3 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.351 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.245 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.297 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.330 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.226 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.246 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.294 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.194 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.234 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.274 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.182 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.220 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.257 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.168 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.211 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,45 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,47 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,07 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,78 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,9 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,14 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,3 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,94 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,06 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,04 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,82 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,37 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.300 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.094 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.279 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.078 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.245 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.048 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.227 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.038 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.210 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.025 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,38 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,54 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,77 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,8 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,38 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,88 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,08 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,69 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;51 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;151 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;51 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;148 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;49 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;146 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;47 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;144 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;47 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;143 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,01 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,08 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,69 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,16 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,36 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,16 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,7 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.376 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.257 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.201 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.343 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.222 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.188 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.322 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.214 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.179 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.308 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.200 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.170 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.188 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.155 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,6 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,22 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,92 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,08 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,58 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,17 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,06 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,47 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,42 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,51 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,17 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.330 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.120 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;964 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.298 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.088 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;953 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.280 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.083 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;947 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.266 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.071 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;940 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.060 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;926 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,59 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,14 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,86 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,24 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,7 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,24 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,19 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,63 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,51 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,64 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,06 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;46 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;137 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;237 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;45 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;134 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;235 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;42 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;131 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;232 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;42 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;129 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;230 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;128 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;229 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,83 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,81 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,16 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,3 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,62 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,89 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,3 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,16 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,05 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,43 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,62 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.344 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.282 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.232 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.320 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.267 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.218 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.296 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.250 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.201 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.230 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.185 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.215 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.170 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,21 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,83 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,86 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,43 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,5 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,48 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,94 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,19 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,77 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,97 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.302 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.247 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.095 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.279 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.233 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.081 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.256 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.216 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.066 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.196 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.052 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.182 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.038 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,23 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,88 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,72 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,47 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,51 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,35 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,91 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,07 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,79 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,79 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;42 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;35 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;137 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;41 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;34 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;137 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;40 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;34 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;135 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;34 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;133 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;33 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;132 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,62 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,14 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,24 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,14 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,54 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,14 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,08 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,29 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,35 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.327 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.293 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.242 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.311 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.278 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.222 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.263 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.199 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.243 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.178 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.224 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.170 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,79 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,84 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,39 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,68 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,54 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,13 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,85 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,66 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,2 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.296 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.245 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.066 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.280 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.230 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.047 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.215 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.026 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.195 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.006 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.179 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.000 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,77 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,8 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,22 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,59 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,25 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,98 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,37 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,7 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,81 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;31 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;48 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;176 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;31 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;48 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;175 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;48 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;173 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;48 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;172 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;45 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;170 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,43 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,3 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,73 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,75 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,59 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.726 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.603 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.675 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.705 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.594 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.650 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.670 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.569 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.636 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.648 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.565 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.624 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.640 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.555 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.610 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,78 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,44 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,51 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,76 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,88 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,67 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,48 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,63 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,96 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,02 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,01 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,12 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.627 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.301 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.606 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.292 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.573 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.269 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.552 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.267 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.546 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.260 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,71 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,31 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,68 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,54 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,39 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,39 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,02 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,85 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;99 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;302 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;99 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;302 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;97 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;300 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;96 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;298 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;94 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;295 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,98 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,34 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,97 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,68 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,95 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,68 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.712 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.604 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.586 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.685 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.584 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.571 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.669 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.578 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.559 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.659 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.570 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.545 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.556 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.535 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 25 Lleida;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,42 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,75 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,05 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,49 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,38 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,3 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,9 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,88 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,41 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,01 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,78 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.614 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.327 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.169 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.588 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.308 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.157 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.572 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.303 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.150 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.564 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.297 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.141 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.285 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.133 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,39 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,57 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,97 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,4 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,19 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,37 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,9 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,74 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,6 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,83 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,92 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;98 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;277 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;417 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;97 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;276 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;414 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;97 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;275 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;409 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;95 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;273 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;404 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;271 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;402 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,98 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,64 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,28 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,98 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,28 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,08 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,94 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,56 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,88 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,83 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,4 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.727 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.670 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.599 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.712 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.663 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.587 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.696 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.646 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.574 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.631 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.562 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.617 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.555 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,13 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,58 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,25 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,2 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,56 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,44 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,66 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,69 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,83 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,25 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.640 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.578 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.355 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.625 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.572 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.344 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.611 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.555 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.332 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.541 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.321 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.527 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.316 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,09 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,62 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,19 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,23 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,54 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,3 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,66 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,49 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,77 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,12 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;87 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;92 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;244 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;87 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;91 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;243 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;85 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;91 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;242 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;90 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;241 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;90 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;239 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,91 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,59 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,7 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,91 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,18 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,83 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,77 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,83 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,95 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.685 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.646 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.612 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.676 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.635 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.604 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.621 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.592 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.600 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.579 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.587 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.575 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,47 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,33 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,5 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,48 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,76 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,21 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,95 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,42 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,7 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.602 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.567 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.240 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.594 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.557 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.233 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.544 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.222 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.524 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.211 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.512 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.210 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,5 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,36 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,44 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,53 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,55 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,26 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,66 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,49 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,58 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;83 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;79 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;372 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;82 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;78 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;371 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;77 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;370 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;76 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;368 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;75 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;365 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,8 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,73 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,73 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,47 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,46 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,2 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,92 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,94 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,12 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;86 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;84 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;77 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;86 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;84 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;76 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;86 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;84 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;75 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;86 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;84 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;74 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;86 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;84 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;74 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,7 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,4 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,1 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,1 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;81 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;64 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;81 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;64 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;81 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;64 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;81 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;64 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;81 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;64 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;5 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;20 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;5 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;20 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;5 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;20 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;5 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;20 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;5 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;20 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;89 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;86 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;77 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;88 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;86 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;76 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;88 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;86 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;76 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;88 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;86 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;76 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;86 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;76 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,88 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,7 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,88 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,7 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,88 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,7 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,7 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;82 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;66 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;54 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;81 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;66 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;53 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;81 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;66 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;53 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;81 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;66 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;53 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;66 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;53 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,78 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,15 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,78 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,15 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,78 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,15 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,15 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;20 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;20 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;20 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;23 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;20 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;23 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;20 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;23 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;96 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;88 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;87 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;96 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;88 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;87 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;96 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;88 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;87 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;88 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;86 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;88 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;86 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,85 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,85 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;90 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;78 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;67 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;90 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;78 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;67 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;90 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;78 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;67 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;78 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;66 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;78 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;66 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,51 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,51 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;10 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;20 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;10 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;20 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;10 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;20 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;10 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;20 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;10 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;20 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;96 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;93 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;91 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;95 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;92 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;90 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;92 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;90 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;92 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;90 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;92 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;90 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,96 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,92 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,9 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,92 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,9 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,92 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,9 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,92 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,9 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;89 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;82 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;63 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;88 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;81 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;62 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;81 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;62 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;81 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;62 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;81 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;62 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,88 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,78 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,41 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,78 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,41 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,78 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,41 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,78 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,41 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;7 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;11 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;28 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;7 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;11 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;28 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;11 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;28 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;11 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;28 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;11 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;28 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;39 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;32 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;34 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;39 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;32 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;34 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;39 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;32 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;34 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;38 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;32 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;33 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;38 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;32 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;33 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,44 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,06 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,44 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,06 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;34 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;22 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;34 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;22 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;34 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;22 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;33 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;22 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;33 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;22 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,06 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,06 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;5 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;10 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;5 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;10 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;5 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;10 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;5 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;10 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;5 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;10 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;37 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;33 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;30 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;37 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;33 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;30 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;36 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;33 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;29 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;36 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;33 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;29 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;33 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;29 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,3 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,67 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,3 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,67 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,67 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;33 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;21 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;20 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;33 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;21 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;20 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;32 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;21 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;19 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;32 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;21 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;19 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;21 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;19 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,97 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,97 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;12 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;10 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;12 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;10 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;12 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;10 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;12 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;10 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;12 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;10 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;38 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;40 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;35 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;37 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;40 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;34 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;36 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;39 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;33 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;39 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;33 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;39 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;33 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,37 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,14 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,74 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,5 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,29 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,5 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,29 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,5 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,29 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;34 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;36 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;25 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;33 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;36 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;24 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;32 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;35 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;23 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;35 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;23 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;35 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;23 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,06 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,12 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,22 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,22 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;92 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,22 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;10 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;10 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;10 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;10 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;10 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;37 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;35 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;29 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;37 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;35 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;29 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;35 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;29 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;35 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;29 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;34 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;29 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,14 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;33 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;30 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;17 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;33 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;30 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;17 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;30 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;17 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;30 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;29 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,67 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;5 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;12 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;5 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;12 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;5 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;12 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;5 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;12 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;5 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;12 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 25 Lleida;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.927 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.843 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;9.266 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;8.462 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;8.434 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;8.488 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;8.101 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;8.130 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;8.216 27 Lugo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.868 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.932 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.985 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.632 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.743 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.742 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,79 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,37 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,6 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,75 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,94 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,67 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,14 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,7 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;86,18 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,49 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,56 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;83,55 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.585 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8.092 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.136 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.708 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.789 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7.417 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.564 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7.225 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.334 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7.047 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,77 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,25 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,73 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,66 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,11 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,29 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,43 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,09 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;342 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;751 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;326 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;726 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;312 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;713 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;304 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;707 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;298 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;696 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,32 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,67 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,23 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,94 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,89 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,14 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,13 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,68 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.848 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.750 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.835 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;8.422 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;8.383 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;8.523 27 Lugo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;8.154 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.152 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;8.267 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.846 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.926 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.984 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;7.625 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;7.726 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 27 Lugo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,19 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,81 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,47 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,16 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,17 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,57 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,68 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,58 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,37 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,14 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,45 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.532 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.919 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7.438 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;8.114 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.571 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7.150 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.857 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7.349 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;6.919 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.556 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;7.140 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6.673 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.853 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.460 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,1 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,61 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,13 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,09 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,8 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,02 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,56 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,16 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,71 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,54 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,85 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;316 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;831 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.397 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;308 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;812 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.373 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;297 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;803 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.348 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;290 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;786 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.311 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;772 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.266 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,47 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,71 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,28 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,99 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,63 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,49 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,77 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,58 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,84 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,9 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,62 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.935 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.920 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.858 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.530 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.562 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.515 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;8.082 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.205 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;8.178 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;7.869 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;7.904 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;7.663 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.727 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,47 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,99 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,13 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,45 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,98 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,32 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,22 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,23 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,91 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,23 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.665 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.695 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.968 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.268 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8.339 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7.640 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.827 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.986 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;7.324 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.654 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;7.077 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.454 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.915 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,42 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,91 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,88 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,33 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,85 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,92 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,03 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,82 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,73 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,78 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;270 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;225 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;890 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;262 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;223 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;875 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;255 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;219 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;854 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;215 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;827 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;209 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;812 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,04 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,11 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,31 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,44 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,33 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,96 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,56 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,92 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,89 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,24 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.934 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;9.016 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.968 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;8.382 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.546 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.513 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;8.174 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;8.188 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;7.868 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;7.939 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.661 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.769 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,82 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,79 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,93 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,66 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,3 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,27 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,53 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,97 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,63 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.688 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.640 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;8.110 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.141 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;8.184 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7.680 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.831 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7.380 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.541 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7.143 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.346 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.982 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,7 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,72 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,7 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,64 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,28 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,08 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,02 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,09 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;246 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;376 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;858 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;241 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;362 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;833 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;343 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;808 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;327 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;796 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;315 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;787 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,97 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,28 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,09 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,22 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,17 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,97 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,77 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,78 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,72 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;7.091 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;7.123 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;7.443 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;6.650 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;6.732 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;6.696 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;6.333 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;6.470 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;6.445 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.113 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;6.285 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.233 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.898 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;6.105 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.010 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,78 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,51 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,96 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,31 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,83 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,59 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,21 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,24 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,74 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,18 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,71 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,75 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.837 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.720 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.412 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.351 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.107 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.097 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.893 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.918 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.682 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.746 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,78 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,51 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,32 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,73 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,19 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,07 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,11 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,51 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;254 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;403 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;238 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;381 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;226 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;373 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;220 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;367 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;216 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;359 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;93,7 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;94,54 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;88,98 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,56 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,61 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,07 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,04 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,08 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;7.003 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.035 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.117 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;6.615 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;6.715 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;6.824 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.360 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;6.495 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;6.586 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.072 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;6.282 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;6.319 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;6.004 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;6.075 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 27 Lugo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,46 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,45 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,88 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,82 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,32 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,54 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,71 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,3 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,79 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,34 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,36 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.780 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.546 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.215 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6.398 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.239 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.943 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.152 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.028 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.724 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.870 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.828 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.489 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.563 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.286 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,37 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,31 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,62 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,74 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,09 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,1 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,58 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,03 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,32 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,98 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,05 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;223 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;489 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;902 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;217 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;476 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;881 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;208 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;467 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;862 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;202 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;454 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;830 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;441 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;789 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,31 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,34 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,67 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,27 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,5 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,57 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,58 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,84 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,02 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,18 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,47 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;7.033 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;7.125 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;7.127 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.642 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.782 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.801 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.231 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;6.446 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;6.479 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;6.132 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;6.221 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.944 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;6.063 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,44 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,19 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,43 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,6 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,47 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,91 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,06 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,29 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,42 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,07 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.846 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.980 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6.634 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.462 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.639 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.319 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6.057 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;6.306 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.015 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.996 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.781 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.812 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.631 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,39 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,11 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,25 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,48 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,34 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,67 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,9 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,14 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,27 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,88 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;187 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;145 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;493 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;180 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;143 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;482 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;174 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;140 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;464 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;136 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;440 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;132 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;432 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,26 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,62 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,77 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,05 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,55 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,12 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,79 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,25 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,03 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;87,63 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7.026 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;7.163 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;7.197 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.505 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.713 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.761 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;6.366 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;6.452 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;6.100 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;6.237 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.907 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;6.081 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,58 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,72 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,94 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,87 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,65 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,16 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,66 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,47 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,49 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.854 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.888 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6.739 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;6.338 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.451 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.322 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.122 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.034 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.870 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.827 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.688 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5.677 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,47 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,66 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,81 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,88 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,54 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,22 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,47 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,58 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,24 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;172 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;275 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;458 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;167 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;262 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;439 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;244 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;418 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;230 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;410 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;219 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;404 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,09 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,27 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,85 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;88,73 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,27 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;83,64 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,52 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;79,64 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,21 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;876 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;823 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;869 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;862 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;814 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;844 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;835 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;785 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;832 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;827 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;776 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;822 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;813 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;772 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;806 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,4 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,91 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,12 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,32 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,38 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,74 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,41 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,29 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,59 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,81 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,8 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,75 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;845 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;697 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;831 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;689 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;804 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;662 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;797 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;653 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;784 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;649 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,34 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,85 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,15 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;94,98 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,32 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,69 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,78 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,11 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;31 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;126 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;31 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;125 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;31 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;123 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;30 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;123 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;29 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;123 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,21 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,62 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,77 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,62 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,55 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,62 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;875 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;812 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;821 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;850 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;779 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;809 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;841 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;771 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;800 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;832 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;763 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;788 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;748 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;781 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,14 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,94 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,54 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,11 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;94,95 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,44 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,09 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;93,97 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,98 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,12 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,13 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;840 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;683 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;602 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;815 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;654 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;593 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;807 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;646 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;589 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;799 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;639 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;580 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;625 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;576 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,02 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,75 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,5 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,07 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;94,58 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,84 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,12 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,56 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,35 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;91,51 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,68 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;35 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;129 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;219 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;35 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;125 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;216 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;34 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;125 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;211 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;33 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;124 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;208 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;123 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;205 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,9 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,63 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,14 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,9 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,35 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,29 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,12 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,98 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,35 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,61 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;928 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;870 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;831 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;920 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;858 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;822 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;895 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;844 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;814 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;830 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;805 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;820 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;792 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,14 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,62 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,92 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,44 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,01 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,95 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,4 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,87 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,25 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,31 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;893 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;843 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;674 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;885 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;831 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;668 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;861 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;817 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;662 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;803 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;654 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;794 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;645 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,1 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,58 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,11 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,42 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,92 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,22 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,26 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,03 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,19 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,7 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;35 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;27 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;157 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;35 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;27 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;154 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;34 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;27 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;152 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;27 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;151 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;26 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;147 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,09 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,14 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,82 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,18 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,3 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,63 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;922 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;887 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;851 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;899 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;874 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;838 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;857 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;830 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;833 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;809 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;824 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;800 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,51 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,53 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,47 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,62 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,53 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;93,91 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,06 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,9 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,01 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;900 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;845 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;693 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;877 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;832 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;683 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;816 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;677 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;793 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;658 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;784 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;651 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,44 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,46 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,56 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,57 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,69 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,85 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,95 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,78 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,94 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;22 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;42 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;158 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;22 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;42 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;155 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;41 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;153 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;40 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;151 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;40 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;149 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,1 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,62 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,84 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,24 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,57 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,24 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,3 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;914 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;859 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;911 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;904 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;850 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;905 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;889 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;837 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;896 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;885 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;833 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;888 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;879 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;828 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;884 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,91 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,95 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,34 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,26 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,44 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,35 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,83 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,97 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,48 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,17 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,39 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,04 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;863 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;652 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;853 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;645 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;838 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;635 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;834 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;631 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;829 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;629 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,84 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,93 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,1 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,39 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,64 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,78 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,06 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,47 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;51 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;207 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;51 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;205 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;51 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;202 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;51 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;202 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;50 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;199 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,03 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,58 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,58 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,04 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,14 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;926 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;863 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;858 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;915 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;849 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;851 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;912 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;846 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;843 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;901 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;841 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;839 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;833 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;832 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 27 Lugo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,81 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,38 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,18 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,49 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,03 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,25 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,3 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,45 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,79 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,52 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,97 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;875 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;666 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;594 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;864 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;654 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;587 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;861 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;651 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;580 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;850 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;649 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;578 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;641 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;572 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,74 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,2 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,82 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,4 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,75 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,64 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,14 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,45 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,31 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,25 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,3 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;51 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;197 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;264 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;51 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;195 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;264 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;51 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;195 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;263 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;51 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;192 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;261 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;192 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;260 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,98 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,98 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,62 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,46 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,86 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,46 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,48 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;933 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;884 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;862 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;928 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;881 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;855 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;916 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;874 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;848 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;866 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;841 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;860 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;835 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,46 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,66 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,19 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,18 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,87 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,38 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,96 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,56 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,29 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,87 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;890 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;835 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;635 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;885 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;832 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;629 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;873 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;826 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;623 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;818 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;618 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;812 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;615 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,44 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,64 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,06 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,09 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,92 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,11 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,96 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,32 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,25 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,85 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;43 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;49 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;227 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;43 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;49 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;226 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;43 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;48 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;225 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;48 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;223 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;48 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;220 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,56 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,96 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,12 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,96 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,24 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,96 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,92 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;948 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;923 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;881 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;940 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;916 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;875 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;908 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;867 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;894 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;854 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;890 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;849 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,16 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,24 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,32 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,37 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,41 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,86 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,94 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,42 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,37 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;899 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;868 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;654 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;891 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;862 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;651 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;854 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;645 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;840 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;634 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;836 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;630 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,11 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,31 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,54 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,39 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,62 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,77 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,94 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,31 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,33 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;49 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;55 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;227 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;49 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;54 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;224 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;54 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;222 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;54 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;220 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;54 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;219 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,18 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,68 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,18 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,8 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,18 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,92 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,18 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,48 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;29 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;21 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;24 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;29 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;21 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;24 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;28 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;21 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;24 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;28 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;21 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;24 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;27 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;21 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;24 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,55 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,55 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,1 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;26 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;14 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;26 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;14 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;26 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;26 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;25 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;14 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,15 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;66,67 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;66,67 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;66,67 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;27 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;23 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;21 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;26 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;23 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;21 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;26 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;23 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;21 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;26 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;23 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;21 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;23 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;21 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,3 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,3 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,3 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;23 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;15 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;16 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;15 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;16 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;23 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;16 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;23 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;15 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;16 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;15 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;16 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;8 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;8 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;8 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;8 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;75 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;75 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;75 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;27 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;26 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;21 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;27 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;26 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;21 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;27 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;26 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;21 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;26 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;21 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;25 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;21 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,15 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;24 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;23 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;24 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;23 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;24 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;23 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;15 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;23 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;15 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;23 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;15 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;66,67 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;23 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;27 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;22 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;23 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;27 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;22 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;27 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;22 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;26 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;22 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;26 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;22 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,3 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,3 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;22 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;25 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;15 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;22 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;25 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;25 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;15 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;24 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;15 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;24 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;15 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;7 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;7 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;7 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;7 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;7 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;17 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;17 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;19 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;17 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;17 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;19 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;16 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;17 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;19 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;15 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;17 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;18 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;15 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;17 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;18 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;94,12 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,24 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,74 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;88,24 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,74 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;14 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;14 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;14 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;9 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;9 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;8 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;8 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;8 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;8 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;8 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;66,67 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;33,33 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;33,33 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;17 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;17 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;18 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;16 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;18 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;15 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;15 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;17 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 27 Lugo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,12 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,24 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,44 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,24 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,44 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,44 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;14 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;14 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;14 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;9 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;10 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,91 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,91 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;90,91 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;7 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;8 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;7 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;8 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;7 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;8 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;7 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;8 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;7 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;66,67 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;33,33 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;33,33 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;14 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;15 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;17 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;13 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;15 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;16 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;13 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;15 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;16 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;15 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;16 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;14 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;16 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,86 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,12 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,86 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,12 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,12 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,33 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,12 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;12 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;12 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;12 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;14 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;14 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;13 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;90 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;90 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,86 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;90 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;7 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;50 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;50 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;15 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;17 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;15 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;16 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;17 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;16 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;17 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;15 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;17 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;14 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;17 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;93,75 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,5 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;13 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;13 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;14 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;14 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;14 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;8 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;8 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;8 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;8 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;8 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;50 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;0 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 27 Lugo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;170.250 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;164.017 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;170.238 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;161.452 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;155.700 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;151.697 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;154.760 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;150.224 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;146.492 28 Madrid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;149.129 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;145.583 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;141.850 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;145.093 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;141.735 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;137.729 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,83 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,93 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,11 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,9 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,59 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,05 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,59 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,76 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,32 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,22 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;86,41 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,9 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;158.529 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;132.874 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;150.133 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;125.468 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;143.757 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;120.699 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;138.408 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;116.680 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;134.584 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;113.515 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,7 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,43 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,68 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,84 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,31 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,81 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,9 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,43 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;11.721 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;31.143 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;11.319 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;30.232 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;11.003 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;29.525 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;10.721 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;28.903 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;10.509 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;28.220 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,57 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,07 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,87 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,8 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,47 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,81 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,66 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,61 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;170.804 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;164.129 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;158.930 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;162.475 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;157.281 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;152.732 28 Madrid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;155.903 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;151.746 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;147.454 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;151.244 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;147.340 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;142.867 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;141.862 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;137.564 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 28 Madrid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,12 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,83 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,1 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,28 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,46 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,78 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,55 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,77 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,89 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,43 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,56 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;159.474 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;133.437 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;117.168 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;151.487 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;127.315 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;111.514 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;145.201 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;122.422 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;107.264 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;140.740 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;118.715 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;103.704 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;114.048 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;99.625 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,99 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,41 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,17 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,05 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,75 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,55 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,25 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,97 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,51 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,47 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,03 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;11.330 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;30.692 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;41.762 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;10.988 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;29.966 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;41.218 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;10.702 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;29.324 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;40.190 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;10.504 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;28.625 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;39.163 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;27.814 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;37.939 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,98 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,63 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,7 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,46 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,54 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,24 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,71 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,27 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,78 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,62 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,85 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;171.468 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;166.953 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;161.758 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;162.948 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;159.383 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;154.718 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;157.368 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;153.937 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;149.134 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;147.776 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;143.251 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;143.241 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;139.472 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,03 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,47 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,65 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,78 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,2 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,2 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,51 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,56 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,8 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,22 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;165.039 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;155.931 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;127.803 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;156.695 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;148.597 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;121.548 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;151.242 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;143.395 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;116.788 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;137.526 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;111.877 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;133.230 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;108.781 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,94 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,3 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,11 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,64 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,96 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,38 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,2 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,54 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,44 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,12 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6.429 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;11.022 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;33.955 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6.253 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;10.786 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;33.170 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6.126 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;10.542 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;32.346 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;10.250 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;31.374 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;10.011 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;30.691 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,26 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,86 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,69 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,29 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,65 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,26 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,4 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,83 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,39 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;170.560 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;167.679 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;163.090 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;163.715 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;160.773 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;155.882 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;153.765 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;149.146 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;148.375 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;144.677 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;143.492 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;140.621 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,99 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,88 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,58 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,7 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,45 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,49 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,71 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,58 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,22 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;164.924 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;155.357 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;127.459 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;158.189 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;148.794 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;121.162 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;142.196 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;115.456 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;137.121 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;111.733 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;132.517 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;108.375 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,92 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,78 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,06 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,53 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,58 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,26 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,66 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,3 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,03 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5.636 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12.322 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;35.631 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5.526 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;11.979 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;34.720 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;11.569 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;33.690 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;11.254 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;32.944 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;10.975 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;32.246 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,05 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,22 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,44 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,89 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,55 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,33 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,46 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,07 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,5 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;121.043 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;117.693 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;120.832 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;112.854 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;109.964 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;103.903 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;106.894 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;105.040 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;99.281 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;101.885 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;100.912 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;95.236 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;98.339 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;97.552 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;91.640 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,23 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,43 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,99 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,31 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,25 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,16 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,17 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,74 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;78,82 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,24 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,89 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;75,84 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;114.042 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;101.727 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;106.200 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;94.718 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;100.498 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;90.340 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;95.716 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;86.668 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;92.333 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;83.805 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,12 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,11 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,12 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,81 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,93 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,2 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,96 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,38 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7.001 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;15.966 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6.654 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;15.246 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6.396 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;14.700 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6.169 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;14.244 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6.006 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;13.747 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,04 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,49 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,36 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,07 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,12 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,21 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,79 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;86,1 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;121.161 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;117.632 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;113.654 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;113.491 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;111.257 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;107.837 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;107.518 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;106.219 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;103.023 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;103.323 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;102.310 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;98.856 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;97.503 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;94.207 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 28 Madrid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,67 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,58 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,88 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,74 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,3 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,65 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,28 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,97 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,98 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,89 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,89 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;114.442 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;101.897 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;89.748 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;107.060 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;96.130 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;84.364 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;101.327 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;91.577 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;80.379 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;97.292 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;88.192 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;77.049 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;83.982 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;73.321 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,55 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,34 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,54 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,87 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,56 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,01 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,55 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,85 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,42 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,7 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6.719 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;15.735 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23.906 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6.431 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;15.127 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23.473 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6.191 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;14.642 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;22.644 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6.031 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;14.118 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;21.807 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;13.521 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;20.886 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,71 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,14 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,19 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,14 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,05 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,72 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,76 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,72 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,22 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;85,93 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,37 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;121.576 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;119.145 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;115.709 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;113.656 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;112.099 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;109.159 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;108.560 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;107.172 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;104.037 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;101.721 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;98.856 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;97.767 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;95.554 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,49 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,09 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,34 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,29 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,95 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,91 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,38 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,44 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,06 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,58 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;117.778 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;113.369 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;98.174 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;110.016 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;106.522 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;92.249 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;105.029 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;101.800 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;87.779 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;96.569 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;83.301 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;92.794 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;80.505 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,41 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,96 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,96 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,18 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,8 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,41 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,18 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,85 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,85 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3.798 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;5.776 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;17.535 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3.640 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;5.577 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;16.910 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3.531 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;5.372 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;16.258 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;5.152 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;15.555 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4.973 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;15.049 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,84 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,55 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,44 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,97 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,01 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,72 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,2 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,71 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,1 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,82 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;121.037 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;119.617 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;116.940 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;114.588 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;113.140 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;110.141 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;106.797 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;104.068 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;102.037 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;100.111 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;97.738 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;96.554 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,67 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,59 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,19 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,28 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,99 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,3 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,61 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,71 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,57 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;117.795 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;112.031 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;98.600 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;111.446 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;105.867 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;92.565 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;99.880 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;87.268 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;95.388 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;83.875 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;91.318 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;80.825 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,61 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,5 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,88 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,15 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,51 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,14 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,07 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,51 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,97 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3.242 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;7.586 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;18.340 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3.142 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;7.273 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;17.576 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6.917 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;16.800 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6.649 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;16.236 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6.420 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;15.729 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,92 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,87 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,83 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,18 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,6 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,65 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,53 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,63 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85,76 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;18.535 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;17.573 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;18.507 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;18.218 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;17.267 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;17.600 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;17.840 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;16.982 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;17.309 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;17.547 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.728 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;16.992 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;17.295 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;16.504 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;16.725 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,29 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,26 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,1 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,25 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,64 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,53 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,67 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,19 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;91,81 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,31 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,92 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,37 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;16.845 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;12.435 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;16.560 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12.228 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.211 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;12.017 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.943 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.838 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15.715 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.696 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,31 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,34 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,24 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,64 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,65 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,2 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,29 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,06 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.690 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;5.138 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.658 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;5.039 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.629 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4.965 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.604 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4.890 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.580 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4.808 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,11 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,07 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,39 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,63 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,91 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,17 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,49 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,58 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;18.672 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;17.561 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;16.862 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;18.337 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;17.299 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;16.676 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;18.039 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;17.041 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;16.426 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;17.817 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.799 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.213 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;16.469 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;15.906 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,21 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,51 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,9 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,61 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,04 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,41 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,42 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,66 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,15 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,78 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,33 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;17.059 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12.447 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10.032 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;16.746 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.252 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9.892 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.473 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12.074 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.762 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;16.272 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.915 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.647 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.679 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.490 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,17 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,43 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,6 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,56 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,31 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,39 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,73 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,16 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,83 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,6 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.613 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;5.114 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6.830 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.591 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;5.047 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6.784 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.566 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4.967 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6.664 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.545 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4.884 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6.566 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;4.790 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6.416 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,64 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,69 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,33 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,09 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,13 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,57 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,78 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,5 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,13 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,66 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,94 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18.584 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;18.033 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;17.445 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;18.304 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;17.778 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;17.178 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;18.074 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.531 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;16.937 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;17.176 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;16.598 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;16.882 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;16.360 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,49 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,59 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,47 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,26 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,22 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,09 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,25 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,14 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,62 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,78 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;17.629 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;16.207 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11.842 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;17.358 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;15.967 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11.667 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;17.137 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;15.742 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.510 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.423 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11.291 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15.156 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11.135 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,46 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,52 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,52 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,21 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,13 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,2 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,16 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,35 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,52 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,03 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;955 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.826 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;5.603 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;946 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.811 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;5.511 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;937 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.789 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;5.427 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.753 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;5.307 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.726 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;5.225 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,06 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,18 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,36 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,12 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,97 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,86 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,72 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,52 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,25 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;18.303 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;18.045 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;17.367 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;18.113 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;17.828 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;17.142 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;17.499 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;16.805 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;17.181 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;16.554 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;16.908 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;16.318 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,96 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,8 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,7 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,97 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,76 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,21 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,32 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,7 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,96 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;17.460 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;16.388 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;11.476 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;17.274 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;16.189 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;11.326 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15.891 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.110 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.588 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10.943 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15.335 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.788 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,93 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,79 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,69 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,97 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,81 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,12 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,36 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,57 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;843 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.657 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5.891 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;839 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.639 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5.816 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.608 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5.695 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.593 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5.611 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.573 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5.530 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,53 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,91 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,73 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,04 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,67 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,14 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,25 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,93 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,87 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;27.058 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;25.345 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;27.356 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;26.799 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;25.078 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;26.679 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;26.462 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;24.821 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;26.397 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;26.159 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;24.579 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;26.132 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;25.939 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;24.338 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;25.891 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,04 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,95 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,53 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,8 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,93 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,49 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,68 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,98 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,53 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,86 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,03 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,64 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;24.374 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16.604 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;24.136 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16.424 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;23.828 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;16.250 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;23.552 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;16.093 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;23.357 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;15.952 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,02 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,92 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,76 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,87 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,63 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,92 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,83 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,07 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2.684 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;8.741 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2.663 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;8.654 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2.634 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;8.571 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2.607 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;8.486 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2.582 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;8.386 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,22 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,14 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,06 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,13 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,08 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,2 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,94 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;27.304 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;25.525 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;25.028 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;26.994 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;25.321 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;24.838 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;26.721 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;25.098 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;24.632 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;26.503 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;24.864 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;24.441 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;24.561 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;24.114 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 28 Madrid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,86 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,2 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,24 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,86 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,33 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,42 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,07 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,41 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,65 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,22 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,35 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;24.646 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16.926 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;15.036 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;24.368 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.770 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14.911 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;24.115 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;16.619 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;14.782 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;23.914 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;16.473 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;14.677 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;16.276 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;14.496 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,87 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,08 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,17 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,85 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,19 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,31 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,03 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,32 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,61 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,16 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,41 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2.658 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8.599 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9.992 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2.626 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;8.551 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9.927 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2.606 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;8.479 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;9.850 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2.589 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;8.391 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9.764 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;8.285 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9.618 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,8 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,44 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,35 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,04 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,6 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,58 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,4 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,58 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,72 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,35 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,26 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;27.618 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;26.350 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;25.308 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;27.318 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;26.094 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;25.090 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;27.086 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;25.845 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;24.884 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;25.525 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;24.542 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;25.255 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;24.315 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,91 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,03 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,14 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,07 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,08 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,32 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,87 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,97 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,84 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,08 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;26.099 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;23.369 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15.803 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;25.808 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;23.132 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.652 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;25.585 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;22.899 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;15.526 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;22.612 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;15.325 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;22.374 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;15.189 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,89 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,99 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,04 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,03 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,99 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,25 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,76 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,98 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,74 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,11 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.519 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2.981 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;9.505 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.510 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2.962 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;9.438 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.501 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2.946 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;9.358 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2.913 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;9.217 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2.881 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;9.126 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,41 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,36 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,3 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,82 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,83 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,45 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,72 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,97 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,65 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,01 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;27.488 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;26.502 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;25.386 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;27.298 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;26.311 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;25.215 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;26.008 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;24.907 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;25.713 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;24.656 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;25.428 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;24.411 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,31 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,28 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,33 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,14 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,11 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,02 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,12 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,95 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,16 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;26.079 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;23.787 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;15.375 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;25.895 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;23.608 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.268 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;23.328 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;15.087 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;23.064 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;14.930 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;22.808 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;14.787 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,29 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,25 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,3 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,07 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,13 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,96 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,11 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,88 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,18 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1.409 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2.715 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;10.011 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1.403 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2.703 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9.947 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2.680 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;9.820 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2.649 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;9.726 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2.620 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;9.624 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,57 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,56 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,36 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,71 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,09 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,57 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,15 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,5 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,13 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.048 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.904 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.980 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;2.034 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;1.898 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;1.958 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;2.024 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;1.891 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;1.951 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.004 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.881 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.937 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.993 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.867 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.929 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,32 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,68 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,89 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,83 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,32 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,54 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,85 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,79 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,83 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,31 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,06 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,42 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.845 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.221 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.832 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.216 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.822 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.211 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.804 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.204 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.793 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.192 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,3 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,59 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,75 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,18 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,78 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,61 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,18 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,62 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;203 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;683 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;202 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;682 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;202 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;680 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;200 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;677 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;200 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;675 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,51 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,85 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,51 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,56 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,52 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,12 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,52 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,83 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.100 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.921 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.877 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;2.091 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;1.916 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;1.873 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.068 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.907 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.866 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.051 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.895 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.859 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;1.880 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;1.850 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 28 Madrid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,57 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,74 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,79 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,48 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,27 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,41 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,67 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,65 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,04 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,87 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,56 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.891 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.265 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.311 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.882 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.262 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.307 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.859 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.255 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.302 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.842 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.245 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.298 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.238 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.292 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,52 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,76 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,69 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,31 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,21 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,31 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,41 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,42 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;99,01 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,87 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,55 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;209 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;656 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;566 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;209 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;654 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;566 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;209 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;652 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;564 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;209 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;650 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;561 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;642 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;558 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,7 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,39 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,65 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,09 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,12 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,87 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,59 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.108 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.932 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.842 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.093 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.923 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.838 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.078 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.909 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.832 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;1.895 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;1.822 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;1.885 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;1.813 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,29 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,53 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,78 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,58 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,81 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,46 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,08 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,91 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,57 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,43 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.003 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.697 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.130 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.988 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.690 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.127 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.973 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.676 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.124 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.665 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.118 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.656 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.111 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,25 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,59 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,73 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,5 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,76 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,47 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,11 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,94 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,58 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,32 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;105 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;235 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;712 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;105 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;233 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;711 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;105 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;233 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;708 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;230 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;704 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;229 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;702 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,15 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,86 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,15 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,44 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,87 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,88 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,45 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,6 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.110 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.989 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.904 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.100 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.976 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.900 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;1.964 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;1.892 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;1.954 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;1.885 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.934 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.874 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,53 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,35 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,79 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,74 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,37 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,24 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,23 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,42 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.016 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.786 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.145 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.006 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.773 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.143 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.761 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.137 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.752 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.132 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.733 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.126 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,5 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,27 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,83 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,6 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,3 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,1 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,86 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,03 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,34 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;94 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;203 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;759 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;94 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;203 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;757 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;203 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;755 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;202 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;753 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;201 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;748 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,74 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,47 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;99,51 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,21 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;99,01 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,55 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.566 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.502 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.563 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;1.547 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;1.493 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;1.557 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;1.540 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;1.490 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;1.554 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.534 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.483 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.553 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.527 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.474 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.544 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,79 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,4 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,62 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,34 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,2 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,42 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,96 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,74 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;99,36 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,51 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,14 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,78 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.423 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;887 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.405 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;882 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.398 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;881 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.393 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;877 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.386 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;870 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,74 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,44 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,24 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,32 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,89 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,87 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,4 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,08 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;143 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;615 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;142 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;611 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;142 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;609 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;141 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;606 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;141 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;604 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,3 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,35 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,3 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,02 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,6 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,54 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,6 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,21 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.567 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.490 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.509 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;1.562 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;1.488 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;1.508 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.557 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.481 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.507 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.550 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.472 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.498 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;1.449 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;1.487 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 28 Madrid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,68 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,87 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,93 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,36 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,4 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,87 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,92 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,79 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,27 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,25 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,54 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.436 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;902 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.041 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.431 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;901 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.040 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.427 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;897 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.039 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.420 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;890 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.033 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;873 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.026 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,65 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,89 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,9 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,37 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,45 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,81 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,89 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,67 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;99,23 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,78 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,56 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;131 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;588 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;468 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;131 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;587 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;468 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;130 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;584 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;468 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;130 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;582 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;465 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;576 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;461 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,83 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,24 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,32 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;99,24 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,98 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;99,36 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,96 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,5 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.582 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.493 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.454 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.577 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.489 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.453 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.570 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.480 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.444 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;1.459 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;1.433 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;1.452 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;1.430 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,68 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,73 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,93 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,24 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,13 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,31 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,72 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,56 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,25 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,35 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.530 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.289 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;854 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.525 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.286 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;853 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.518 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.278 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;849 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.257 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;842 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.250 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;841 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,67 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,77 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,88 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,22 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,15 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,41 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,52 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,59 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,97 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,48 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;52 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;204 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;600 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;52 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;203 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;600 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;52 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;202 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;595 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;202 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;591 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;202 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;589 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,51 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,02 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,17 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,02 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,5 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;99,02 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,17 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.622 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.526 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.493 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.616 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.518 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.484 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;1.497 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;1.474 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;1.490 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;1.471 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.484 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.464 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,63 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,48 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,4 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,1 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,73 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,64 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,53 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,25 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,06 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.574 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.365 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;863 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.568 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.357 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;860 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.336 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;854 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.329 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;853 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.323 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;849 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,62 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,41 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,65 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,88 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,96 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,36 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,84 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,92 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,38 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;48 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;161 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;630 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;48 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;161 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;624 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;161 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;620 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;161 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;618 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;161 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;615 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,05 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,41 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,1 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,62 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 28 Madrid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;44.808 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;42.391 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;45.787 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;41.834 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;39.376 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;37.736 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;39.816 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;37.792 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;36.120 29 Málaga;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;38.257 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;36.373 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;34.833 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;36.812 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;35.198 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;33.356 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,36 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,89 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;82,42 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,86 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,15 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;78,89 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,38 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,8 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;76,08 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,15 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,03 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;72,85 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;41.348 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;33.683 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;38.510 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;31.035 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;36.610 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;29.642 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;35.138 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;28.408 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;33.777 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;27.436 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,14 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,14 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,54 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,98 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,34 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,69 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,45 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3.460 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;8.708 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3.324 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;8.341 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3.206 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;8.150 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3.119 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7.965 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3.035 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7.762 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,07 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,79 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,66 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,59 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,14 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,47 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,72 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,14 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;45.401 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;42.316 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;40.152 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;42.817 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;40.193 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;38.173 29 Málaga;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;40.854 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;38.421 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;36.625 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;38.828 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;36.859 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;34.828 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;35.335 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;33.203 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 29 Málaga;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,31 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,98 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,07 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,98 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,8 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,22 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,52 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,1 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,74 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,5 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,69 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;41.978 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;34.790 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;29.611 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;39.508 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;32.859 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;27.758 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;37.644 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;31.270 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;26.549 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;35.739 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;29.930 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;25.258 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;28.617 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;24.025 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,12 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,45 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,74 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,68 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,88 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,66 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,14 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,03 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,3 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,26 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,14 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3.423 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;7.526 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;10.541 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3.309 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;7.334 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;10.415 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3.210 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;7.151 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;10.076 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3.089 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6.929 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9.570 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6.718 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9.178 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,67 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,45 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,8 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,78 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,02 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,59 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,24 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,07 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,79 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,26 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,07 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;47.133 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;44.780 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;42.670 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;44.163 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;41.949 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;40.177 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;41.231 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;39.482 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;37.636 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;37.615 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;35.647 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;36.289 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;34.604 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,7 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,68 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,16 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,48 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,17 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,2 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,54 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,04 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,1 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;44.414 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;42.134 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;31.842 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;41.530 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;39.377 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;29.675 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;38.705 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;36.990 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;27.643 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;35.213 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;26.060 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;33.942 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;25.220 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,51 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,46 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,19 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,15 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,79 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,81 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,57 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;81,84 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,56 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;79,2 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2.719 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2.646 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;10.828 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2.633 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2.572 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;10.502 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2.526 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2.492 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;9.993 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2.402 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;9.587 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2.347 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;9.384 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,84 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,2 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,99 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,9 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,18 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,29 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,78 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,54 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,7 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,66 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;46.840 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;45.054 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;43.631 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;43.264 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;41.761 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;39.987 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;39.504 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;37.585 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;37.921 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;36.324 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;36.611 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;35.116 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,37 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,69 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,65 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,68 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,14 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,17 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,25 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,26 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;80,48 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;44.490 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;41.284 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;34.159 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;41.000 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;38.160 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;30.995 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;36.038 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;28.973 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;34.564 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;27.897 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;33.345 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;26.879 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,16 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,43 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,74 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,29 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;84,82 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,72 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;81,67 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,77 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;78,69 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2.350 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3.770 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;9.472 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2.264 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3.601 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;8.992 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3.466 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;8.612 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3.357 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;8.427 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3.266 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;8.237 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,34 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,52 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,93 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,94 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,92 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,05 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,97 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,63 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,96 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;34.420 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;33.174 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;35.100 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;31.608 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;30.304 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;27.566 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;29.785 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;28.859 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;26.080 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;28.363 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;27.553 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;24.927 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;27.060 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;26.473 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;23.650 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,83 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;91,35 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;78,54 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;86,53 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;86,99 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;74,3 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;82,4 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;83,06 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;71,02 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;78,62 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;79,8 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;67,38 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;32.042 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;28.044 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;29.350 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;25.493 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;27.629 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;24.196 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;26.280 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;23.037 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;25.047 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;22.126 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,6 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;90,9 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,23 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;86,28 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,02 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;82,15 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;78,17 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;78,9 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2.378 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;5.130 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2.258 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4.811 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2.156 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4.663 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2.083 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4.516 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2.013 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4.347 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,95 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;93,78 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,66 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;90,9 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,59 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,03 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,65 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;84,74 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;34.588 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;32.959 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;30.907 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;32.178 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;30.953 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;29.010 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;30.354 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;29.303 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;27.575 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;28.593 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;27.895 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;25.976 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;26.522 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;24.512 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 29 Málaga;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,03 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,91 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;93,86 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,76 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,91 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;89,22 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;82,67 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,64 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;84,05 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;80,47 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;79,31 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;32.300 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;28.421 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;24.455 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;29.991 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;26.573 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;22.661 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;28.255 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;25.069 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;21.516 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;26.577 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;23.831 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;20.309 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;22.630 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;19.171 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,85 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,5 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;92,66 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,48 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;88,21 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;87,98 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;82,28 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;83,85 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;83,05 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;79,62 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;78,39 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2.288 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4.538 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6.452 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2.187 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4.380 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6.349 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2.099 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4.234 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6.059 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2.016 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4.064 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.667 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.892 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.341 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,59 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,52 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,4 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,74 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,3 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;93,91 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,11 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,55 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;87,83 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;85,76 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;82,78 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;35.417 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;34.415 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;32.895 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;32.596 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;31.728 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;30.533 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;30.109 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;29.585 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;28.303 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;27.903 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;26.511 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;26.728 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;25.592 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,03 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,19 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,82 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;85,01 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;85,97 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;86,04 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;81,08 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;80,59 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;77,66 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;77,8 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;33.687 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;32.809 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;26.479 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;30.944 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;30.186 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;24.403 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;28.529 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;28.097 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;22.556 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;26.488 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;21.095 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;25.356 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;20.325 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,86 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,01 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,16 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;84,69 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;85,64 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;85,18 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;80,73 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;79,67 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;77,28 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;76,76 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.730 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.606 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6.416 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.652 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.542 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6.130 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.580 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.488 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;5.747 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.415 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;5.416 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.372 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;5.267 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,49 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,01 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95,54 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,33 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,65 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;89,57 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,11 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;84,41 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85,43 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;82,09 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;35.348 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;34.513 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;33.806 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;32.156 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;31.513 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;30.418 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;29.439 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;28.199 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;28.034 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;27.074 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;26.858 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;25.981 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;90,97 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,31 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;89,98 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;85,3 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;83,41 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;81,23 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;80,09 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;77,82 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;76,85 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;33.884 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;31.928 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;28.367 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;30.751 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;29.059 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;25.364 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;27.101 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;23.462 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;25.788 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;22.475 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;24.689 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;21.530 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;90,75 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,01 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;89,41 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;84,88 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;82,71 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;80,77 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;79,23 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;77,33 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;75,9 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1.464 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2.585 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5.439 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1.405 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2.454 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5.054 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2.338 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4.737 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2.246 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;4.599 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2.169 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;4.451 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,97 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,93 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;92,92 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,44 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;87,09 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,89 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;84,56 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,91 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;81,83 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.582 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.174 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.720 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;4.485 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;4.099 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;4.396 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;4.367 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;4.013 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;4.326 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.279 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.945 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.253 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.198 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.899 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.141 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,88 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,2 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;93,14 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,31 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,14 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;91,65 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;93,39 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,51 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;90,11 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;91,62 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,41 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;87,73 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.138 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.782 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.052 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.729 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.943 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.665 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.864 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.614 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.791 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.584 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,92 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,09 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,29 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,79 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;93,38 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,96 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;91,61 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,88 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;444 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.392 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;433 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.370 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;424 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.348 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;415 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.331 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;407 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.315 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,52 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,42 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,5 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,84 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,47 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,62 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,67 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,47 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.775 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.229 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.165 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;4.667 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;4.160 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;4.124 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.576 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.085 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.053 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.422 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.001 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.936 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.911 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.849 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,74 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,37 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,02 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,83 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,59 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,31 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;92,61 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,61 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,5 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,48 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;92,41 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.307 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.075 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.491 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.204 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.024 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.460 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.122 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.969 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.422 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.990 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.913 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.373 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.845 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.321 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,61 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,34 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,76 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,7 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,55 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,23 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,64 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;94,73 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,26 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;92,52 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,18 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;468 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.154 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.674 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;463 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.136 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.664 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;454 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.116 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.631 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;432 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.088 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.563 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.066 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.528 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,93 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,44 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,4 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,01 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,71 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,43 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,31 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,28 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,37 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,37 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,28 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5.029 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.543 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.370 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.941 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.464 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.289 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.724 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.309 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.115 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;4.213 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;4.012 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;4.128 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.945 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,25 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,26 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,15 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;93,94 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;94,85 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;94,16 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92,74 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;91,81 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90,87 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;90,27 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.647 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.153 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.651 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.564 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.078 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.596 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.357 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.930 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.487 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.841 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.423 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.765 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.387 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,21 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,19 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,93 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;93,76 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,63 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;93,81 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;92,49 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;91,4 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,66 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;90,04 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;382 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;390 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.719 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;377 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;386 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.693 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;367 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;379 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.628 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;372 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.589 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;363 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.558 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,69 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,97 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,49 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,07 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,18 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,71 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,38 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,44 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,08 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,63 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.993 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.618 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.461 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.785 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.469 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.299 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;4.367 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;4.201 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;4.262 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;4.125 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.175 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.058 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,83 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,77 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,37 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;94,56 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;94,17 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;92,29 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;92,47 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;90,41 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;90,97 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.660 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.119 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.871 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.461 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.985 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.768 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.894 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.701 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.799 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.651 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.722 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.609 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,73 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,75 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;96,41 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;94,54 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;94,08 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;92,23 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;92,34 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;90,36 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;90,87 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;333 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;499 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.590 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;324 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;484 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.531 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;473 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.500 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;463 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.474 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;453 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.449 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,3 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,99 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,29 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,79 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,34 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,79 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,7 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90,78 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,13 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;5.522 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.781 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;5.674 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;5.461 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;4.714 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;5.485 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;5.384 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;4.661 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;5.426 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.336 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.620 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.368 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.277 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.573 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.280 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,9 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,6 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,67 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,5 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,49 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,63 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,63 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,63 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,61 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,56 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,65 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,06 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.917 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.714 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.861 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.672 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.791 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.640 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.748 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.618 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.695 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.587 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,86 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,45 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,44 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,27 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,56 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,46 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,49 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,32 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;605 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.067 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;600 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.042 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;593 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.021 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;588 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.002 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;582 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.986 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,17 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,79 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,02 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,77 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,19 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,86 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,2 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,08 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;5.738 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.883 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.826 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;5.672 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;4.835 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;4.785 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.626 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.792 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.746 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.517 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.725 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.665 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;4.667 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;4.593 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 29 Málaga;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,85 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,02 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,15 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,05 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,14 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,34 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,15 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,76 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,66 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,58 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,17 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.092 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.152 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.529 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.034 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.120 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.501 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.990 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.092 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.478 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.897 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.047 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.443 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.006 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.402 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,86 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,98 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,89 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,1 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,98 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,17 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,67 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,6 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,37 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,98 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;646 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.731 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.297 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;638 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.715 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.284 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;636 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.700 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.268 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;620 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.678 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.222 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.661 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.191 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,76 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,08 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,43 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,45 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,21 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,74 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,98 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,94 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,73 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,96 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,39 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.361 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.552 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5.157 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.302 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.488 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.109 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.077 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.323 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.972 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;5.239 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;4.880 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;5.173 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;4.823 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,07 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,85 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,07 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,54 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,88 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,41 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,36 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,63 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,17 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,52 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5.777 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.933 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.593 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.721 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.875 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.558 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.521 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.729 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.482 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.655 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.425 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.592 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.391 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,03 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,82 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,65 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,57 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,86 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,72 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,36 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,52 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,09 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,21 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;584 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;619 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.564 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;581 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;613 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.551 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;556 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;594 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.490 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;584 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.455 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;581 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.432 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,49 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,03 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,49 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,21 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,96 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,11 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,35 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,75 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,86 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,85 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.174 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.638 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5.097 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.002 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.499 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.004 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;5.423 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;4.922 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;5.350 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;4.862 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.305 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.815 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,21 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,53 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,18 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,19 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,57 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,89 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,39 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,09 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,47 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5.639 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.979 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.783 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.485 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.863 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.726 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.795 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.675 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.729 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.636 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.688 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.605 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,27 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,67 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,95 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,3 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,12 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,98 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,72 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,16 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,6 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;535 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;659 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.314 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;517 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;636 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.278 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;628 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.247 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;621 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.226 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;617 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.210 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,64 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,51 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,44 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,3 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,1 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,23 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,2 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;93,63 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,51 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;190 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;176 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;205 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;189 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;174 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;201 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;189 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;174 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;200 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;188 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;170 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;198 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;186 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;168 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;198 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,47 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,86 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,05 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,47 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,86 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,56 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,95 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,59 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,59 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,89 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,45 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,59 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;169 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;94 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;168 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;93 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;168 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;93 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;167 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;91 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;165 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;91 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,41 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,94 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,41 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,94 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,82 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,81 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,63 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,81 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;21 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;82 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;21 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;81 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;21 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;81 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;21 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;79 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;21 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;77 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,78 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,78 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,34 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,9 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;204 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;155 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;174 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;204 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;155 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;174 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;202 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;151 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;173 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;200 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;148 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;173 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;148 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;171 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 29 Málaga;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,02 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,42 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,43 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,04 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,48 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,43 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,48 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,28 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;190 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;88 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;87 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;190 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;88 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;87 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;188 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;86 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;86 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;186 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;85 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;86 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;85 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;84 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,95 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,73 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,85 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,89 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,59 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,85 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,59 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,55 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;14 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;67 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;87 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;14 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;67 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;87 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;14 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;65 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;87 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;14 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;63 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;87 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;63 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;87 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,01 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,03 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,03 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;233 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;184 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;169 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;231 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;183 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;168 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;228 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;179 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;168 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;176 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;166 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;176 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;166 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,14 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,46 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,41 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,85 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,28 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,41 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,65 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,22 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,65 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,22 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;214 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;162 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;75 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;212 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;161 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;75 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;209 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;157 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;75 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;154 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;74 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;154 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;74 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,07 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,38 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,66 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,91 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,06 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,67 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,06 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,67 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;19 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;22 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;94 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;19 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;22 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;93 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;19 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;22 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;93 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;22 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;92 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;22 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;92 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,94 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,94 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,87 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,87 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;225 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;194 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;183 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;221 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;189 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;182 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;188 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;179 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;188 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;179 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;186 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;178 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,22 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,42 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,45 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,91 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,81 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,91 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,81 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,88 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,27 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;210 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;176 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;90 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;206 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;171 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;89 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;170 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;87 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;170 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;87 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;168 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;87 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,1 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,16 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,89 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,59 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,67 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,59 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,67 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,45 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,67 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;15 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;18 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;93 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;15 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;18 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;93 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;18 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;92 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;18 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;92 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;18 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;91 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,92 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,92 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,85 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;94 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;86 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;88 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;91 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;85 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;88 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;91 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;85 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;88 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;91 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;85 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;87 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;91 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;85 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;87 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;96,81 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,84 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,81 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,84 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,81 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,84 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,86 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,81 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,84 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,86 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;82 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;49 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;79 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;48 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;79 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;48 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;79 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;48 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;79 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;48 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;96,34 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,96 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,34 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,96 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,34 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,96 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,34 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,96 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;12 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;37 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;12 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;37 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;12 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;37 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;12 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;37 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;12 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;37 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;96 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;90 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;80 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;96 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;90 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;80 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;96 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;90 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;78 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;96 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;90 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;78 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;87 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;78 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,5 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,5 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,67 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,5 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;89 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;54 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;49 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;89 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;54 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;49 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;89 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;54 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;47 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;89 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;54 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;47 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;51 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;47 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,92 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,92 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,44 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,92 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;36 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;31 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;36 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;31 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;36 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;31 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;36 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;31 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;36 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;31 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;93 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;86 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;79 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;93 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;86 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;78 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;93 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;86 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;78 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;84 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;78 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;84 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;78 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,73 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,73 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,67 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,73 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,67 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,73 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;89 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;77 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;44 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;89 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;77 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;43 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;89 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;77 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;43 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;75 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;43 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;75 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;43 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,73 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,73 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,4 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,73 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,4 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,73 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;9 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;35 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;9 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;35 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;9 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;35 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;9 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;35 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;9 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;35 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;91 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;84 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;91 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;84 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;87 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;84 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;87 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;84 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;87 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;84 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,6 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,6 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,6 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;97 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;82 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;48 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;97 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;82 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;48 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;78 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;48 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;78 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;48 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;78 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;48 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,12 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,12 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,12 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;9 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;36 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;9 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;36 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;9 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;36 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;9 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;36 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;9 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;36 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 29 Málaga;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;35.351 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;33.961 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;35.373 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;33.397 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;32.056 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;30.905 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;31.869 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;30.916 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;29.808 30 Murcia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;30.682 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;29.945 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;28.853 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;29.801 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;29.199 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;28.031 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,47 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,39 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,37 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,15 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,03 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,27 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,79 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,17 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,57 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,3 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,98 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,24 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;34.007 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;31.017 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;32.104 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;29.196 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;30.617 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;28.119 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;29.465 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;27.212 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;28.616 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;26.523 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,4 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,13 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,03 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,66 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,64 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,73 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,15 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,51 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.344 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.944 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.293 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.860 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.252 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.797 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.217 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.733 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.185 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.676 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,21 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,15 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,15 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,01 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,55 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,83 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,17 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,9 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;35.420 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;34.026 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;32.456 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;33.491 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;32.541 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;31.083 30 Murcia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;32.056 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;31.307 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;29.977 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;30.966 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;30.345 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;29.024 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;29.304 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;27.940 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 30 Murcia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,55 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,64 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,77 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,5 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,01 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,36 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,43 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,18 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,43 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,12 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,09 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;34.106 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;31.055 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;26.779 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;32.228 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;29.637 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;25.491 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;30.839 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;28.474 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;24.523 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;29.775 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;27.569 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;23.748 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;26.612 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;22.840 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,49 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,43 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,19 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,42 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,69 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,58 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,3 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,77 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,68 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,69 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,29 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.314 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.971 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.677 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.263 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.904 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5.592 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.217 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.833 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.454 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.191 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.776 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.276 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.692 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.100 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,12 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,74 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,5 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,62 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,36 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,07 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,64 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,44 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,94 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,61 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,84 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;35.662 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;34.995 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;34.000 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;33.598 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;33.068 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;32.134 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;32.137 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;31.747 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;30.753 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;30.525 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;29.500 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;29.552 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;28.763 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,21 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,49 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,51 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,12 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,72 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,45 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,23 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,76 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,45 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,6 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;34.543 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;33.917 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;30.804 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;32.519 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;32.022 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;29.011 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;31.082 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;30.723 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;27.733 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;29.527 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;26.568 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;28.575 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;25.884 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,14 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,41 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,18 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,98 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,58 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,03 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,06 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,25 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,25 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,03 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.119 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.078 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.196 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.079 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.046 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.123 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.055 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.024 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.020 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;998 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.932 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;977 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.879 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,43 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,03 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,72 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,28 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,99 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,49 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,58 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,74 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,63 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,08 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;35.285 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;34.897 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;33.910 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;33.473 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;33.168 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;32.111 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;31.730 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;30.657 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;30.557 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;29.773 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;29.587 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;28.971 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,86 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,05 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,69 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,92 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,41 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,56 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,8 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,78 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,43 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;34.279 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;33.478 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;30.534 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;32.487 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;31.777 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;28.849 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;30.386 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;27.494 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;29.246 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;26.674 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;28.313 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;25.943 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,77 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,92 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,48 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,76 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,04 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,36 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,36 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,57 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,96 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1.006 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.419 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.376 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;986 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.391 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.262 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.344 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3.163 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.311 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3.099 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.274 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3.028 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,01 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,03 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,62 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,71 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,69 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,39 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,8 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,78 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,69 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;25.693 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;24.981 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;25.774 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;23.861 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;23.224 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;21.650 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;22.479 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;22.184 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;20.659 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;21.404 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;21.293 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;19.818 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;20.623 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;20.630 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;19.096 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,87 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,97 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;84 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,49 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,8 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;80,15 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,31 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,24 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;76,89 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,27 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,58 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;74,09 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;24.900 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;23.533 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;23.112 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;21.847 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;21.766 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;20.858 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;20.720 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;20.016 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;19.965 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;19.398 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,82 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,84 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,41 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,63 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,21 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,06 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,18 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,43 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;793 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.448 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;749 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.377 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;713 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.326 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;684 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.277 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;658 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.232 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,45 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,1 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;89,91 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,57 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,25 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,19 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;82,98 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,08 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;25.695 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;24.982 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;23.866 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;23.911 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;23.606 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;22.576 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;22.589 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;22.450 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;21.558 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;21.615 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;21.590 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;20.676 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;20.661 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;19.741 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 30 Murcia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,06 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,49 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,59 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,91 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,86 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,33 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,12 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,42 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,63 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,7 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,72 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;24.926 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;23.433 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;20.503 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23.188 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;22.115 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;19.288 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;21.908 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;21.023 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;18.390 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;20.955 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;20.211 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;17.657 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;19.353 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;16.863 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,03 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,38 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,07 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,89 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,72 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,69 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,07 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,25 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,12 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,59 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,25 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;769 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.549 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.363 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;723 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.491 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.288 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;681 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.427 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.168 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;660 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.379 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.019 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.308 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.878 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,02 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,26 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,77 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;88,56 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,12 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,2 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;85,83 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,03 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;89,77 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;84,44 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;85,58 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;25.562 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;25.380 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;24.897 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;23.666 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;23.570 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;23.158 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;22.409 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;22.414 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;21.899 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;21.315 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;20.806 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;20.448 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;20.142 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,58 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,87 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,02 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,67 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,31 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,96 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,98 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,57 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,57 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;80,9 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;24.946 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;24.843 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;23.338 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;23.086 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;23.062 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;21.667 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;21.848 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;21.925 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;20.494 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;20.847 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;19.473 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;19.995 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;18.850 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,54 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,83 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,84 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,58 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,25 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,81 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,91 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,44 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,49 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,77 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;616 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;537 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.559 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;580 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;508 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.491 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;561 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;489 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.405 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;468 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.333 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;453 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.292 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,16 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,6 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95,64 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,07 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,06 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;90,12 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;87,15 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;85,5 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;84,36 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;82,87 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;25.491 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;25.462 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;24.886 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;23.824 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;23.846 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;23.181 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;22.525 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;21.883 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;21.471 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;21.083 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;20.604 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;20.354 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,46 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,65 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,15 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,47 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,93 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,33 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,72 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,92 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,79 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;24.965 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;24.592 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;23.231 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;23.314 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;22.999 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;21.627 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;21.722 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;20.408 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;20.697 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;19.660 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;19.864 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;18.983 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,39 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,52 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,1 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,33 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,85 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,16 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,63 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,77 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,71 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;526 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;870 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.655 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;510 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;847 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.554 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;803 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.475 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;774 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.423 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;740 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.371 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,96 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,36 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;93,9 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,3 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;89,12 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,97 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;85,98 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,06 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;82,84 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.038 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.819 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.060 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.981 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.750 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.849 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.907 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.693 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.793 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.854 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.642 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.729 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.798 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.600 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.668 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,59 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,19 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;94,8 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,76 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,7 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,42 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,44 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,37 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;91,85 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,06 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,27 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,34 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.824 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.282 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.769 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.219 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.698 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.168 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.647 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.127 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.594 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.092 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,56 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,08 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,71 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,53 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,37 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,28 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,99 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,21 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;214 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;537 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;212 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;531 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;209 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;525 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;207 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;515 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;204 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;508 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,07 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,88 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,66 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,77 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,73 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,9 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,33 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,6 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.039 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.836 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.614 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.967 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.766 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.576 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.907 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.720 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.529 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.838 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.665 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.485 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.605 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.403 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,22 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,18 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,95 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,73 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,98 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,65 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,02 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,54 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,43 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,98 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,16 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.827 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.328 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.690 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.758 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.264 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.656 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.701 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.221 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.617 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.633 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.171 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.592 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.117 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.527 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,2 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,08 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,74 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,71 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,78 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,29 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,93 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,28 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,36 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,66 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,94 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;212 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;508 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;924 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;209 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;502 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;920 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;206 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;499 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;912 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;205 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;494 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;893 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;488 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;876 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,58 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,82 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,57 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,17 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,23 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,7 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,7 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,24 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,65 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,06 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,81 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.201 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.083 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.889 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.105 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.015 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.821 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.984 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.915 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.741 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.851 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.659 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.798 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.610 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,71 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,33 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,25 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;94,83 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95,89 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,19 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,32 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,09 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,02 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,83 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.022 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.895 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.310 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.929 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.829 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.247 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.809 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.731 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.175 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.667 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.618 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.055 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,69 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,31 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,1 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;94,7 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,79 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,92 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,15 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,66 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,89 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,3 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;179 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;188 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;579 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;176 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;186 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;574 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;175 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;184 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;566 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;184 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;559 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;180 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;555 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,32 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,94 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,14 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,77 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,87 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,75 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,87 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,55 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,74 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,85 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.087 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.981 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.878 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.991 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.921 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.818 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.852 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.733 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.793 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.681 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.740 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.640 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,65 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,49 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,45 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,76 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,26 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,28 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,92 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,95 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,86 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.913 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.773 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.247 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.819 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.716 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.195 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.650 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.122 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.594 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.075 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.542 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.044 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,6 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,49 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,4 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,74 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,15 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,26 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,7 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,88 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,75 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;174 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;208 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;631 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;172 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;205 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;623 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;202 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;611 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;199 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;606 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;198 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;596 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,85 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,56 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,73 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,12 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,83 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,67 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,04 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,19 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,45 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;5.313 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.847 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;5.231 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;5.250 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;4.773 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;5.101 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;5.181 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;4.732 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;5.053 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.126 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.707 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.006 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.086 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.668 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.969 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,81 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,47 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,51 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,52 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,63 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,6 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,48 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,11 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,7 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,73 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,31 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,99 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.999 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.965 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.941 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.897 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.874 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.862 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.823 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.842 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.786 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.808 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,84 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,28 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,5 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,4 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,48 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,9 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,74 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,04 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;314 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;882 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;309 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;876 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;307 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;870 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;303 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;865 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;300 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;860 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,41 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,32 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,77 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,64 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,5 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,07 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,54 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,51 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;5.366 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.901 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.681 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;5.298 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;4.862 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;4.638 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.249 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.836 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.600 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.206 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.791 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.575 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;4.739 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;4.512 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 30 Murcia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,73 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,2 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,08 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,82 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,67 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,27 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,02 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,76 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,74 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,69 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,39 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.056 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.059 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.359 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.990 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4.023 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.322 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.941 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.001 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.294 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.902 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.960 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.279 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.915 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.233 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,69 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,11 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,9 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,73 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,57 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,06 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,95 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,56 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,62 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,45 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,25 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;310 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;842 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.322 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;308 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;839 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.316 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;308 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;835 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.306 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;304 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;831 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.296 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;824 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.279 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,35 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,64 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,55 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,35 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,17 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,79 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,06 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,69 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,03 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,86 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,75 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5.561 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.213 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.916 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;5.495 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.169 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.865 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.416 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.107 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.824 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;5.050 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;4.751 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;4.998 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;4.727 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,81 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,16 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,96 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,39 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,97 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,13 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,87 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,64 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,88 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,16 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5.259 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.885 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.930 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.193 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.842 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.879 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.118 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.781 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.847 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.729 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.782 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.679 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.766 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,75 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,12 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,7 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,32 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,87 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,89 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,81 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,23 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,78 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,83 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;302 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;328 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;986 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;302 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;327 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;986 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;298 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;326 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;977 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;321 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;969 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;319 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;961 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,7 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,68 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,39 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,09 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,87 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,28 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,26 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,46 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5.385 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.153 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.845 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.340 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.105 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.812 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;5.059 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;4.745 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;5.001 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;4.715 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.953 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.686 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,16 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,07 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,32 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,18 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,94 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,05 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,32 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,12 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,72 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5.096 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.830 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.833 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.053 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.784 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.805 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.738 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.745 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.681 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.722 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.635 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.701 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,16 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,05 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,27 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,1 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,7 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,92 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,1 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,96 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,56 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;289 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;323 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.012 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;287 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;321 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.007 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;321 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.000 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;320 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;993 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;318 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;985 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,31 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,38 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,51 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,38 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,81 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;99,07 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,12 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,45 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,33 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;206 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;217 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;215 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;204 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;212 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;213 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;201 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;210 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;211 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;198 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;206 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;209 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;195 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;205 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;207 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,03 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,7 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,07 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,57 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,77 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,14 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,12 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,93 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,21 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,66 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,47 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,28 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;188 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;162 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;186 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;158 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;183 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;156 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;180 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;152 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;177 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;151 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,94 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,53 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,34 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,3 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,74 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,83 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,15 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,21 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;55 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;54 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;54 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;54 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;54 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,18 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;217 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;207 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;201 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;212 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;207 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;199 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;209 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;201 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;199 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;206 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;200 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;197 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;200 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;193 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 30 Murcia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,7 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,31 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,1 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,93 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,62 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,01 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,62 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,02 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;199 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;156 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;156 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;194 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;156 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;154 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;192 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;150 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;154 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;189 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;149 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;152 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;149 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;149 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,49 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,72 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,48 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,15 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,72 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,97 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,51 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,44 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,51 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,51 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;18 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;51 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;45 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;18 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;51 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;45 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;17 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;51 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;45 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;17 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;51 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;45 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;51 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;44 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,44 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,44 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,78 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;229 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;228 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;203 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;225 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;223 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;199 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;223 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;221 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;198 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;219 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;193 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;218 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;193 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,25 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,81 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,03 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,38 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,93 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,54 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,05 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,07 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,61 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,07 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;213 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;212 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;151 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;210 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;207 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;147 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;208 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;205 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;146 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;203 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;142 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;202 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;142 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,59 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,64 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,35 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,65 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,7 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,69 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,75 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,04 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,28 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,04 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;16 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;16 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;52 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;15 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;16 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;52 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;15 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;16 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;52 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;16 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;51 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;16 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;51 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,75 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,75 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,08 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,08 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;217 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;210 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;208 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;215 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;205 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;207 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;203 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;203 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;202 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;201 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;200 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;198 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,08 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,62 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,52 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,67 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,6 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,19 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,63 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,24 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,19 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;206 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;200 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;150 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;204 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;195 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;149 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;193 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;146 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;192 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;144 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;190 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;142 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,03 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,5 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,33 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,5 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,33 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,67 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;10 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;58 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;10 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;58 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;10 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;57 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;10 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;57 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;10 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;56 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,28 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,28 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,55 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;101 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;97 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;93 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;101 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;97 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;92 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;101 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;97 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;92 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;100 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;97 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;91 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;99 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;96 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;91 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,92 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,92 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,01 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,85 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,02 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,97 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,85 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;96 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;75 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;96 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;75 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;96 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;75 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;95 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;75 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;94 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;74 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,96 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,92 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,67 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;5 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;22 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;5 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;22 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;5 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;22 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;5 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;22 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;5 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;22 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;103 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;94 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;103 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;94 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;102 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;91 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;101 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;99 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;91 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;99 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;91 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,03 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,81 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,06 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;99 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,81 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,81 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;98 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;79 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;71 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;98 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;79 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;71 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;97 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;79 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;68 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;96 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;78 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;68 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;78 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;68 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,98 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,77 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,96 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,73 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,77 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,73 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,77 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;5 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;21 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;23 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;5 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;21 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;23 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;5 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;21 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;23 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;5 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;21 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;23 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;21 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;23 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;109 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;91 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;95 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;107 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;91 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;91 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;105 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;90 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;91 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;90 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;91 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;90 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;91 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,17 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,79 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,33 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,9 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,79 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,9 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,79 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,9 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,79 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;103 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;82 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;75 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;101 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;82 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;71 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;99 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;81 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;71 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;81 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;71 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;81 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;71 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,06 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,67 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,12 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,78 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;94,67 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,78 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,67 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,78 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,67 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;9 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;20 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;9 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;20 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;9 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;20 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;9 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;20 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;9 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;20 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;105 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;91 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;93 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;103 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;91 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;93 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;91 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;93 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;90 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;93 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;90 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;93 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,1 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,9 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,9 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;99 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;83 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;73 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;97 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;83 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;73 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;83 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;73 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;82 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;73 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;82 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;73 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,98 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,8 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,8 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;20 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;20 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;20 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;20 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;20 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 30 Murcia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;14.719 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;14.334 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;14.803 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;13.988 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;13.696 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;13.609 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;13.410 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;13.163 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;13.140 31 Navarra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;13.055 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;12.850 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;12.817 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;12.713 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;12.540 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;12.512 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,03 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,55 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,93 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,11 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,83 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,77 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,69 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,65 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;86,58 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,37 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,48 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;84,52 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14.108 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;12.698 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;13.392 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12.092 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;12.827 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11.589 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12.486 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.302 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12.152 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.019 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,92 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,23 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,92 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,27 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,5 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,01 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,14 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,78 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;611 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.636 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;596 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.604 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;583 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.574 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;569 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.548 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;561 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.521 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,55 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,04 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,42 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,21 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,13 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,62 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,82 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,97 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;14.673 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;14.342 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;14.120 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;13.946 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;13.690 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;13.567 31 Navarra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;13.504 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;13.289 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;13.189 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;13.101 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;12.921 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;12.845 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;12.536 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;12.472 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 31 Navarra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,05 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,45 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,08 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,03 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,66 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,41 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,29 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,09 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,97 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,41 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,33 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14.078 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12.717 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10.727 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;13.366 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.096 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.242 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;12.932 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11.722 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.927 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;12.548 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.382 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.658 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.036 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.355 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,94 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,12 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,48 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,86 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,18 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,54 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,13 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,5 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,03 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,78 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87,21 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;595 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.625 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.393 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;580 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.594 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.325 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;572 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.567 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.262 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;553 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.539 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.187 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.500 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.117 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,48 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,09 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,13 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,43 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,14 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,94 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,71 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,93 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,31 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,87 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;14.761 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;14.530 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14.245 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;14.068 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;13.870 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;13.693 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;13.554 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;13.387 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;13.245 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;12.939 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;12.829 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;12.622 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;12.519 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,31 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,46 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,12 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,82 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,13 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,98 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,05 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;90,06 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,87 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,88 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;14.272 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;13.920 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12.635 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;13.586 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;13.271 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.111 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;13.086 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12.798 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.697 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12.360 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11.313 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12.049 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11.028 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,19 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,34 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,85 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,69 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,94 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,58 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,79 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;89,54 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,56 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;87,28 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;489 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;610 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.610 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;482 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;599 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.582 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;468 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;589 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.548 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;579 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.516 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;573 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.491 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,57 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,2 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,26 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,71 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,56 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,15 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,92 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,16 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,93 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,61 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;14.686 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;14.648 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14.376 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;14.029 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;14.017 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;13.741 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;13.461 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;13.255 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;13.002 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;12.829 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;12.704 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;12.573 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,53 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,69 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,58 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,9 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,2 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,76 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,24 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,73 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,46 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;14.237 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14.033 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;12.592 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;13.593 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13.419 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;11.993 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;12.878 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.539 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12.433 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;11.144 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;12.144 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.913 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,48 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,62 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,24 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,77 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,64 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,6 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,5 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,54 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,67 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;449 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;615 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.784 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;436 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;598 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.748 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;583 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.716 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;569 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.685 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;560 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.660 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,1 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,24 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,98 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,8 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,19 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,52 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,45 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,06 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,05 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;10.364 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;10.218 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;10.475 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;9.665 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;9.611 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;9.367 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;9.156 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;9.138 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;8.949 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;8.828 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;8.845 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;8.655 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;8.520 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;8.563 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.383 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,26 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,06 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,42 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,34 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,43 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,43 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,18 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,56 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,63 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,21 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,8 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,03 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;10.042 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9.462 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;9.357 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;8.882 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;8.857 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;8.430 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;8.542 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8.161 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;8.240 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7.900 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,18 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,87 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,2 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,09 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,06 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,25 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,06 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,49 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;322 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;756 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;308 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;729 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;299 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;708 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;286 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;684 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;280 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;663 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,65 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,43 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,86 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,65 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,82 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,48 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,96 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,7 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;10.305 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;10.216 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;9.981 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;9.647 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;9.625 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;9.477 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;9.233 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;9.246 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;9.123 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;8.865 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;8.910 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;8.810 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;8.554 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;8.473 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 31 Navarra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,61 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,21 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,95 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,6 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,51 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,4 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,03 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,22 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,27 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;83,73 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,89 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;10.005 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9.468 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;8.069 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;9.359 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;8.899 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7.621 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8.953 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;8.546 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7.322 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8.599 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8.231 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7.070 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;7.908 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.792 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,54 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,99 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,45 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,49 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,26 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,74 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,95 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,93 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,62 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,52 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,17 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;300 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;748 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.912 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;288 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;726 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.856 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;280 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;700 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.801 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;266 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;679 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.740 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;646 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.681 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,06 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,07 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,33 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,58 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,19 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,67 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,78 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,36 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,92 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;10.353 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;10.278 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;10.114 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;9.692 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;9.647 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;9.593 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;9.223 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;9.197 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;9.179 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;8.782 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;8.798 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;8.493 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;8.515 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,62 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,86 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,85 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,09 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,48 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,76 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,44 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,99 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,63 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,19 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;10.126 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;10.009 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9.375 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;9.471 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;9.389 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8.879 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;9.012 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8.947 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8.493 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8.540 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8.138 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8.256 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;7.873 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,53 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,81 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,71 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,39 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,59 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,32 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,81 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,49 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,98 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;227 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;269 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;739 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;221 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;258 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;714 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;211 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;250 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;686 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;242 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;660 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;237 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;642 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,36 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,91 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,62 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,95 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,94 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,83 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,96 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,31 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,1 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,87 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;10.262 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;10.346 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;10.182 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;9.649 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;9.749 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;9.580 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;9.224 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;9.130 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;8.820 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;8.750 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;8.547 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;8.508 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,03 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,23 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,09 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,16 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,67 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,25 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,94 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,61 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,56 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;10.064 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10.023 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9.419 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;9.462 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;9.442 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8.844 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;8.931 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;8.422 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;8.540 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.062 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;8.275 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7.845 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,02 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,2 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,9 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,11 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,42 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,2 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,59 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,56 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,29 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;198 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;323 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;763 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;187 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;307 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;736 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;293 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;708 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;280 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;688 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;272 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;663 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,44 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,05 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,46 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,71 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,79 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,69 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,17 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,21 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,89 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.621 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.510 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.576 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.605 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.494 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.532 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.570 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.459 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.507 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.558 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.448 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.493 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.542 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.435 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.477 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,01 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,94 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,21 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,85 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,62 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,62 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,11 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,89 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,73 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,13 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,03 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,72 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.545 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.220 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.529 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.207 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.497 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.178 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.486 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.169 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.470 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.157 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,96 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,93 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,89 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,56 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,18 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,82 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,15 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,84 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;76 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;290 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;76 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;287 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;73 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;281 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;72 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;279 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;72 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;278 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,97 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,05 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,9 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,74 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,21 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,74 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,86 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.569 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.487 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.517 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.533 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.451 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.491 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.521 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.439 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.481 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.507 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.421 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.464 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.407 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.445 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,71 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,58 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,29 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,94 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,77 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,63 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,05 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,56 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,51 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,62 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,25 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.470 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.197 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;977 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.436 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.167 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;957 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.424 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.156 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;949 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.412 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.141 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;943 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.127 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;931 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,69 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,49 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,95 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,87 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,57 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,13 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,05 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,32 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,52 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,15 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,29 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;99 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;290 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;540 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;97 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;284 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;534 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;97 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;283 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;532 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;95 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;280 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;521 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;280 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;514 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,98 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,93 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,89 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,98 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,59 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,52 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,96 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,55 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,48 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,55 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,19 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.607 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.573 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.537 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.591 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.559 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.519 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.568 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.544 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.503 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.524 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.485 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.514 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.471 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,11 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,83 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,57 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,16 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,79 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,88 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,62 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,25 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,71 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.524 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.470 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.270 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.509 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.456 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.252 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.487 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.442 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.240 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.422 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.225 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.412 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.215 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,02 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,05 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,58 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,57 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,1 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,64 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,73 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,46 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,05 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,67 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;83 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;103 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;267 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;82 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;103 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;267 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;81 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;102 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;263 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;102 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;260 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;102 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;256 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,8 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,59 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,03 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,5 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,03 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,38 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;99,03 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,88 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.612 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.569 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.548 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.590 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.552 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.531 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.540 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.512 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.515 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.489 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.503 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.483 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,64 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,92 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,9 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,15 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,67 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,56 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,19 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,79 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,8 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.523 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.478 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.219 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.502 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.461 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.208 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.449 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.192 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.425 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.174 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.414 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.168 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,62 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,85 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,1 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,04 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,79 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,41 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,31 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,67 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,82 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;89 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;91 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;329 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;88 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;91 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;323 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;91 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;320 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;90 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;315 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;89 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;315 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,88 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,18 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,26 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,9 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,74 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,8 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,74 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.480 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.366 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.503 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.465 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.352 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.463 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.432 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.328 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;2.438 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.418 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.319 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.424 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.400 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.305 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.408 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,4 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,41 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,4 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,06 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,39 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,4 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,5 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,01 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,84 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,77 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,42 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,2 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.299 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.846 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.285 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.834 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.253 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.813 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.239 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.804 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.223 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.794 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,39 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,35 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,21 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,39 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,72 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,69 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,18 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;181 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;520 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;180 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;518 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;179 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;515 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;179 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;515 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;177 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;511 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,45 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,62 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,9 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,04 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,9 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,04 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,79 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,27 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.535 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.401 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.387 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.503 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.377 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;2.364 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.488 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.367 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.351 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.467 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.354 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.338 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.339 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.321 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 31 Navarra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,74 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,04 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,15 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,58 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,49 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,32 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,04 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,95 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,42 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,24 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.362 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.881 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.517 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.331 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.860 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.500 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.316 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.850 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.493 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.298 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.840 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.483 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.831 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.470 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,69 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,88 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,88 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,05 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,35 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,42 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,29 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,82 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,76 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,34 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,9 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;173 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;520 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;870 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;172 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;517 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;864 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;172 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;517 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;858 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;169 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;514 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;855 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;508 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;851 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,42 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,42 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,31 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,42 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,42 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,62 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,69 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,85 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,28 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,69 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,82 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.534 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.437 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.364 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.519 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.422 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.352 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.497 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.405 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.335 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;2.392 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.319 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;2.374 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.306 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,41 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,38 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,49 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,54 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,69 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,77 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,15 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,1 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,41 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,55 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.376 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.225 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.831 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.361 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.210 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.822 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.342 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.193 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.807 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.182 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.794 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.165 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.784 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,37 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,33 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,51 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,57 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,56 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,69 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,07 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,98 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,3 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,43 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;158 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;212 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;533 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;158 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;212 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;530 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;155 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;212 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;528 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;210 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;525 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;209 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;522 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,44 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,1 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,06 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,06 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,5 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,58 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,94 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.540 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.471 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.404 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.518 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.455 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.389 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;2.437 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;2.373 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;2.407 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.350 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.395 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.342 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,13 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,35 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,38 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,62 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,71 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,41 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,75 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,92 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,42 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.401 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.297 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.792 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.380 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.281 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.780 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.264 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.765 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.234 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.748 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.222 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.740 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,13 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,3 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,33 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,56 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,49 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,26 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,54 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,73 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,1 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;139 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;174 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;612 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;138 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;174 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;609 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;173 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;608 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;173 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;602 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;173 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;602 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,28 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,51 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,43 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,35 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;99,43 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,37 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;99,43 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,37 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;172 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;162 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;170 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;172 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;161 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;169 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;171 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;160 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;168 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;170 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;160 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;168 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;170 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;159 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;168 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,38 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,41 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,42 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,77 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,82 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,84 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,77 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,82 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,84 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,15 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,82 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;146 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;113 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;146 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;112 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;145 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;111 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;144 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;111 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;144 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;111 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,12 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,32 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,23 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,63 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,23 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,63 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,23 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;26 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;49 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;26 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;49 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;26 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;49 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;26 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;49 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;26 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;48 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,96 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;179 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;161 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;155 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;178 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;160 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;155 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;177 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;160 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;155 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;177 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;159 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;155 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;159 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;155 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,44 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,38 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,88 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,38 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,88 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,76 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,76 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;163 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;115 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;106 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;162 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;114 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;106 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;161 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;114 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;106 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;161 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;114 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;106 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;114 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;106 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,39 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,13 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,77 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,13 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,77 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;99,13 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;99,13 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;16 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;46 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;49 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;16 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;46 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;49 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;16 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;46 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;49 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;16 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;45 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;49 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;45 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;49 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,83 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,83 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;179 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;162 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;149 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;178 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;162 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;149 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;178 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;161 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;149 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;161 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;149 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;161 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;149 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,44 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,44 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,38 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,38 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,38 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;164 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;143 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;103 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;163 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;143 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;103 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;163 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;143 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;103 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;143 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;103 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;143 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;103 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,39 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,39 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;15 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;19 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;46 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;15 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;19 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;46 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;15 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;18 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;46 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;18 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;46 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;18 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;46 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,74 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,74 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,74 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;184 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;181 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;163 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;184 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;180 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;163 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;180 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;163 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;180 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;163 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;179 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;163 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,45 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,45 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,45 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,9 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;167 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;160 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;108 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;167 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;160 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;108 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;160 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;108 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;160 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;108 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;159 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;108 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;99,38 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;17 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;21 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;55 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;17 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;20 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;55 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;20 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;55 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;20 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;55 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;20 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;55 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,24 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,24 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,24 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,24 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;82 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;78 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;79 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;81 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;78 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;78 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;81 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;78 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;78 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;81 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;78 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;77 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;81 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;78 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;76 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,78 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,73 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,78 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,73 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,78 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,47 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,78 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,2 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;76 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;57 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;75 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;57 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;75 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;57 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;75 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;57 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;75 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;57 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,68 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,68 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,68 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,68 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;6 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;21 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;21 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;21 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;21 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;21 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;85 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;77 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;80 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;85 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;77 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;80 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;85 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;77 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;79 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;85 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;77 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;78 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;77 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;78 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,75 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,5 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,5 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;78 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;58 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;78 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;58 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;78 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;57 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;78 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;56 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,28 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,55 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,55 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;21 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;22 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;21 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;22 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;21 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;22 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;21 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;22 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;21 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;22 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;88 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;80 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;81 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;88 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;80 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;80 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;88 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;80 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;79 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;80 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;78 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;80 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;78 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,77 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,53 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,3 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,3 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;82 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;73 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;56 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;82 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;73 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;55 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;82 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;73 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;54 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;73 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;53 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;73 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;53 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,21 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,43 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,64 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,64 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;7 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;25 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;7 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;25 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;7 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;25 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;7 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;25 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;7 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;25 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;88 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;81 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;79 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;88 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;81 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;78 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;80 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;77 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;80 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;77 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;80 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;77 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,73 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,77 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,47 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,77 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,47 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,77 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,47 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;82 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;75 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;54 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;82 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;75 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;53 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;74 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;52 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;74 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;52 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;74 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;52 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,15 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,67 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,3 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,67 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,3 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,67 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,3 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;25 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;25 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;25 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;25 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;25 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 31 Navarra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.130 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.071 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.462 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;7.678 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;7.657 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;7.706 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;7.395 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;7.417 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;7.496 32 Ourense;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.127 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.182 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.252 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.949 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;6.978 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.038 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,44 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,87 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,07 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,96 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,9 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,58 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,66 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,99 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,7 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,47 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;86,46 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;83,17 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.752 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.154 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.316 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.771 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.044 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.550 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.783 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.334 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.609 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.151 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,38 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,65 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,87 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,56 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,5 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,54 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,26 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,98 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;378 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;917 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;362 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;886 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;351 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;867 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;344 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;848 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;340 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;827 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,77 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,62 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,86 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,55 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,01 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,48 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,95 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,19 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.010 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.965 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.997 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;7.665 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;7.677 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;7.754 32 Ourense;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.359 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.399 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.479 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.155 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.161 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.242 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;6.898 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;6.976 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 32 Ourense;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,69 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,38 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,96 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,87 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,89 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,52 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,33 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,91 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,56 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,6 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,23 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7.648 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.008 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.200 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.318 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.742 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.978 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.022 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.484 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.745 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.827 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.269 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.547 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.033 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.330 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,69 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,2 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,42 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,81 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,52 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,66 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,27 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,45 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,47 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,09 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,97 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;362 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;957 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.797 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;347 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;935 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.776 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;337 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;915 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.734 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;328 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;892 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.695 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;865 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.646 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,86 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,7 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,83 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,09 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,61 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,49 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,61 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,21 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,32 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,39 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,6 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.063 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.127 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.110 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;7.642 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;7.726 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.758 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.373 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.423 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.464 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;7.117 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;7.173 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;6.933 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.003 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,78 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,07 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,66 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,44 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,34 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,03 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,57 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,45 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,31 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,35 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;7.925 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.860 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.000 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.509 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.469 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.668 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.243 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.172 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.398 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.874 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.137 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;6.696 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.989 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,75 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,03 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,26 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,39 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,25 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,4 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,46 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,67 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,19 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,56 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;138 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;267 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.110 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;133 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;257 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.090 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;130 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;251 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.066 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;243 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.036 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;237 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.014 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,38 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,25 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,2 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,2 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,01 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,04 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,01 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,33 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,76 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,35 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7.975 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.084 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.172 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.629 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;7.700 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;7.774 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;7.352 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;7.437 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;7.129 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;7.236 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.899 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.023 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,66 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,25 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,13 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,95 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,01 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,19 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,55 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,34 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,94 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7.866 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.677 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.152 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.523 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.307 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.780 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.974 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.472 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.765 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.291 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.545 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.097 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,64 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,18 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,8 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,84 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,49 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,12 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,96 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,25 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,25 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;109 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;407 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.020 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;106 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;393 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;994 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;378 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;965 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;364 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;945 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;354 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;926 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,25 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,56 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,45 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,87 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,61 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,43 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,65 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,98 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,78 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.542 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.598 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.833 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;6.112 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;6.202 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;6.119 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;5.850 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;5.978 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.921 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.596 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.758 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.693 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.429 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.562 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.492 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,43 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,55 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,42 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,6 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,65 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,54 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,27 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,32 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,99 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,3 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,37 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.271 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.029 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5.856 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.661 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.603 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.452 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.355 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.248 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.192 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.072 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,38 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,9 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,35 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,43 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,39 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,05 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,79 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,13 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;271 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;569 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;256 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;541 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;247 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;526 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;241 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;510 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;237 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;490 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,46 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,08 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,14 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,44 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,93 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,63 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,45 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;86,12 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.423 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.493 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.502 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;6.096 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;6.216 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;6.268 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.806 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.955 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;6.005 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.615 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.726 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.778 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;5.480 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;5.530 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 32 Ourense;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,91 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,73 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,4 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,39 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,71 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,36 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,42 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,19 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,86 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,4 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,05 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.154 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.881 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.275 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.841 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.624 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.059 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.561 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5.380 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.834 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.377 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.172 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.643 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.949 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.438 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,91 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,63 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,91 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,36 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,48 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,64 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,37 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,94 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,02 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,15 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,13 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;269 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;612 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.227 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;255 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;592 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.209 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;245 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;575 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.171 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;238 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;554 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.135 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;531 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.092 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,8 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,73 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,53 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,08 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,95 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,44 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,48 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,52 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,5 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,76 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.462 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.589 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.623 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.055 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.203 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.282 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.801 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.911 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.997 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;5.624 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.725 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.450 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;5.565 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,7 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,14 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,85 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,77 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,71 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,55 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,35 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,44 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,71 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,03 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.347 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.424 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.942 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.945 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.048 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.617 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.694 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.761 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.352 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.480 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.105 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.310 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.964 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,67 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,15 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,53 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,71 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,68 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,07 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,31 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,91 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,66 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,54 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;115 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;165 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;681 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;110 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;155 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;665 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;107 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;150 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;645 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;144 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;620 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;140 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;601 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,65 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;93,94 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,65 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,04 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,91 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,71 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;87,27 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,04 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;84,85 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,25 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.363 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.537 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.634 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.029 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.161 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.244 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;5.831 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;5.926 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;5.624 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;5.740 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.410 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.541 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,75 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,25 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,12 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,2 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,33 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,03 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,52 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,76 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,52 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.275 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.228 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6.014 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.944 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5.866 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.646 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.550 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.353 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.354 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.182 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.149 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.998 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,73 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,19 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,88 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,11 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,01 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,97 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,17 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,68 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,11 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;88 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;309 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;620 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;85 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;295 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;598 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;281 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;573 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;270 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;558 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;261 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;543 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,59 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,47 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,45 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,94 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,42 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,38 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,47 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,58 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;752 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;694 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;771 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;741 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;682 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;744 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;729 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;673 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;736 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;724 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;666 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;727 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;719 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;662 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;718 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,54 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,27 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,5 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,94 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,97 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,46 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,28 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,97 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,29 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,61 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,39 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,13 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;702 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;543 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;692 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;533 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;681 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;527 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;676 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;520 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;671 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;516 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,58 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,16 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,01 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,05 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,3 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,76 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,58 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,03 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;50 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;151 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;49 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;149 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;48 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;146 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;48 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;146 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;48 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;146 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,68 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,69 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,69 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,69 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;737 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;681 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;699 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;727 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;676 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;693 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;717 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;667 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;686 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;713 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;664 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;680 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;654 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;669 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,64 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,27 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,14 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,29 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,94 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,14 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,74 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,5 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,28 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,04 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,71 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;697 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;538 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;434 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;688 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;534 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;430 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;678 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;525 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;425 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;675 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;522 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;422 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;514 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;416 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,71 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,26 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,08 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,27 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,58 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,93 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,84 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,03 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,24 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,54 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,85 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;40 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;143 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;265 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;39 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;142 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;263 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;39 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;142 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;261 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;38 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;142 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;258 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;140 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;253 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,5 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,3 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,25 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,5 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,3 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,49 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,3 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,36 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,9 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,47 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;733 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;706 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;696 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;727 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;699 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;691 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;720 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;695 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;686 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;683 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;674 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;677 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;669 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,18 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,01 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,28 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,23 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,44 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,56 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,74 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,84 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,89 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,12 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;722 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;667 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;512 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;716 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;660 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;508 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;709 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;656 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;506 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;645 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;498 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;641 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;494 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,17 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,95 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,22 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,2 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,35 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,83 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,7 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,27 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,1 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,48 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;11 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;39 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;184 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;11 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;39 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;183 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;11 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;39 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;180 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;38 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;176 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;36 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;175 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,46 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,83 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,44 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,65 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,31 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,11 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;748 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;715 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;730 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;743 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;712 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;725 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;702 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;712 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;692 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;704 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;683 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;698 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,33 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,58 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,32 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,18 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,53 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,78 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,44 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,52 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,62 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;739 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;674 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;567 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;734 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;671 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;564 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;661 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;554 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;653 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;549 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;645 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;544 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,32 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,55 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,47 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,07 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,71 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,88 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,83 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,7 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,94 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;9 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;41 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;163 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;9 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;41 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;161 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;41 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;158 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;39 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;155 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;38 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;154 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,77 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,93 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,12 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,09 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,68 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,48 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;789 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;737 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;818 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;778 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;731 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;803 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;769 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;724 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;799 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;761 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;716 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;792 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;755 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;712 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;788 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,61 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,19 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,17 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,47 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,24 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,68 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,45 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,15 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,82 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,69 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,61 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,33 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;734 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;549 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;723 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;544 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;715 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;538 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;708 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;533 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;702 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;530 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,5 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,09 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,41 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,46 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,09 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,64 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,54 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;55 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;188 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;55 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;187 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;54 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;186 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;53 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;183 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;53 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;182 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,47 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,18 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,94 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,36 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,34 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,36 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,81 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;802 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;747 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;754 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;794 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;741 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;751 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;789 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;733 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;746 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;780 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;727 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;742 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;720 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;735 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 32 Ourense;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,2 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,6 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,38 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,13 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,94 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,26 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,32 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,41 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,39 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,48 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;750 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;554 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;463 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;742 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;549 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;461 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;737 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;544 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;458 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;729 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;540 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;454 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;535 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;448 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,93 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,1 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,57 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,27 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,19 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,92 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,2 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,47 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,06 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,57 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,76 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;52 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;193 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;291 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;52 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;192 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;290 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;52 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;189 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;288 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;51 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;187 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;288 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;185 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;287 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,48 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,66 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,93 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,97 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,08 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,89 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,97 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,85 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,63 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;818 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;786 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;749 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;811 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;778 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;743 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;803 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;771 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;739 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;764 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;732 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;760 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;727 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,14 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,98 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,2 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,17 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,09 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,66 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,2 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,73 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,69 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,06 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;807 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;728 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;517 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;800 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;720 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;514 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;792 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;714 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;511 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;708 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;505 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;704 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;502 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,13 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,9 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,42 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,14 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,08 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,84 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,25 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,68 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,7 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,1 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;11 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;58 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;232 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;11 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;58 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;229 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;11 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;57 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;228 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;56 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;227 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;56 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;225 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,71 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,28 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,28 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,55 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,84 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,55 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,98 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;813 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;786 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;764 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;806 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;781 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;761 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;773 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;755 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;767 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;748 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;761 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;740 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,14 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,36 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,61 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,35 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,82 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,58 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,91 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,82 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,86 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;802 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;731 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;539 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;795 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;726 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;538 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;719 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;533 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;714 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;528 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;708 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;523 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,13 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,32 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,81 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,36 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,89 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,67 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,96 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,85 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,03 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;55 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;225 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;55 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;223 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;54 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;222 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;53 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;220 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;53 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;217 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,11 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,18 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,67 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,36 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,78 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,36 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,44 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;35 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;29 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;28 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;35 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;29 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;28 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;35 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;29 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;28 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;34 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;29 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;28 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;34 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;29 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;28 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,14 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,14 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;33 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;27 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;33 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;27 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;33 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;27 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;32 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;27 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;32 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;27 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,97 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,97 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;36 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;31 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;30 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;36 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;31 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;30 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;35 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;31 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;30 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;35 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;31 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;30 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;31 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;30 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,22 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,22 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;36 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;29 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;21 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;36 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;29 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;21 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;35 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;29 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;21 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;35 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;29 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;21 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;29 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;21 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,22 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,22 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;9 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;9 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;9 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;9 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;9 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;37 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;34 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;30 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;36 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;34 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;30 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;36 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;34 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;30 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;34 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;30 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;34 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;30 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,3 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,3 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;37 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;33 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;23 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;36 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;33 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;23 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;36 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;33 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;23 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;33 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;23 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;33 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;23 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,3 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,3 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;7 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;7 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;7 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;7 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;7 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;38 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;33 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;30 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;38 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;33 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;30 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;33 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;30 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;33 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;30 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;32 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;30 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,97 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;38 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;33 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;25 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;38 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;33 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;25 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;33 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;25 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;33 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;25 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;32 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;25 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,97 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;12 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;13 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;13 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;13 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;13 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;13 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;12 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;12 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;12 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;12 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;13 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;12 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;13 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;13 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;13 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;13 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;12 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;11 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;7 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;7 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;7 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;7 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;7 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;13 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;12 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;13 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;13 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;12 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;12 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;12 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;12 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;13 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;13 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;13 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;13 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;14 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;13 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;14 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;13 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;14 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;13 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;14 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;12 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;11 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;12 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;11 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;11 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;11 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;11 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;7 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;7 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;7 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;7 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;7 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 32 Ourense;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.486 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.397 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.598 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.297 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.257 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.291 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.195 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.155 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.205 34 Palencia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.103 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.096 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.127 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.006 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.027 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.040 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,58 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,88 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,47 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,65 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,88 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;89,08 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,01 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;91,14 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;86,91 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,23 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;89,11 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;84,49 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.358 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.995 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.172 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.860 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.074 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.767 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.984 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.713 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.889 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.650 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,46 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,49 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,54 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,39 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,86 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;90,58 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,03 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;88,48 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;128 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;402 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;125 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;397 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;121 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;388 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;119 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;383 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;117 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;377 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,66 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,76 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,53 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,52 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,97 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,27 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,41 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,78 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.442 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.404 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.398 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.311 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.275 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.302 34 Palencia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.206 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.200 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.209 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.088 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.116 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.107 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.010 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.017 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 34 Palencia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,19 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,21 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;97,17 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;93,14 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;94,01 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,44 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,72 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,54 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;91,44 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,43 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,79 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.305 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.980 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.621 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.179 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.862 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.534 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.078 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.792 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.453 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.963 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.714 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.372 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.616 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.296 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,19 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,04 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,68 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;93,13 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,69 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,59 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,65 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;91,07 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,5 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,79 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87,6 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;137 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;424 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;777 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;132 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;413 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;768 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;128 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;408 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;756 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;125 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;402 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;735 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;394 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;721 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,35 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,41 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,84 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,43 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,23 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,3 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,24 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,81 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,59 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,92 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,79 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.519 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.495 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.459 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.346 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.357 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.326 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.190 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.234 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.187 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.114 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.091 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.042 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.022 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,08 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;96,05 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,15 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,65 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,53 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,14 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,1 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,36 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,04 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,37 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.472 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.389 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.974 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.299 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.254 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.848 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.145 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.134 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.720 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.016 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.631 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.945 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.571 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,02 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;96,02 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,76 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,58 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,48 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,46 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,99 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,47 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,9 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,45 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;47 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;106 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;485 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;47 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;103 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;478 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;45 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;100 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;467 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;98 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;460 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;97 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;451 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,17 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,56 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,74 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,34 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,29 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,45 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,85 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,51 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,99 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.472 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.502 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.479 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.284 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.341 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.285 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.201 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.174 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.122 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.097 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.037 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.041 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,59 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,4 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,42 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,4 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,23 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,15 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,02 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,72 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,41 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.431 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.368 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.016 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.244 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.210 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.835 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.075 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.732 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.999 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.668 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.917 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.618 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,55 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,31 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,3 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,58 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,04 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,46 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,61 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,8 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;41 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;134 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;463 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;40 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;131 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;450 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;126 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;442 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;123 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;429 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;120 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;423 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,56 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,76 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,19 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,03 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,46 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,79 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,66 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,55 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,36 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.775 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.711 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.851 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;2.590 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;2.573 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;2.556 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;2.498 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;2.481 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;2.476 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.414 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.430 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.401 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.324 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.367 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.322 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,33 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,91 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,65 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,02 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,52 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,85 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,99 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,63 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,22 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,75 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,31 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,45 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.697 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.473 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.515 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.340 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.426 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.254 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.343 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.206 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.255 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.148 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,25 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,62 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,95 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,14 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,87 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,2 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,61 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,86 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;78 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;238 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;75 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;233 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;72 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;227 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;71 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;224 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;69 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;219 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,15 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,9 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,31 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,38 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,03 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,12 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,46 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,02 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.714 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.697 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.692 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;2.595 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;2.578 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;2.601 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.496 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.512 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.511 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.386 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.436 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.416 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;2.338 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;2.329 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 34 Palencia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,62 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,59 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,62 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,97 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,14 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,28 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,91 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,32 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,75 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,69 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,52 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.627 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.440 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.187 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.513 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.331 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.103 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.417 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.269 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.024 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.310 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.198 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.947 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.105 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.874 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,66 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,53 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,16 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,01 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,99 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,55 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,93 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,08 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,03 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,27 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,69 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;87 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;257 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;505 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;82 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;247 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;498 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;79 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;243 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;487 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;76 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;238 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;469 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;233 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;455 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,25 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,11 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,61 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,8 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,55 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,44 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,36 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,61 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,87 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,66 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,1 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.754 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.780 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.748 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.588 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.649 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.617 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.444 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.535 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.488 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;2.424 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;2.395 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;2.358 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;2.335 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,97 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,29 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,23 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,74 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,19 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,54 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,19 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,15 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,82 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,97 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.724 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.714 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.469 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.558 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.586 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.345 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.416 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.475 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.223 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.365 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.137 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.300 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.083 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,91 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,28 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,98 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,69 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,19 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,04 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,14 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,55 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,75 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,37 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;30 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;66 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;279 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;30 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;63 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;272 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;28 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;60 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;265 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;59 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;258 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;58 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;252 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,45 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,49 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,33 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,91 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,98 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,39 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,47 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,88 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,32 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.740 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.794 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.759 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.564 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.640 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.576 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;2.508 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;2.466 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;2.436 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;2.397 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.357 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.350 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,58 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,49 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,37 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,76 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,38 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,19 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,88 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,36 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,18 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.712 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.707 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.486 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.537 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.554 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.310 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.426 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.208 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.357 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.149 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.281 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.106 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,55 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,35 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,92 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,62 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,82 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,07 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,44 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,26 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,71 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;28 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;87 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;273 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;27 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;86 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;266 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;82 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;258 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;79 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;248 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;76 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;244 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,43 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,85 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,44 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,25 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,51 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,8 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,84 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,36 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,38 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;305 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;281 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;318 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;304 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;279 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;311 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;297 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;276 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;306 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;294 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;271 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;305 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;290 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;267 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;302 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,67 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,29 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,8 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,38 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,22 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,23 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,39 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,44 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,91 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,08 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,02 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,97 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;286 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;225 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;285 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;223 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;279 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;221 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;276 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;218 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;272 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;215 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,65 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,11 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,55 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,22 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,5 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,89 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,1 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,56 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;19 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;56 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;19 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;56 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;18 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;55 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;18 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;53 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;18 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;52 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,74 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,21 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,74 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,64 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,74 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,86 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;315 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;305 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;304 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;307 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;302 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;301 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;305 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;295 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;300 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;299 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;288 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;296 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;286 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;293 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,46 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,02 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,01 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,83 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,72 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,68 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,92 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,43 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,37 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,77 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,38 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;296 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;249 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;196 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;288 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;246 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;194 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;286 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;240 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;194 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;280 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;234 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;191 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;233 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;188 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,3 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,8 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,98 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,62 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,39 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,98 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,59 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,98 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,45 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,57 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,92 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;19 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;56 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;108 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;19 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;56 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;107 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;19 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;55 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;106 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;19 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;54 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;105 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;53 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;105 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,07 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,21 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,15 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,43 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,22 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,64 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,22 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;338 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;298 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;301 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;335 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;294 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;301 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;329 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;288 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;294 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;285 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;291 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;280 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;287 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,11 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,66 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,34 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,64 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,67 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,64 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,68 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,96 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,35 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;333 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;290 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;227 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;330 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;286 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;227 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;324 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;280 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;224 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;277 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;221 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;272 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;218 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,1 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,62 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,3 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,55 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,68 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,52 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,36 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,79 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,04 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;5 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;8 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;74 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;5 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;8 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;74 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;5 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;8 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;70 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;8 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;70 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;8 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;69 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,59 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,59 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,24 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;324 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;303 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;303 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;317 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;300 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;297 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;298 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;296 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;293 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;294 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;292 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;289 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,84 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,01 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,02 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,35 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,69 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,7 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,03 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,37 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,38 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;320 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;286 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;236 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;313 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;284 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;233 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;282 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;232 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;277 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;231 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;276 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;227 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,81 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,3 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,73 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,6 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,31 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,85 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,88 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,5 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,19 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;17 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;67 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;16 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;64 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;16 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;64 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;16 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;63 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;16 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;62 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,12 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,52 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,12 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,52 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,12 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,03 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,12 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,54 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;373 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;370 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;392 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;371 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;370 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;387 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;368 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;363 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;387 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;363 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;361 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;385 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;360 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;359 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;380 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,46 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,72 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,66 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,11 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,72 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,32 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,57 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,21 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,51 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,03 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,94 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;344 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;273 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;342 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;273 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;339 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;268 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;335 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;266 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;332 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;264 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,42 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,55 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,17 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,38 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,44 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,51 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,7 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;29 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;97 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;29 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;97 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;29 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;95 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;28 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;95 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;28 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;95 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,94 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,55 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,94 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,55 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,94 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;381 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;369 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;366 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;377 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;362 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;365 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;373 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;361 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;363 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;371 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;360 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;360 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;355 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;360 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 34 Palencia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,95 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,1 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,73 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,9 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,83 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,18 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,38 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,56 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,36 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,21 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,36 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;351 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;268 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;214 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;347 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;262 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;214 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;344 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;261 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;212 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;342 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;260 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;211 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;257 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;211 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,86 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,76 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,01 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,39 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,07 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,44 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,01 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,6 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,9 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,6 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;30 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;101 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;152 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;30 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;151 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;29 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;151 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;29 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;149 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;98 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;149 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,01 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,34 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,67 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,01 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,34 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,67 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,01 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,03 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,03 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,03 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;393 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;384 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;375 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;389 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;382 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;373 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;383 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;379 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;370 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;374 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;370 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;373 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;365 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,98 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,48 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,47 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,46 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,7 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,67 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,4 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,67 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,14 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,33 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;382 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;355 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;256 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;378 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;353 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;254 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;372 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;350 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;251 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;346 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;251 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;345 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;248 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,95 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,44 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,22 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,38 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,59 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,05 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,46 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,05 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,18 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,88 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;11 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;29 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;119 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;11 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;29 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;119 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;11 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;29 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;119 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;28 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;119 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;28 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;117 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,55 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,55 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,32 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;372 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;373 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;383 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;367 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;369 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;378 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;364 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;378 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;362 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;372 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;357 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;369 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,66 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,93 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,69 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,59 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,69 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,05 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,13 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,71 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,34 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;364 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;345 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;271 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;359 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;342 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;269 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;338 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;269 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;336 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;265 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;331 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;263 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,63 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,13 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,26 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,97 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,26 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,39 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,79 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,94 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,05 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;28 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;112 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;27 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;109 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;26 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;109 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;26 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;107 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;26 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;106 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,43 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,32 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,86 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,32 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,86 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,54 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,86 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,64 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;21 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;23 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;25 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;20 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;23 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;25 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;20 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;23 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;25 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;20 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;22 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;25 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;20 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;22 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;25 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,24 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,24 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;95,24 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,65 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,24 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,65 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;19 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;14 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;18 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;14 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;18 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;18 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;13 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;18 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,74 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;94,74 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,74 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;92,86 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,74 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,86 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;9 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;9 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;9 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;9 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;9 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;19 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;20 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;24 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;19 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;20 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;23 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;19 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;19 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;23 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;19 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;19 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;23 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;18 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;23 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,83 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;95 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;95,83 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,83 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;90 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,83 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;18 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;18 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;18 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;10 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;13 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;92,86 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,67 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,86 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;91,67 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;92,86 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,33 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;92,86 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;10 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;8 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;10 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;8 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;10 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;8 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;10 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;8 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;10 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;20 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;20 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;23 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;20 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;19 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;23 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;20 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;19 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;23 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;18 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;23 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;18 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;23 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;95 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;90 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;90 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;17 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;13 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;19 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;16 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;13 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;19 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;13 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,12 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,12 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,24 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;88,24 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;10 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;10 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;10 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;10 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;10 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;21 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;20 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;22 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;21 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;20 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;22 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;19 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;22 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;19 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;22 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;19 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;21 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,45 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;20 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;20 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;18 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;13 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;17 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;13 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;17 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;17 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;12 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;94,44 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,44 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,44 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;92,31 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;9 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;9 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;9 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;9 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;12 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;12 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;11 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;11 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;12 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;11 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;91,67 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;91,67 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,67 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;12 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;12 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;10 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;10 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;13 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;13 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;12 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;12 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;12 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;12 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;13 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;12 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;13 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;11 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;13 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;11 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;13 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;13 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;10 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;14 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;13 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;14 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;13 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;12 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;14 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;13 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;12 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;13 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;12 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;13 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;12 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;14 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;13 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;14 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;13 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;13 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;13 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;9 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;13 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;9 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;15 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;12 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;12 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;15 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;12 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;15 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;12 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;12 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;12 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 34 Palencia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;27.460 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;26.629 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;28.508 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;25.941 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;25.011 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;24.749 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;24.677 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;24.144 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;23.819 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;23.749 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;23.354 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;23.097 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;23.052 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;22.676 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;22.372 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,47 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,92 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,81 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,87 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,67 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,55 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,49 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,7 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,02 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,95 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,16 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,48 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;26.184 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;21.080 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;24.712 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;19.645 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;23.495 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18.892 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;22.600 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;18.209 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;21.934 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;17.676 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,38 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,19 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,73 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,62 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,31 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,38 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,77 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,85 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.276 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;5.549 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.229 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;5.366 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.182 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;5.252 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.149 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;5.145 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.118 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;5.000 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,32 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,7 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,63 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,65 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,05 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,72 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,62 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,11 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;27.467 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;26.173 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;25.938 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;25.922 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;25.085 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;24.848 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;24.803 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;24.160 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;24.010 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;24.016 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;23.402 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;23.200 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;22.533 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;22.256 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 35 Palmas, Las;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,38 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,84 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,8 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,3 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,31 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,57 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,44 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,41 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,44 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,09 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,8 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;26.207 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;22.569 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;19.012 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;24.718 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;21.579 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;18.015 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;23.631 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;20.740 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17.312 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;22.871 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;20.088 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;16.673 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;19.327 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;15.955 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,32 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,61 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,76 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,17 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,9 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,06 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,27 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,01 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,7 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,64 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,92 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.260 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.604 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6.926 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.204 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.506 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6.833 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.172 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.420 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6.698 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.145 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.314 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6.527 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.206 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6.301 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,56 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,28 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,66 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,02 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,89 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,71 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90,87 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,95 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,24 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,96 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,98 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;27.445 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;26.447 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;26.131 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;26.043 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;25.239 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;25.047 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;25.110 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;24.348 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;24.077 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;23.366 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;23.032 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;22.548 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;22.434 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,89 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,43 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,85 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,49 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,06 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,14 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,35 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,14 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,26 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,85 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;27.016 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;25.158 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;20.044 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;25.626 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;23.991 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;19.069 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;24.705 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;23.144 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;18.247 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;22.205 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;17.398 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;21.424 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;16.915 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,85 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,36 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,14 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,45 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,99 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,03 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,26 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,8 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,16 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,39 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;429 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.289 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6.087 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;417 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.248 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;5.978 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;405 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.204 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;5.830 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.161 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;5.634 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.124 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;5.519 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,2 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,82 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,21 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,41 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,41 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,78 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,07 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,56 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,2 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,67 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;27.539 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;26.869 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;26.561 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;26.355 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;25.690 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;25.295 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;24.520 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;24.029 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;23.529 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;23.316 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;22.726 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;22.632 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,7 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,61 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,23 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,26 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,47 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,57 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,78 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,58 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,21 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;27.256 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;25.135 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;20.779 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;26.080 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;24.021 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;19.661 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;22.911 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;18.580 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;21.995 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17.978 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;21.250 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17.403 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,69 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,57 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,62 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,15 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,42 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,51 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,52 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,54 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,75 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;283 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.734 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5.782 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;275 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.669 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5.634 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.609 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5.449 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.534 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5.338 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.476 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5.229 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,17 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,25 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,44 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,79 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,24 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,47 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,32 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,12 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,44 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;20.038 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;19.673 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;20.670 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;18.633 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;18.154 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;17.257 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;17.505 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;17.361 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;16.435 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.672 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.639 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;15.793 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;16.060 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;16.041 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.158 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,99 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,28 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,49 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,36 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,25 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;79,51 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,2 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,58 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;76,41 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,15 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;81,54 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;73,33 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;19.199 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16.875 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17.833 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15.500 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.744 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14.796 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.938 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.159 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15.351 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13.674 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,89 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,85 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,21 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,68 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,01 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,91 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,96 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,03 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;839 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.798 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;800 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.654 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;761 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.565 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;734 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.480 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;709 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.367 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,35 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;94,85 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,7 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,67 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,49 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,63 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,51 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;84,6 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;20.023 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;19.424 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;19.035 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;18.608 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;18.406 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;18.003 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;17.580 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;17.545 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;17.219 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.878 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.862 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.488 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;16.096 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;15.643 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,93 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,76 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,58 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,8 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,33 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,46 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,29 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,81 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,62 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,87 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,18 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;19.231 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;17.417 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;15.247 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;17.865 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.477 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14.295 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.866 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.693 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.630 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;16.186 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;15.103 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13.034 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;14.419 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12.366 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,9 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,6 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,76 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,7 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,1 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,39 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,17 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,71 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,49 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,79 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,1 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;792 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.007 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.788 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;743 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.929 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.708 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;714 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.852 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.589 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;692 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.759 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.454 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.677 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.277 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;93,81 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,11 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,89 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,15 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,28 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,75 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,37 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;87,64 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,18 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;83,56 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;86,51 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;19.980 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;19.454 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19.165 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;18.657 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;18.298 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;18.128 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;17.802 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.490 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;17.243 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;16.620 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;16.303 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;15.905 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;15.767 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,38 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,06 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,59 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,1 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,9 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,97 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,43 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,07 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,76 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,27 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19.663 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;18.687 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16.102 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;18.352 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17.570 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.163 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;17.508 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.798 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.393 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.963 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.605 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15.278 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.158 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,33 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,02 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,17 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,04 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,89 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,39 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,42 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,49 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,76 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,72 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;317 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;767 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.063 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;305 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;728 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.965 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;294 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;692 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.850 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;657 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.698 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;627 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.609 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,21 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,92 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,8 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,74 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,22 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,05 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;85,66 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,08 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;81,75 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,18 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;19.967 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;19.673 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;19.564 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;18.846 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;18.567 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;18.365 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;17.512 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;17.203 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;16.628 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;16.562 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.916 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;15.946 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,39 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,38 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,87 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,02 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,93 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,52 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,66 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,9 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,51 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;19.769 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18.427 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;16.618 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;18.656 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17.384 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.544 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;16.386 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.529 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.569 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13.970 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14.907 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.442 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,37 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,34 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,54 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,92 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,43 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,49 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,07 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,9 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,89 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;198 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.246 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.946 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;190 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.183 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.821 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.126 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.674 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.059 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.592 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.009 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.504 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,96 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,94 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,76 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,37 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,77 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;84,99 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,98 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;80,98 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.163 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.047 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.393 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.975 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.161 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.016 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.927 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.098 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.959 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.880 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.047 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.910 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.832 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.996 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,01 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,64 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;93,16 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,35 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,06 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;91,31 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;93,55 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,52 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;89,8 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,94 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,3 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.999 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.090 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.939 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.044 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.862 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.009 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.808 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.978 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.762 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.950 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,8 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,43 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,12 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;93,63 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,64 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,1 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,3 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;164 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;957 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;161 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;931 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;154 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;918 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;151 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;902 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;148 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;882 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,17 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,28 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,9 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,92 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,07 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,25 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,24 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,16 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.143 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.908 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.981 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.059 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.865 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.946 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.006 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.820 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.908 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.954 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.773 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.853 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.715 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.793 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,33 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,52 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,83 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,64 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,97 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,55 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;93,99 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,36 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,71 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,36 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,69 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.961 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.370 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.816 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.880 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.340 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.785 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.829 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.301 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.758 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.780 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.261 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.729 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.217 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.695 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,26 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,73 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,29 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,54 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,09 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,81 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;93,89 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,4 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,21 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,54 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,34 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;182 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;538 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.165 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;179 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;525 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.161 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;177 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;519 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.150 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;174 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;512 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.124 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;498 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.098 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,35 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,58 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,66 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,25 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,47 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,71 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,6 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,17 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,48 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,57 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,25 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.128 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.036 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.012 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.087 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.001 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.980 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.041 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.950 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.925 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.881 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.861 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.819 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.821 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,69 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,85 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,94 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,22 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,17 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,11 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,89 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,99 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,85 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,66 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.075 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.842 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.966 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.034 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.809 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.940 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.989 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.764 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.908 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.697 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.870 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.640 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.846 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,67 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,84 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,68 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,2 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,26 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,05 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,9 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,12 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,89 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,9 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;53 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;194 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.046 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;53 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;192 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.040 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;52 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;186 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.017 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;184 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;991 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;179 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;975 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,97 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,43 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98,11 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,88 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,23 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,85 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,74 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,27 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,21 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.144 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.084 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.029 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.108 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.043 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.985 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.974 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.913 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.912 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.867 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.856 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.824 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,85 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,67 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,55 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,43 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,17 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,42 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,65 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,61 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,23 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.108 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.895 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.058 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.072 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.855 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.028 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.787 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.980 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.728 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.951 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.677 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.921 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,84 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,62 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,54 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,27 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,21 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,23 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,8 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,47 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,34 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;36 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;189 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;971 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;36 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;188 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;957 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;187 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;933 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;184 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;916 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;179 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;903 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,47 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,56 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,94 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,09 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,35 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,34 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,71 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.926 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.610 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.095 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.876 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;3.585 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.981 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.824 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;3.559 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.938 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.787 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.538 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.909 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.753 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.506 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.872 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,73 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,31 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,22 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,4 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,59 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,17 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,46 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,01 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,46 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,59 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,12 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,55 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.675 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.002 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.630 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.989 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.579 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.975 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.545 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.960 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.514 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.940 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,78 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,35 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,39 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,65 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,46 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,9 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,62 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,9 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;251 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.608 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;246 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.596 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;245 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.584 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;242 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.578 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;239 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.566 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,01 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,25 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,61 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,51 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,41 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,13 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,22 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,39 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.952 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.548 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.611 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.906 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;3.521 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;3.589 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.870 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.502 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.573 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.839 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.474 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.550 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;3.431 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;3.513 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,84 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,24 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,39 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,93 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,7 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,95 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,14 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,91 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,31 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,7 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,29 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.683 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.616 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.827 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.641 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.596 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.813 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.606 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.580 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.802 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.576 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.558 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.788 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.526 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.773 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,86 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,24 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,23 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,91 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,62 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,63 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,09 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,78 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,87 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,56 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,04 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;269 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;932 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.784 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;265 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;925 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.776 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;264 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;922 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.771 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;263 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;916 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.762 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;905 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.740 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,51 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,25 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,55 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,14 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,93 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,27 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,77 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,28 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,77 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,1 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,53 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.995 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.668 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.656 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.958 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.651 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.641 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.928 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.619 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.611 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.578 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;3.572 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.537 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;3.550 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,07 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,54 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,59 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,32 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,66 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,77 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,55 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,7 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,43 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,1 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.939 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.375 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.877 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.902 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.358 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.867 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.872 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.328 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.847 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.293 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.825 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.254 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.813 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,06 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,5 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,47 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,3 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,61 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,4 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,57 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,23 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,41 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,59 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;56 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;293 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.779 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;56 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;293 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.774 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;56 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;291 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.764 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;285 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.747 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;283 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.737 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,72 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,32 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,16 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,27 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,2 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,59 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,64 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.073 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.794 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.663 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.046 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.762 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.640 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.718 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.610 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.673 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;3.584 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.639 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.559 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,34 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,16 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,37 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,55 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,81 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,84 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,91 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,16 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.028 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.518 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.994 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.001 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.487 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.980 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.445 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.963 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.405 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.949 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.374 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.932 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,33 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,12 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,3 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,92 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,45 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,79 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,74 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,91 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,89 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;45 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;276 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.669 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;45 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;275 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.660 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;273 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.647 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;268 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.635 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;265 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.627 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,64 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,46 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,91 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,68 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,1 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,96 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,01 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,48 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;236 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;221 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;259 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;236 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;220 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;259 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;236 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;220 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;257 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;235 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;220 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;257 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;234 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;220 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;255 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,55 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,55 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,23 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,58 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;99,55 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;99,23 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,15 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;99,55 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,46 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;219 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;81 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;219 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;81 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;219 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;81 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;218 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;81 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;217 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;81 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,54 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,09 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;17 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;140 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;17 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;139 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;17 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;139 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;17 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;139 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;17 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;139 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,29 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,29 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;99,29 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;99,29 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;252 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;214 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;223 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;252 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;214 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;222 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;250 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;214 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;222 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;249 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;214 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;221 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;213 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;220 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,55 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,21 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,55 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,81 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,1 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,53 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,65 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;239 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;126 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;85 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;239 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;126 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;85 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;237 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;126 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;85 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;236 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;126 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;85 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;126 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;85 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,16 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,74 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;13 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;88 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;138 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;13 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;88 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;137 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;13 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;88 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;137 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;13 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;88 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;136 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;87 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;135 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,28 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,28 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,55 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,86 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,83 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;240 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;207 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;211 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;239 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;207 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;211 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;237 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;207 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;211 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;206 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;210 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;206 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;210 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,58 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,75 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,52 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;99,53 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,52 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;99,53 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;238 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;185 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;70 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;237 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;185 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;70 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;235 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;185 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;70 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;184 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;70 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;184 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;70 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,58 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,74 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,46 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,46 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;22 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;141 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;22 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;141 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;22 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;141 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;22 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;140 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;22 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;140 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,29 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;99,29 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;248 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;225 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;221 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;248 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;225 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;221 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;224 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;220 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;224 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;220 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;223 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;220 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,56 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,55 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,56 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,55 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,11 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;99,55 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;245 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;212 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;81 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;245 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;212 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;81 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;211 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;81 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;211 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;81 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;210 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;81 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,53 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;99,53 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;99,06 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;13 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;140 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;13 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;140 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;13 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;139 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;13 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;139 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;13 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;139 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,29 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,29 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;99,29 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;97 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;78 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;91 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;96 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;77 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;91 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;96 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;77 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;91 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;96 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;77 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;91 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;95 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;77 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;91 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,97 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,72 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,97 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,72 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,97 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,72 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,94 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,72 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;92 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;32 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;91 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;31 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;91 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;31 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;91 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;31 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;90 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;31 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,91 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,88 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,91 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,88 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,91 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,88 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,83 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,88 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;5 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;46 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;5 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;46 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;5 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;46 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;5 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;46 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;5 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;46 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;97 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;79 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;88 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;97 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;79 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;88 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;97 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;79 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;88 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;96 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;79 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;88 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;78 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;87 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,97 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,73 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,86 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;93 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;40 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;37 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;93 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;40 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;37 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;93 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;40 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;37 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;93 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;40 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;37 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;39 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;36 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,5 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,3 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;39 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;51 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;39 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;51 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;39 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;51 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;39 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;51 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;39 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;51 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;75 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;102 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;82 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;87 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;102 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;82 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;87 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;102 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;82 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;87 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;81 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;86 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;81 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;86 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,78 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,85 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,78 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,85 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;101 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;69 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;29 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;101 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;69 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;29 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;101 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;69 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;29 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;68 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;28 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;68 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;28 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,55 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,55 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,55 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,55 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;58 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;58 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;13 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;58 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;13 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;58 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;13 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;58 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;107 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;93 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;84 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;107 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;93 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;84 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;92 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;83 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;92 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;83 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;92 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;83 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,92 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,81 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,92 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,81 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,92 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,81 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;106 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;83 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;28 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;106 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;83 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;28 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;82 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;27 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;82 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;27 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;82 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;27 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,8 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,43 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,8 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,43 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,8 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,43 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;10 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;56 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;10 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;56 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;10 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;56 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;10 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;56 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;10 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;56 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 35 Palmas, Las;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;25.664 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;24.860 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;25.886 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;24.381 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;23.640 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;23.442 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;23.456 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;22.945 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;22.768 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;22.718 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;22.323 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;22.163 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;22.114 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;21.825 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;21.548 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,09 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,56 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,4 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,3 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,95 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,52 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,79 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,62 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,17 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,79 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;83,24 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;24.308 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;21.744 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;23.074 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;20.593 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;22.202 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;19.953 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;21.501 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;19.377 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;20.916 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;18.936 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,92 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,71 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,34 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,76 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,45 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,11 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,05 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,09 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.356 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3.116 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.307 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.047 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.254 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.992 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.217 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.946 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.198 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.889 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,39 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,79 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,48 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,02 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,75 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,54 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,35 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,72 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;25.583 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;24.893 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;24.479 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;24.450 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;23.996 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;23.653 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;23.564 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;23.224 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;22.945 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;22.797 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;22.580 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;22.250 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;21.876 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;21.509 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 36 Pontevedra;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,57 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,4 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,63 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,11 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,3 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,73 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,11 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,71 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,89 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,88 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,87 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;24.266 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;21.522 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;19.302 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23.178 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;20.692 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;18.535 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;22.323 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;19.973 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17.943 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;21.580 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;19.396 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;17.379 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;18.765 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;16.765 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,52 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,14 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,03 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,99 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,8 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,96 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,93 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,12 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,04 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,19 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,86 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.317 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.371 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.177 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.272 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.304 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5.118 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.241 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.251 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.002 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.217 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.184 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4.871 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.111 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4.744 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,58 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,01 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,86 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,23 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,44 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,62 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,41 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,45 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,09 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,29 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,64 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;26.089 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;25.936 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;25.107 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;24.671 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;24.515 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;23.966 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;23.553 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;23.522 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;22.954 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;22.701 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;22.133 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;22.058 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;21.638 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,56 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,52 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,46 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,28 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,69 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,42 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,53 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,15 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,05 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,18 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;25.255 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;24.740 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;20.527 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;23.865 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;23.341 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;19.473 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;22.764 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;22.376 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;18.568 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;21.580 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;17.847 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;20.970 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;17.422 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,5 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,35 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,87 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,14 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,44 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,46 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,23 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,94 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,76 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,87 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;834 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.196 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4.580 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;806 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.174 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4.493 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;789 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.146 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;4.386 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.121 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;4.286 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.088 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;4.216 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,64 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,16 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,1 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,6 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,82 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,76 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,73 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,58 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,97 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,05 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;25.714 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;25.739 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;25.289 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;24.334 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;24.436 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;23.841 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;23.484 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;22.874 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;22.723 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;22.305 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;22.089 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;21.784 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,63 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,94 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,27 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,24 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,45 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,28 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,2 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,82 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,14 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;24.948 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;24.310 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;22.072 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;23.585 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;23.040 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;20.700 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;22.146 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;19.805 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;21.435 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;19.290 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;20.837 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;18.819 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,54 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,78 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,78 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,1 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,73 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,17 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,4 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,71 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,26 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;766 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.429 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.217 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;749 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.396 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.141 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.338 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3.069 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.288 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3.015 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.252 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.965 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,78 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,69 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,64 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,63 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,4 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,13 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,72 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,61 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,17 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;19.652 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;19.301 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;19.908 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;18.416 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;18.131 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;17.593 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;17.570 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;17.501 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;16.962 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.879 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.917 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;16.406 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;16.317 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;16.456 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.849 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,71 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,94 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,37 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,41 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,67 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,2 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,89 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,65 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,41 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,03 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,26 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,61 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;18.752 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;17.496 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17.563 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16.385 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.763 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;15.801 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;16.105 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;15.253 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15.562 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;14.835 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,66 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,65 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,39 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,31 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,88 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,18 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,99 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,79 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;900 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.805 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;853 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.746 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;807 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.700 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;774 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.664 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;755 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.621 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,78 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,73 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;89,67 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,18 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,19 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,89 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,81 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;19.504 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;19.272 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;18.990 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;18.440 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;18.440 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;18.194 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;17.599 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;17.705 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;17.522 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.890 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;17.102 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.873 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;16.445 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;16.190 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,54 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,68 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,81 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,23 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,87 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,27 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,6 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,74 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,85 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,33 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,26 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18.654 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;17.276 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;15.632 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;17.633 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.501 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;14.886 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.820 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.811 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;14.316 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;16.131 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;15.263 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;13.785 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;14.667 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;13.209 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,53 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,51 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,23 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,17 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,52 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,58 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,47 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,35 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,18 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,9 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,5 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;850 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.996 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.358 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;807 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.939 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.308 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;779 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.894 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.206 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;759 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.839 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.088 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.778 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.981 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,94 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,14 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,51 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,65 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,89 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,47 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;89,29 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,13 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,96 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,08 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,77 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;19.719 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;19.873 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19.401 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;18.378 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;18.534 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;18.319 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;17.388 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.653 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;17.390 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;16.890 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;16.634 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;16.300 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;16.187 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,2 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,26 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,42 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,18 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,83 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,63 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,99 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,74 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,02 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,43 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19.140 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;19.171 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16.704 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;17.823 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17.852 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.697 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16.845 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.992 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.860 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;16.249 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;14.185 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15.687 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.793 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,12 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,12 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,97 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,01 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,63 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,96 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,76 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,92 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,83 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,57 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;579 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;702 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.697 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;555 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;682 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.622 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;543 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;661 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.530 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;641 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.449 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;613 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.394 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,85 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,15 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,22 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,78 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,16 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,81 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,31 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,8 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,32 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,77 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;19.459 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;19.745 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;19.551 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;18.179 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;18.522 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;18.159 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;17.618 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;17.254 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;16.926 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;16.743 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;16.336 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;16.255 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,42 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,81 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,88 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,23 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,25 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,72 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,64 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,73 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,14 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;18.925 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18.761 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;17.759 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;17.660 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17.564 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;16.434 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;16.715 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;15.589 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;16.067 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;15.121 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15.506 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;14.670 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,32 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,62 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,54 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,09 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,78 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,64 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,15 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,65 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,61 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;534 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;984 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.792 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;519 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;958 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.725 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;903 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.665 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;859 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.622 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;830 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.585 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,19 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,36 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,26 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,77 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,91 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,3 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,51 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;84,35 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,45 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.667 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.434 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.642 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.641 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.410 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.561 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.596 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.376 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.536 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.570 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.354 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.502 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.550 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.335 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.468 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,03 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,01 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,93 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,34 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,62 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,99 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,36 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,71 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,7 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,61 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,93 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,41 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.470 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.965 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.444 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.948 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.402 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.919 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.378 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.904 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.358 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.891 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,95 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,13 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,25 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,66 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,28 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,9 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,47 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,23 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;197 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;469 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;197 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;462 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;194 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;457 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;192 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;450 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;192 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;444 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,51 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,48 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,44 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,46 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,95 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,46 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,67 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.735 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.503 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.397 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.690 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.467 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.377 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.664 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.444 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.353 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.628 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.423 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.324 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.395 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.290 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,35 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,56 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,17 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,4 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,64 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,16 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,09 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,8 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,95 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,69 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,54 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.549 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.003 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.634 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.506 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.971 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.619 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.482 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.954 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.606 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.449 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.937 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.584 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.913 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.561 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,31 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,4 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,08 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,37 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,55 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,29 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,08 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,7 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,94 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,51 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,53 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;186 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;500 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;763 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;184 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;496 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;758 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;182 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;490 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;747 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;179 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;486 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;740 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;482 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;729 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,92 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,2 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,34 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,85 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,9 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,24 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,2 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,99 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,4 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,54 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.821 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.722 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.527 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.768 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.662 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.481 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.687 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.582 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.427 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.547 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.395 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.516 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.372 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,12 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,8 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,18 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,25 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;94,86 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,04 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,57 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,78 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,43 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,87 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.705 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.544 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.786 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.655 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.485 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.750 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.576 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.409 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.705 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.377 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.684 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.349 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.668 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,15 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,68 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,98 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,23 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,69 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,46 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,44 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,29 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,33 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,39 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;116 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;178 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;741 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;113 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;177 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;731 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;111 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;173 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;722 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;170 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;711 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;167 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;704 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,41 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,44 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,65 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,69 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,19 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,44 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,51 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,95 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,82 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,01 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.789 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.664 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.540 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.722 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.610 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.502 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.581 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.473 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.539 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.443 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.513 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.426 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,6 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,97 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,5 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,88 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,36 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,31 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,18 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,33 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,51 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.687 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.504 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.027 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.621 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.455 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.995 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.427 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.975 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.388 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.952 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.369 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.943 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,54 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,04 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,42 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,92 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,43 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,37 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,3 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,61 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,86 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;102 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;160 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;513 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;101 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;155 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;507 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;154 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;498 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;151 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;491 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;144 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;483 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,02 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,88 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,83 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,25 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,08 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;94,38 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,71 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,15 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.152 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.940 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.133 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.131 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.915 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.085 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.098 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.884 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.068 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.077 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.868 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.053 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.055 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.851 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.029 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,33 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,15 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,47 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,29 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,1 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,93 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,62 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,55 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,45 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,92 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,97 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,68 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.916 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.164 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.897 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.142 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.868 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.115 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.849 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.102 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.827 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.093 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,35 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,98 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,35 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,74 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,7 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,13 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,95 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,72 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;236 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;776 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;234 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;773 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;230 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;769 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;228 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;766 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;228 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;758 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,15 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,61 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,46 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,1 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,61 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,71 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,61 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,68 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.141 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.934 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.900 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.117 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.905 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;2.890 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.098 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.891 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.878 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.076 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.872 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.861 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.854 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.838 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,24 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,01 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,66 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,63 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,53 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,24 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,93 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,89 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,66 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,27 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,86 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.881 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.121 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.909 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.857 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.098 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.903 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.839 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.086 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.894 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.818 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.075 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.883 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.064 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.869 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,17 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,92 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,69 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,54 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,35 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,21 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,81 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,83 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,64 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,31 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,9 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;260 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;813 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;991 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;260 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;807 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;987 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;259 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;805 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;984 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;258 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;797 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;978 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;790 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;969 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,26 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,6 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,62 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,02 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,29 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;99,23 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,03 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,69 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,17 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,78 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.344 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.152 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.982 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.320 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.130 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.969 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.273 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.099 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.940 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.077 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.908 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.056 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.883 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,28 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,3 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,56 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,88 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,32 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,59 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,62 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,52 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,95 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,68 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.218 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.863 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.915 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.195 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.842 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.904 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.151 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.814 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.881 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.794 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.857 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.775 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.840 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,29 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,27 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,43 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,92 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,29 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,22 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,59 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,97 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,93 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,08 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;126 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;289 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.067 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;125 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;288 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.065 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;122 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;285 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.059 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;283 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.051 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;281 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.043 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,21 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,65 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,81 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,83 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,62 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,25 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,92 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,5 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,23 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,75 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.249 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.136 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.999 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.216 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.111 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.981 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.093 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;2.949 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.067 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.921 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.049 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.905 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,98 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,2 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,4 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,63 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,33 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,8 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,4 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,23 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,87 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.131 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.873 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.166 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.099 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.850 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.151 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.833 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.122 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.810 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.098 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.792 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.087 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,98 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,2 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,31 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,61 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,97 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,81 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,86 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,18 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,35 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;118 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;263 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;833 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;117 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;261 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;830 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;260 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;827 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;257 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;823 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;257 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;818 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,15 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,24 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,64 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,86 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,28 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,72 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,8 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,72 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,2 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;128 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;122 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;145 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;128 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;122 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;145 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;128 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;122 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;144 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;128 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;122 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;144 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;128 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;122 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;144 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,31 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;99,31 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;99,31 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;115 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;81 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;115 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;81 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;115 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;81 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;115 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;81 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;115 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;81 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;13 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;41 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;13 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;41 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;13 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;41 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;13 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;41 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;13 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;41 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;138 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;123 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;136 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;138 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;123 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;136 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;138 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;123 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;136 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;138 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;123 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;136 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;122 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;136 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,19 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;125 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;85 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;93 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;125 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;85 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;93 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;125 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;85 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;93 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;125 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;85 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;93 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;85 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;93 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;13 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;38 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;43 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;13 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;38 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;43 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;13 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;38 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;43 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;13 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;38 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;43 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;37 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;43 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,37 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;138 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;123 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;141 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;138 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;123 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;141 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;138 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;123 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;141 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;122 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;141 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;122 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;141 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,19 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,19 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;128 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;111 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;89 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;128 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;111 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;89 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;128 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;111 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;89 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;110 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;89 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;110 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;89 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,1 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,1 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;10 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;12 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;52 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;10 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;12 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;52 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;10 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;52 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;52 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;52 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;147 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;127 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;135 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;147 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;127 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;135 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;126 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;135 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;126 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;135 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;126 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;135 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,21 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,21 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,21 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;138 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;115 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;85 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;138 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;115 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;85 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;115 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;85 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;115 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;85 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;115 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;85 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;9 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;50 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;9 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;12 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;50 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;11 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;50 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;11 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;50 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;11 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;50 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,67 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,67 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,67 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;65 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;63 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;58 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;65 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;62 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;58 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;64 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;62 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;58 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;64 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;62 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;58 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;64 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;61 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;58 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,41 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,46 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,41 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,46 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,41 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,46 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,83 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;55 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;38 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;55 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;37 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;54 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;37 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;54 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;37 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;54 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;36 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,37 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,18 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,37 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,18 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,37 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,18 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,74 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;10 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;25 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;10 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;25 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;10 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;25 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;10 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;25 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;10 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;25 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;65 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;61 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;56 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;65 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;61 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;56 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;65 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;61 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;56 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;65 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;60 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;56 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;60 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;55 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,36 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,36 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,21 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;57 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;37 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;34 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;57 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;37 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;34 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;57 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;37 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;34 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;57 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;36 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;34 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;36 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;33 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,3 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,3 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,06 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;8 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;24 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;22 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;8 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;24 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;22 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;8 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;24 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;22 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;8 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;24 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;22 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;24 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;22 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;67 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;66 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;56 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;67 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;66 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;56 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;67 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;65 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;56 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;65 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;55 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;64 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;55 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,48 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,48 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,21 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,97 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,21 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;64 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;51 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;33 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;64 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;51 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;33 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;64 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;50 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;33 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;50 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;32 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;49 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;32 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,04 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,04 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,97 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,08 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,97 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;15 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;23 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;15 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;23 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;15 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;23 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;15 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;23 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;15 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;23 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;70 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;67 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;64 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;70 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;66 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;64 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;66 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;63 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;65 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;63 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;65 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;63 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,51 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,51 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,44 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,01 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,44 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,01 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,44 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;67 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;57 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;35 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;67 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;56 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;35 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;56 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;34 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;55 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;34 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;55 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;34 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,25 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,25 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,14 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,49 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,14 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,49 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,14 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;10 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;29 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;10 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;29 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;10 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;29 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;10 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;29 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;10 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;29 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 36 Pontevedra;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.360 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.229 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.653 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;7.982 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;7.822 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;7.856 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;7.678 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;7.595 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;7.629 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.441 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.390 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.413 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.277 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.254 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.211 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,48 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,05 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,79 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,84 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,3 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,17 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,01 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,8 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,67 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,05 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,15 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;83,34 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.781 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.262 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.420 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.885 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.138 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.675 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.916 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.490 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.762 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.376 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,36 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,81 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,74 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,92 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,88 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,37 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,9 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,8 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;579 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;967 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;562 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;937 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;540 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;920 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;525 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;900 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;515 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;878 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,06 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,9 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,26 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,14 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,67 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,07 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,95 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,8 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.375 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.140 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.115 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;7.987 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;7.840 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;7.838 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.708 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.604 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.595 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.507 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.432 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.378 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;7.231 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;7.123 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 26 Rioja, La;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,37 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,31 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,59 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,04 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,42 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,59 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,64 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,3 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,92 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,83 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,78 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7.829 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.935 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6.386 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.459 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.658 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6.142 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.197 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.449 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.931 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.007 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.302 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.753 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.127 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.552 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,27 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,01 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,18 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,93 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,99 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,88 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,5 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,87 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,09 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;88,35 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,94 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;546 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.205 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.729 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;528 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.182 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.696 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;511 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.155 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.664 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;500 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.130 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.625 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.104 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.571 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,7 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,09 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,09 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,59 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,85 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,24 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,58 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,78 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,98 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,62 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,86 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.401 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.266 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.260 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.002 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;7.883 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.905 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.732 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.647 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.631 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;7.421 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;7.348 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;7.240 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;7.212 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,25 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,37 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,7 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;92,04 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,51 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,38 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,78 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,96 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,59 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,31 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;7.920 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.903 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.345 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.538 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.529 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7.006 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.277 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.301 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6.747 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.078 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.490 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;6.907 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.368 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,18 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,27 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,38 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,88 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,38 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,86 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,56 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,36 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,4 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,7 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;481 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;363 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;915 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;464 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;354 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;899 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;455 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;346 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;884 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;343 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;858 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;333 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;844 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,47 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,52 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,25 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,59 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,32 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,61 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,49 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,77 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,74 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,24 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.336 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.243 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.271 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.988 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;7.908 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;7.884 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;7.643 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;7.562 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;7.415 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;7.389 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.227 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.226 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,83 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,94 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,32 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,72 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,43 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,96 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,34 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,67 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,37 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7.913 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.660 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.065 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.572 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.336 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.703 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.085 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;6.419 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.882 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.264 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.707 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.120 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,69 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,77 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,88 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,49 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,86 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,84 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,66 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;87,56 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,62 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;423 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;583 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.206 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;416 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;572 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.181 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;558 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.143 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;533 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.125 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;520 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.106 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,35 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,11 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,93 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,71 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,78 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,42 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,28 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,19 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,71 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.141 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.166 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.381 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;5.776 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;5.780 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;5.634 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;5.521 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;5.580 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.440 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.307 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.396 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.251 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.161 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.271 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.069 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,06 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,74 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,29 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,9 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,5 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,25 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,42 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,51 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,29 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,04 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,48 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,44 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5.744 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5.698 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5.394 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.333 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.155 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.144 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.954 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4.977 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.816 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4.867 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,91 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,59 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,75 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,28 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,25 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,35 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,84 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,42 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;397 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;468 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;382 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;447 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;366 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;436 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;353 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;419 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;345 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;404 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,22 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,51 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,19 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,16 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,92 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,53 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,9 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;86,32 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.109 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.083 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.031 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;5.770 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;5.811 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;5.783 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.514 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.595 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;5.564 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.330 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.438 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.362 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;5.253 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;5.126 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,45 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,53 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,89 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,26 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,98 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,26 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,25 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,4 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,91 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,36 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,99 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.739 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.416 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.038 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.415 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.161 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.813 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.173 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.969 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.618 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.997 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.830 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.451 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.669 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.259 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,35 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,29 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,53 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,14 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,75 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,66 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,07 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,18 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,35 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,21 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,54 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;370 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;667 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;993 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;355 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;650 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;970 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;341 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;626 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;946 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;333 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;608 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;911 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;584 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;867 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,95 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,45 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,68 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,16 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,85 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,27 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,15 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,74 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,56 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,31 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.143 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.137 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.168 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;5.767 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.777 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.837 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.515 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.560 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.582 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;5.356 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.319 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.194 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;5.197 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,88 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,13 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,63 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,78 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,6 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,5 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,27 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,24 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,63 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,26 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5.819 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5.936 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.729 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.458 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.585 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.408 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.213 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.375 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.164 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.174 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.920 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.021 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.807 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,8 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,09 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,4 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,59 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,55 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,14 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,16 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,88 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,59 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,91 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;324 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;201 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;439 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;309 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;192 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;429 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;302 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;185 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;418 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;182 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;399 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;173 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;390 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,37 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,52 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,72 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,21 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,04 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,22 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,55 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,89 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,07 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,84 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.084 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.082 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.171 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.765 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.768 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.803 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;5.522 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;5.501 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;5.326 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;5.345 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.154 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.194 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,76 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,84 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,04 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,79 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,14 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,57 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,61 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,74 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,17 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5.810 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5.682 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5.576 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.496 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5.379 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.227 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.147 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4.951 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.969 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.806 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.805 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.671 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,6 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,67 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,74 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,58 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,79 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,45 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,19 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,57 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,77 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;274 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;400 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;595 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;269 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;389 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;576 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;375 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;550 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;357 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;539 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;349 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;523 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,18 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,25 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,81 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,75 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,44 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,25 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,59 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,25 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,9 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;926 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;821 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;939 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;919 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;811 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;903 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;892 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;800 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;884 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;879 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;788 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;866 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;869 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;778 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;854 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,24 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,78 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,17 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,33 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,44 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,14 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,92 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,98 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,23 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,84 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,76 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,95 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;841 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;635 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;836 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;628 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;813 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;619 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;801 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;607 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;792 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;604 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,41 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,9 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,67 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,48 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,24 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,59 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,17 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,12 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;85 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;186 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;83 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;183 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;79 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;181 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;78 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;181 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;77 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;174 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,65 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,39 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,94 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,31 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,76 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,31 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,59 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,55 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;940 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;825 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;847 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;916 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;811 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;832 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;901 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;802 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;817 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;891 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;789 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;811 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;778 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;802 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,45 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,3 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,23 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,85 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,21 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,46 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,79 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,64 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,75 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,3 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,69 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;861 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;623 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;547 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;837 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;611 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;536 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;824 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;602 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;525 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;816 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;596 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;520 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;586 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;515 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,21 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,07 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,99 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,7 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,63 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,98 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,77 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,67 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,06 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,06 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,15 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;79 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;202 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;300 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;79 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;200 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;296 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;77 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;200 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;292 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;75 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;193 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;291 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;192 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;287 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,01 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,67 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,47 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,01 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,33 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,94 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,54 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,05 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,67 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;920 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;880 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;853 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;906 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;868 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;837 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;899 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;854 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;828 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;837 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;817 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;825 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;809 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,48 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,64 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,12 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,72 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,05 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,07 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,11 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,78 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,75 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,84 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;853 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;814 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;678 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;840 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;802 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;665 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;834 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;789 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;657 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;772 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;648 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;761 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;644 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,48 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,53 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,08 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,77 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,93 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,9 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,84 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,58 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,49 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,99 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;67 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;66 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;175 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;66 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;66 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;172 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;65 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;65 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;171 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;65 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;169 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;64 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;165 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,51 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,29 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,01 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,48 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,71 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,48 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,57 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,97 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,29 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;909 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;874 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;821 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;890 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;862 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;813 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;849 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;803 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;830 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;795 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;823 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;787 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,91 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,63 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,03 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,14 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,81 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,97 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,83 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,16 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,86 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;844 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;791 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;602 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;826 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;779 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;597 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;766 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;593 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;751 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;588 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;744 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;581 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,87 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,48 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,17 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,84 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,5 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,94 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,67 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,06 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,51 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;65 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;83 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;219 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;64 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;83 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;216 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;83 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;210 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;79 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;207 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;79 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;206 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,46 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,63 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,89 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,18 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,52 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,18 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,06 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.220 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.169 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.255 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.214 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.159 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.241 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.192 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.143 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.227 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.182 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.134 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.219 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.174 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.133 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.212 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,51 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,14 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,88 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,7 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,78 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,77 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,89 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,01 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,13 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,23 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,92 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,57 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.130 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;882 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.124 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;878 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.104 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;866 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.095 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;860 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.088 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;859 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,47 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,55 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,7 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,19 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,9 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,51 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,28 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,39 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;90 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;287 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;90 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;281 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;88 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;277 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;87 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;274 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;86 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;274 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,91 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,78 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,52 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,67 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,47 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,56 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,47 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.251 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.163 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.162 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.226 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.149 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.148 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.218 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.138 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.140 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.211 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.136 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.132 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.131 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.122 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,8 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,8 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,36 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,85 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,11 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,8 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,68 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,42 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,25 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,56 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.161 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;853 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;748 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.139 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;843 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;740 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.132 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;835 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;735 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.126 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;833 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;730 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;829 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;726 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,11 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,83 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,93 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,5 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,89 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,26 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,99 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,66 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,59 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,19 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,06 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;90 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;310 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;414 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;87 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;306 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;408 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;86 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;303 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;405 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;85 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;303 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;402 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;302 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;396 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,67 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,71 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,55 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,56 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,74 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,83 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,44 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,74 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,1 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,42 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,65 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.262 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.177 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.167 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.253 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.166 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.160 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.242 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.161 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.151 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.156 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.143 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.149 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.137 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,29 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,07 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,4 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,42 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,64 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,63 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,22 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,94 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,62 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,43 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.179 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.091 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;892 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.171 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.080 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;887 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.161 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.075 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;881 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.070 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;878 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.063 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;873 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,32 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,99 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,44 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,47 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,53 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,77 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,08 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,43 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,43 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,87 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;83 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;86 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;275 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;82 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;86 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;273 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;81 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;86 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;270 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;86 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;265 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;86 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;264 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,8 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,27 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,59 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,18 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,36 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.263 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.215 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.205 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.253 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.206 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.195 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.200 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.186 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.187 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.177 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.178 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.173 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,21 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,26 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,17 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,77 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,42 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,7 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,68 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,95 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,34 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.186 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.123 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;837 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.177 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.114 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;830 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.108 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;827 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.098 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;822 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.094 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;820 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,24 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,2 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,16 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,66 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,81 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,77 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,21 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,42 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,97 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;77 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;92 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;368 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;76 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;92 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;365 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;92 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;359 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;89 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;355 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;84 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;353 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,7 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,18 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,55 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,74 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,47 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,3 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,92 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;53 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;58 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;60 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;53 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;57 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;60 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;53 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;57 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;60 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;53 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;57 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;60 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;53 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;57 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;60 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,28 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,28 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,28 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,28 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;48 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;37 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;48 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;36 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;48 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;36 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;48 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;36 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;48 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;36 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,3 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,3 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,3 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,3 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;5 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;21 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;5 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;21 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;5 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;21 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;5 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;21 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;5 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;21 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;54 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;52 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;58 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;54 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;52 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;58 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;54 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;52 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;58 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;54 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;52 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;57 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;52 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;57 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,28 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,28 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;50 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;31 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;42 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;50 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;31 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;42 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;50 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;31 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;42 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;50 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;31 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;41 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;31 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;41 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,62 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,62 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;4 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;21 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;16 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;4 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;21 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;16 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;4 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;21 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;16 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;4 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;21 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;16 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;21 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;16 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;55 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;54 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;55 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;55 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;54 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;54 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;55 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;54 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;53 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;54 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;52 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;54 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;52 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,18 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,36 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,55 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,55 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;51 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;46 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;35 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;51 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;46 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;35 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;51 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;46 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;34 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;46 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;33 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;46 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;33 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,14 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,29 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,29 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;8 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;20 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;8 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;19 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;8 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;19 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;8 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;19 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;8 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;19 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;57 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;54 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;58 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;57 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;54 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;57 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;54 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;56 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;54 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;56 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;54 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;56 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,28 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,55 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,55 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,55 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;52 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;47 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;40 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;52 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;47 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;39 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;47 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;38 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;47 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;38 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;47 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;38 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,5 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;7 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;18 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;7 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;18 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;7 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;18 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;7 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;18 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;18 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;20 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;15 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;18 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;20 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;15 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;18 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;20 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;15 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;18 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;20 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;15 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;17 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;20 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;15 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;16 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,44 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;88,89 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;18 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;18 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;18 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;18 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;10 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;18 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;10 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;5 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;5 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;5 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;5 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;5 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;21 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;21 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;21 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;16 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;21 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;16 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;17 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;16 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;94,12 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;94,12 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,12 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;12 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;18 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;11 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;18 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;11 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;18 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;12 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;11 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;12 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;83,33 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;83,33 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;83,33 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;21 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;18 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;17 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;21 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;18 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;17 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;21 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;18 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;17 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;18 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;17 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;18 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;17 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;18 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;16 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;11 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;18 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;16 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;18 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;16 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;16 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;11 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;23 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;18 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;16 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;23 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;18 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;16 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;18 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;16 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;18 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;16 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;18 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;16 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;21 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;17 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;21 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;10 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;17 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;10 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;17 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;17 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 26 Rioja, La;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;7.725 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;7.570 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;8.025 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;7.398 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;7.221 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;7.207 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;7.134 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;7.001 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;6.971 37 Salamanca;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.949 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;6.845 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.781 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.759 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;6.699 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.614 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,77 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,39 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,81 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;92,35 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,48 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,87 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,95 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,42 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,5 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,5 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,49 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,42 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;7.431 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.526 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;7.115 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.201 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.853 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.012 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.679 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.871 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.500 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5.742 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,75 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,02 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;92,22 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,12 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,88 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,96 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;87,47 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,99 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;294 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.044 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;283 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.020 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;281 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;989 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;270 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;974 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;259 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;957 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,26 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,7 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,58 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,73 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,84 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,3 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,1 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,67 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;7.731 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;7.557 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;7.462 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;7.400 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;7.262 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;7.179 37 Salamanca;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.178 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;7.063 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;6.968 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.945 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;6.888 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;6.784 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;6.706 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;6.577 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 37 Salamanca;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,72 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,1 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,21 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,85 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,46 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,38 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,83 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,15 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,91 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,74 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,14 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;7.453 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.603 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.904 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.128 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.335 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.639 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.915 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.152 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.466 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.692 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5.992 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.321 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5.828 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.151 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,64 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,94 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,51 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,78 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,17 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,58 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,79 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,75 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,13 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;88,26 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87,25 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;278 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;954 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.558 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;272 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;927 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.540 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;263 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;911 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.502 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;253 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;896 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.463 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;878 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.426 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,84 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,17 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,84 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,6 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,49 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,41 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,01 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,92 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,9 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,03 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,53 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;7.818 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;7.745 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;7.626 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;7.441 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;7.371 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;7.286 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.147 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;7.115 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.012 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;6.910 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;6.787 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;6.751 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;6.630 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,18 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,17 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,54 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,42 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,87 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,95 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,22 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,17 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,94 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;7.660 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;7.505 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6.433 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;7.289 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;7.140 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6.119 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.002 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;6.892 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.872 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.690 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.676 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;6.534 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.549 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,16 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,14 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,12 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,41 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,83 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,28 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,14 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,23 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,06 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,26 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;158 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;240 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.193 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;152 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;231 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.167 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;145 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;223 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.140 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;220 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.111 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;217 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.081 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,2 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,25 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,82 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,77 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,92 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,56 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,67 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,13 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,42 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,61 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7.727 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;7.685 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;7.645 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;7.362 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;7.335 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;7.268 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;7.095 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;7.005 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;6.896 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;6.825 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.755 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;6.702 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,28 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,45 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,07 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,32 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,63 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,73 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,27 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,9 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,67 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7.592 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;7.359 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6.491 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7.233 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.019 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6.144 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.787 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.909 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.595 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.758 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6.460 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5.652 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,27 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,38 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,65 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,23 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,03 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,62 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,71 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;87,78 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;87,07 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;135 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;326 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.154 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;129 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;316 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.124 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;308 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.096 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;301 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.067 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;295 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.050 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,56 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,93 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,4 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,48 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,97 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,33 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,46 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90,49 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,99 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;5.850 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;5.825 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.102 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;5.540 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;5.493 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;5.319 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;5.298 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;5.298 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;5.104 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.125 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.152 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.932 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.950 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.016 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.789 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,7 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,3 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,17 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,56 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,95 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,64 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,61 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,45 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;80,83 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,62 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;86,11 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,48 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5.668 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5.273 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5.367 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4.959 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.125 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;4.786 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.963 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4.652 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.798 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4.532 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,69 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,05 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,42 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,76 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,56 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,22 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,65 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,95 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;182 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;552 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;173 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;534 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;173 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;512 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;162 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;500 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;152 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;484 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,05 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,74 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,05 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,75 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,01 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,58 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,52 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,68 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;5.808 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;5.781 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;5.710 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;5.505 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;5.515 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;5.443 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;5.296 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.327 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;5.243 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.085 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.166 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;5.078 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;5.002 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;4.884 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,78 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,4 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,32 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,18 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,15 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,82 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,55 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,36 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,93 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,52 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,53 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.634 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.266 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;4.750 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.335 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.019 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.498 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.135 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.845 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4.332 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.933 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.699 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4.196 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.546 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4.032 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,69 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,31 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,69 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,14 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,01 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,2 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,56 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,23 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,34 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,33 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,88 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;174 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;515 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;960 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;170 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;496 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;945 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;161 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;482 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;911 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;152 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;467 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;882 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;456 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;852 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,7 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,31 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,44 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,53 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,59 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,9 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,36 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,68 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,88 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;88,54 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,75 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5.878 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.931 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5.869 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;5.525 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.578 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.546 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;5.260 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.346 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.297 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;5.159 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;5.085 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;5.009 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;4.945 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,99 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,05 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,5 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,49 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,14 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,25 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,98 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,64 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,45 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,26 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5.781 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5.795 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.228 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5.434 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.450 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.927 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.175 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.226 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4.699 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.042 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.510 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.894 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.391 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,05 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,24 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,52 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,18 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,88 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,01 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,27 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,45 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,99 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;97 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;136 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;641 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;91 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;128 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;619 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;85 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;120 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;598 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;117 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;575 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;115 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;554 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,81 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,12 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,57 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;87,63 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;88,24 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,29 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,03 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,7 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;84,56 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,43 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5.803 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.821 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5.866 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;5.462 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.488 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.510 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;5.266 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;5.264 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;5.080 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;5.100 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.950 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.985 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,12 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,28 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,93 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,47 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,74 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,27 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,94 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,04 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,98 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5.722 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5.611 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5.251 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5.386 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5.288 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4.919 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.072 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4.694 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.892 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.552 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.768 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.451 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,13 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,24 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,68 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,39 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,39 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,19 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,69 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,98 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,76 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;81 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;210 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;615 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;76 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;200 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;591 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;194 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;570 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;188 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;548 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;182 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;534 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;93,83 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,24 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,1 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,38 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,68 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,52 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,11 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,67 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,83 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;819 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;776 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;845 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;810 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;765 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;826 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;797 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;751 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;819 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;792 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;744 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;808 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;784 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;737 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;793 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,9 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,58 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,75 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,31 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,78 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,92 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,7 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,88 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,62 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,73 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,97 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,85 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;772 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;583 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;764 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;576 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;753 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;566 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;748 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;562 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;741 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;556 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,96 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,8 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,54 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,08 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,89 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,4 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,98 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,37 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;47 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;193 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;46 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;189 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;44 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;185 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;44 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;182 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;43 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;181 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,87 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,93 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,62 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,85 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,62 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,3 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,49 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,78 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;847 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;807 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;783 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;829 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;794 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;778 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;823 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;786 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;770 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;811 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;775 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;759 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;763 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;753 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,87 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,39 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,36 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,17 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,4 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,34 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,75 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,03 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,93 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,55 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,17 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;807 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;638 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;526 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;791 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;629 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;521 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;785 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;623 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;515 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;774 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;612 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;509 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;606 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;507 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,02 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,59 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,05 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,27 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,65 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,91 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,91 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,92 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,77 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,98 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,39 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;40 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;169 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;257 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;38 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;165 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;257 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;38 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;163 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;255 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;37 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;163 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;250 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;157 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;246 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,63 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,45 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,22 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,5 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,45 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,28 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,9 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,72 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;827 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;804 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;781 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;814 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;786 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;769 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;795 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;773 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;755 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;763 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;748 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;758 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;740 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,43 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,76 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,46 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,13 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,14 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,67 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,9 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,77 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,28 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,75 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;803 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;764 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;559 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;790 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;747 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;549 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;772 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;734 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;537 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;724 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;534 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;719 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;530 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,38 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,77 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,21 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,14 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,07 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,06 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,76 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,53 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,11 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,81 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;24 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;40 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;222 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;24 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;39 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;220 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;23 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;39 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;218 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;39 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;214 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;39 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;210 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,5 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,1 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,83 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,5 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,2 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,5 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,4 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,5 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,59 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;806 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;837 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;796 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;789 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;827 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;783 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;818 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;772 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;812 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;763 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;805 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;758 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,89 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,81 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,37 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,73 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,98 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,01 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,85 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,18 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,23 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;788 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;791 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;581 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;772 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;781 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;570 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;773 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;564 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;767 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;558 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;760 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;556 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,97 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,74 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,11 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,72 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,07 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,97 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,04 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,08 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,7 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;18 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;46 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;215 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;17 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;46 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;213 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;45 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;208 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;45 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;205 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;45 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;202 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,44 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,07 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,83 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,74 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,83 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,35 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,83 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,95 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.009 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;924 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.032 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.001 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;918 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.016 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;992 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;907 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.002 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;985 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;904 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;995 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;978 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;901 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;987 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,21 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,35 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,45 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,32 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,16 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,09 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,62 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,84 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,41 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,93 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,51 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,64 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;947 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;642 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;940 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;638 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;931 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;632 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;924 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;629 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;917 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;626 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,26 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,38 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,31 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,44 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,57 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,98 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,83 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,51 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;62 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;282 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;61 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;280 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;61 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;275 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;61 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;275 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;61 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;275 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,39 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,29 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,39 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,52 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,39 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,52 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,39 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,52 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.031 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;926 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;924 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.021 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;910 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;913 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.014 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;907 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;910 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.004 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;904 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;903 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;898 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;896 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,03 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,27 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,81 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,35 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,95 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,48 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,38 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,62 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,73 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,98 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,97 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;970 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;669 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;602 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;960 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;657 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;594 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;953 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;654 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;593 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;943 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;651 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;590 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;646 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;586 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,97 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,21 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,67 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,25 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,76 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,5 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,22 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,31 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,01 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,56 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,34 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;61 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;257 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;322 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;61 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;253 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;319 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;61 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;253 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;317 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;61 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;253 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;313 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;252 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;310 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,44 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,07 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,44 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,45 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,44 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,2 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,05 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,27 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.067 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;968 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;935 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.056 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;965 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;930 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.046 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;954 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;920 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;946 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;914 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;942 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;905 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,97 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,69 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,47 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,03 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,55 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,4 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,73 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,75 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,31 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,79 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.033 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;908 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;624 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.022 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;905 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;621 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.012 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;894 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;614 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;886 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;610 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;883 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;606 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,94 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,67 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,52 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,97 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,46 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,4 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,58 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,76 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,25 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,12 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;34 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;60 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;311 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;34 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;60 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;309 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;34 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;60 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;306 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;60 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;304 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;59 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;299 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,36 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,39 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,75 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,33 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,14 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.071 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;982 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;940 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.064 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;975 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;933 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;966 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;927 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;959 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;920 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;955 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;917 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,35 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,29 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,26 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,37 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,62 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,66 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,87 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,25 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,55 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.037 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;914 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;632 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.030 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;907 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;628 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;899 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;624 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;893 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;621 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;889 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;618 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,32 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,23 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,37 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,36 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,73 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,7 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,26 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,26 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,78 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;34 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;68 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;308 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;34 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;68 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;305 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;67 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;303 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;66 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;299 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;66 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;299 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,03 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,53 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,38 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,06 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,08 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,06 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,08 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;29 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;27 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;28 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;29 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;27 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;28 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;29 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;27 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;28 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;29 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;27 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;28 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;29 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;27 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;27 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,43 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;27 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;17 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;27 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;17 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;27 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;17 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;27 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;17 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;27 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;17 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;10 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;10 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;10 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;2 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;10 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;2 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;10 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;27 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;26 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;28 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;27 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;26 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;28 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;27 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;26 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;28 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;27 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;26 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;27 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;26 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;27 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,43 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,43 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;26 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;19 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;17 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;26 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;19 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;17 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;26 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;19 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;26 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;19 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;17 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;19 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;17 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;7 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;11 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;7 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;11 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;7 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;11 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;7 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;10 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;7 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;10 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,91 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,91 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;28 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;28 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;28 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;24 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;24 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;25 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;24 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;27 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;24 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;27 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;24 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;27 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;24 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;12 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;24 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;12 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;24 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;12 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;13 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;13 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;12 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;12 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;12 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,31 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,31 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,31 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;30 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;28 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;28 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;30 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;28 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;27 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;28 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;27 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;28 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;27 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;28 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;27 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,43 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,43 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,43 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,43 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;29 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;28 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;18 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;29 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;28 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;18 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;28 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;18 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;28 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;18 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;28 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;18 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;10 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;9 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;9 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;9 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;90 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;18 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;17 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;11 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;11 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;17 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;17 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;17 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;18 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;18 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;18 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;18 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;17 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;16 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;11 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;9 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;16 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;11 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;9 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;16 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;6 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;2 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;6 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;2 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;6 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;2 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;6 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;6 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;8 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;17 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;16 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;18 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;17 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;16 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;18 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;17 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;16 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;17 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;16 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;17 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;16 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;16 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;16 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;10 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;14 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;14 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;10 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;15 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;15 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;15 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;15 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;17 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;15 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;16 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;15 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;6 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;6 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 37 Salamanca;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;26.246 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;25.208 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;27.126 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;24.710 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;23.672 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;23.130 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;23.584 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;22.786 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;22.165 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;22.624 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;22.036 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;21.477 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;21.970 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;21.401 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;20.856 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,15 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,91 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,27 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,86 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,39 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;81,71 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,2 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,42 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,17 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,71 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,9 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76,89 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;24.958 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;20.445 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;23.472 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;19.075 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;22.384 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18.305 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;21.459 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;17.645 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;20.835 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;17.133 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,05 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,3 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,69 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,53 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,98 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,3 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,48 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,8 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.288 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4.763 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.238 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4.597 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.200 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4.481 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.165 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4.391 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.135 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4.268 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,12 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,51 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,17 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,08 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,45 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,19 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,12 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,61 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;26.226 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;24.946 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;24.239 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;24.809 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;23.815 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;23.120 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;23.675 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;22.912 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;22.332 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;22.928 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;22.204 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;21.626 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;21.352 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;20.743 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,6 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,47 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,38 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,27 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,85 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,13 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,42 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,01 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,22 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,59 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,58 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;24.987 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;21.614 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;18.162 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;23.610 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;20.577 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;17.113 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;22.517 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;19.743 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;16.455 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;21.792 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;19.131 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;15.898 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;18.373 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;15.217 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,49 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,2 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,22 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,11 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,34 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,6 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,21 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,51 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,53 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,01 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,78 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.239 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3.332 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6.077 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.199 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3.238 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6.007 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.158 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3.169 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5.877 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.136 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3.073 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5.728 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.979 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5.526 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,77 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,18 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,85 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,46 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,11 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,71 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,69 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,23 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,26 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,41 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;90,93 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;26.277 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;25.322 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;24.573 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;24.830 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;24.097 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;23.497 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;23.941 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;23.230 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;22.588 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;22.268 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;21.587 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;21.537 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;20.982 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,49 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,16 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,62 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,11 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,74 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,92 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,94 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,85 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,05 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,39 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;25.513 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;24.107 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19.480 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;24.090 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;22.915 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;18.509 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;23.214 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;22.081 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;17.721 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;21.150 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;16.884 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;20.443 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;16.384 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,42 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,06 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,02 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,99 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,6 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,97 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,73 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,67 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,8 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,11 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;764 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.215 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;5.093 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;740 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.182 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4.988 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;727 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.149 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;4.867 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.118 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;4.703 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.094 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;4.598 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,86 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,28 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,94 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,16 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;94,57 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,56 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,02 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,34 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,04 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,28 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;26.313 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;25.708 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;25.230 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;25.143 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;24.536 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;23.953 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;23.393 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;22.734 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;22.505 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;22.006 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;21.680 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;21.356 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,55 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,44 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,94 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,11 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,54 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,22 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,33 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,65 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;25.788 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;24.102 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;20.171 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;24.627 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;22.987 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;19.015 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;21.900 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;17.963 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;21.071 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17.350 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;20.292 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;16.792 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,5 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,37 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,27 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,86 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,05 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,42 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,01 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,19 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,25 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;525 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.606 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5.059 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;516 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.549 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;4.938 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.493 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4.771 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.434 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;4.656 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.388 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;4.564 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,29 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,45 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,61 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,96 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,31 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,29 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,03 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,43 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,22 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;19.595 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;19.060 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;20.221 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;18.157 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;17.619 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;16.499 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;17.117 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;16.806 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;15.606 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.268 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.122 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;14.991 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;15.684 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;15.557 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;14.451 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,66 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,44 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;81,59 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,35 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,17 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;77,18 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,02 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,59 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;74,14 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,04 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;81,62 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;71,47 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;18.765 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16.483 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17.373 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15.177 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.367 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14.456 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.545 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;13.840 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;14.988 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13.375 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,58 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,08 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,22 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,7 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;82,84 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,97 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,87 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,14 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;830 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.577 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;784 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.442 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;750 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.350 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;723 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.282 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;696 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.182 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,46 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;94,76 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,36 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,19 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,11 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,55 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;83,86 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;84,67 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;19.564 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;18.837 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;18.256 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;18.228 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;17.775 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;17.179 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;17.193 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;16.944 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;16.441 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;16.521 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.304 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;15.804 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;15.546 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;15.022 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,17 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,36 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,1 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,88 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,95 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,06 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,45 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,55 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,57 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,53 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,29 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18.761 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16.889 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14.760 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;17.463 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;15.906 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.740 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.462 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.131 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.112 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;15.811 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;14.574 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12.599 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;13.890 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11.976 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,08 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,18 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,09 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,75 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,59 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;88,83 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,28 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,29 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,36 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,24 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,14 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;803 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.948 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.496 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;765 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.869 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.439 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;731 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.813 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.329 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;710 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.730 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.205 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.656 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.046 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,27 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,94 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,37 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,03 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,07 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,22 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,42 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;88,81 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,68 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;85,01 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,13 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;19.526 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;19.084 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;18.494 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;18.174 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;17.919 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;17.469 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;17.360 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.120 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;16.636 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;16.256 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;15.729 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;15.595 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;15.190 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,08 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,9 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,46 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,91 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,71 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,95 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,18 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,05 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,72 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,13 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;19.015 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;18.352 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15.843 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;17.684 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17.218 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;14.910 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;16.882 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.448 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.172 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;15.610 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.386 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;14.969 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;12.925 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,82 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,11 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,78 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,63 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,45 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,06 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,49 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,57 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,58 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;511 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;732 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.651 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;490 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;701 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.559 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;478 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;672 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.464 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;646 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.343 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;626 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.265 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,89 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,77 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,53 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,54 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,8 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,95 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;88,25 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,38 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85,52 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,44 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;19.524 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;19.206 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;18.982 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;18.424 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;18.090 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;17.777 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;17.049 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;16.663 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;16.244 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;16.009 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;15.521 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;15.434 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,37 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,19 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,65 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,77 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,78 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,58 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,34 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,81 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,31 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;19.194 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18.060 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;16.297 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;18.103 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;16.997 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.190 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;16.008 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.202 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.257 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13.637 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;14.572 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.123 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,32 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,11 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,21 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,64 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,14 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,48 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,68 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;80,69 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,52 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;330 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.146 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.685 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;321 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.093 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.587 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.041 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.461 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;987 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.372 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;949 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.311 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,27 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,38 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,35 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;90,84 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,66 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,13 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,34 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,81 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,07 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.020 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.773 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.046 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.962 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.717 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.873 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.910 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.676 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.827 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.846 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.636 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.783 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.803 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.593 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.739 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,08 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,98 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;94,32 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,36 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,5 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;92,81 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,24 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,06 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;91,37 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,81 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,51 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;89,92 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.833 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.006 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.779 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.963 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.728 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.932 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.668 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.902 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.628 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.871 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,09 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,86 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,29 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,31 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,18 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,82 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,76 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,27 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;187 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;767 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;183 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;754 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;182 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;744 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;178 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;734 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;175 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;722 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,86 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,31 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,33 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,19 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,7 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,58 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,13 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.987 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.797 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.617 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.940 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.752 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.587 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.884 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.703 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.555 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.842 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.660 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.517 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.601 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.460 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,43 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,39 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,85 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,55 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,64 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,63 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,15 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,1 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,18 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,99 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.813 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.305 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.611 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.767 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.268 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.588 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.715 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.230 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.570 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.674 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.195 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.544 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.148 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.509 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,36 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,39 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,57 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,52 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,75 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,45 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,06 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,23 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,84 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,19 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,67 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;174 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;492 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.006 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;173 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;484 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;999 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;169 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;473 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;985 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;168 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;465 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;973 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;453 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;951 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,43 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,37 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,3 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,13 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,14 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,91 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,55 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,51 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,72 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,07 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,53 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.039 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.834 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.696 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.981 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.793 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.668 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.935 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.754 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.624 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.694 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.570 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.651 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.525 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,09 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,55 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,96 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,58 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,18 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,33 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,06 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,33 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,54 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,66 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.950 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.660 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.808 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.894 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.620 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.789 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.849 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.583 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.754 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.528 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.724 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.486 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.695 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,1 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,5 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,95 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,58 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,11 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,01 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,04 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,35 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,46 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,75 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;89 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;174 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;888 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;87 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;173 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;879 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;86 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;171 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;870 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;166 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;846 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;165 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;830 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,75 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,43 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,99 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,63 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,28 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,97 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,4 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,27 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,83 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,47 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.988 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.931 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.794 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.946 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.904 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.748 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.841 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.686 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.789 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.638 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.732 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.592 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,59 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,08 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,35 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,93 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,13 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,16 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,42 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,21 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;92,77 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.924 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.738 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.946 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.882 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.713 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.913 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.652 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.873 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.603 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.840 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.549 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.811 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,56 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,09 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,3 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,86 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,25 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,07 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,55 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,1 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,06 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;64 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;193 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;848 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;64 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;191 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;835 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;189 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;813 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;186 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;798 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;183 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;781 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,96 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,47 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,93 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,87 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,37 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,1 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,82 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,1 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.405 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.159 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.621 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.366 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;3.121 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.522 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.333 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;3.089 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.496 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.287 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.064 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.467 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.262 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.037 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.431 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,85 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,8 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,27 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,89 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,78 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,55 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,53 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,99 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,75 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,8 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,14 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,75 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.149 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.864 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.110 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.844 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.080 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.826 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.038 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.813 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.013 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.797 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,76 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,93 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,81 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,96 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,48 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,26 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,68 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,41 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;256 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.295 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;256 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.277 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;253 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.263 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;249 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.251 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;249 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.240 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,61 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,83 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,53 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,27 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,6 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,27 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,75 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.440 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.103 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.154 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.407 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;3.080 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;3.142 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.366 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.059 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.124 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.335 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.034 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.094 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;3.000 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;3.051 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,04 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,26 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,62 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,85 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,58 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,05 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,95 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,78 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,1 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,68 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,73 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.194 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.303 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.692 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.162 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.287 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.686 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.124 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.268 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.674 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.093 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.248 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.656 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.221 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.634 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,31 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,65 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,81 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,48 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,94 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,84 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,61 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,87 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,44 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,57 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;246 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;800 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.462 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;245 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;793 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.456 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;242 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;791 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.450 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;242 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;786 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.438 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;779 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.417 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,59 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,13 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,59 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,37 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,88 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,18 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,37 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,25 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,36 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,38 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,92 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.482 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.206 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.174 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.445 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.187 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.151 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.418 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.158 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.120 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.121 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;3.081 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.094 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;3.060 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,94 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,41 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,28 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,16 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,5 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,3 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,35 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,07 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,51 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,41 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.331 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.935 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.746 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.295 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.917 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.727 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.268 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.890 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.712 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.853 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.692 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.829 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.682 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,92 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,39 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,91 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,11 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,47 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,05 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,21 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,91 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,39 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,33 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;151 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;271 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.428 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;150 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;270 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.424 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;150 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;268 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.408 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;268 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.389 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;265 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.378 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,34 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,63 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,72 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;99,34 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,89 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,6 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,89 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,27 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;97,79 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,5 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.557 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.357 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.242 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.531 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.329 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.217 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.291 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.175 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.260 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;3.149 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.216 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.120 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,27 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,17 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,23 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,03 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,93 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,11 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,13 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,8 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,24 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.435 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.110 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.840 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.409 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.084 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.824 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.048 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.801 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.019 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.786 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.980 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.771 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,24 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,16 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,13 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,01 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,88 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,07 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,07 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,82 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,25 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;122 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;247 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.402 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;122 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;245 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.393 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;243 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.374 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;241 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.363 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;236 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.349 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,19 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,36 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,38 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,57 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,22 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95,55 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,22 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;147 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;151 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;165 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;146 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;150 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;163 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;146 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;150 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;163 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;149 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;163 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;143 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;149 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;163 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,32 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,34 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,32 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,34 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,64 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,68 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,28 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,68 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;139 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;72 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;138 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;138 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;137 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;70 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;135 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;70 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,28 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,61 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,28 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,61 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,56 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,22 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,12 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,22 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;157 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;147 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;156 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;147 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;154 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;152 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;147 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,36 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,09 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,64 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,82 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,64 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,96 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;99,32 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;147 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;88 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;77 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;146 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;88 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;77 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;86 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;77 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;142 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;86 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;77 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;86 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;76 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,32 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,96 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,73 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,6 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,73 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,73 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,7 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;10 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;59 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;10 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;59 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;10 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;59 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;10 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;59 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;58 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;71 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,31 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;153 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;136 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;153 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;136 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;151 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;136 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;135 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;135 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,69 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,26 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;99,31 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,26 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;99,31 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;117 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;64 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;117 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;64 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;142 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;117 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;64 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;116 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;63 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;116 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;63 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,61 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,15 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,44 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,15 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,44 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;9 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;19 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;81 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;9 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;19 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;81 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;9 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;19 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;81 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;19 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;81 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;19 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;81 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;165 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;146 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;149 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;163 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;145 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;149 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;144 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;143 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;148 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,79 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,32 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,63 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,33 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,63 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,33 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,95 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;99,33 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;161 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;138 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;67 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;159 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;137 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;67 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;136 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;66 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;136 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;66 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;135 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;66 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,76 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,28 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,55 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,51 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,55 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,51 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,83 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,51 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;82 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;82 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;82 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;82 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;82 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;79 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;65 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;79 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;65 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;65 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;65 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;65 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,73 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,63 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;20 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;20 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;71 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;20 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;71 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;20 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;71 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;20 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,61 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,61 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,61 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;64 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;61 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;64 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;61 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;64 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;78 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;61 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;63 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;61 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;63 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,39 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,39 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,39 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,44 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,39 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,44 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;29 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;22 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;28 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;22 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;28 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;22 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;72 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;28 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;22 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;28 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;22 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,55 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,55 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,55 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,55 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;33 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;42 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;33 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;42 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;33 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;42 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;33 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;41 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;33 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;41 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,62 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,62 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;77 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;64 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;77 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;64 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;77 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;63 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;63 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;63 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,44 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,44 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,44 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;43 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;43 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;73 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;43 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;43 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;43 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;45 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;44 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;44 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;19 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;44 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,78 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,78 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,78 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;79 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;68 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;63 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;79 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;68 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;68 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;68 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;68 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;74 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;56 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;21 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;74 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;56 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;21 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;56 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;21 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;56 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;21 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;56 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;21 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;12 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;42 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;12 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;12 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;12 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;41 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,62 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 38 Santa Cruz de Tenerife;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.038 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.913 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.052 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.848 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.725 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.723 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.722 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.612 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.618 40 Segovia;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.599 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.515 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.517 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.495 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.446 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.427 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,29 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,2 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91,88 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;92,17 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,31 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;89,29 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,13 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,83 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;86,8 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,55 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,07 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;84,58 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.893 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.446 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.711 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.268 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.590 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.165 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.471 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.077 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.370 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.016 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,32 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,83 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;92,22 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;91,85 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,16 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,29 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,57 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,52 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;145 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;467 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;137 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;457 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;132 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;447 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;128 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;438 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;125 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;430 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,48 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,86 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,03 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,72 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,28 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,79 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;86,21 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92,08 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.028 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.883 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.859 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.883 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.744 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.728 40 Segovia;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.739 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.629 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.617 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.614 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.540 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.515 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.448 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.393 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 40 Segovia;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,4 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,42 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,61 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,83 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,46 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,73 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,72 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,17 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;91,09 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,8 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,92 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.889 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.407 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.091 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.747 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.278 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.969 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.605 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.171 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.871 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.482 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.091 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.781 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.009 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.683 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,35 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,21 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,05 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,7 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,07 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,88 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,53 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,72 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,97 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;88,32 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,8 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;139 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;476 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;768 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;136 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;466 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;759 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;134 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;458 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;746 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;132 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;449 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;734 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;439 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;710 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,84 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,9 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,83 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,4 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,22 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,14 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,96 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,33 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,57 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;92,23 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,45 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.141 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.036 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.942 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.890 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.822 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.768 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.729 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.685 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.627 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.574 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.497 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.500 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.419 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,94 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,7 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,59 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,05 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,3 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,01 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,55 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,71 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,72 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,73 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.093 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.924 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.411 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.844 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.712 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.246 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.684 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.578 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.114 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.470 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.995 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.397 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.927 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,92 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,6 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,16 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,01 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,18 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,29 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,43 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,8 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,57 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,81 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;48 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;112 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;531 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;46 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;110 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;522 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;45 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;107 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;513 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;104 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;502 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;103 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;492 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,83 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,21 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,31 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,75 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,54 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,61 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,86 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,54 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,96 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,66 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.049 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.011 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.979 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.847 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.830 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.774 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.696 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.617 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.601 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.526 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.494 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.445 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,01 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,49 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,85 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,15 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,9 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,78 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,62 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,11 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,58 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.010 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.859 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.511 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.809 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.683 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.314 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.552 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.166 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.461 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.085 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.357 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.012 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,99 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,44 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,39 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,04 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,17 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,69 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,87 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,99 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;85,79 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;39 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;152 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;468 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;38 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;147 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;460 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;144 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;451 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;140 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;441 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;137 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;433 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,44 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,71 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,29 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,74 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,37 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,11 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,23 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90,13 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,52 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.140 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.085 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.134 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;2.958 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;2.906 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;2.821 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;2.837 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;2.802 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;2.726 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.722 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.713 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.634 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.625 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.646 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.554 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,2 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,2 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,01 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,35 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,83 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;86,98 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,69 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,94 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,05 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,6 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,77 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,49 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.033 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.806 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.859 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.637 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.742 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.539 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.631 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.456 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.537 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.396 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,26 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,98 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,41 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,48 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,75 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,53 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,65 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,39 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;107 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;279 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;99 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;269 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;95 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;263 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;91 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;257 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;88 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;250 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;92,52 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,42 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;88,79 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,27 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;85,05 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,11 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;82,24 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,61 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.113 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.046 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.005 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;2.972 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;2.917 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;2.883 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.835 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.808 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.781 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.717 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.720 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.683 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;2.636 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;2.569 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 40 Segovia;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,47 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,76 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,94 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,07 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,19 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,55 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,28 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,3 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,28 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,54 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,49 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.025 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.758 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.526 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.887 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.635 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.413 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.752 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.533 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.322 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.636 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.454 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.234 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.378 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.143 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,44 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,54 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,53 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,98 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,84 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,92 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,14 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,98 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,44 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,22 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,84 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;88 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;288 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;479 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;85 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;282 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;470 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;83 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;275 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;459 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;81 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;266 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;449 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;258 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;426 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,59 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,92 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,12 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,32 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,49 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,82 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;92,05 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,36 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,74 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,58 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,94 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.170 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.118 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.090 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.935 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.915 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.926 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.784 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.783 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.791 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;2.680 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;2.669 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;2.609 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;2.599 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,59 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,49 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,69 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,82 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,26 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,32 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,95 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,38 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,68 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,11 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.129 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.052 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.776 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.896 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.849 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.619 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.746 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.720 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.490 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.620 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.378 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.550 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.313 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,55 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,35 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,34 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,76 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,12 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,7 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,85 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,66 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,55 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,32 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;41 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;66 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;314 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;39 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;66 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;307 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;38 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;63 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;301 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;60 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;291 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;59 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;286 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,12 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,77 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,68 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,45 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,86 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,91 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,68 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;89,39 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,08 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.118 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.109 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.129 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.923 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.931 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.928 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;2.806 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;2.778 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;2.714 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;2.695 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.614 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.621 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,75 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,27 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,58 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,25 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,78 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,29 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,13 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,08 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,76 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.085 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.004 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.865 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.891 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.831 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.670 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.709 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.529 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.621 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.451 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.524 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.382 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,71 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,24 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,19 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,18 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,27 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,25 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,55 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,02 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,14 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;33 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;105 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;264 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;32 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;258 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;97 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;249 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;93 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;244 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;90 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;239 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,97 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,24 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,73 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,38 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,32 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,57 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,42 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,71 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,53 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;399 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;373 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;423 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;395 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;367 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;412 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;392 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;362 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;403 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;387 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;356 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;397 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;384 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;354 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;391 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,39 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,4 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,25 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,05 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,27 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,99 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,44 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,85 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,24 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,91 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,43 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;390 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;306 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;386 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;300 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;384 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;296 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;379 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;292 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;376 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;291 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,97 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,04 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,46 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,73 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,18 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,42 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,41 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,1 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;9 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;67 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;9 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;67 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;66 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;64 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;63 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;88,89 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,51 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,89 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,52 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,89 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,03 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;413 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;367 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;386 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;410 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;361 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;379 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;408 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;357 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;372 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;404 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;356 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;370 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;351 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;367 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,27 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,37 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,19 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,79 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,28 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,37 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,82 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,85 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,64 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,08 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;394 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;300 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;249 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;391 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;295 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;242 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;389 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;291 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;237 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;385 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;290 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;237 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;285 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;235 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,24 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,33 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,19 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,73 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,18 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,72 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,67 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,18 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,38 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;19 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;67 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;137 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;19 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;66 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;137 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;19 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;66 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;135 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;19 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;66 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;133 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;66 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;132 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,51 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,51 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,54 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,51 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,08 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,51 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,35 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;449 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;429 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;382 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;437 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;422 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;374 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;432 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;417 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;371 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;413 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;368 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;411 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;365 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,33 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,37 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,91 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,21 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,2 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,12 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,27 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,34 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,8 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,55 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;446 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;414 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;295 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;434 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;408 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;289 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;429 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;403 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;288 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;399 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;286 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;397 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;285 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,31 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,55 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,97 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,19 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,34 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,63 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,38 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,95 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,89 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,61 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;15 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;87 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;14 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;85 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;14 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;83 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;14 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;82 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;14 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;80 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;93,33 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,7 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,33 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,4 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,33 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,25 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,33 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,95 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;416 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;402 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;393 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;412 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;399 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;391 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;394 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;388 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;393 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;384 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;391 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;379 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,04 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,25 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,49 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,01 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,73 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,76 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,71 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,26 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,44 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;413 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;383 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;316 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;409 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;380 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;316 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;375 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;313 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;374 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;311 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;372 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;308 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,03 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,22 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,91 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,05 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,65 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,42 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,13 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,47 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;19 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;77 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;19 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;75 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;19 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;75 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;19 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;73 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;19 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;71 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,4 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,4 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,81 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,21 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;480 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;437 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;476 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;477 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;434 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;471 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;475 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;430 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;470 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;472 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;428 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;467 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;468 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;428 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;463 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,38 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,31 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,95 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,96 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,4 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,74 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,33 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,94 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,11 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,5 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,94 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,27 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;453 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;322 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;450 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;319 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;448 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;318 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;445 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;317 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;441 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;317 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,34 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,07 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,9 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,76 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,23 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,45 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,35 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,45 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;27 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;115 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;27 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;115 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;27 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;112 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;27 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;111 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;27 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;111 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,39 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,52 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,52 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;482 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;451 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;449 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;481 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;447 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;447 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;476 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;445 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;445 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;473 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;445 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;443 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;443 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;438 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 40 Segovia;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,79 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,11 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,55 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,76 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,67 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,11 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,13 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,67 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,66 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,23 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,55 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;453 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;336 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;302 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;452 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;335 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;300 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;447 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;334 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;298 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;444 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;334 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;296 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;334 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;291 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,78 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,7 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,34 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,68 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,4 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,68 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,01 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;99,4 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,01 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;99,4 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,36 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;29 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;115 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;147 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;29 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;112 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;147 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;29 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;111 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;147 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;29 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;111 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;147 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;109 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;147 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,39 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,52 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,52 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,78 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;500 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;470 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;451 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;496 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;466 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;449 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;491 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;466 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;446 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;463 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;441 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;462 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;436 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,2 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,15 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,56 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,2 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,15 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,89 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,51 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,78 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,3 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,67 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;497 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;443 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;326 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;493 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;440 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;324 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;488 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;440 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;322 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;437 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;317 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;436 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;315 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,2 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,32 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,39 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,19 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,32 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,77 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,65 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,24 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,42 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,63 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;27 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;125 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;26 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;125 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;26 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;124 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;26 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;124 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;26 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;121 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,2 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,2 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,3 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,8 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;492 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;481 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;439 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;489 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;481 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;437 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;478 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;433 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;476 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;429 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;471 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;427 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,39 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,54 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,38 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,63 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,96 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,72 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,92 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,27 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;489 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;457 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;318 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;486 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;457 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;316 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;454 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;312 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;452 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;311 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;447 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;310 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,39 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,37 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,34 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,11 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,91 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,8 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,81 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,48 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;24 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;121 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;24 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;121 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;24 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;121 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;24 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;118 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;24 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;117 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,52 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,69 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;13 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;13 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;13 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;13 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;13 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;12 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;13 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,31 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;92,31 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;92,31 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,31 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;11 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;8 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;11 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;8 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;11 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;11 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,67 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,67 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;91,67 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;91,67 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;13 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;13 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;13 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;13 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;12 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;14 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,31 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;11 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;10 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;88,89 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;16 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;16 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;16 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;13 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;13 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;14 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92,86 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,86 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;15 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;15 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;11 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;15 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;11 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;90,91 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,91 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;3 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;3 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;3 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;4 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;3 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;4 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;3 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;4 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;16 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;16 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;12 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;12 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;12 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;13 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,31 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;92,31 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,31 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;16 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;8 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;16 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;8 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;8 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;9 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;90 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;90 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;6 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;6 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;6 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;4 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;4 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;4 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;4 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;6 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;6 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;5 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;5 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;5 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;5 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;6 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;5 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;4 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;6 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;6 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;5 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;7 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;6 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;5 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;6 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;5 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;6 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;5 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;6 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;5 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 40 Segovia;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;44.265 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;42.332 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;44.449 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;41.465 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;39.766 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;36.972 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;39.368 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;38.086 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;35.617 41 Sevilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;37.699 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;36.774 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;34.459 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;36.455 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;35.677 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;33.309 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,67 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,94 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,18 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,94 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,97 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;80,13 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,17 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;86,87 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;77,52 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,36 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;84,28 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;74,94 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;42.120 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;36.625 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;39.393 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;34.223 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;37.355 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;32.662 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;35.739 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;31.451 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;34.539 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;30.467 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,53 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,44 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,69 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,18 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,85 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,87 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,19 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2.145 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;5.707 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2.072 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;5.543 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;2.013 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;5.424 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.960 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;5.323 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.916 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;5.210 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,6 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,13 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,85 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,04 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,38 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,27 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,32 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,29 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;44.621 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;42.673 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;39.065 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;41.793 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;40.375 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;37.361 41 Sevilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;39.696 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;38.694 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;35.960 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;38.202 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;37.321 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;34.608 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;35.877 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;33.308 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 41 Sevilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,66 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,61 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,64 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,96 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;90,68 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,05 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,61 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,46 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,59 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,07 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,26 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;42.561 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;37.861 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;30.383 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;39.797 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;35.680 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;28.771 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;37.771 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;34.090 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;27.542 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;36.326 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;32.826 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;26.436 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;31.503 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;25.370 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,51 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,24 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,69 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,75 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,04 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,65 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,35 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,7 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,01 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,21 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,5 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2.060 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4.812 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8.682 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.996 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4.695 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8.590 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.925 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4.604 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8.418 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.876 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4.495 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8.172 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;4.374 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;7.938 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,89 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,57 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,94 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,45 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,68 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,96 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,07 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,41 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,13 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,9 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,43 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;44.661 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;43.659 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;41.973 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;41.772 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;41.095 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;39.614 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;39.853 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;39.243 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;37.547 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;37.549 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;35.942 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;36.305 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;34.920 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,53 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,13 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,38 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,23 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,89 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,46 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,01 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,63 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,16 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,2 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;44.091 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;41.987 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;35.041 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;41.233 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;39.457 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;32.809 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;39.337 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;37.647 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;30.919 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;35.999 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;29.509 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;34.789 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;28.626 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,52 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,97 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,63 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,22 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,66 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,24 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,74 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,21 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,86 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,69 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;570 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.672 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;6.932 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;539 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.638 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;6.805 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;516 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.596 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;6.628 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.550 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;6.433 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.516 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;6.294 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,56 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,97 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,17 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90,53 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,45 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,61 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,7 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,8 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,67 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,8 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;44.243 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;43.710 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;42.488 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;41.711 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;41.182 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;39.614 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;39.149 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;37.680 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;37.578 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;36.428 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;36.218 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;35.363 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,28 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,22 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,24 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,57 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,68 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,97 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,74 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,86 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,23 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;43.809 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;41.425 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;36.021 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;41.296 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;38.972 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;33.318 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;37.011 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;31.559 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;35.514 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;30.441 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;34.219 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;29.483 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,26 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,08 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,5 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,34 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,61 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,73 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,51 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,6 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,85 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;434 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2.285 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;6.467 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;415 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2.210 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;6.296 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2.138 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;6.121 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2.064 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5.987 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.999 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5.880 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,62 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,72 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,36 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,57 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,65 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;90,33 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,58 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,48 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,92 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;33.120 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;32.177 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;33.292 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;30.470 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;29.757 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;26.418 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;28.569 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;28.206 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;25.198 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;27.044 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;26.988 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;24.149 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;25.927 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;26.016 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;23.146 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,48 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;79,35 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;86,26 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,66 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;75,69 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;81,65 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;83,87 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;72,54 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;78,28 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,85 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;69,52 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;31.764 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;29.214 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;29.178 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;26.925 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;27.328 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;25.470 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;25.848 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;24.324 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;24.775 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;23.436 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,86 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,16 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,03 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,18 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;81,38 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,26 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;78 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;80,22 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1.356 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.963 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1.292 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.832 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.241 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.736 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.196 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.664 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.152 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.580 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,28 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,58 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,52 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,34 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,2 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,91 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,96 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,07 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;33.300 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;32.374 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;29.538 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;30.680 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;30.207 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;27.918 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;28.727 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;28.625 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;26.611 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;27.373 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;27.374 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;25.379 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;26.092 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;24.228 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,13 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,31 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,52 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;86,27 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,42 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,09 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;82,2 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,56 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;85,92 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;80,6 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,02 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;32.026 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;29.797 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;24.422 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;29.459 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;27.727 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;22.874 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;27.570 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;26.218 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;21.719 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;26.262 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;25.056 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;20.677 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;23.862 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;19.701 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;91,98 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,05 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;93,66 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;86,09 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;87,99 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;88,93 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;82 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;84,09 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;84,67 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;80,08 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;80,67 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1.274 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.577 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5.116 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.221 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.480 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5.044 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.157 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.407 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4.892 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.111 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.318 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4.702 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.230 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4.527 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,84 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,24 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,59 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,82 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,4 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,62 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,21 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,95 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,91 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,53 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,49 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;33.249 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;32.827 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;31.586 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;30.510 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;30.391 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;29.354 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;28.772 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;28.701 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;27.483 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;27.185 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;26.055 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;26.061 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;25.146 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,76 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,58 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,93 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,53 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,43 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;87,01 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;82,81 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;82,49 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;79,39 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;79,61 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;32.779 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;31.910 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;27.922 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;30.069 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;29.502 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;25.803 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;28.354 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;27.846 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;24.065 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;26.363 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;22.778 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;25.262 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;21.972 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,73 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,45 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,41 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,5 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,26 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,19 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,62 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;81,58 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;79,17 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;78,69 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;470 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;917 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3.664 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;441 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;889 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3.551 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;418 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;855 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3.418 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;822 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3.277 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;799 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3.174 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,83 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,95 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,92 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;88,94 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,24 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,29 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,64 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,44 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;87,13 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,63 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;32.938 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;32.827 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;32.024 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;30.575 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;30.448 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;29.317 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;28.590 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;27.555 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;27.164 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;26.425 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;25.932 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;25.446 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,83 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,75 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,55 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,09 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,04 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;82,75 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;82,52 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;79 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;79,46 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;32.572 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;31.296 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;28.682 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;30.228 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;28.989 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;26.113 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;27.192 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;24.480 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;25.829 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;23.453 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;24.650 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;22.554 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,8 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,63 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,04 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;86,89 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,35 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;82,53 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;81,77 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;78,76 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;78,63 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;366 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1.531 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3.342 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;347 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1.459 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3.204 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1.398 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3.075 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1.335 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.972 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.282 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.892 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;94,81 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,3 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,87 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,31 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,01 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;87,2 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,93 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,74 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,54 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;4.746 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;4.470 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;4.743 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;4.652 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;4.391 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;4.374 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;4.543 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;4.314 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;4.284 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;4.462 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;4.264 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;4.226 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;4.392 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;4.189 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;4.156 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,02 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,23 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;92,22 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,72 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,51 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;90,32 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,02 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,39 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;89,1 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,54 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,71 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;87,62 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4.433 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.380 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4.347 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.320 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4.241 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.260 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4.163 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.222 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4.093 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.163 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,06 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,22 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,67 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,45 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;93,91 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,33 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,33 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,58 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;313 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.090 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;305 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.071 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;302 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.054 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;299 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.042 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;299 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.026 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,44 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,26 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,49 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,7 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,53 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,6 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,53 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,13 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;4.766 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;4.485 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;4.127 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;4.653 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;4.405 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;4.071 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;4.570 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;4.348 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.008 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;4.486 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;4.277 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.941 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;4.183 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.863 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,63 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,22 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,64 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,89 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,95 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,12 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,13 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,36 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,49 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,27 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,6 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4.468 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.610 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.603 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4.360 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.544 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.560 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4.283 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.494 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.509 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4.201 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.431 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.476 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3.358 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.424 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,58 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,17 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,35 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,86 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,79 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,39 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,02 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,04 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,12 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,02 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,12 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;298 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;875 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.524 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;293 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;861 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.511 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;287 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;854 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.499 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;285 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;846 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.465 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;825 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.439 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,32 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,4 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,15 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,31 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,6 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,36 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,64 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,69 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,13 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94,29 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,42 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;4.852 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;4.699 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;4.507 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;4.761 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;4.619 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;4.431 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;4.656 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;4.527 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;4.303 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;4.416 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;4.220 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;4.347 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;4.161 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,12 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,3 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,31 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,96 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,34 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;95,47 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,98 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;93,63 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;92,51 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,32 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4.802 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;4.414 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.272 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4.712 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;4.336 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.204 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4.607 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;4.248 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.104 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;4.147 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.042 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;4.086 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.005 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,13 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,23 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;97,92 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,94 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,24 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;94,87 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,95 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;92,97 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,57 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;91,84 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;50 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;285 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.235 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;49 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;283 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.227 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;49 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;279 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.199 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;269 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.178 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;261 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.156 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,3 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,35 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;98 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,89 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,09 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,39 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,38 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,58 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,6 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;4.771 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4.679 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;4.526 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;4.672 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;4.584 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;4.422 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;4.472 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;4.334 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;4.392 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;4.264 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;4.327 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;4.218 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,92 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,97 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,7 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,58 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,76 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;93,87 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,21 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,48 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,19 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;4.736 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4.395 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.332 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;4.637 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4.302 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.247 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4.199 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.180 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4.122 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.128 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4.064 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.093 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,91 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,88 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,45 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;95,54 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,44 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;93,79 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,88 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;92,47 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;92,83 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;35 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;284 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.194 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;35 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;282 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.175 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;273 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.154 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;270 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.136 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;263 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.125 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,3 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,41 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,13 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,65 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,07 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,14 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,61 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,22 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.011 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;5.317 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.031 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;5.958 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;5.252 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;5.805 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;5.873 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;5.200 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;5.762 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;5.811 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;5.156 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;5.713 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;5.754 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;5.107 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;5.638 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,12 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,78 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,25 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,7 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,8 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,54 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,67 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,97 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,73 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,72 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,05 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;93,48 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5.576 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.776 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5.524 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.725 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5.443 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.679 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5.386 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3.652 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5.329 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3.616 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,07 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,65 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,61 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,43 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,59 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,72 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,57 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,76 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;435 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.541 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;434 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.527 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;430 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.521 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;425 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.504 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;425 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.491 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,77 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,09 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,85 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,7 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,7 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,6 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,7 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,76 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.159 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;5.450 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;5.044 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;6.065 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;5.399 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;5.018 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.005 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;5.357 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;4.988 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;5.949 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;5.307 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;4.937 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;5.241 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;4.868 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,47 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,06 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,48 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,5 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,29 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,89 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,59 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,38 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,88 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,17 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,51 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5.717 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;4.196 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.090 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5.629 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;4.151 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.071 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5.570 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.120 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.049 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5.515 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.082 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.020 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.028 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.983 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,46 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,93 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,39 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,43 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,19 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,67 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,47 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,28 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,73 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,54 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;442 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.254 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.954 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;436 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.248 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.947 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;435 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.237 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.939 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;434 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.225 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.917 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.213 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.885 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,64 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,52 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,64 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;98,42 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,64 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;99,23 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,19 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,69 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,11 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,73 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,47 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6.154 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5.770 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5.540 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.096 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;5.722 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;5.490 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.020 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;5.654 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;5.424 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;5.589 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;5.333 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;5.539 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;5.279 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,06 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,17 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,1 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,82 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,99 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,91 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,86 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,26 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,29 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.111 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5.339 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.631 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.054 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5.295 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.587 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5.978 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5.231 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.537 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5.169 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.478 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.122 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3.438 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,07 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,18 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,79 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,82 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,98 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,41 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,82 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,79 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,94 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,68 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;43 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;431 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.909 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;42 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;427 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.903 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;42 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;423 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.887 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;420 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.855 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;417 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.841 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,67 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,07 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,69 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,67 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,14 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,85 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,45 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,17 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,75 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,44 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.119 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5.817 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5.566 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.050 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;5.765 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;5.505 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;5.704 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;5.423 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;5.642 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;5.371 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;5.580 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;5.331 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,87 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,11 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,9 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,06 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,43 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,99 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,5 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,93 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,78 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.089 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;5.386 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.758 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;6.020 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;5.335 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.711 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;5.276 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.653 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;5.221 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.614 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.164 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3.590 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,87 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,05 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,75 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,96 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,21 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,94 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,17 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,88 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,53 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;30 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;431 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.808 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;30 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;430 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.794 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;428 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.770 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;421 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.757 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;416 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.741 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,77 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,23 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,3 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,9 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,68 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,18 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,52 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,29 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;250 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;243 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;246 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;249 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;241 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;241 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;248 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;241 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;241 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;247 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;241 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;240 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;247 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;240 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;238 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,6 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,18 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,97 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,2 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;99,18 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,97 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,8 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;99,18 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,56 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,8 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,77 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,75 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;222 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;175 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;221 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;173 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;221 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;173 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;220 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;173 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;220 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;172 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,55 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,86 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,55 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,86 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,1 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,86 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,1 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,29 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;28 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;68 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;28 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;68 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;27 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;68 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;27 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;68 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;27 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;68 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,43 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,43 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,43 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;255 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;241 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;228 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;255 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;241 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;227 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;254 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;241 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;227 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;254 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;240 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;226 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;239 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;224 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,56 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,61 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,56 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,61 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;99,59 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;99,12 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,17 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,25 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;224 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;177 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;170 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;224 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;177 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;169 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;223 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;177 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;169 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;223 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;176 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;168 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;175 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;167 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,41 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,55 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,41 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,55 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;99,44 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,82 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,87 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;98,24 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;31 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;64 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;58 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;31 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;64 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;58 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;31 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;64 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;58 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;31 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;64 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;58 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;64 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;57 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,28 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;271 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;241 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;216 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;270 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;241 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;216 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;270 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;239 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;215 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;238 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;212 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;237 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;212 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,63 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,63 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,17 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,54 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,76 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,15 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,34 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,15 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;268 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;214 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;138 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;267 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;214 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;138 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;267 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;212 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;137 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;211 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;135 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;210 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;135 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,63 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,63 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,07 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,28 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,6 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,83 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,13 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,83 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;27 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;78 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;27 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;78 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;27 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;78 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;27 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;77 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;27 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;77 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,72 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,72 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;271 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;256 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;244 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;270 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;254 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;242 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;253 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;240 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;251 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;240 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;250 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;240 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,63 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,22 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,18 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,83 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,36 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,05 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,36 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,66 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,36 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;270 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;226 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;168 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;269 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;224 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;166 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;223 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;165 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;222 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;165 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;221 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;165 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,63 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,12 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,81 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,67 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,21 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,23 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,21 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,79 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,21 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;30 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;76 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;30 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;76 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;30 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;75 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;29 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;75 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;29 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;75 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,68 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,67 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,68 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,67 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,68 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;138 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;125 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;137 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;136 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;125 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;134 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;135 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;125 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;132 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;135 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;125 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;131 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;135 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;125 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;131 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,55 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,81 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,83 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,35 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,83 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,62 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,83 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,62 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;125 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;80 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;123 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;80 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;122 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;80 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;122 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;80 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;122 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;80 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,4 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,6 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,6 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,6 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;13 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;45 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;13 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;45 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;13 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;45 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;13 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;45 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;13 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;45 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;141 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;123 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;128 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;140 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;123 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;127 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;140 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;123 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;126 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;140 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;123 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;125 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;122 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;125 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 41 Sevilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,29 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,22 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,29 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,44 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,29 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,66 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,19 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,66 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;126 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;81 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;98 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;125 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;81 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;97 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;125 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;81 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;96 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;125 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;81 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;95 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;80 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;95 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,21 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,98 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,21 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,96 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,21 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,94 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,77 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,94 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;42 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;30 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;42 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;30 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;42 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;30 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;42 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;30 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;42 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;30 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;135 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;122 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;124 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;135 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;122 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;123 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;135 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;122 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;122 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;121 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;122 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;121 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;122 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,19 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,39 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,18 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,39 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,18 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,39 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;131 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;110 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;78 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;131 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;110 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;77 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;131 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;110 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;76 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;109 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;76 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;109 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;76 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,72 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,44 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,09 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,44 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,09 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,44 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;12 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;46 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;12 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;46 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;46 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;46 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;46 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;144 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;131 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;128 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;144 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;131 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;128 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;130 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;128 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;129 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;128 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;129 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;128 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,24 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,47 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,47 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;142 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;122 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;81 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;142 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;122 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;81 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;121 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;81 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;120 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;81 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;120 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;81 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,18 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,36 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,36 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;9 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;47 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;9 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;47 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;9 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;47 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;9 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;47 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;9 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;47 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 41 Sevilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.181 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.130 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.248 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.084 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.051 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.043 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.005 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.983 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.979 42 Soria;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.956 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.932 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.925 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.905 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.885 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.859 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,55 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;96,29 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,88 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,93 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;93,1 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,03 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;89,68 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,7 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,63 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,35 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,5 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,7 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.108 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.880 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.012 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.807 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.933 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.744 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.886 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.699 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.836 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.655 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,45 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,12 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,7 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,77 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,47 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;90,37 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;87,1 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;88,03 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;73 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;250 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;72 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;244 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;72 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;239 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;70 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;233 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;69 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;230 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,63 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,6 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,63 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,6 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95,89 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,2 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,52 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;92 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.191 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.146 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.105 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.093 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.065 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.036 42 Soria;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.033 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.001 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.969 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.969 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.935 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.897 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.883 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.853 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 42 Soria;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,53 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,23 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,72 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,79 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,24 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,54 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,87 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,17 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,12 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,74 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,03 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.128 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.899 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.575 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.031 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.823 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.516 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.973 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.765 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.457 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.909 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.703 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.402 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.657 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.366 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 42 Soria;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,44 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,25 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,72 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,94 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,51 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,71 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,68 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,02 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,26 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,73 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;63 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;247 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;530 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;62 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;242 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;520 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;60 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;236 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;512 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;60 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;232 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;495 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;226 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;487 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 42 Soria;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,41 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,98 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,11 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,24 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,55 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,6 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,24 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,93 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,4 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,5 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,89 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.252 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.200 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.157 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.136 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.095 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.052 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.053 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.009 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.962 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.948 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.913 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.905 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.871 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,85 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,23 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,13 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,16 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,32 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,96 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,55 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,69 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,59 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,74 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.236 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.143 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.878 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.121 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.042 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.775 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.038 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.957 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.696 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.896 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.651 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.853 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.614 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,86 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,29 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,52 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,14 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,32 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,31 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,47 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,91 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,47 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,94 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;16 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;57 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;279 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;15 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;53 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;277 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;15 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;52 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;266 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;52 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;262 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;52 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;257 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;93,75 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;92,98 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,28 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,75 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,23 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,34 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,23 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,91 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,23 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,11 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.213 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.200 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.164 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.110 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.080 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.046 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.012 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.987 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.951 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.929 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.914 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.887 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,35 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,55 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,55 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,45 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;91,82 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,68 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,14 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,2 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.202 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.130 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.877 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.099 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.011 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.768 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.944 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.714 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.883 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.661 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.851 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.622 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,32 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,41 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,19 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,27 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,32 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,4 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,49 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,9 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,41 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;70 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;287 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;11 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;69 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;278 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;68 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;273 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;68 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;268 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;63 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;265 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,57 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,86 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,14 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,12 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,14 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,38 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,33 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.610 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.605 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.697 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;1.516 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;1.526 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;1.501 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;1.440 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;1.461 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;1.439 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.395 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.414 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.389 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.346 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.369 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.327 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,16 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,08 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,45 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,44 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,03 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,8 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,65 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,1 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,85 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,6 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,3 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,2 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.566 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.450 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.473 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.377 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.397 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.317 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.354 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.276 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.306 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.234 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,06 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,97 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,21 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,83 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,46 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,4 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,1 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;44 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;155 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;43 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;149 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;43 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;144 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;41 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;138 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;40 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;135 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,73 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,13 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,73 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,9 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,18 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,03 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,91 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,1 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.623 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.607 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.596 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;1.528 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;1.528 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;1.529 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.472 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.468 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.466 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.410 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.404 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.397 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;1.354 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;1.354 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 42 Soria;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,15 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,08 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,8 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,7 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,35 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,85 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,88 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,37 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,53 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,26 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,84 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.588 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.454 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.252 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.494 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.380 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.195 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.440 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.326 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.138 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.378 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.266 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.085 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.220 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.050 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,08 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,91 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,45 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,68 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,2 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,89 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,78 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,07 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,66 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,91 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,87 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;35 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;153 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;344 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;34 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;148 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;334 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;32 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;142 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;328 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;32 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;138 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;312 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;134 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;304 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,14 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,73 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,09 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,43 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,81 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,35 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,43 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,2 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,7 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;87,58 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,37 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.667 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.652 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.631 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.557 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.552 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.529 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.478 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.470 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.443 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;1.411 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;1.396 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;1.371 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;1.356 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,4 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,95 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,75 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,66 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,98 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,47 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,41 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,59 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,99 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,14 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.657 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.616 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.475 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.548 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.520 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.375 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.469 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.439 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.299 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.380 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.256 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.340 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.221 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,42 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,06 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,22 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,65 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,05 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,07 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,4 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,15 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,92 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;82,78 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;10 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;36 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;156 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;9 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;32 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;154 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;9 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;31 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;144 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;31 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;140 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;31 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;135 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;90 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;88,89 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,72 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;86,11 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,31 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,11 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,74 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,11 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,54 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.638 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.635 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.631 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.537 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.520 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.516 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;1.454 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;1.460 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;1.396 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;1.404 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.362 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.367 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,83 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,97 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,95 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,93 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,52 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,38 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,08 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,3 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,81 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.630 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.586 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.470 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.529 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.472 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.363 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.407 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.312 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.349 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.261 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.320 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.227 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,8 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,81 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,72 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,71 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,25 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,06 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,78 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,23 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,47 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;49 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;161 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;48 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;153 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;47 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;148 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;47 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;143 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;42 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;140 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,96 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,03 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,92 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;91,93 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,92 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,82 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,71 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;86,96 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;244 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;226 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;227 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;241 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;226 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;221 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;239 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;223 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;220 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;236 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;222 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;219 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;234 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;222 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;217 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,77 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,36 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,95 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,67 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,92 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,72 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,23 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,48 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,9 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,23 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,59 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;237 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;189 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;234 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;189 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;232 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;186 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;229 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;185 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;227 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;185 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,73 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,89 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,41 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,62 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,88 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,78 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,88 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;37 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;37 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;37 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;37 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;37 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;248 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;233 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;203 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;246 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;233 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;201 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;243 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;232 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;200 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;241 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;231 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;198 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;229 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;197 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,19 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,01 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,98 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,57 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,52 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,18 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;99,14 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,54 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,28 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,04 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;236 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;191 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;127 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;234 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;191 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;125 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;231 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;190 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;124 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;229 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;189 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;122 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;189 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;121 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,15 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,43 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,88 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,48 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,64 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,03 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,95 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,06 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;98,95 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,28 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;12 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;42 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;76 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;12 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;42 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;76 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;12 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;42 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;76 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;12 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;42 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;76 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;40 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;76 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,24 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;245 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;227 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;223 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;241 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;225 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;222 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;239 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;222 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;219 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;220 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;217 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;219 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;215 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,37 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,12 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,55 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,55 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,8 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,21 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,92 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,31 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,48 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,41 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;241 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;220 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;172 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;237 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;218 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;171 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;235 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;215 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;168 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;213 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;166 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;212 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;164 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,34 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,09 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,42 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,51 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,73 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,67 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,82 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,51 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,36 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,35 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;7 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;51 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;7 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;51 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;7 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;51 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;7 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;51 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;7 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;51 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;246 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;243 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;233 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;244 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;239 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;231 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;237 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;228 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;236 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;226 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;234 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;224 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,19 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,35 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,14 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,53 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,85 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,12 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,3 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,14 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;244 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;237 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;177 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;242 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;233 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;175 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;231 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;172 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;230 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;170 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;228 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;168 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,18 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,31 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,87 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,47 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,18 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,05 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,05 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,2 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,92 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;6 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;56 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;6 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;56 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;6 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;56 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;6 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;56 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;6 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;56 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;304 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;275 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;298 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;304 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;275 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;295 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;303 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;275 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;294 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;302 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;272 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;291 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;302 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;270 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;289 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,99 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,67 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,66 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;99,34 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,91 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,65 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;99,34 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,18 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,98 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;283 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;220 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;283 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;220 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;282 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;220 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;281 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;217 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;281 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;215 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,65 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;99,29 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,64 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;99,29 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,73 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;21 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;55 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;21 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;55 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;21 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;55 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;21 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;55 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;21 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;55 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;298 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;282 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;279 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;297 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;280 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;279 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;296 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;277 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;276 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;296 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;276 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;275 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;276 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;275 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 42 Soria;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,66 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,29 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,33 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,23 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,92 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,33 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,87 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,57 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,87 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,57 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;282 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;233 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;176 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;281 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;231 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;176 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;280 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;228 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;175 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;280 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;227 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;175 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;227 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;175 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,65 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,14 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,29 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,85 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,43 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,29 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,42 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;99,43 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,42 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;99,43 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;16 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;49 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;103 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;16 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;49 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;103 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;16 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;49 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;101 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;16 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;49 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;49 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,06 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,09 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,09 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;316 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;298 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;279 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;314 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;295 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;277 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;312 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;294 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;276 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;294 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;276 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;292 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;276 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,37 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,99 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,28 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,73 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,66 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,92 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,66 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,92 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,99 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,92 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;314 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;285 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;212 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;312 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;282 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;210 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;310 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;281 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;210 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;281 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;210 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;279 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;210 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,36 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,95 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,06 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,73 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,6 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,06 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,6 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;99,06 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,89 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;99,06 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;67 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;67 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;13 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;66 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;13 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;66 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;13 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;66 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,51 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,51 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,51 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;304 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;300 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;276 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;304 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;299 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;275 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;299 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;275 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;297 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;275 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;296 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;272 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,67 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,64 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,67 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,64 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,64 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,67 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,55 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;303 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;286 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;211 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;303 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;285 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;211 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;285 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;211 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;283 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;211 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;282 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;208 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,65 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,65 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,95 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,6 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,58 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;65 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;14 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;64 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;14 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;64 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;14 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;64 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;14 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;64 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,46 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,46 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,46 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,46 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;17 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;18 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;19 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;17 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;18 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;19 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;17 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;18 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;19 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;17 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;18 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;19 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;17 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;18 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;19 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;16 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;14 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;18 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;21 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;14 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;18 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;21 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;14 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;18 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;21 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;14 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;18 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;21 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;18 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;21 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;16 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;17 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;14 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;17 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;14 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;16 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;14 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;16 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;17 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;16 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;17 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;18 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;17 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;18 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;18 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;17 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;18 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;18 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;17 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;18 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;17 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;18 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;17 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;18 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;18 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;17 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;18 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;17 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;16 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;18 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;17 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;16 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;17 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;16 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;17 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;16 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;18 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;18 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;18 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;16 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;18 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;16 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;18 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;16 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;18 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;16 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;18 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;18 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;18 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;15 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;3 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;3 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;3 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;3 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;3 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;6 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;6 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;7 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;7 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;7 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;7 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;6 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;7 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;8 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;6 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;6 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;8 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;8 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;8 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;6 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 42 Soria;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;8 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;6 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;6 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;7 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;7 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;6 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;7 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;7 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;6 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 42 Soria;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;19.382 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;18.732 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;19.615 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;18.272 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;17.721 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;17.381 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;17.433 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;17.015 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;16.758 43 Tarragona;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;16.780 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;16.429 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;16.234 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;16.228 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;15.936 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;15.660 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,27 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,6 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,61 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,94 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,83 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,43 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,58 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,71 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,76 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,73 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,07 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,84 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;18.527 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;16.175 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;17.438 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;15.245 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;16.625 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;14.598 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;15.990 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;14.074 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;15.459 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;13.642 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,12 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,25 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,73 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,25 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,31 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,01 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,44 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,34 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;855 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.557 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;834 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.476 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;808 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.417 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;790 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.355 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;769 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.294 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,54 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,83 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,5 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,52 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,4 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,1 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,94 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,71 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;19.645 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;19.028 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;18.396 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;18.595 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;18.139 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;17.632 43 Tarragona;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;17.783 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;17.373 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;17.011 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;17.012 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;16.624 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;16.293 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;16.012 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;15.668 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 43 Tarragona;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,66 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,33 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,85 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,52 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,3 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,47 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,6 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,37 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,57 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,15 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,17 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;18.790 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;17.001 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;13.883 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;17.765 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;16.167 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.205 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;16.977 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;15.454 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;12.686 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;16.231 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;14.768 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12.164 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;14.199 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;11.656 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,54 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,09 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,12 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,35 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;90,9 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,38 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,38 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,87 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,62 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;83,52 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,96 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;855 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.027 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4.513 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;830 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.972 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4.427 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;806 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.919 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4.325 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;781 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.856 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4.129 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.813 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4.012 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,08 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,29 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,09 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,27 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,67 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,83 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,35 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,56 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,49 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,44 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,9 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;20.471 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;20.092 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;19.281 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;19.081 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;18.711 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;18.132 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;17.741 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;17.475 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;17.046 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;16.732 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;16.345 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;16.230 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;15.904 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,21 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,13 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,04 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;86,66 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;86,97 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,41 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,28 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,77 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,78 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,49 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;20.160 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;19.360 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;16.337 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;18.779 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;18.003 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;15.251 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;17.450 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;16.796 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;14.282 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;16.070 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.663 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;15.582 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;13.286 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,15 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,99 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,35 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,56 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;86,76 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;87,42 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;83,01 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,63 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,49 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,32 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;311 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;732 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.944 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;302 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;708 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.881 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;291 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;679 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.764 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;662 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.682 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;648 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.618 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,11 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,72 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,86 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,57 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,76 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,89 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90,44 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,1 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,52 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,93 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;20.072 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;19.766 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;19.306 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;18.518 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;18.277 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;17.873 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;17.431 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;17.059 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;16.762 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;16.477 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;16.227 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;15.983 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,26 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,47 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,58 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,19 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,36 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,8 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,35 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,1 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,79 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;19.861 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;18.842 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;16.381 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;18.314 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;17.395 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;15.066 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;16.569 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;14.339 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15.933 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13.814 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15.419 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.383 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,21 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,32 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,97 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,94 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,53 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,56 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,33 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,83 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,7 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;211 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;924 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.925 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;204 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;882 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.807 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;862 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.720 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;829 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.663 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;808 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.600 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,68 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,45 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,97 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,29 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,99 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,72 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,04 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,45 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,89 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;14.842 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;14.537 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;15.107 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;13.793 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;13.579 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;13.006 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;13.018 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;12.933 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;12.434 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;12.408 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;12.391 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;11.949 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;11.910 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;11.938 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;11.421 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,93 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,41 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,09 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,71 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,97 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,31 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,6 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,24 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;79,1 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,25 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,12 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;75,6 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14.289 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;13.018 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;13.260 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12.129 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;12.510 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11.535 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;11.918 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.042 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;11.439 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;10.640 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,8 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,17 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,55 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;88,61 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,41 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,82 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,05 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,73 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;553 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.519 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;533 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.450 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;508 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.398 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;490 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.349 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;471 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.298 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,38 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;95,46 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,86 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,03 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,61 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,81 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,17 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,45 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;14.902 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;14.658 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;14.255 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;13.909 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;13.830 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;13.533 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;13.142 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;13.110 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;12.949 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;12.459 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;12.446 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;12.286 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;11.890 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;11.725 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,34 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,35 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;94,94 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,19 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,44 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,84 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,61 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,91 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;86,19 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,12 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,25 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14.365 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;13.446 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;11.371 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;13.395 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.667 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.716 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;12.652 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;11.991 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10.217 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;11.987 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.378 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.720 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;10.860 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.255 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,25 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,21 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,24 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,08 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,18 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;89,85 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,45 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;84,62 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;85,48 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;80,77 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,39 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;537 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.212 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.884 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;514 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.163 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.817 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;490 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.119 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.732 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;472 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.068 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.566 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.030 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.470 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,72 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,96 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,68 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,25 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,33 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,73 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;87,9 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;88,12 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;88,97 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;84,98 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;85,64 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;15.227 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;15.197 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14.813 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;13.930 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;13.924 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;13.752 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;12.871 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;12.909 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;12.786 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;12.241 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;12.154 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;11.777 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;11.753 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,48 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;91,62 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,84 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;84,53 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;84,94 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;86,32 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;80,55 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;82,05 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;77,5 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;79,34 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;15.001 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14.776 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;13.093 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;13.713 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;13.525 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12.084 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;12.659 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;12.530 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.210 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;11.876 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;10.641 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;11.426 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10.294 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,41 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;91,53 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,29 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;84,39 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;84,8 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;85,62 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;80,37 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;81,27 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;77,33 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;78,62 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;226 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;421 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.720 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;217 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;399 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.668 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;212 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;379 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.576 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;365 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.513 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;351 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.459 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,02 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,77 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,98 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,81 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;90,02 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;91,63 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,7 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;87,97 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;83,37 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;84,83 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;15.151 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;15.074 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14.927 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;13.801 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;13.742 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;13.594 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;12.961 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;12.840 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;12.349 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;12.317 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;11.853 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;11.863 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;91,09 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;91,16 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,07 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;85,98 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,02 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;81,92 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;82,51 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;78,63 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;79,47 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15.001 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14.451 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;13.235 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;13.654 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13.156 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12.001 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;12.391 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.319 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;11.809 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;10.844 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;11.334 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.440 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;91,02 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;91,04 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;90,68 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;85,74 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;85,52 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;81,72 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;81,93 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;78,43 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;78,88 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;150 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;623 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.692 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;147 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;586 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.593 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;570 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.521 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;540 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.473 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;519 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.423 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;94,06 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,15 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;91,49 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;89,89 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,68 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,06 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;83,31 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;84,1 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.010 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.853 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.987 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.974 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.834 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.900 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.933 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.798 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.871 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.908 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.772 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.848 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.875 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.747 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.824 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,21 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,97 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,62 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,17 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,03 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,16 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,93 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,63 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,28 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,28 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,8 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.890 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.456 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.855 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.442 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.815 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.413 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.790 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.392 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.758 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.374 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,15 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,04 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,03 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,05 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,71 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,6 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,02 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,37 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;120 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;397 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;119 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;392 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;118 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;385 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;118 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;380 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;117 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;373 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,17 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,74 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,33 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,98 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,33 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,72 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,5 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,95 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.055 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.958 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.795 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.019 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.920 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.773 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.996 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.897 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.746 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.940 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.841 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.710 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.804 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.683 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,25 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,06 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,77 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,13 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,88 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,27 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,4 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,02 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,26 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;92,13 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,76 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.936 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.658 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.107 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.901 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.624 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.094 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.878 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.603 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.077 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.828 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.554 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.059 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.522 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.041 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,19 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,95 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,83 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,68 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,29 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,42 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,73 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,66 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;91,8 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,04 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;119 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;300 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;688 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;118 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;296 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;679 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;118 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;294 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;669 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;112 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;287 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;651 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;282 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;642 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,16 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,67 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,69 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,16 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,24 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,12 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,67 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,62 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;94 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,31 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.210 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.101 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.947 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.153 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.034 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.891 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.019 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.917 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.826 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.871 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.796 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.845 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.769 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,42 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;96,81 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,12 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,36 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,24 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;93,79 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,05 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;92,24 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,82 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;90,86 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.174 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.004 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.487 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.117 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.938 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.436 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.985 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.824 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.382 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.780 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.360 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.754 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.341 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,38 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;96,71 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,57 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,31 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,02 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,94 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,82 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;91,46 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,52 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;90,18 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;36 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;97 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;460 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;36 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;96 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;455 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;34 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;93 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;444 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;91 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;436 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;91 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;428 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,97 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,91 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,44 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,88 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,52 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,81 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,78 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,81 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,04 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.108 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.050 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.891 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.978 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.948 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.828 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.908 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.802 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.869 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.769 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.845 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.742 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,83 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,02 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,67 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;93,07 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;95,29 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;91,17 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;93,55 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;90 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;92,12 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.076 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.932 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.448 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.949 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.834 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.394 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.798 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.374 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.761 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.348 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.737 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.327 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,88 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,93 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;96,27 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;93,06 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;94,89 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;91,15 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;93,09 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;89,91 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;91,64 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;32 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;118 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;443 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;29 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;114 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;434 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;110 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;428 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;108 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;421 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;108 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;415 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;90,63 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,61 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,97 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,22 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,61 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,53 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,03 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,53 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,68 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.349 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.165 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.344 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.326 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;2.135 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.298 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;2.304 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;2.114 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;2.277 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.287 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.097 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.262 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.266 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.083 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.241 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,02 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,61 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,04 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,08 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,64 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,14 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,36 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,86 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,5 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,47 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,21 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,61 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.187 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.580 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.164 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.556 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.142 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.535 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.125 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.526 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.105 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.514 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,95 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,48 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,94 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,15 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,17 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,58 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,25 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,82 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;162 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;585 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;162 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;579 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;162 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;579 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;162 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;571 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;161 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;569 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,97 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,97 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,61 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;99,38 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,26 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.503 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.235 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.179 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.482 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;2.214 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;2.160 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.462 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.193 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.151 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.430 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.165 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.133 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;2.149 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;2.098 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,16 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,06 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,13 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,36 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,12 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,72 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,08 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,87 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,89 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,15 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,28 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.325 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.770 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.286 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.305 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.751 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.277 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.285 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.737 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.275 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.254 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.713 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.269 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.697 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.246 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,14 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,93 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,3 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,28 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,14 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,14 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,95 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,78 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,68 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,88 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,89 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;178 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;465 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;893 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;177 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;463 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;883 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;177 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;456 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;876 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;176 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;452 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;864 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;452 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;852 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;99,44 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,57 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,88 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,44 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,06 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,1 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,88 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,2 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,75 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,2 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,41 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.820 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.601 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.353 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.785 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.560 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.321 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.640 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.457 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.267 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;2.431 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;2.230 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;2.419 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;2.219 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,76 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,42 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,64 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;93,62 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;94,46 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,35 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;93,46 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,77 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,31 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.780 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.412 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.643 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.745 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.372 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.617 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.604 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.274 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.577 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.249 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.550 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.237 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.541 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,74 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,34 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,42 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;93,67 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,28 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;95,98 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;93,24 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,34 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,74 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,79 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;40 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;189 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;710 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;40 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;188 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;704 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;36 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;183 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;690 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;182 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;680 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;182 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;678 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,47 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,15 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;90 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,83 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,18 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,3 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,77 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,3 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,49 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.606 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.455 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.312 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.532 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.401 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.276 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;2.379 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;2.244 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;2.361 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;2.220 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.347 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.207 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,16 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,8 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,44 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,9 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,06 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,17 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,02 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,6 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,46 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.583 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.288 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.584 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.510 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.235 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.558 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.213 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.534 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.196 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.512 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.182 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.506 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,17 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,68 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,36 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,72 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,84 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,98 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,45 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,37 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,08 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;23 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;167 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;728 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;22 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;166 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;718 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;166 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;710 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;165 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;708 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;165 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;701 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;95,65 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,4 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,63 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;99,4 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,53 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,8 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,25 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;98,8 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,29 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;119 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;110 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;111 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;118 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;106 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;111 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;117 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;105 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;110 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;117 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;105 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;109 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;117 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;105 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;108 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,16 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;96,36 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,32 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,45 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;99,1 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,32 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,45 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,2 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,32 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,45 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,3 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;106 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;82 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;105 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;79 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;104 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;78 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;104 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;78 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;104 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;78 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,06 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,34 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,11 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,12 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,11 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,12 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,11 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,12 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;13 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;28 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;13 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;27 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;13 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;27 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;13 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;27 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;13 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;27 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,43 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,43 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,43 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,43 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;122 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;112 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;102 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;122 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;112 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;101 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;121 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;110 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;100 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;121 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;110 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;99 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;110 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;97 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,02 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,18 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,21 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,04 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,18 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,21 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,06 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,21 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,1 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;108 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;86 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;72 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;108 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;86 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;71 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;107 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;84 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;70 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;107 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;84 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;69 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;84 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;67 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,61 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;99,07 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,67 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,22 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;99,07 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,67 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,83 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,67 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,06 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;14 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;26 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;30 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;14 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;26 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;30 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;14 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;26 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;30 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;14 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;26 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;30 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;26 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;30 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;144 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;126 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;107 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;144 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;126 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;107 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;142 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;126 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;106 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;125 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;104 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;125 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;104 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,61 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,07 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,21 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,2 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;99,21 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,2 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;137 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;114 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;79 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;137 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;114 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;79 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;135 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;114 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;78 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;113 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;77 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;113 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;77 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,54 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,73 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,12 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,47 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;99,12 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,47 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;7 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;12 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;28 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;7 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;12 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;28 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;7 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;28 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;27 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;27 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,43 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,43 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;137 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;121 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;114 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;137 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;121 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;113 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;120 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;111 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;120 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;111 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;120 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;111 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,12 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,17 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,37 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,17 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,37 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,17 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,37 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;133 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;112 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;80 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;133 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;112 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;79 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;111 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;78 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;111 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;78 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;111 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;78 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,75 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,11 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,5 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;99,11 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;97,5 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;99,11 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,5 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;9 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;34 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;9 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;34 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;9 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;33 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;9 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;33 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;9 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;33 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,06 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,06 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,06 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;62 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;67 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;66 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;61 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;67 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;66 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;61 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;65 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;66 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;60 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;64 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;66 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;60 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;63 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;66 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,39 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,39 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,01 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,77 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,52 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,77 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,03 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;55 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;39 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;54 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;39 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;54 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;37 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;53 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;36 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;53 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;36 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,18 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,18 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;94,87 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,36 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;92,31 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,36 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;92,31 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;7 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;28 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;7 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;28 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;28 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;7 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;28 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;7 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;27 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,43 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;63 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;65 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;65 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;63 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;63 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;65 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;62 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;63 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;65 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;62 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;62 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;65 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;59 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;65 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,92 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,41 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,92 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,41 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,38 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;90,77 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;56 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;41 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;47 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;56 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;39 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;47 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;55 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;39 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;47 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;55 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;39 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;47 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;36 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;47 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,12 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,21 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;95,12 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,21 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,12 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,8 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;7 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;24 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;18 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;7 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;24 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;18 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;7 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;24 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;18 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;7 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;23 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;18 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;23 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;18 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,83 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,83 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;70 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;67 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;61 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;69 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;67 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;61 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;69 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;66 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;61 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;64 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;61 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;64 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;59 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,57 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,57 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,51 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,52 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,52 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,72 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;68 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;54 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;35 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;67 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;54 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;35 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;67 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;54 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;35 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;52 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;35 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;52 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;33 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,53 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,53 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,3 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,3 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,29 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;26 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;26 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;26 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;26 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;26 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,31 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,31 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,31 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;70 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;66 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;62 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;70 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;65 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;62 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;63 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;62 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;63 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;60 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;62 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;60 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,48 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;95,45 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,45 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,77 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,94 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,77 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;68 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;59 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;34 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;68 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;58 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;34 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;56 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;34 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;56 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;32 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;55 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;32 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,31 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;94,92 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,92 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,12 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,22 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,12 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;7 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;28 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;7 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;28 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;7 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;28 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;7 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;28 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;7 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;28 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 43 Tarragona;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.525 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.424 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.624 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.320 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.246 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.298 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.185 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.158 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.177 44 Teruel;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.077 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.079 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.079 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.980 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.016 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.003 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,18 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,8 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;91 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,35 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,23 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,67 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,29 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,92 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,96 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,54 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,08 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,86 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.448 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.113 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.243 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.946 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.113 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.865 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.008 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.793 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.912 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.733 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,05 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,64 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,28 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,03 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;87,24 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,72 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,45 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,79 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;77 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;311 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;77 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;300 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;72 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;293 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;69 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;286 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;68 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;283 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,46 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,51 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,21 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;89,61 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;91,96 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,31 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.463 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.368 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.437 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.307 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.253 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.298 44 Teruel;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.182 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.163 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.186 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.071 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.089 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.095 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.978 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.974 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 44 Teruel;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,5 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,59 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,96 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,89 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,91 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,7 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,68 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91,72 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,05 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,42 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;86,53 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.377 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.154 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.777 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.227 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.041 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.647 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.102 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.957 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.551 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.992 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.886 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.477 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.782 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.373 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,56 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,42 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,32 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,86 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,75 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,86 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,6 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;91,5 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,2 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;88,21 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,45 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;86 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;214 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;660 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;80 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;212 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;651 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;80 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;206 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;635 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;79 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;203 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;618 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;196 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;601 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;93,02 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,07 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,64 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,02 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,26 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,21 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,86 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;94,86 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,64 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,59 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,06 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.513 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.495 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.466 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.310 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.319 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.318 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.166 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.206 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.187 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.076 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.058 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.000 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.004 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,22 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,96 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,73 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,12 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,73 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,95 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,01 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;88,23 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;85,84 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,67 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.488 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.436 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.112 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.285 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.262 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.972 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.141 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.151 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.852 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.022 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.732 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.948 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.688 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,18 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,94 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,5 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,05 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,71 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,65 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;87,95 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;87,79 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,8 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,38 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;25 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;59 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;354 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;25 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;57 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;346 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;25 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;55 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;335 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;54 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;326 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;52 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;316 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,61 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,74 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,22 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,63 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;91,53 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;92,09 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;88,14 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,27 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.469 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.474 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.477 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.287 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.326 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.294 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.176 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.146 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.080 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.081 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.995 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.011 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,75 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,74 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,74 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,42 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,48 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,66 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,61 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,21 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;86,6 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.447 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.388 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.107 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.265 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.242 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.936 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.096 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.800 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.004 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.742 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.919 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.681 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,72 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,69 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,5 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,38 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,12 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,67 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,25 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,16 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,29 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;22 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;86 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;370 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;22 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;84 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;358 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;80 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;346 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;76 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;339 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;76 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;330 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,67 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,76 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,02 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,51 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,37 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,62 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,37 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,19 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.735 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.682 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.845 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;2.549 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;2.509 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;2.534 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;2.420 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;2.426 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;2.417 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.319 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.350 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.329 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.228 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.291 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.258 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,2 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,55 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,07 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,48 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,45 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,96 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,79 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,62 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,86 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,46 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,42 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,37 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.674 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.500 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.488 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.338 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.364 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.262 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.266 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.193 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.176 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.136 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,04 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,52 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,41 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,48 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,74 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,72 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,38 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,44 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;61 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;182 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;61 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;171 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;56 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;164 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;53 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;157 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;52 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;155 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;93,96 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,8 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;90,11 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;86,89 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;86,26 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;85,25 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,16 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.662 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.624 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.692 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;2.515 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;2.516 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;2.561 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.398 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.430 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.455 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.296 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.362 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.368 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;2.262 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;2.253 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 44 Teruel;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,48 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,88 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,13 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,08 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;92,61 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,2 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,25 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,02 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,96 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,2 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;83,69 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.599 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.504 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.266 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.458 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.398 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.143 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.341 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.318 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.052 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.240 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.252 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.980 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.155 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.880 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,57 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,77 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,57 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,07 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,57 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,56 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,19 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;89,94 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,38 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;86,06 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,97 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;63 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;120 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;426 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;57 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;118 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;418 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;57 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;112 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;403 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;56 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;110 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;388 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;107 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;373 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;90,48 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,33 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,12 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,48 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,33 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,6 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,89 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,67 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,08 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,17 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,56 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.702 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.702 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.724 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.509 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.530 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.582 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.373 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.424 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.455 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;2.308 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;2.331 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;2.235 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;2.282 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,86 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;93,63 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,79 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,82 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,71 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,12 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;85,42 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,57 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;82,72 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,77 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.682 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.665 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.508 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.489 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.495 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.372 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.353 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.391 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.255 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.276 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.139 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.205 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.099 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,8 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,62 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,58 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,73 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,72 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,91 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;85,4 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,29 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;82,74 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,69 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;20 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;37 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;216 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;20 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;35 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;210 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;20 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;33 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;200 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;32 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;192 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;30 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;183 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,59 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,22 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;89,19 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,59 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;86,49 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;88,89 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;81,08 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;84,72 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.671 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.689 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.716 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.497 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.546 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.538 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;2.407 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;2.395 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;2.315 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;2.336 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.237 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.271 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,49 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,68 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,45 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,51 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,18 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,09 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;86,01 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83,19 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,62 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.652 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.630 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.508 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.478 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.489 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.342 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.352 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.210 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.264 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.155 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.186 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.099 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,44 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,64 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,38 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,43 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,12 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,08 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,93 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,12 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,69 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;19 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;59 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;208 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;19 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;57 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;196 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;55 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;185 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;51 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;181 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;51 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;172 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,61 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;94,23 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,22 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;88,94 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;86,44 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,02 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,44 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;82,69 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;349 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;345 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;358 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;344 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;343 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;352 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;342 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;340 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;350 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;339 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;338 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;348 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;337 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;337 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;345 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,57 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,42 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,32 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,99 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,55 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,77 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,13 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,97 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,21 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,56 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,68 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,37 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;346 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;297 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;341 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;295 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;339 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;292 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;336 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;290 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;334 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;289 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,55 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,33 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,98 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,32 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,11 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,64 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,53 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,31 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;48 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;48 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;48 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;48 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;48 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;367 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;330 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;348 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;361 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;326 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;344 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;357 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;324 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;343 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;352 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;320 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;339 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;316 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;334 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,37 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,79 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,85 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,28 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,18 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,56 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,91 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,97 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,41 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,76 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,98 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;361 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;301 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;242 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;355 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;297 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;239 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;351 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;295 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;239 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;346 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;292 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;237 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;289 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;234 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,34 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,67 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,76 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,23 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,01 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,76 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,84 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,01 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,93 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,01 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,69 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;29 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;106 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;29 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;105 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;29 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;104 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;28 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;102 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;27 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,06 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,11 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,55 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,23 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,1 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,34 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;353 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;362 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;340 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;346 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;359 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;338 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;343 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;354 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;334 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;347 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;330 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;345 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;325 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,02 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,17 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,41 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,17 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,79 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,24 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,86 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,06 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,3 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,59 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;351 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;356 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;286 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;344 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;353 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;285 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;341 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;348 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;282 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;341 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;279 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;339 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;275 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,01 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,16 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,65 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,15 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,75 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,6 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,79 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,55 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,22 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,15 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;54 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;53 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;52 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;51 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;50 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,15 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,3 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,44 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,59 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;355 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;345 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;354 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;351 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;342 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;350 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;338 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;347 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;336 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;341 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;331 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;337 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,87 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,13 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,87 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,97 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,02 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,39 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,33 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,94 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,2 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;354 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;337 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;289 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;350 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;334 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;285 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;330 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;283 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;328 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;280 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;323 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;276 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,87 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,11 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,62 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,92 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,92 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,33 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,89 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,85 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,5 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;65 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;65 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;64 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;61 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;61 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,46 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,85 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,85 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;422 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;379 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;402 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;408 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;376 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;393 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;404 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;374 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;391 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;400 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;373 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;383 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;396 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;370 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;381 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;96,68 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,21 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,76 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,73 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,68 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,26 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,79 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,42 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,27 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,84 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,63 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,78 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;411 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;303 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;397 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;300 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;393 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;298 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;389 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;297 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;385 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;295 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;96,59 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,01 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,62 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,35 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,65 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,02 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,67 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,36 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;11 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;76 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;11 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;76 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;11 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;76 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;11 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;76 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;11 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;75 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,68 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;416 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;396 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;377 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;413 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;393 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;373 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;409 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;391 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;368 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;405 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;389 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;368 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;382 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;367 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 44 Teruel;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,28 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,24 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,94 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,32 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,74 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,61 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,36 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,23 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,61 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,46 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,35 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;401 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;336 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;257 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;398 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;333 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;253 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;394 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;331 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;248 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;390 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;329 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;248 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;325 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;247 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,25 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,11 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,44 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,25 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,51 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,5 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,26 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,92 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,5 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,73 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,11 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;15 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;60 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;120 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;15 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;60 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;120 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;15 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;60 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;120 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;15 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;60 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;120 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;57 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;120 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;437 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;412 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;384 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;434 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;411 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;380 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;429 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;409 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;380 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;402 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;379 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;401 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;379 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,31 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,76 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,96 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,17 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,27 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,96 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,57 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,7 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,33 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;98,7 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;435 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;397 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;304 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;432 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;396 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;301 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;427 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;394 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;301 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;387 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;300 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;386 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;300 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,31 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,75 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,01 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,16 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,24 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,01 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,48 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,68 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,23 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;98,68 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;15 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;80 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;15 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;79 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;15 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;79 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;15 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;79 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;15 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;79 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,75 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,75 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,75 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,75 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;421 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;420 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;388 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;417 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;418 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;387 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;411 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;385 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;409 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;385 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;407 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;384 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,05 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,52 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,74 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,86 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;99,23 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,38 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;99,23 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,9 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,97 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;419 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;403 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;295 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;415 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;401 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;294 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;396 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;292 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;394 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;292 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;392 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;291 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,05 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,5 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,66 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,26 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,98 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,77 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,98 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,27 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,64 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;17 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;93 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;17 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;93 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;15 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;93 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;15 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;93 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;15 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;93 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;88,24 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,24 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,24 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;13 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;13 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;13 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;13 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;13 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;14 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;13 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;13 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;10 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;13 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;10 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;13 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;10 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;13 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;10 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;3 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;15 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;15 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;15 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;15 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;13 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;15 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;12 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;12 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;12 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;12 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;10 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;3 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;5 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;3 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;5 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;3 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;5 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;3 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;5 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;5 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;16 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;14 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;13 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;16 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;14 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;13 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;16 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;14 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;13 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;14 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;13 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;14 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;13 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;15 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;13 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;15 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;13 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;12 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;15 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;13 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;12 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;13 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;12 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;13 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;12 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;17 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;15 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;17 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;15 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;14 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;15 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;14 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;15 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;14 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;15 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;14 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;17 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;15 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;12 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;17 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;15 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;12 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;15 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;12 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;15 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;12 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;5 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;5 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;5 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;3 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;3 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;1 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;1 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;5 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;4 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;4 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;4 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;4 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;1 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;5 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;3 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;3 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;3 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;3 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;3 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;5 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;5 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;5 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 44 Teruel;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;15.595 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;15.016 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;15.672 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;14.704 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;14.217 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;13.575 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;14.089 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;13.726 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;13.153 45 Toledo;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;13.586 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;13.291 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;12.768 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;13.200 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;12.902 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;12.436 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,29 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,68 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,62 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,34 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,41 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,93 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;87,12 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,51 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,47 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,64 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,92 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,35 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;14.839 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;13.175 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;13.983 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;12.425 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;13.383 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;11.968 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;12.895 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;11.569 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;12.526 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;11.214 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,23 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,31 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,19 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,84 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,9 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,81 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,41 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,12 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;756 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.841 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;721 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.792 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;706 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.758 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;691 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.722 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;674 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.688 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,37 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,34 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,39 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,49 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,4 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,54 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;89,15 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,69 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;15.610 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;15.119 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;14.181 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;14.822 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;14.436 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;13.666 45 Toledo;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;14.204 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;13.886 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;13.215 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;13.736 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;13.401 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;12.837 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;12.912 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;12.398 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 45 Toledo;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,95 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,48 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,37 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,99 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,84 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,19 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,99 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,64 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,52 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,4 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,43 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;14.866 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;13.240 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;10.823 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;14.102 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;12.595 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;10.335 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;13.501 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;12.087 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;9.959 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;13.053 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;11.635 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;9.643 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;11.197 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;9.300 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,86 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,13 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,49 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,82 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,29 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,02 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,8 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,88 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,1 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,57 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,93 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;744 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.879 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.358 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;720 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.841 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.331 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;703 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.799 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;3.256 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;683 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.766 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;3.194 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.715 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;3.098 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,77 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,98 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,2 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,49 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,74 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,96 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,8 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,99 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,12 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,27 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,26 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;15.785 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;15.588 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;14.915 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;14.851 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;14.668 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;14.113 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;14.247 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;14.023 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;13.564 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;13.457 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;13.048 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;13.085 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;12.752 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,08 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,1 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,62 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,26 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,96 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,94 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,33 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,48 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,94 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,5 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;15.540 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;14.942 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;12.759 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;14.616 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;14.037 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;11.999 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14.018 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;13.406 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;11.493 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;12.859 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;11.032 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;12.500 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;10.772 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,05 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;93,94 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,04 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,21 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,72 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,08 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,06 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,46 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,66 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,43 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;245 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;646 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.156 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;235 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;631 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.114 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;229 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;617 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.071 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;598 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.016 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;585 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.980 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,92 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,68 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,05 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,47 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,51 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,06 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,57 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,51 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,56 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,84 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;15.581 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;15.507 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;14.974 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;14.787 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;14.638 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;14.210 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;13.982 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;13.590 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;13.526 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;13.217 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;13.126 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;12.860 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,9 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,4 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,9 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,17 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,76 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,23 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;88,27 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,65 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,88 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15.376 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;14.675 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;12.852 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;14.587 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;13.830 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;12.139 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;13.216 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;11.570 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;12.785 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;11.234 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;12.403 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;10.913 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,87 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,24 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,45 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,06 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,02 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,12 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;87,41 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,52 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,91 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;205 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;832 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.122 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;200 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;808 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.071 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;766 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.020 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;741 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.983 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;723 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.947 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,56 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,12 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,6 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,07 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,19 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,06 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,45 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;86,9 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,75 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;11.797 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;11.476 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;11.859 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;10.959 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;10.729 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;9.900 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;10.406 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;10.269 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;9.517 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;9.942 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;9.865 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;9.169 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;9.591 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;9.512 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.877 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;92,9 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,49 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,48 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;88,21 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;89,48 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;80,25 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;84,28 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;85,96 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;77,32 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;81,3 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;82,89 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;74,85 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;11.326 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;10.481 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10.520 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9.771 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;9.979 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9.341 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;9.527 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8.966 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;9.192 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8.638 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,88 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,23 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,11 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,12 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;84,12 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;85,55 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;81,16 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;82,42 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;471 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;995 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;439 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;958 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;427 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;928 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;415 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;899 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;399 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;874 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;93,21 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,28 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,66 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,27 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,11 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,35 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,71 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;87,84 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;11.796 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;11.586 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;10.805 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;11.065 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;10.939 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;10.310 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;10.488 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;10.422 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;9.884 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.047 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;9.974 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;9.535 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;9.532 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;9.142 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 45 Toledo;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,8 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,42 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,42 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,91 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,95 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,48 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,17 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,09 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,25 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,27 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;84,61 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11.345 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;10.532 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;8.719 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;10.633 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9.919 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8.248 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;10.071 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9.436 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7.886 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;9.649 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;9.013 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7.587 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8.616 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7.269 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,72 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,18 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,6 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,77 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,59 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,45 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,05 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,58 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,02 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,81 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;83,37 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;451 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.054 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.086 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;432 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.020 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.062 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;417 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;986 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.998 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;398 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;961 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.948 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;916 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.873 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,79 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,77 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,85 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;92,46 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,55 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,78 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,25 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,18 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,38 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,91 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,79 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11.910 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;11.865 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;11.365 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;11.032 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;10.989 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;10.597 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;10.465 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;10.386 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;10.086 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;9.870 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;9.630 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;9.538 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;9.365 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,63 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,62 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,24 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,87 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,53 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,75 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;83,19 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,73 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,39 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;82,4 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.717 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11.494 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;10.210 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;10.848 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10.630 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9.479 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.287 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10.039 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9.001 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;9.537 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8.584 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;9.216 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8.345 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,58 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,48 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,84 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,8 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,34 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,16 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;82,97 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,07 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,18 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,73 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;193 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;371 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.155 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;184 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;359 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.118 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;178 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;347 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.085 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;333 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.046 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;322 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.020 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,34 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,77 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,8 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;92,23 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,53 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,94 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,76 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,56 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,79 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,31 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;11.760 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.776 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.389 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.007 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;10.945 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;10.661 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;10.347 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;10.098 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;9.937 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;9.758 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;9.570 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;9.427 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,6 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;92,94 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,61 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,87 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,66 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,38 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,68 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,27 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,77 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.596 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;11.228 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;10.238 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;10.848 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10.417 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9.550 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;9.856 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.025 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9.466 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.715 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;9.116 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8.412 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,55 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,78 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,28 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;87,78 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,15 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,31 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;85,12 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,19 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,16 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;164 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;548 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.151 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;159 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;528 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.111 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;491 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.073 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;471 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.043 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;454 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.015 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,95 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,35 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,52 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,6 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,22 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;85,95 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,62 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,85 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;88,18 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.675 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.539 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.651 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.637 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.514 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.571 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.597 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.504 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.548 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.578 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.489 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.528 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.555 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.468 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.505 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;97,73 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,38 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,15 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,34 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,73 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,76 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,21 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,75 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,55 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;92,84 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,39 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;91,16 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.566 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.218 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.529 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.199 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.491 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.189 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.475 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.178 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.453 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.160 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;97,64 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,44 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,21 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,62 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,19 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,72 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;92,78 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,24 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;109 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;321 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;108 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;315 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;106 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;315 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;103 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;311 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;102 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;308 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,08 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,13 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,25 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,13 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,5 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,88 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,58 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,95 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.672 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.534 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.450 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.637 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.520 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.436 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.615 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.504 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.422 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.601 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.481 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.405 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.445 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.384 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,91 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,09 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,03 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,59 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,04 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,07 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,75 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,54 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,9 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,2 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,45 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.544 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.214 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;898 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.511 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.201 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;886 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.490 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.190 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;877 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.477 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.170 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;867 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.138 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;856 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,86 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,93 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,66 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,5 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,02 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,66 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,66 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,38 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,55 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,74 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,32 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;128 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;320 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;552 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;126 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;319 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;550 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;125 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;314 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;545 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;124 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;311 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;538 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;307 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;528 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,44 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,69 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,64 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,66 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,13 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,73 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,88 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,19 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,46 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,94 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,65 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.679 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.646 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.542 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.647 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.623 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.526 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.623 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.595 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.501 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.564 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.473 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.541 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.461 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,09 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,6 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,96 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,66 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,9 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,34 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,02 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,53 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,62 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,75 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.647 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.534 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.153 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.616 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.511 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.140 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.592 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.484 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.122 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.455 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.101 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.434 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.094 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,12 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,5 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,87 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,66 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,74 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,31 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,85 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,49 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;93,48 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,88 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;32 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;112 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;389 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;31 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;112 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;386 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;31 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;111 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;379 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;109 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;372 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;107 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;367 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,88 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,23 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,88 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,11 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,43 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;97,32 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,63 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,54 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,34 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.618 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.626 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.529 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.588 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.603 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.506 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.563 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.478 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.533 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.466 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.516 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.454 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,15 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,59 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,5 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,13 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,66 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;94,28 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,88 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,23 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,09 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.596 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.515 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.153 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.566 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.493 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.137 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.457 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.116 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.430 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.107 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.414 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.099 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,12 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,55 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,61 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,17 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,79 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;94,39 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,01 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,33 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,32 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;22 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;111 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;376 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;22 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;110 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;369 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;106 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;362 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;103 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;359 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;102 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;355 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,1 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,14 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;95,5 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,28 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;92,79 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;95,48 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;91,89 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,41 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.014 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.906 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.062 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;2.000 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.880 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;2.004 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.978 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.860 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.988 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.958 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.844 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.971 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.946 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.829 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.954 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,3 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,64 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,19 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,21 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,59 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,41 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,22 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,75 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,59 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,62 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,96 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,76 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.852 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.407 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.840 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.387 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.819 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.371 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.799 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.358 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.787 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.349 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,35 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,58 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,22 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,44 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,14 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,52 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,49 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,88 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;162 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;499 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;160 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;493 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;159 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;489 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;159 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;486 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;159 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;480 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,77 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,8 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;98,15 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;98,15 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,39 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;98,15 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,19 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.032 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.900 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.831 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;2.010 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.879 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.825 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.991 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.862 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.814 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.978 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.848 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.802 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.838 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.778 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 45 Toledo;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,92 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,89 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,67 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,98 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,07 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,34 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,26 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,42 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,74 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,11 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.879 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.423 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.137 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.860 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.405 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.132 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.842 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.391 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.127 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.829 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.382 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.120 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.374 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.107 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,99 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,74 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,56 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,03 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,75 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,12 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,34 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,12 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,5 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,56 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,36 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;153 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;477 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;694 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;150 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;474 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;693 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;149 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;471 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;687 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;149 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;466 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;682 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;464 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;671 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,04 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,37 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,86 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,39 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,74 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,99 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,39 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,69 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,27 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,27 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,69 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.086 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.974 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.911 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.062 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.953 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.893 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.049 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.939 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.880 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.921 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.849 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.904 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.831 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,85 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,94 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,06 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,23 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,23 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,38 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,32 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,76 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,45 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,81 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.068 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.824 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.330 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.044 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.806 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.314 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.031 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.793 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.304 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.778 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.282 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.761 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.269 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,84 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,01 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,8 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,21 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,3 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,05 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,48 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,39 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,55 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,41 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;18 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;150 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;581 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;18 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;147 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;579 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;18 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;146 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;576 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;143 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;567 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;143 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;562 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,66 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,33 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,14 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,33 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,59 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,33 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,73 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.084 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.998 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.959 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.073 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.983 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.946 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.966 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.918 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.950 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.898 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.934 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.884 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,47 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,25 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,34 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,4 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,91 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,6 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,89 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,8 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,17 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.067 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.837 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.389 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.056 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.825 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.380 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.809 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.358 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.795 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.342 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.779 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.332 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,47 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,35 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,35 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,48 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,77 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,71 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,62 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,84 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,9 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;17 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;161 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;570 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;17 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;158 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;566 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;157 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;560 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;155 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;556 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;155 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;552 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,14 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,3 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;97,52 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,25 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,27 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,54 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,27 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,84 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;74 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;62 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;68 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;73 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;61 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;68 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;73 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;60 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;68 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;73 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;60 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;68 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;73 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;60 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;68 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,65 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,39 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,65 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,77 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,65 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,77 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,65 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,77 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;63 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;45 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;62 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;44 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;62 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;43 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;62 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;43 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;62 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;43 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,41 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,78 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,41 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,56 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,41 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,56 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,41 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,56 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;11 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;17 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;11 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;17 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;11 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;17 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;11 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;17 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;11 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;17 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;73 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;62 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;64 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;73 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;61 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;64 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;73 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;61 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;64 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;73 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;61 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;64 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;60 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;63 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,39 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,39 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,39 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,77 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;98,44 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;64 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;45 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;64 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;64 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;64 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;44 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;43 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;43 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,78 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,78 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,78 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,56 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,73 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;9 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;17 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;20 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;9 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;17 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;20 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;9 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;17 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;20 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;9 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;17 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;20 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;17 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;20 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;71 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;65 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;66 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;71 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;65 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;66 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;71 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;65 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;66 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;64 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;65 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;64 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;64 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,46 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,48 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,46 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,97 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;69 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;58 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;44 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;69 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;58 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;44 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;69 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;58 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;44 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;57 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;43 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;57 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;42 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,28 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,73 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,28 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,45 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;7 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;22 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;7 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;22 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;7 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;22 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;7 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;22 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;7 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;22 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;82 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;69 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;64 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;82 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;69 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;64 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;68 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;63 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;68 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;62 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;68 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;62 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,55 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,44 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,55 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,88 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,55 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,88 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;80 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;61 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;50 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;80 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;61 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;50 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;60 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;49 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;60 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;48 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;60 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;48 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,36 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,36 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,36 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;14 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;14 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;14 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;14 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;14 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;35 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;33 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;32 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;35 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;33 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;32 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;35 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;33 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;32 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;35 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;33 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;32 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;35 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;33 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;32 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;32 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;24 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;32 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;24 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;32 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;24 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;32 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;24 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;32 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;24 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;9 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;9 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;9 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;9 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;9 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;37 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;37 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;31 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;31 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;31 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;31 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;37 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;31 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;34 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;26 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;25 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;34 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;26 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;25 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;34 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;26 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;25 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;34 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;26 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;25 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;26 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;25 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;11 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;6 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;11 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;6 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;11 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;6 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;11 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;6 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;11 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;6 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;39 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;38 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;31 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;39 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;38 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;31 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;39 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;38 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;31 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;38 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;31 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;38 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;31 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;39 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;32 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;22 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;39 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;32 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;22 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;39 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;32 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;22 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;32 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;22 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;32 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;22 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;6 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;9 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;6 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;9 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;6 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;9 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;6 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;9 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;6 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;9 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;37 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;38 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;33 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;37 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;38 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;33 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;38 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;33 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;38 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;33 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;38 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;33 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;37 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;34 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;22 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;37 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;34 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;22 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;34 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;22 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;34 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;22 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;34 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;22 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;4 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;11 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;4 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;11 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;4 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;11 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;4 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;11 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;4 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;11 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 45 Toledo;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;66.017 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;64.029 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;66.014 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;62.372 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;60.110 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;58.474 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;59.604 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;57.754 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;56.414 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;57.337 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;55.864 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;54.645 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;55.657 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;54.439 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;53.045 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,48 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,88 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,58 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;90,29 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,2 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,46 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,85 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,25 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,78 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;84,31 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,02 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;80,35 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;62.510 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;56.213 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;58.992 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;52.569 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;56.321 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;50.386 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;54.137 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;48.637 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;52.542 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;47.367 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,37 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,52 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,1 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,63 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,61 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,52 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;84,05 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;84,26 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;3.507 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;7.816 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;3.380 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;7.541 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;3.283 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;7.368 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;3.200 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;7.227 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;3.115 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;7.072 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,38 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,48 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;93,61 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,27 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;91,25 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,46 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,82 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,48 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;66.036 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;63.518 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;61.508 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;62.597 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;60.567 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;59.037 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;59.851 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;58.227 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;56.950 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;57.827 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;56.509 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;55.074 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;54.480 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;52.835 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 46 Valencia/València;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,79 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,35 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,98 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,63 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,67 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,59 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,57 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,97 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,54 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,77 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,9 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;62.617 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;55.334 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;47.095 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;59.287 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;52.595 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;44.807 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;56.640 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;50.426 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;43.129 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;54.686 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;48.880 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;41.666 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;47.035 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;39.955 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,68 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,05 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,14 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,45 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,13 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,58 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;87,33 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,34 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,47 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,84 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;3.419 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;8.184 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;14.413 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;3.310 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;7.972 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;14.230 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;3.211 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;7.801 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;13.821 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;3.141 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;7.629 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;13.408 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;7.445 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;12.880 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,81 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,41 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,73 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,92 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;95,32 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,89 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,87 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,22 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,03 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;90,97 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;89,36 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;66.738 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;65.334 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;63.383 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;62.789 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;61.630 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;60.129 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;60.176 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;59.303 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;57.705 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;56.956 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;55.098 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;55.289 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;53.635 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,08 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,33 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,87 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,17 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,77 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,04 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,18 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,93 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,63 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,62 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;64.277 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;62.531 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;54.098 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;60.404 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;58.907 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;51.073 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;57.836 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;56.638 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;48.901 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;54.359 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;46.599 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;52.748 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;45.323 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,97 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,2 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,41 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,98 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,58 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,39 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,93 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,14 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;84,35 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,78 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2.461 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;2.803 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;9.285 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2.385 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;2.723 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;9.056 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2.340 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;2.665 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;8.804 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;2.597 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;8.499 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;2.541 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;8.312 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,91 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,15 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,53 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;95,08 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,08 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,82 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,65 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,53 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,65 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,52 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;65.873 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;65.020 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;63.652 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;62.645 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;62.010 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;60.471 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;59.277 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;57.384 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;57.190 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;55.565 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;55.270 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;54.043 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,1 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,37 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,17 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,15 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,96 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,29 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,9 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;63.790 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;61.427 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;54.051 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;60.596 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;58.517 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;51.149 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;55.891 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;48.396 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;53.889 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;46.780 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;52.061 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;45.410 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,99 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,26 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,63 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,99 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,54 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,73 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,55 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;84,75 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,01 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2.083 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;3.593 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;9.601 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2.049 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;3.493 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;9.322 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;3.386 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;8.988 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;3.301 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;8.785 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;3.209 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;8.633 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,37 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,22 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,09 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,24 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,62 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,87 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,5 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,31 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,92 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;48.910 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;47.990 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;49.108 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;45.493 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;44.304 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;42.079 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;43.022 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;42.202 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;40.289 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;40.985 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;40.478 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;38.725 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;39.464 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;39.184 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;37.323 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,01 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,32 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;85,69 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,96 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;87,94 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;82,04 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,8 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,35 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;78,86 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;80,69 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;81,65 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;76 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;46.779 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;43.964 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;43.471 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;40.505 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;41.084 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;38.534 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;39.117 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;36.921 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;37.667 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;35.754 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;92,93 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,13 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,83 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,65 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,62 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,98 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;80,52 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;81,33 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;2.131 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4.026 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;2.022 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;3.799 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;1.938 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;3.668 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;1.868 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;3.557 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;1.797 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;3.430 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;94,89 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;94,36 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,94 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,11 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;87,66 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,35 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;84,33 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,2 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;48.847 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;47.695 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;45.958 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;45.694 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;44.967 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;43.706 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;43.173 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;42.811 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;41.788 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;41.325 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;41.243 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;40.095 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;39.415 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;38.076 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,55 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;94,28 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,1 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;88,38 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,76 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;90,93 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;84,6 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;86,47 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,24 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;82,64 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,85 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;46.782 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;43.167 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;37.012 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;43.721 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;40.612 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;34.912 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;41.277 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;38.601 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;33.344 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;39.491 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;37.181 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;31.984 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;35.498 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;30.403 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,46 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,08 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,33 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;88,23 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,42 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,09 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;84,41 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;86,13 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;86,42 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;82,23 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;82,14 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;2.065 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4.528 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;8.946 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;1.973 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4.355 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;8.794 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;1.896 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4.210 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;8.444 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;1.834 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4.062 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;8.111 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;3.917 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;7.673 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,54 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,18 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,3 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;91,82 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;92,98 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,39 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,81 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,71 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;90,67 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,51 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;85,77 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;49.202 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;48.630 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;47.508 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;45.533 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;45.183 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;44.466 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;43.194 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;43.103 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;42.299 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;40.989 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;39.939 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;39.474 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;38.630 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;92,54 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,91 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;93,6 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,79 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,63 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,04 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,29 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,07 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;81,17 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,31 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;47.673 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;47.118 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;42.735 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;44.070 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;43.736 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;39.882 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;41.771 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;41.704 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;37.902 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;39.642 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;35.777 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;38.174 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;34.607 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;92,44 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,82 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;93,32 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,62 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,51 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;88,69 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,13 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,72 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81,02 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,98 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1.529 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1.512 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4.773 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1.463 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1.447 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4.584 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1.423 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1.399 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;4.397 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1.347 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;4.162 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1.300 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;4.023 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;95,68 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,7 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,04 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;93,07 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,53 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;92,12 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;89,09 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;87,2 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;85,98 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;84,29 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;48.631 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;48.359 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;47.769 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;45.599 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;45.528 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;44.787 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;43.018 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;41.953 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;41.145 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;40.330 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;39.413 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;38.946 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,77 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,15 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,76 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,96 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,82 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,08 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,43 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;81,5 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;81,53 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;47.389 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;46.076 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;42.784 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;44.388 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;43.338 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;40.023 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;40.914 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;37.459 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;39.116 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;35.986 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;37.460 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;34.720 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,67 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,06 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,55 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,8 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;87,55 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,89 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,11 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,3 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;81,15 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1.242 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;2.283 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;4.985 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1.211 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;2.190 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;4.764 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;2.104 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;4.494 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;2.029 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;4.344 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1.953 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;4.226 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,5 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,93 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,57 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;92,16 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,15 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;88,87 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;87,14 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,55 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;84,77 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;6.970 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;6.618 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;6.939 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;6.856 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;6.492 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;6.640 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;6.710 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;6.368 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;6.511 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;6.586 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;6.279 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;6.410 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;6.498 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;6.209 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;6.293 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,36 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,1 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,69 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,27 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,22 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;93,83 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,49 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,88 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;92,38 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,23 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;93,82 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;90,69 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;6.463 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;5.309 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;6.359 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5.208 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;6.217 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5.104 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;6.099 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5.027 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;6.018 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;4.975 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,39 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,1 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,19 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,14 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,37 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,69 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,11 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,71 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;507 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.309 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;497 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.284 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;493 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.264 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;487 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.252 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;480 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.234 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,03 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,09 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,24 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,56 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,06 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,65 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;94,67 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,27 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;6.891 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;6.434 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;6.367 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;6.747 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;6.319 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;6.264 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;6.620 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;6.222 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;6.183 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;6.522 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;6.140 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;6.080 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;6.035 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;5.960 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,91 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,21 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,38 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,07 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,71 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,11 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,65 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,43 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,49 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,8 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,61 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;6.400 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5.125 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;4.091 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;6.263 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5.029 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;4.008 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;6.148 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;4.942 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.957 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;6.055 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;4.875 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3.897 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;4.788 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3.823 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,86 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,13 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,97 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,06 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,43 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,72 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,61 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,12 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,26 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,42 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,45 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;491 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.309 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.276 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;484 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.290 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.256 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;472 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.280 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.226 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;467 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.265 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.183 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.247 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.137 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,57 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,55 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,12 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,13 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,78 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,8 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,11 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,64 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,91 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,26 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,89 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;7.077 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;6.899 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6.671 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;6.917 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;6.753 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;6.557 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;6.771 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;6.623 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;6.418 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;6.501 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;6.276 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;6.423 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;6.194 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,74 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,88 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,29 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;95,68 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;96,21 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;94,23 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;94,08 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;93,1 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;92,85 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;6.709 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;6.439 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.077 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;6.554 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;6.299 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;4.984 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;6.413 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;6.176 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;4.876 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;6.059 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;4.771 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5.985 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;4.716 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,69 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,83 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,17 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;95,59 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;95,92 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,04 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;94,1 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;93,97 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;92,95 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,89 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;368 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;460 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.594 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;363 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;454 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.573 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;358 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;447 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.542 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;442 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.505 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;438 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.478 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,64 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,7 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,68 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,28 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,17 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,74 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,09 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,42 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;95,22 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,72 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;6.927 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;6.816 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6.594 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;6.812 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;6.721 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;6.476 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;6.609 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;6.339 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;6.505 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;6.241 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;6.398 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;6.170 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,34 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,61 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,21 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,96 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,13 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,44 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;94,65 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;93,87 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,57 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;6.601 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;6.336 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;4.985 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;6.489 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;6.246 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;4.899 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;6.144 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;4.794 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;6.045 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;4.721 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;5.945 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;4.662 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,3 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,58 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,27 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,97 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,17 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,41 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,7 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;93,83 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,52 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;326 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;480 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.609 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;323 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;475 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.577 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;465 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.545 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;460 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.520 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;453 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.508 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,08 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,96 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,01 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,88 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,02 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95,83 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,47 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,38 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,72 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;9.395 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.734 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;9.266 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;9.286 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;8.636 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;9.061 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;9.143 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;8.511 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;8.924 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;9.046 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;8.440 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;8.829 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;8.979 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;8.383 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;8.753 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,84 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,88 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,79 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,32 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,45 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;96,31 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,29 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,63 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,28 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,57 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;95,98 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,46 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.597 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6.488 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.496 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;6.412 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;8.362 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;6.308 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;8.272 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.255 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;8.212 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.208 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,83 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,83 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,27 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;97,23 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,22 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,41 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,52 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;95,68 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;798 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.246 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;790 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.224 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;781 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.203 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;774 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.185 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;767 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;2.175 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,02 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,87 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,09 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,99 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,28 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,12 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,84 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;9.555 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.709 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.514 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;9.417 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;8.605 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;8.400 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;9.328 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.528 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;8.324 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;9.256 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;8.467 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;8.260 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;8.374 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;8.166 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,56 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,81 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,66 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,62 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,92 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,77 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,87 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,22 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,02 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,15 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,91 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.766 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;6.583 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;5.516 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;8.637 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;6.498 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;5.412 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;8.558 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;6.436 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;5.365 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;8.489 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.384 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;5.337 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.311 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;5.287 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,53 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,71 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,11 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,63 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,77 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,26 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,84 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,98 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,75 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,87 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,85 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;789 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.126 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.998 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;780 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.107 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.988 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;770 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.092 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.959 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;767 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;2.083 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.923 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;2.063 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.879 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,86 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,11 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,67 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;97,59 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,4 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,7 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;97,21 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,98 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,5 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,04 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,03 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;9.712 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;9.138 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.584 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;9.596 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;9.032 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.492 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;9.471 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.919 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;8.382 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;8.813 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;8.282 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;8.743 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;8.212 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,81 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,84 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,93 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,52 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,6 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,65 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,44 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,48 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,68 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,67 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;9.178 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.378 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;5.917 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;9.067 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8.281 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;5.843 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;8.942 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8.171 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;5.767 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8.076 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5.699 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8.011 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5.650 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,79 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,84 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,75 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,43 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,53 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,46 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,4 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,32 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,62 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,49 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;534 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;760 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.667 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;529 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;751 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.649 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;529 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;748 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.615 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;737 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.583 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;732 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.562 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;99,06 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,82 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,33 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;99,06 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;98,42 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,05 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,97 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,85 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,32 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,06 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;9.573 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;9.161 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.631 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;9.497 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;9.081 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.563 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;8.975 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;8.452 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;8.872 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;8.359 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;8.798 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;8.295 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,21 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,13 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,21 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,97 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,93 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,85 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,85 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,04 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,11 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;9.085 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.409 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;5.878 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;9.009 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;8.331 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;5.835 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;8.236 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5.755 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;8.138 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5.689 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;8.073 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5.647 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,16 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,07 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,27 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,94 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,91 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,78 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,78 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,07 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;488 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;752 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.753 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;488 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;750 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.728 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;739 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;2.697 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;734 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;2.670 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;725 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;2.648 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;99,73 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,09 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,27 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,97 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,61 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,99 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,41 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,19 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;501 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;448 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;460 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;498 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;445 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;456 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;492 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;442 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;453 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;488 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;440 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;449 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;485 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;436 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;447 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,4 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,33 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;99,13 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,2 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,66 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,48 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,41 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,21 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,61 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,81 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,32 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,17 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;450 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;305 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;447 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;302 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;441 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;299 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;437 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;297 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;434 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;293 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,33 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,02 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,03 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,11 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,38 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,44 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,07 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;51 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;143 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;51 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;143 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;51 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;143 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;51 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;143 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;51 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;143 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;501 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;447 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;446 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;498 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;445 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;445 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;492 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;438 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;437 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;486 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;433 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;426 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;431 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;425 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,4 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,55 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,78 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,2 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,99 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,98 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,01 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,87 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,52 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,42 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,29 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;454 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;310 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;319 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;451 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;308 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;318 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;445 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;302 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;310 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;439 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;297 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;299 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;295 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;298 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,34 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,35 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,69 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,02 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,42 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,18 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;96,7 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,81 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;93,73 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,16 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,42 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;47 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;137 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;127 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;47 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;137 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;127 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;47 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;136 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;127 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;47 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;136 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;127 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;136 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;127 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,27 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;99,27 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;99,27 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;515 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;446 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;420 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;511 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;441 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;414 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;508 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;438 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;409 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;436 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;407 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;433 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;406 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,22 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,88 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,57 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,64 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,21 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,38 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,76 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,9 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,09 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,67 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;493 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;401 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;250 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;489 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;396 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;245 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;486 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;393 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;240 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;391 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;238 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;388 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;237 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,19 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,75 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,58 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,51 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,2 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,76 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,8 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;22 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;45 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;170 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;22 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;45 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;169 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;22 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;45 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;169 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;45 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;169 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;45 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;169 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,41 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;99,41 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;99,41 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;99,41 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;498 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;454 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;445 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;495 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;451 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;435 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;449 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;433 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;444 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;430 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;439 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;429 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,4 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,34 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,75 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,9 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,3 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,8 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,63 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,7 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,4 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;479 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;404 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;280 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;476 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;401 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;271 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;399 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;269 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;394 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;266 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;389 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;265 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,37 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,26 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;96,79 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,76 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,07 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,52 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,29 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,64 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;19 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;50 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;165 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;19 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;50 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;164 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;50 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;164 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;50 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;164 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;50 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;164 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,39 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;99,39 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;99,39 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;99,39 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;241 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;239 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;241 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;239 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;233 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;238 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;237 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;231 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;237 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;232 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;227 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;232 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;231 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;227 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;229 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,17 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,49 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,76 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,34 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,65 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,34 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,27 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,98 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,27 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;95,85 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,98 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,02 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;221 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;147 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;219 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;142 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;217 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;141 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;212 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;137 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;211 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;137 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,1 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,6 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,19 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;95,92 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;95,93 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;93,2 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;95,48 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,2 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;20 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;92 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;20 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;91 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;20 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;90 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;20 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;90 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;20 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;90 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,91 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,83 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,83 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,83 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;242 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;233 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;223 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;241 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;231 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;222 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;238 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;228 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;218 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;238 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;226 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;213 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;225 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;208 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;99,59 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,14 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,55 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,35 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,85 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,76 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,35 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,52 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,57 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,27 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;215 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;149 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;157 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;215 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;148 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;157 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;212 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;145 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;153 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;212 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;143 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;149 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;143 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;144 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,33 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,6 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,32 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,45 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,6 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,97 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;94,9 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,97 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;91,72 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;27 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;84 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;66 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;26 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;83 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;65 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;26 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;83 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;65 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;26 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;83 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;64 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;82 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;64 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,3 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,81 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,48 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,3 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,81 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,48 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,3 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,81 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,97 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,62 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,97 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;232 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;221 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;200 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;232 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;221 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;200 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;232 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;220 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;197 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;217 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;194 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;216 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;193 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,55 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,5 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,19 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,74 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,5 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;224 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;195 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;119 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;224 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;195 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;119 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;224 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;194 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;116 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;191 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;114 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;190 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;113 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,49 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,48 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,95 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,8 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,44 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,96 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;8 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;26 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;81 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;8 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;26 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;81 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;8 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;26 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;81 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;26 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;80 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;26 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;80 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,77 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,77 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;244 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;230 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;213 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;242 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;229 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;210 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;226 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;207 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;224 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;205 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;222 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;203 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,18 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,57 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,59 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,26 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,18 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,39 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,24 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,52 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,31 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;236 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;202 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;124 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;234 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;201 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;121 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;198 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;119 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;196 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;118 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;194 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;116 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,15 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,5 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,58 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,02 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;95,97 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,03 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,16 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,04 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,55 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;28 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;89 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;28 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;89 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;28 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;88 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;28 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;87 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;28 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;87 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,88 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,75 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,75 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 46 Valencia/València;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;11.991 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;11.699 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;12.278 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;11.428 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;11.199 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;11.120 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;10.951 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;10.828 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;10.739 47 Valladolid;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;10.598 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;10.546 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;10.443 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;10.306 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;10.330 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;10.158 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,3 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,73 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,57 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,33 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,55 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,47 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,38 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,14 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,05 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;85,95 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,3 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;82,73 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;11.357 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;9.969 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10.812 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;9.509 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;10.349 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;9.172 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10.006 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8.922 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;9.724 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8.720 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,2 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,39 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,12 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,01 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,1 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,5 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,62 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,47 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;634 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.730 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;616 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1.690 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;602 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1.656 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;592 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1.624 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;582 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.610 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,16 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,69 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,95 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,72 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,38 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,87 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,8 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,06 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;11.946 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;11.673 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;11.538 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;11.361 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;11.209 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;11.099 47 Valladolid;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;10.934 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;10.878 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;10.768 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;10.600 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;10.622 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;10.456 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;10.331 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;10.151 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 47 Valladolid;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,1 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,03 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,2 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,53 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,19 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,33 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,73 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,62 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,5 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,98 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11.331 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;9.943 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;8.934 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;10.763 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;9.514 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;8.541 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;10.346 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;9.217 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;8.259 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;10.021 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8.976 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;8.017 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8.718 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7.768 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,99 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,69 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,6 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,31 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,7 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,44 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,44 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,27 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;89,74 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,68 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,95 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;615 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1.730 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;2.604 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;598 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1.695 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;2.558 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;588 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1.661 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.509 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;579 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.646 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.439 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.613 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.383 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,24 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,98 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,23 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,61 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,01 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,35 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,15 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,14 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,66 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,24 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,51 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11.948 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;11.851 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;11.671 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;11.345 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;11.329 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;11.193 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;10.928 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;10.983 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;10.794 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;10.639 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;10.459 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;10.347 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;10.212 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,95 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,6 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,9 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,46 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,68 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,49 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,77 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,62 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;87,31 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,5 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11.761 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11.248 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;9.893 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;11.163 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;10.735 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;9.444 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;10.748 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;10.393 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;9.091 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;10.059 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8.791 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;9.776 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8.572 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,92 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,44 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,46 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,39 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,4 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,89 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,43 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;88,86 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,91 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;86,65 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;187 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;603 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.778 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;182 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;594 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.749 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;180 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;590 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.703 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;580 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.668 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;571 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1.640 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,33 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,51 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,37 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,26 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;97,84 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,78 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;96,19 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,81 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,69 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;92,24 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;11.815 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;11.839 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;11.746 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;11.285 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;11.372 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;11.200 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;10.962 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;10.807 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;10.613 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;10.523 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;10.319 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;10.278 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,51 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;96,06 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,35 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;92,59 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,01 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;89,64 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,59 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;87,16 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,5 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;11.663 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;11.162 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9.894 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;11.135 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10.704 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9.400 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10.311 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9.043 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;9.978 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;8.791 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;9.695 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;8.578 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,47 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,9 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,01 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;92,38 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,4 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;89,39 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;88,85 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,86 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;86,7 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;152 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;677 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1.852 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;150 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;668 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1.800 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;651 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.764 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;635 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.732 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;624 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.700 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,68 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,67 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,19 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,16 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,25 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;93,8 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,52 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,17 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,79 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;8.927 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;8.872 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;9.218 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;8.389 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;8.406 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;8.121 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;7.956 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;8.064 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;7.785 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;7.647 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;7.808 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;7.524 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;7.381 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;7.613 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;7.261 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,97 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,75 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,1 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,12 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,89 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,45 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,66 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;88,01 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,62 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,68 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,81 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,77 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;8.546 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7.918 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;8.025 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7.487 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;7.603 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7.176 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;7.301 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;6.942 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;7.042 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;6.757 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,9 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,56 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;88,97 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,63 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,43 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,67 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,4 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,34 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;381 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;954 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;364 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;919 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;353 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;888 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;346 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;866 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;339 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;856 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,54 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,33 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;92,65 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;93,08 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,81 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;90,78 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,98 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,73 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;8.882 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;8.793 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;8.707 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;8.341 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;8.361 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;8.299 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;7.960 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;8.055 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;7.998 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;7.649 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;7.819 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;7.704 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;7.546 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;7.435 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,91 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,09 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,31 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,62 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,61 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,86 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,12 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,92 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,48 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;85,82 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,39 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;8.521 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7.872 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7.153 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;7.992 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7.472 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6.784 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;7.617 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7.190 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;6.521 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;7.311 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;6.965 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6.285 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;6.720 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6.062 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,79 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,92 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;94,84 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,39 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,34 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,16 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,8 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,48 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,87 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,37 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,75 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;361 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;921 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.554 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;349 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;889 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.515 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;343 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;865 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.477 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;338 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;854 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.419 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;826 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.373 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;96,68 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,53 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,49 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,01 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,92 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,05 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,63 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;92,73 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,31 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;89,69 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,35 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;8.816 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;8.858 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8.804 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;8.258 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;8.360 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;8.355 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;7.870 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;8.035 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;7.978 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;7.716 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;7.681 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;7.450 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;7.461 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,67 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,38 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,9 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,27 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,71 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,62 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;87,11 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,24 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;84,1 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,75 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;8.673 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8.547 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;7.872 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;8.117 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8.057 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;7.445 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;7.730 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;7.736 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;7.104 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;7.425 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;6.837 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;7.164 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;6.640 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,59 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,27 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,58 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,13 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,51 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,24 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,87 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,85 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,82 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,35 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;143 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;311 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;932 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;141 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;303 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;910 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;140 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;299 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;874 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;291 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;844 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;286 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;821 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,6 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;97,43 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,64 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,9 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;96,14 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,78 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;93,57 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;90,56 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;91,96 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;88,09 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;8.721 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;8.844 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;8.854 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;8.219 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;8.393 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;8.330 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;8.010 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;7.974 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;7.689 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;7.715 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;7.432 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;7.496 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,24 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,9 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,08 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,57 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,06 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,94 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,14 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;84,03 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,66 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;8.594 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;8.423 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7.866 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;8.093 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;7.980 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7.385 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;7.612 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7.059 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;7.305 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;6.827 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;7.054 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;6.628 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,17 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,74 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,89 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,37 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,74 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;86,73 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,79 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;83,75 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,26 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;127 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;421 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;988 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;126 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;413 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;945 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;398 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;915 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;384 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;888 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;378 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;868 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;99,21 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,1 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,65 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,54 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,61 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,21 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;89,88 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;89,79 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,85 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.229 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.141 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.247 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.218 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.120 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.214 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.191 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.103 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.185 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.165 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.093 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.169 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.153 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.079 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.157 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,1 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,16 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,35 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,91 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,67 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,03 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,79 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,79 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,74 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,82 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,57 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,78 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.126 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;865 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.115 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;846 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.089 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;832 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.065 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;828 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.054 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;816 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,02 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;97,8 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,71 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,18 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,58 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,72 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,61 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,34 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;103 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;276 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;103 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;274 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;102 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;271 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;265 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;99 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;263 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,28 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;99,03 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,19 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,09 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,01 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,12 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,29 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.223 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.186 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.149 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.197 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.164 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.130 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.168 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.153 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.114 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.157 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.140 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.102 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.133 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.078 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,87 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,15 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,35 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;95,5 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;97,22 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,95 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;94,6 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,12 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;95,91 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;95,53 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;93,82 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.128 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;884 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;730 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.103 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;864 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;715 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.076 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;859 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;706 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.066 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;848 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;702 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;842 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;684 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,78 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,74 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,95 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;95,39 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,17 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,71 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;94,5 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,93 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,16 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;95,25 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;93,7 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;95 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;302 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;419 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;94 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;300 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;415 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;92 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;294 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;408 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;91 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;292 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;400 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;291 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;394 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,95 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,34 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,05 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,84 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,35 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,37 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;95,79 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,69 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,47 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,36 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,03 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.294 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.230 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.192 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.263 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.218 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.177 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.249 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.206 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.163 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.195 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.137 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.179 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.121 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,6 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,02 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,74 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,52 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,05 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,57 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,15 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,39 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,85 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,04 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.271 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.124 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;888 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.242 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.112 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;876 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.228 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;867 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.089 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;842 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.075 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;828 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,72 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,93 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,65 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,62 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,86 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,64 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,89 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;94,82 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;95,64 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;93,24 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;23 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;106 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;304 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;21 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;106 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;301 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;21 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;106 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;296 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;106 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;295 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;104 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;293 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;91,3 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,01 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,3 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,37 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,04 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;98,11 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,38 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.241 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.217 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.192 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.227 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.206 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.180 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.194 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.158 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.180 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.144 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.159 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.133 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,87 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,1 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,99 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,11 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,15 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,96 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,97 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,23 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,05 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.228 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.122 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;885 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.214 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.112 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;875 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;856 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.086 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;844 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.069 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;841 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,86 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,11 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,87 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,04 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,72 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,79 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,37 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,28 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,03 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;13 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;95 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;307 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;13 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;94 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;305 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;94 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;302 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;94 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;300 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;90 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;292 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,95 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,35 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,95 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,37 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;98,95 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,72 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;94,74 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;95,11 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.682 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.535 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.674 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;1.669 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;1.523 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;1.646 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;1.653 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;1.513 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;1.630 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.636 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.499 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.613 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.622 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.496 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.603 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,23 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,22 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,33 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,28 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,57 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,37 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,27 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,65 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;96,36 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,43 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,46 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;95,76 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.547 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.093 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.535 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.083 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.521 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.073 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.505 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.062 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.493 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.059 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,22 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,09 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,32 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,17 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,29 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,16 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,51 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,89 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;135 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;442 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;134 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;440 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;132 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;440 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;131 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;437 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;129 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;437 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;99,26 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,55 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,78 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;99,55 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,04 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98,87 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95,56 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98,87 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.689 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.554 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.549 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;1.672 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;1.545 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;1.537 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.656 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.533 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.525 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.644 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.527 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.519 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;1.517 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;1.508 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,99 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,42 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,23 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,05 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,65 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,45 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,34 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,26 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,06 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,62 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,35 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.549 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.101 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;975 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.536 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.093 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;966 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.522 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.084 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;957 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.513 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.079 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;955 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.073 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;947 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;99,16 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,27 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,08 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,26 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,46 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,15 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,68 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,95 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,46 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,13 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;140 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;453 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;574 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;136 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;452 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;571 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;134 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;449 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;568 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;131 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;448 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;564 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;444 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;561 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,14 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,78 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,48 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,71 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;99,12 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,95 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,57 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,9 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;98,26 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,01 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;97,74 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.687 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.617 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.542 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.674 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.606 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.530 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.659 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.598 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.522 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;1.585 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;1.511 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;1.575 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;1.503 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,23 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,32 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,22 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,34 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,82 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,7 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,02 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,99 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,4 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,47 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.669 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.454 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.058 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.657 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.444 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.049 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.643 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.436 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.046 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.425 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.038 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.417 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.033 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,28 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,31 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,15 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,44 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,76 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,87 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,01 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,11 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,46 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,64 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;18 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;163 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;484 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;17 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;162 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;481 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;16 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;162 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;476 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;160 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;473 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;158 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;470 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,44 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,39 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,38 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;88,89 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,39 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,35 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;98,16 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,73 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;96,93 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,11 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.704 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.628 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.553 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.690 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.623 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.543 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;1.609 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;1.529 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;1.595 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;1.521 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.580 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.508 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,18 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,69 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,36 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,83 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,45 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,97 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,94 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;97,05 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,1 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.693 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.485 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.054 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.680 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.480 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.051 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.468 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.039 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.456 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.034 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.442 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.024 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,23 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,66 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,72 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,86 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,58 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,05 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,1 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,1 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,15 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;11 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;143 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;499 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;10 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;143 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;492 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;141 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;490 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;139 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;487 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;138 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;484 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;90,91 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,6 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,6 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,2 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,2 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,6 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,5 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,99 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;98 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;101 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;91 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;97 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;91 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;96 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;99 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;91 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;96 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;97 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;90 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;96 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;93 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;90 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,98 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,01 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,96 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,02 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,96 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;96,04 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,9 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,96 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,08 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;98,9 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;92 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;64 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;91 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;64 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;90 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;63 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;90 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;62 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;90 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;60 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,91 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,83 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,44 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,83 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,88 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,83 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,75 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;6 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;37 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;6 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;36 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;6 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;36 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;35 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;33 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,3 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,3 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,59 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,19 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;98 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;88 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;86 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;97 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;87 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;86 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;97 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;85 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;85 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;97 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;84 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;85 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;83 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;84 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,98 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,86 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,98 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,59 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,84 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,98 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,45 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,84 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,32 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,67 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;87 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;56 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;50 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;86 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;55 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;50 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;86 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;54 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;50 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;86 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;54 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;50 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;53 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;50 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,85 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,21 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,85 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,43 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,85 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,43 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;94,64 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;11 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;32 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;36 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;11 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;32 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;36 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;11 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;31 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;35 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;11 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;30 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;35 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;30 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;34 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,88 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,22 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,75 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,22 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,75 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,44 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;99 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;96 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;86 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;99 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;95 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;85 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;99 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;94 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;85 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;93 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;84 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;93 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;82 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,96 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,84 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,92 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,84 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,88 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,67 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,88 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,35 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;98 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;81 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;48 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;98 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;80 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;48 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;98 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;79 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;48 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;78 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;48 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;78 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;46 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,77 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,53 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;96,3 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,3 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,83 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;15 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;38 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;15 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;37 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;15 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;37 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;15 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;36 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;15 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;36 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,37 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,37 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,74 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;94,74 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;95 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;95 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;96 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;94 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;96 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;92 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;96 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;90 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,95 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,84 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,97 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,74 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;97 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;87 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;60 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;97 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;87 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;60 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;86 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;60 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;86 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;58 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;86 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;57 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,85 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,85 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,67 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,85 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;10 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;35 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;10 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;35 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;10 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;34 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;10 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;34 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;10 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;33 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,14 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,14 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,29 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;55 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;50 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;48 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;55 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;50 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;48 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;55 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;49 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;48 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;54 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;49 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;47 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;54 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;49 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;47 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,18 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,92 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,18 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,92 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;46 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;29 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;46 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;29 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;46 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;28 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;45 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;28 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;45 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;28 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,55 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,83 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,55 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,83 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,55 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;9 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;21 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;9 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;21 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;9 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;21 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;9 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;21 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;9 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;21 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;54 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;52 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;47 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;54 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;52 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;47 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;53 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;52 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;46 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;53 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;52 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;46 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;52 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;46 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,15 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,87 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;98,15 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,87 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,87 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;46 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;30 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;26 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;46 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;30 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;26 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;45 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;30 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;25 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;45 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;30 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;25 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;30 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;25 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,83 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,15 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,83 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,15 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,15 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;8 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;22 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;21 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;8 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;22 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;21 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;8 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;22 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;21 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;8 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;22 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;21 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;22 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;21 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;52 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;50 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;47 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;51 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;50 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;46 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;51 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;50 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;46 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;50 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;46 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;50 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;45 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,08 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,87 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,08 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,87 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,87 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,74 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;50 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;42 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;27 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;49 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;42 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;26 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;49 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;42 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;26 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;42 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;26 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;42 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;25 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,3 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,3 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,3 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;92,59 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;8 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;20 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;8 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;20 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;8 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;20 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;8 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;20 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;8 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;20 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;52 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;53 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;52 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;52 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;53 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;52 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;53 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;52 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;53 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;51 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;52 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;51 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,08 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,11 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,08 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;51 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;45 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;29 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;51 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;45 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;29 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;45 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;29 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;45 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;28 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;44 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;28 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,55 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,78 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,55 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;23 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;23 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;23 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;23 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;23 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 47 Valladolid;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.909 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.706 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.984 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;3.702 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;3.523 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;3.533 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;3.565 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;3.428 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;3.413 49 Zamora;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.452 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.361 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.339 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.365 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.290 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.231 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,7 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,06 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,68 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,2 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,5 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,67 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,31 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,69 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;83,81 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,08 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;88,77 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,1 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.751 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;3.303 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.549 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;3.133 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.413 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;3.042 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.304 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.977 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.219 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.912 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,61 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,85 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;90,99 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,1 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,08 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;90,13 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;85,82 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;88,16 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;158 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;403 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;153 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;390 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;152 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;386 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;148 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;384 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;146 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;378 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;96,84 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,77 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,2 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,78 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;93,67 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,29 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;92,41 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;93,8 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.905 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.756 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.670 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;3.729 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;3.629 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;3.528 49 Zamora;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.587 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.543 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.445 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.472 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.418 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.325 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;3.319 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;3.202 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 49 Zamora;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,49 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,62 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,13 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,86 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;94,33 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,87 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;88,91 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;91 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;90,6 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;88,37 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;87,25 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.750 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3.354 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3.265 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.577 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3.231 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3.126 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.438 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3.148 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3.049 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.325 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3.029 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.939 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.936 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.823 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,39 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;96,33 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,74 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,68 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;93,86 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,38 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;88,67 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,31 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,02 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,54 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;86,46 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;155 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;402 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;405 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;152 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;398 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;402 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;149 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;395 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;396 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;147 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;389 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;386 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;383 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;379 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,06 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,26 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,13 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,26 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,78 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,84 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;96,77 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,31 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,27 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,58 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.979 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.910 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.813 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.760 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.750 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.666 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.599 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.577 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.472 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;3.456 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;3.339 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;3.364 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;3.281 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,5 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,91 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;96,14 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;90,45 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;91,48 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,06 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;88,39 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,57 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,04 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;86,05 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.927 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.801 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3.480 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.709 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.643 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3.338 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.549 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.473 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3.151 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.352 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3.025 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.261 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.969 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,45 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,84 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,92 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;90,37 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;91,37 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,55 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;88,19 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,93 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;85,79 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;85,32 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;52 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;109 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;333 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;51 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;107 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;328 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;50 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;104 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;321 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;104 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;314 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;103 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;312 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;98,08 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,17 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,5 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;96,15 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,41 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,4 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;95,41 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,29 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,5 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,69 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.904 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.942 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.860 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.697 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.721 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.588 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;3.570 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;3.436 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;3.461 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;3.362 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.365 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.302 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,7 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,39 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;92,95 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,56 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,02 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;87,8 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,1 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;85,36 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,54 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.857 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.764 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3.518 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.651 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.548 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3.256 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.401 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3.112 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.298 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3.041 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.204 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.984 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,66 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,26 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;92,55 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,36 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,46 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;87,62 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,44 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;85,12 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,82 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;47 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;178 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;342 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;46 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;173 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;332 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;169 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;324 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;163 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;321 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;161 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;318 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,87 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,19 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,08 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,94 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,74 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,57 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,86 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;90,45 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;92,98 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.180 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.037 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.251 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;2.980 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;2.862 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;2.815 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;2.858 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;2.770 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;2.702 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.751 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.707 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.634 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.668 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.638 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.535 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,71 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,24 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,59 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,87 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;91,21 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;83,11 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;86,51 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;89,13 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;81,02 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;83,9 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;86,86 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;77,98 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.069 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.792 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.874 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.626 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.752 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.537 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.648 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.476 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.567 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.413 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,65 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,05 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,67 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,87 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;86,28 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;88,68 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;83,64 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;86,43 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;111 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;245 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;106 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;236 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;106 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;233 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;103 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;231 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;101 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;225 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,5 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,33 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,5 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,1 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,79 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;94,29 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,99 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;91,84 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.163 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.084 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.998 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;3.003 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;2.960 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;2.862 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.866 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.878 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.784 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.754 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.757 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.669 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;2.663 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;2.557 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 49 Zamora;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,94 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,98 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,46 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;90,61 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,32 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,86 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;87,07 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;89,4 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,03 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;86,35 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,29 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.052 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.841 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.784 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.894 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.720 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.650 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.760 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.641 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.576 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.650 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.526 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.470 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.436 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.361 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,82 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,74 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,19 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;90,43 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,96 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;92,53 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,83 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,91 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,72 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;85,74 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,81 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;111 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;243 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;214 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;109 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;240 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;212 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;106 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;237 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;208 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;104 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;231 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;199 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;227 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;196 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;98,2 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,77 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,07 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;95,5 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,53 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,2 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;93,69 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,06 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;92,99 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,42 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,59 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.204 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.206 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.123 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.993 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.056 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.982 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.838 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.890 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.797 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;2.773 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;2.674 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;2.689 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;2.617 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,41 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,32 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,49 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,58 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,14 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;89,56 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,49 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;85,62 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,87 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,8 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.165 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.142 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.954 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.954 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.994 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.817 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.800 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.831 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.638 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.714 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.519 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.631 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.464 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,33 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,29 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,36 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,47 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,1 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;89,3 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,38 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;85,27 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,74 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,41 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;39 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;64 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;169 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;39 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;62 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;165 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;38 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;59 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;159 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;59 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;155 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;58 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;153 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,88 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,63 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,44 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,19 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,08 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;92,19 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,72 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;90,63 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,53 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.152 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.217 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.158 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.955 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.004 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.896 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;2.860 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;2.754 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;2.764 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;2.684 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.670 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.627 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;93,75 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,38 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,7 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,9 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;87,21 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,92 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;84,99 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;83 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,19 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.116 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.087 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.984 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.920 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.879 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.730 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.739 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.593 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.648 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.525 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.556 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.471 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,71 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,26 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,49 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,73 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,9 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,78 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,62 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,8 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,81 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;36 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;130 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;174 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;35 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;125 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;166 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;121 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;161 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;116 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;159 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;114 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;156 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;97,22 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,15 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,4 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;93,08 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92,53 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;89,23 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;91,38 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;87,69 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;89,66 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;332 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;304 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;340 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;329 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;301 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;329 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;322 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;299 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;325 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;319 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;297 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;319 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;315 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;297 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;315 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,1 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,01 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,76 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,99 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,36 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,59 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,08 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,7 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,82 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;94,88 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,7 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,65 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;305 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;241 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;302 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;240 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;296 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;239 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;293 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;237 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;289 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;237 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,02 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,59 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;97,05 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,17 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,07 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,34 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;94,75 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;98,34 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;27 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;63 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;27 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;61 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;26 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;60 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;26 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;60 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;26 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;60 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,83 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;96,3 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,24 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;96,3 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,24 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;96,3 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;95,24 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;342 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;303 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;311 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;333 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;302 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;308 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;331 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;300 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;303 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;328 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;297 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;302 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;294 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;294 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,37 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,67 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,04 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,78 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,01 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,43 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,91 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,02 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,11 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,03 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,53 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;323 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;245 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;218 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;315 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;245 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;215 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;313 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;243 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;212 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;310 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;240 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;211 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;238 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;206 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,52 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,62 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,9 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,18 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,25 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,98 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,96 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,79 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,14 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,5 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;19 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;58 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;93 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;18 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;57 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;93 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;18 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;57 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;91 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;18 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;57 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;91 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;56 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;88 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;94,74 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,28 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;94,74 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,28 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,85 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;94,74 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;98,28 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,85 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,55 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,62 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;379 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;309 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;318 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;373 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;301 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;313 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;367 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;298 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;309 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;296 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;303 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;293 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;302 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,42 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,41 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,43 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,83 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;96,44 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,17 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,79 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,28 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,82 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,97 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;371 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;293 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;257 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;365 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;285 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;253 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;359 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;282 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;249 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;280 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;245 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;277 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;244 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,38 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,27 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,44 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,77 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;96,25 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,89 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,56 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,33 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,54 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,94 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;8 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;16 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;61 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;8 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;16 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;60 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;8 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;16 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;60 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;16 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;58 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;16 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;58 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,36 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,36 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;95,08 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;95,08 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;343 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;317 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;312 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;335 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;312 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;308 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;309 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;303 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;303 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;300 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;302 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;299 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,67 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,42 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,72 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,48 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,12 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,58 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,15 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,27 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,83 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;337 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;289 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;245 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;329 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;284 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;242 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;281 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;239 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;276 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;237 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;275 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;236 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,63 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,27 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,78 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,23 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,55 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,5 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,73 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,16 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,33 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;28 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;67 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;28 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;66 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;28 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;64 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;27 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;63 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;27 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;63 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,51 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,52 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;96,43 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;94,03 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;96,43 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;94,03 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;380 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;347 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;376 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;376 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;343 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;372 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;369 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;342 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;369 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;366 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;340 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;369 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;366 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;338 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;364 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,95 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,85 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,94 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;97,11 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,56 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,14 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;96,32 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,98 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;98,14 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,32 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,41 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,81 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;360 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;256 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;356 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;254 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;349 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;253 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;347 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;251 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;347 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;249 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,89 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,22 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,94 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,83 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;96,39 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,05 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,39 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;97,27 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;20 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;91 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;20 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;89 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;20 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;89 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;19 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;89 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;19 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;89 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,8 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,8 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;95 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,8 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;95 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,8 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;382 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;353 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;344 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;376 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;351 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;341 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;373 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;349 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;341 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;373 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;348 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;337 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;346 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;335 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 49 Zamora;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,43 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,43 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,13 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,64 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,87 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,13 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,64 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,58 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,97 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,02 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,38 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;357 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;256 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;250 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;351 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;254 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;248 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;348 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;252 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;248 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;348 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;251 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;245 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;250 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;244 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,32 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,22 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,2 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,48 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,44 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,2 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,48 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;98,05 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,66 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,6 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;25 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;97 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;94 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;25 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;97 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;93 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;25 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;97 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;93 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;25 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;97 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;92 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;96 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;91 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,94 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,94 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;97,87 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;98,97 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;96,81 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;380 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;378 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;354 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;378 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;376 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;353 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;378 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;372 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;348 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;370 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;345 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;366 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;345 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,47 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,47 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,72 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,47 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,41 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,31 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,88 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,46 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;96,83 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,46 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;375 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;350 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;255 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;374 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;348 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;254 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;374 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;344 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;250 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;342 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;248 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;338 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;248 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,73 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,43 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,61 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,73 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,29 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;98,04 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,71 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,25 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;96,57 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,25 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;5 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;28 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;99 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;28 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;99 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;28 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;98 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;28 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;97 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;28 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;97 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;80 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;80 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,99 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,98 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,98 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;392 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;391 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;372 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;390 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;388 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;366 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;384 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;362 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;378 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;361 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;377 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;359 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,49 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,23 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,39 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,21 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,31 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,68 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,04 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,42 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,51 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;387 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;372 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;276 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;385 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;369 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;271 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;365 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;268 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;359 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;267 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;358 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;265 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,48 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,19 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,19 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,12 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,1 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;96,51 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,74 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,24 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;96,01 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;5 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;19 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;96 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;5 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;19 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;95 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;19 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;94 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;19 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;94 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;19 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;94 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;98,96 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;97,92 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,92 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;97,92 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;10 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;10 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;11 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;10 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;11 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;10 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;11 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;12 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;10 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,67 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;91,67 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;91,67 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;12 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;8 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;12 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;8 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;11 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;8 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;11 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;8 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;11 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;8 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,67 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;91,67 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;91,67 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;4 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;4 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;4 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;4 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;4 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;13 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;11 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;10 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;12 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;11 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;10 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;12 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;11 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;10 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;12 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;11 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;10 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;11 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;10 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,31 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,31 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;92,31 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;13 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;7 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;6 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;12 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;7 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;6 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;12 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;7 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;6 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;12 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;7 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;6 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;7 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,31 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,31 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,31 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;4 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;11 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;11 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;11 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;12 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;91,67 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;11 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;10 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;90,91 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;4 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;4 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;4 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;4 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;4 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;13 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;13 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;13 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;12 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;92,31 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;92,31 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;7 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;12 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;7 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;12 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;7 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;11 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;7 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;11 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;7 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;91,67 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;91,67 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;1 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;5 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;1 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;5 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;1 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;5 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;1 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;5 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;1 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;5 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;5 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;6 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;7 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;7 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;7 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;7 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;5 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;7 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;83,33 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;83,33 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;83,33 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,33 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;6 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;5 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;83,33 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;83,33 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;83,33 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,33 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;.. 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;5 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;5 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;7 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;7 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;7 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;7 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;5 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;6 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,71 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;5 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;6 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,71 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;.. 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;5 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;6 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;6 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;6 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;5 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;83,33 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;83,33 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;6 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;6 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;6 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;5 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,33 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;83,33 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;.. 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;4 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;6 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;4 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;6 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;4 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;5 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;4 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;5 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;4 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;83,33 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;83,33 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;83,33 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;4 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;6 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;4 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;6 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;4 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;5 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;4 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;5 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;4 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;5 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;83,33 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;83,33 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;83,33 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;.. 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 49 Zamora;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;22.596 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;22.140 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;23.177 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;21.512 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;21.173 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;21.054 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;20.664 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;20.483 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;20.409 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;20.002 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;19.964 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;19.861 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;19.503 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;19.470 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;19.337 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,2 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;95,63 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;90,84 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;91,45 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;92,52 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;88,06 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,52 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;90,17 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;85,69 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;86,31 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;87,94 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;83,43 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;21.924 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;19.987 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;20.859 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;19.088 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;20.031 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;18.440 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;19.379 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;17.956 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;18.887 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;17.512 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,14 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;95,5 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;91,37 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;92,26 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;88,39 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;89,84 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;86,15 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;87,62 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;672 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;2.153 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;653 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;2.085 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;633 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;2.043 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;623 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;2.008 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;616 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1.958 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,17 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,84 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;94,2 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,89 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;92,71 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,27 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;91,67 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,94 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;22.512 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;22.163 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;21.819 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;21.468 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;21.303 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;21.077 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;20.671 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;20.667 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;20.446 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;20.089 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;20.073 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;19.859 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;19.427 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;19.248 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;95,36 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;96,12 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,6 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;91,82 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;93,25 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;93,71 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;89,24 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;90,57 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;91,02 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;87,66 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;88,22 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;21.861 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;20.039 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;18.726 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;20.844 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;19.220 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;18.038 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;20.063 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;18.625 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;17.464 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;19.491 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;18.083 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;16.950 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;17.483 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;16.412 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;95,35 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,91 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,33 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;91,78 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;92,94 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;93,26 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;89,16 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;90,24 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;90,52 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;87,24 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;87,64 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;651 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;2.124 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;3.093 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;624 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;2.083 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;3.039 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;608 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;2.042 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;2.982 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;598 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1.990 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;2.909 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1.944 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;2.836 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;95,85 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,07 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,25 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;93,39 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,14 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,41 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;91,86 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;93,69 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,05 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;91,53 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,69 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;22.565 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;22.458 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;22.168 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;21.459 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;21.526 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;21.259 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;20.733 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;20.770 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;20.514 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;20.045 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;19.843 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;19.536 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;19.415 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;95,1 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,85 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,9 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,88 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;92,48 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;92,54 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;89,26 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;89,51 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;86,99 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;87,58 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;22.184 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;21.853 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;19.728 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;21.091 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;20.927 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;18.859 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;20.373 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;20.190 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;18.171 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;19.476 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;17.563 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;18.978 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;17.173 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;95,07 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,76 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;95,6 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,84 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,39 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;92,11 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;89,12 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;89,03 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;86,84 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;87,05 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;381 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;605 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2.440 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;368 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;599 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2.400 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;360 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;580 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2.343 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;569 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2.280 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;558 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2.242 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;96,59 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,01 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,36 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;94,49 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,87 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;96,02 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,05 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,44 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;92,23 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,89 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;22.432 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;22.530 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;22.192 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;21.518 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;21.566 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;21.219 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;20.721 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;20.459 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;20.046 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;19.912 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;19.481 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;19.464 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;95,93 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;95,72 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,62 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;91,97 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;92,19 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;88,97 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;89,73 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;86,47 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;87,71 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;22.130 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;21.826 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;20.081 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;21.222 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;20.879 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;19.166 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;20.045 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;18.467 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;19.385 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;17.951 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;18.831 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;17.536 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;95,9 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;95,66 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,44 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;91,84 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;91,96 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;88,82 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;89,39 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;86,28 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;87,33 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;302 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;704 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;2.111 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;296 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;687 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;2.053 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;676 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1.992 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;661 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1.961 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;650 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1.928 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;98,01 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,59 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,25 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96,02 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,36 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;93,89 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,89 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;92,33 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,33 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;16.410 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;16.291 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;16.866 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;15.386 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;15.381 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;14.930 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;14.638 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;14.775 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;14.374 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;14.029 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;14.317 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;13.884 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;13.577 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;13.869 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;13.421 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,76 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;94,41 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;88,52 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,2 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90,69 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;85,22 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,49 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,88 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;82,32 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,74 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;85,13 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;79,57 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;16.061 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;15.269 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;15.052 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;14.413 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;14.320 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;13.837 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;13.719 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;13.405 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;13.273 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;12.997 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,72 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;94,39 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,16 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;90,62 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,42 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;87,79 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,64 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;85,12 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;349 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1.022 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;334 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;968 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;318 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;938 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;310 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;912 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;304 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;872 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;95,7 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;94,72 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;91,12 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;91,78 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,83 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,24 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;87,11 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,32 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;16.289 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;16.241 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;15.954 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;15.336 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;15.462 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;15.279 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;14.588 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;14.887 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;14.692 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;14.064 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;14.345 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;14.155 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;13.759 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;13.611 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;94,15 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,2 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;95,77 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,56 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,66 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,09 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;86,34 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;88,33 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;88,72 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,72 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,31 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;15.952 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;15.246 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;14.386 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;15.024 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;14.498 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;13.743 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;14.290 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;13.953 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;13.207 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;13.775 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;13.452 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;12.726 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;12.899 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;12.233 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;94,18 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;95,09 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,53 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,58 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,52 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,8 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;86,35 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;88,23 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,46 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,61 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;85,03 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;337 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;995 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1.568 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;312 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;964 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1.536 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;298 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;934 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1.485 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;289 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;893 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1.429 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;860 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1.378 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;92,58 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,88 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,96 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;88,43 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;93,87 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;94,71 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;85,76 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;89,75 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,14 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,43 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;87,88 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;16.340 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;16.392 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;16.283 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;15.281 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;15.516 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;15.414 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;14.621 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;14.817 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;14.717 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;14.165 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;14.115 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;13.706 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;13.729 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,52 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,66 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,66 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,48 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,39 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,38 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,41 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;86,69 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,61 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;84,31 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;16.111 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;16.102 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;15.161 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;15.064 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;15.230 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;14.326 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;14.412 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;14.547 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;13.669 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;13.904 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;13.110 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;13.455 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;12.754 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,5 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,58 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,49 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,45 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,34 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,16 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,35 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,47 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,56 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,12 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;229 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;290 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1.122 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;217 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;286 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1.088 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;209 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;270 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1.048 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;261 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1.005 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;251 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;975 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;94,76 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,62 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;96,97 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;91,27 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,1 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;93,4 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;90 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;89,57 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;86,55 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,9 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;16.169 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;16.438 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;16.318 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;15.310 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;15.526 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;15.390 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;14.749 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;14.691 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;14.151 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;14.207 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;13.635 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;13.813 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,69 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,45 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;94,31 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;89,73 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,03 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;86,09 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,06 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,95 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;84,65 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;15.993 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;16.044 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;15.384 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;15.140 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;15.145 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;14.500 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;14.376 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;13.844 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;13.791 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;13.381 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;13.286 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;13.011 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,67 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,4 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;94,25 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;89,6 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;89,99 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,96 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,98 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,81 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,57 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;176 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;394 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;934 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;170 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;381 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;890 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;373 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;847 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;360 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;826 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;349 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;802 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;96,59 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,7 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;95,29 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;94,67 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;90,69 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;91,37 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;88,44 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;88,58 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85,87 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;2.386 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;2.268 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;2.447 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;2.350 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;2.236 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;2.365 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;2.293 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;2.190 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;2.324 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;2.258 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;2.154 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;2.293 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;2.237 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;2.132 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;2.254 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;98,49 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,59 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,65 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;96,1 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,56 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;94,97 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;94,64 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;94,97 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;93,71 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,76 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,11 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2.290 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.917 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2.256 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.892 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2.201 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.851 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2.167 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.819 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2.147 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.801 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;98,52 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,7 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;96,11 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,56 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;94,63 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,89 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,76 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;93,95 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;96 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;351 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;94 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;344 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;92 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;339 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;91 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;335 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;90 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;331 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;97,92 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,01 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;95,83 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,58 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;94,79 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;95,44 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;93,75 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;94,3 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;2.371 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;2.335 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;2.297 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;2.323 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;2.290 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;2.264 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;2.295 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;2.252 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;2.244 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;2.264 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;2.227 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;2.210 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;2.193 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;2.173 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,98 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,07 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,56 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;96,79 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,45 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,69 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;95,49 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;95,37 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,21 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,92 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,6 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2.280 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.996 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.793 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2.234 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.956 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.768 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2.207 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.924 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.748 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2.176 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.903 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.723 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.875 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.695 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,98 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,61 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;96,8 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,39 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;97,49 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,44 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,34 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,1 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,94 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,53 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;91 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;339 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;504 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;89 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;334 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;496 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;88 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;328 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;496 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;88 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;324 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;487 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;318 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;478 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;97,8 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,53 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,41 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;96,7 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;96,76 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;98,41 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;96,7 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;95,58 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,63 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;93,81 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,84 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;2.366 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2.383 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;2.300 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;2.335 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;2.350 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;2.282 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;2.298 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;2.319 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;2.251 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;2.276 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;2.209 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;2.247 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;2.181 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,69 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,62 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,22 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,13 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,31 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,87 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;95,51 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,04 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;94,29 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;94,83 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;2.320 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2.287 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.895 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;2.290 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2.255 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.878 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;2.253 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2.227 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.857 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2.185 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.825 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2.157 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.801 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,71 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,6 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,1 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,11 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,38 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,99 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,54 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,31 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,32 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,04 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;46 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;96 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;405 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;45 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;95 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;404 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;45 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;92 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;394 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;91 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;384 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;90 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;380 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;97,83 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;98,96 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,75 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;97,83 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;95,83 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,28 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,79 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;94,81 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,75 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;93,83 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2.363 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;2.347 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2.239 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;2.335 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;2.321 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;2.212 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;2.280 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;2.182 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;2.238 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;2.144 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;2.210 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;2.116 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,82 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,89 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;98,79 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;97,15 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,45 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;95,36 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,76 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;94,16 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;94,51 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2.332 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;2.247 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.906 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2.304 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;2.223 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.886 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;2.184 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.865 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;2.143 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.831 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;2.115 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.806 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,8 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,93 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;98,95 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;97,2 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,85 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,37 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;96,07 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;94,13 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;94,75 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;31 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;333 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;31 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;98 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;326 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;96 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;317 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;95 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;313 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;95 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;310 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,9 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;96 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,2 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;95 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,99 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;95 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,09 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;3.484 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;3.285 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;3.547 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;3.461 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;3.261 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;3.451 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;3.418 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;3.224 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;3.403 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;3.402 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;3.200 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;3.378 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;3.376 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;3.177 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;3.357 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,34 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,27 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,29 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,11 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,14 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,94 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;97,65 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,41 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;95,24 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;96,9 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;96,71 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,64 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3.286 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2.590 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3.265 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2.572 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3.224 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2.542 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3.209 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2.523 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3.183 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2.506 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,36 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,31 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,11 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;98,15 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;97,66 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;97,41 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;96,87 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,76 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;198 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;695 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;196 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;689 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;194 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;682 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;193 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;677 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;193 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;671 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;98,99 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;99,14 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;97,98 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98,13 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;97,47 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,41 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;97,47 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,55 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;3.530 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;3.292 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;3.275 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;3.487 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;3.256 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;3.241 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;3.468 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;3.234 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;3.219 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;3.441 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;3.208 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;3.204 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;3.183 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;3.175 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,78 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,91 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,96 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;98,24 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,24 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,29 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;97,48 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,45 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,83 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;96,69 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,95 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3.336 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2.585 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2.351 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3.293 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2.554 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2.331 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3.275 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2.537 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2.315 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3.249 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2.518 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2.308 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2.499 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2.291 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,71 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;98,8 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,15 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,17 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,14 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,47 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;97,39 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,41 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,17 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,67 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,45 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;194 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;707 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;924 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;194 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;702 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;910 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;193 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;697 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;904 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;192 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;690 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;896 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;684 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;884 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;99,29 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,48 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;99,48 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;98,59 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;97,84 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;98,97 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,6 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;96,97 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;96,75 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,67 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3.537 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3.381 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3.296 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;3.523 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;3.359 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;3.276 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;3.494 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;3.334 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;3.260 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;3.306 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;3.234 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;3.286 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;3.220 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,6 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;99,35 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,39 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;98,78 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;98,61 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,91 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,78 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;98,12 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,19 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,69 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3.438 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3.192 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2.485 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3.424 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3.171 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2.470 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3.395 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3.146 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2.461 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3.118 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2.444 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3.098 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2.434 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,59 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;99,34 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,4 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;98,75 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;98,56 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;99,03 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,68 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;98,35 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,06 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,95 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;99 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;189 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;811 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;99 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;188 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;806 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;99 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;188 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;799 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;188 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;790 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;188 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;786 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;99,47 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;99,38 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;99,47 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;98,52 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;99,47 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,41 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;99,47 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,92 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;3.570 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3.434 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3.342 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;3.543 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;3.409 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;3.325 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;3.385 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;3.295 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;3.350 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;3.270 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;3.330 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;3.246 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;99,24 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,27 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,49 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,57 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,59 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;97,55 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;97,85 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;96,97 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;97,13 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;3.482 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3.257 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2.588 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;3.455 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3.234 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2.578 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3.211 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2.556 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3.177 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2.537 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3.157 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2.519 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;99,22 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,29 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,61 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,59 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;98,76 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;97,54 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;98,03 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;96,93 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;97,33 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;88 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;177 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;754 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;88 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;175 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;747 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;174 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;739 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;173 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;733 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;173 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;727 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;98,87 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;99,07 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;98,31 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,01 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;97,74 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;97,21 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;97,74 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,42 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;210 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;197 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;219 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;209 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;196 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;210 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;209 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;195 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;210 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;207 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;195 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;208 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;207 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;195 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;207 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,52 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,49 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;95,89 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;99,52 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;98,98 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,89 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,57 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,98 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,98 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;98,57 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;98,98 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,52 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;193 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;147 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;192 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;147 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;192 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;146 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;190 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;146 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;190 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;146 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,48 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;99,48 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;99,32 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,45 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;99,32 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;98,45 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;99,32 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;17 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;50 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;17 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;49 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;17 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;49 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;17 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;49 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;17 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;49 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;98 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;98 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;98 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;212 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;196 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;193 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;212 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;196 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;193 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;210 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;196 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;191 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;210 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;196 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;190 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;195 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;189 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;99,06 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,96 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;99,06 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;98,45 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;99,49 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,93 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;196 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;148 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;135 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;196 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;148 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;135 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;194 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;148 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;133 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;194 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;148 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;132 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;148 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;132 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;98,98 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;98,52 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;98,98 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,78 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;97,78 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;16 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;48 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;58 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;16 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;48 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;58 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;16 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;48 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;58 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;16 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;48 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;58 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;47 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;57 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;97,92 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;98,28 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;215 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;203 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;192 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;213 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;203 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;190 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;213 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;203 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;189 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;201 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;188 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;200 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;188 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;99,07 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,96 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;99,07 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,44 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;99,01 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,92 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;98,52 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;97,92 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;212 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;185 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;131 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;210 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;185 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;129 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;210 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;185 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;128 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;184 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;128 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;183 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;128 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;99,06 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,47 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;99,06 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,71 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;99,46 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,71 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;98,92 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;97,71 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;18 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;61 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;18 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;61 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;18 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;61 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;17 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;60 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;17 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;60 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;94,44 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;98,36 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;94,44 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;98,36 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;212 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;208 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;195 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;212 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;208 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;194 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;205 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;193 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;205 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;193 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;204 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;192 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,49 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,56 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,97 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,56 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;98,97 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,08 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,46 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;209 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;189 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;143 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;209 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;189 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;142 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;186 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;142 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;186 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;142 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;185 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;141 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,3 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,41 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;99,3 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,41 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;99,3 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;97,88 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,6 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;3 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;19 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;52 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;3 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;19 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;52 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;19 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;51 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;19 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;51 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;19 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;51 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;98,08 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;98,08 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;98,08 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;106 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;99 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;106 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;99 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;106 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;99 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;106 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;106 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;97 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;98,99 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,98 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;94 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;64 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;94 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;64 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;94 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;64 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;94 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;63 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;94 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;62 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;98,44 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,88 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;12 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;35 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;12 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;35 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;12 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;35 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;12 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;35 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;12 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;35 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;110 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;99 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;110 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;99 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;110 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;98 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;110 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;97 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;97 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,99 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;97,98 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;97,98 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;97 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;64 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;61 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;97 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;64 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;61 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;97 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;63 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;61 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;97 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;62 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;61 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;62 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;61 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;98,44 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;96,88 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;96,88 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;13 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;35 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;39 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;13 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;35 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;39 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;13 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;35 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;39 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;13 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;35 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;39 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;35 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;39 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;107 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;99 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;107 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;98 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;107 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;97 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,99 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,98 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;97,98 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,98 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;103 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;87 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;56 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;103 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;86 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;56 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;103 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;85 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;56 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;85 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;56 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;85 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;56 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,85 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,7 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;97,7 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,7 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;4 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;12 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;41 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;4 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;12 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;41 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;4 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;12 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;41 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;12 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;41 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;12 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;41 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;118 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;103 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;98 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;118 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;102 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;98 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;102 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;98 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;102 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;98 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;102 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;97 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,03 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,03 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;99,03 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;99,03 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;98,98 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;114 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;89 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;60 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;114 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;60 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;60 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;60 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;59 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,88 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;98,33 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;38 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;14 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;38 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;14 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;38 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;14 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;38 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;14 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;38 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 50 Zaragoza;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.504 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.500 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.543 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.425 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.409 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.379 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.346 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.350 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.343 51 Ceuta;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.291 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.310 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.297 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.243 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.258 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.262 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;94,75 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,93 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;89,37 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;89,49 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;90 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;87,04 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;85,84 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;87,33 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;84,06 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;82,65 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;83,87 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;81,79 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.444 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.329 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.369 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.242 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.295 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.185 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.241 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.151 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.195 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.105 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;94,81 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;93,45 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;89,68 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;89,16 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;85,94 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;86,61 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;82,76 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;83,15 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;60 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;171 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;56 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;167 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;51 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;165 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;50 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;159 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;48 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;153 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;93,33 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,66 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;85 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,49 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;83,33 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;92,98 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;80 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;89,47 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.517 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.482 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.480 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.424 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.408 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.431 51 Ceuta;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.356 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.361 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.372 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.296 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.304 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.331 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.252 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.265 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 51 Ceuta;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;93,87 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;95,01 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,69 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;89,39 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;91,84 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;92,7 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;85,43 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;87,99 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;89,93 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;84,48 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;85,47 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.466 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.329 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.232 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.377 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.257 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.184 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.310 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.216 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.132 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.251 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.165 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.096 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.120 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;1.038 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;93,93 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;94,58 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;96,1 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;89,36 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;91,5 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;91,88 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;85,33 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;87,66 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;88,96 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;84,27 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;84,25 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;51 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;153 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;248 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;47 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;151 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;247 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;46 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;145 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;240 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;45 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;139 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;235 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;132 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;227 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;92,16 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;98,69 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,6 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90,2 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,77 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,77 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;88,24 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;90,85 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;94,76 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,27 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,53 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.496 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.497 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.486 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.410 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.426 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.414 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.337 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.355 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.367 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.300 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.298 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.245 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.264 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,25 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;95,26 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;95,15 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;89,37 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;90,51 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;91,99 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;86,84 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;87,35 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;83,17 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;85,06 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.484 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.434 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.303 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.398 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.365 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.236 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.325 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.297 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.194 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.247 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.130 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.193 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.098 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,2 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;95,19 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,86 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;89,29 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;90,45 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;91,63 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;86,96 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;86,72 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;83,19 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;84,27 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;12 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;63 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;183 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;12 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;61 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;178 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;12 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;58 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;173 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;53 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;168 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;52 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;166 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,83 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,27 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;92,06 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,54 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;84,13 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,8 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;82,54 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;90,71 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.486 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.503 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.489 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.399 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.418 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.430 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.355 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.351 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.289 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.306 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.239 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.270 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,15 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,34 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;96,04 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;90,15 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;90,73 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;85,76 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;87,71 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;82,44 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;85,29 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.480 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.418 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.316 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.393 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.335 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.261 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.279 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.187 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.216 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.144 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.169 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.113 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;94,12 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,15 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,82 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;90,2 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;90,2 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;85,75 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;86,93 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;82,44 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;84,57 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;6 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;85 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;173 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;6 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;83 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;169 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;76 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;164 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;73 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;162 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;70 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;157 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;97,65 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,69 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,41 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,8 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;85,88 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,64 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;82,35 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;90,75 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.175 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.179 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.222 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;1.097 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;1.092 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;1.067 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;1.026 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;1.038 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;1.033 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;976 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.000 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;988 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;932 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;949 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;955 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;93,36 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;92,62 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;87,32 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;87,32 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,04 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;84,53 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;83,06 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,82 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;80,85 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;79,32 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,49 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;78,15 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.136 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.081 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.062 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;997 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;995 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;945 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;946 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;913 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;904 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;868 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;93,49 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,23 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;87,59 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,42 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;83,27 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;84,46 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79,58 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;80,3 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;39 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;98 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;35 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;95 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;31 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;93 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;30 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;87 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;28 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;81 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;89,74 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,94 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;79,49 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;94,9 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;76,92 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;88,78 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;71,79 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;82,65 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.187 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.165 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.172 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;1.101 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;1.095 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;1.127 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.040 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.048 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.072 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;985 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;995 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.031 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;945 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;969 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,75 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,99 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;96,16 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,62 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;89,96 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;91,47 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;82,98 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;85,41 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;87,97 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;81,12 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;82,68 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.152 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.075 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.010 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.070 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.007 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;966 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.010 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;966 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;918 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;956 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;919 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;882 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;876 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;826 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,88 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;93,67 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;95,64 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,67 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;89,86 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;90,89 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;82,99 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;85,49 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;87,33 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;81,49 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;81,78 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;35 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;90 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;162 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;31 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;88 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;161 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;30 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;82 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;154 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;29 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;76 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;149 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;69 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;143 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;88,57 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,78 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;99,38 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;85,71 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;91,11 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,06 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;82,86 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;84,44 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;91,98 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;76,67 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;88,27 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.157 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.166 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.160 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.081 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.098 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.094 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.016 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.034 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.048 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;982 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;982 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;934 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;951 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,43 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,17 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;94,31 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;87,81 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;88,68 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;90,34 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,22 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,66 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,1 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,98 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.151 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.128 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.052 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.075 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.062 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;991 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.010 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.001 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;950 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;954 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;888 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;906 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;859 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,4 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,15 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;94,2 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;87,75 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;88,74 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;90,3 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,57 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;84,41 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;80,32 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;81,65 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;6 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;38 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;108 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;6 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;36 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;103 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;6 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;33 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;98 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;28 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;94 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;28 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;92 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;94,74 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;95,37 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;86,84 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;90,74 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;73,68 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;87,04 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;73,68 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;85,19 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.145 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.176 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.162 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.064 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.096 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.107 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;1.034 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;1.032 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;975 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;992 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;928 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;958 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,93 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,2 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;95,27 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;87,93 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;88,81 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;82,91 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,37 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;78,91 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82,44 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.144 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.113 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.062 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.063 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.035 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.011 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;980 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;940 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;924 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;902 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;880 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;873 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,92 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;92,99 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;95,2 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,05 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,51 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;83,02 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,93 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;79,07 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;82,2 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;63 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;61 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;96 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;54 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;92 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;51 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;90 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;48 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;85 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;96,83 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;85,71 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;92 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;80,95 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;76,19 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;85 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;141 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;145 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;139 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;140 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;143 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;134 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;134 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;140 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;133 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;130 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;138 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;132 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;127 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;137 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;131 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99,29 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,62 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,4 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,04 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,55 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,68 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;92,2 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,17 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,96 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;90,07 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;94,48 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;94,24 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;132 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;117 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;131 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;116 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;126 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;113 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;122 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;111 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;119 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;110 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,24 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,15 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,45 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,58 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;92,42 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;94,87 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;90,15 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;94,02 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;9 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;28 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;9 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;27 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;8 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;27 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;8 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;27 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;8 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;27 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;96,43 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;88,89 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;96,43 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;88,89 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;96,43 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;88,89 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;96,43 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;134 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;130 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;129 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;129 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;129 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;127 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;124 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;129 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;125 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;122 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;125 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;125 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;123 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;122 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,27 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;99,23 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,45 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;92,54 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;99,23 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;96,9 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;91,04 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;96,15 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;96,9 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;94,62 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;94,57 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;128 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;110 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;92 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;123 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;109 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;90 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;118 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;109 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;88 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;116 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;105 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;88 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;103 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;87 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,09 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;99,09 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;97,83 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;92,19 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;99,09 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;95,65 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;90,63 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;95,45 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;95,65 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,64 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;94,57 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;6 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;20 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;37 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;6 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;20 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;37 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;6 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;20 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;37 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;6 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;20 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;37 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;20 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;35 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;94,59 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;143 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;133 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;146 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;135 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;130 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;142 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;131 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;124 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;142 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;122 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;140 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;118 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;139 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;94,41 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;97,74 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;97,26 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;91,61 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;93,23 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,26 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;91,73 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;95,89 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;88,72 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;95,21 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;140 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;124 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;116 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;132 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;121 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;112 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;128 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;115 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;112 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;113 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;111 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;109 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;110 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;94,29 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;97,58 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;96,55 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;91,43 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;92,74 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;96,55 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;91,13 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;95,69 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;87,9 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,83 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;9 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;30 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;9 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;30 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;9 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;30 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;9 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;29 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;9 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;29 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;96,67 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;96,67 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;146 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;138 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;145 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;143 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;134 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;142 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;133 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;140 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;127 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;138 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;125 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;136 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;97,95 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,1 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,93 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;96,38 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;96,55 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;92,03 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,17 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;90,58 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,79 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;145 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;130 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;116 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;142 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;126 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;113 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;125 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;112 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;119 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;110 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;117 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;108 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;97,93 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;96,92 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,41 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;96,15 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;96,55 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;91,54 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,83 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;90 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,1 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;1 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;8 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;29 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;1 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;8 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;29 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;8 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;28 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;8 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;28 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;8 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;28 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;96,55 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;96,55 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;96,55 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;175 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;166 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;174 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;175 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;164 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;170 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;173 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;162 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;169 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;172 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;162 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;169 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;171 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;162 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;168 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;98,8 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;97,7 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;98,86 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;97,59 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;97,13 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;98,29 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;97,59 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,13 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;97,71 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;97,59 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;96,55 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;163 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;122 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;163 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;120 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;161 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;118 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;160 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;118 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;159 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;118 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;98,36 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;98,77 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,72 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;98,16 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;96,72 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;97,55 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;96,72 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;12 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;44 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;12 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;44 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;12 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;44 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;12 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;44 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;12 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;44 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;183 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;176 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;169 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;181 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;173 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;167 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;179 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;173 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;165 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;176 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;173 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;165 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;173 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;164 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;98,91 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;98,3 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,82 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;97,81 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;98,3 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;97,63 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;96,17 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;98,3 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,63 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;98,3 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;97,04 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;173 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;134 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;120 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;171 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;131 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;118 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;169 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;131 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;116 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;166 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;131 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;116 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;131 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;115 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;98,84 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,76 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;98,33 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;97,69 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;97,76 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;96,67 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;95,95 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;97,76 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;96,67 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;97,76 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,83 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;10 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;42 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;49 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;10 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;42 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;49 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;10 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;42 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;49 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;10 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;42 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;49 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;42 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;49 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;182 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;186 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;169 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;180 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;186 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;167 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;176 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;185 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;166 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;184 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;165 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;181 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;163 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;98,9 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;98,82 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,7 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;99,46 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;98,22 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;98,92 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,63 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;97,31 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,45 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;179 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;171 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;125 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;177 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;171 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;123 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;173 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;170 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;122 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;169 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;121 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;167 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;119 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;98,88 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;98,4 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,65 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;99,42 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,6 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;98,83 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;96,8 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;97,66 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;95,2 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;15 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;44 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;15 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;44 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;15 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;44 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;15 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;44 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;14 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;44 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;93,33 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;181 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;176 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;170 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;178 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;175 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;169 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;175 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;167 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;174 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;164 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;173 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;164 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,34 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;99,43 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;99,41 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;99,43 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,24 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;98,86 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,47 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;98,3 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;96,47 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;177 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;162 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;127 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;174 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;161 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;126 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;161 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;124 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;160 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;121 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;159 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;121 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,31 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;99,38 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;99,21 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;99,38 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,64 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;98,77 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,28 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;98,15 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;95,28 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;43 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;14 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;43 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;14 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;43 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;14 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;43 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;14 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;43 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;10 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;8 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;5 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;10 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;8 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;5 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;10 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;8 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;5 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;10 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;8 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;5 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;10 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;8 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;5 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;10 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;7 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;10 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;7 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;10 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;7 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;10 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;7 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;10 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;7 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;11 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;9 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;7 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;11 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;9 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;7 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;11 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;9 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;7 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;11 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;9 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;7 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;9 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;7 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;11 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;8 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;7 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;11 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;8 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;7 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;11 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;8 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;7 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;11 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;8 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;7 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;8 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;7 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;.. 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;11 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;9 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;8 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;11 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;9 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;8 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;11 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;9 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;8 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;9 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;8 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;9 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;8 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;11 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;11 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;11 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;8 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;1 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;1 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;1 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;1 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;1 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;.. 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;12 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;12 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;10 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;12 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;10 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;9 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;12 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;10 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;9 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;10 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;9 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;10 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;9 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;10 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;9 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;1 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;1 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;1 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;1 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;1 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;2 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;2 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;2 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;2 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;3 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;3 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;3 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;3 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;3 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;3 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;.. 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;3 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;3 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;3 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;3 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;2 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;3 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;.. 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;3 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;2 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;2 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;2 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;2 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;3 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;1 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;1 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;1 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;1 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;1 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;3 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;3 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;3 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;3 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;2 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;.. 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 51 Ceuta;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.535 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.485 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.691 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2022QI;1.409 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2021QI;1.387 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the first trimester;2020QI;1.465 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QII;1.319 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QII;1.317 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QII;1.342 52 Melilla;Total ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;1.254 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;1.252 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;1.266 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIV;1.211 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIV;1.201 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIV;1.211 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;91,79 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;93,4 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;86,64 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;85,93 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;88,69 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;79,36 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;81,69 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;84,31 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;74,87 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;78,89 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;80,88 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;71,61 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.462 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;1.280 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;1.341 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;1.185 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;1.258 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;1.122 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;1.198 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;1.061 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;1.155 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;1.016 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;91,72 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;92,58 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;86,05 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;87,66 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;81,94 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;82,89 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;79 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;79,38 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;73 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;205 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;68 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;202 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;61 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;195 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;56 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;191 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;56 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;185 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;93,15 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;98,54 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;83,56 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;95,12 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;76,71 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;93,17 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;76,71 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;90,24 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.517 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.501 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.570 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QII;1.406 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QII;1.400 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QII;1.421 52 Melilla;Total ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QIII;1.323 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QIII;1.325 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.335 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;1.273 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;1.268 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;1.273 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2022QI;1.199 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2021QI;1.224 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 52 Melilla;Total ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;92,68 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;93,27 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;90,51 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;87,21 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;88,27 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;85,03 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;83,92 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;84,48 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;81,08 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;79,88 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;77,96 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.461 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.304 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.308 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;1.355 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;1.210 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;1.162 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;1.276 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;1.139 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;1.083 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;1.226 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;1.087 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;1.027 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;1.029 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;982 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;Total ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;92,74 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;92,79 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;88,84 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;87,34 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;87,35 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;82,8 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;83,92 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;83,36 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;78,52 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;78,91 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;75,08 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;56 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;197 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;262 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;51 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;190 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;259 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;47 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;186 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;252 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;47 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;181 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;246 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;170 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;242 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;Total ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;91,07 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;96,45 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,85 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;83,93 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;94,42 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;96,18 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;83,93 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;91,88 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,89 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;86,29 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;92,37 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.500 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.489 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.484 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.397 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.403 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.380 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIV;1.331 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIV;1.336 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIV;1.306 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;1.257 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;1.255 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QII;1.206 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QII;1.209 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;93,13 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;94,22 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;92,99 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;88,73 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;89,72 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;88,01 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;84,42 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;84,57 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;80,99 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;81,47 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.483 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.426 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.295 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.383 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.342 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1.194 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1.317 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;1.277 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1.126 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;1.203 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1.079 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;1.155 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1.039 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;93,26 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;94,11 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;92,2 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;88,81 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;89,55 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;86,95 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;84,36 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;83,32 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;81 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;80,23 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;17 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;63 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;189 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;14 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;61 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;186 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;14 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;59 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;180 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;54 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;176 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;51 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;170 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;82,35 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;96,83 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,41 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;82,35 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;93,65 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;95,24 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;85,71 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;93,12 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;80,95 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;89,95 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.493 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.485 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.483 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.404 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.405 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.388 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2022QI;1.315 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2021QI;1.327 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;1.254 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;1.272 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QIII;1.201 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QIII;1.216 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;94,04 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;94,61 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;93,59 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;88,55 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;89,48 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;84,44 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;85,77 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;80,88 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;82 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.479 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.376 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.299 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.390 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1.301 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;1.209 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1.217 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;1.151 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1.166 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;1.101 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1.116 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;1.048 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;93,98 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;94,55 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;93,07 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;88,44 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;88,61 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;84,74 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;84,76 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;81,1 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;80,68 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;14 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;109 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;184 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;14 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;104 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;179 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;98 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;176 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;88 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;171 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;85 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;168 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95,41 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;97,28 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;89,91 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;95,65 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;80,73 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;92,93 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;77,98 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;91,3 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;Total ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;1.133 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;1.120 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;1.324 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2022QI;1.018 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2021QI;1.028 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the first trimester;2020QI;1.106 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QII;942 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QII;967 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QII;986 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;887 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;907 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;913 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIV;847 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIV;865 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIV;863 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;89,85 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;91,79 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;83,53 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;83,14 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;86,34 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;74,47 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;78,29 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;80,98 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;68,96 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;74,76 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;77,23 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;65,18 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;1.079 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;996 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;968 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;907 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;898 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;852 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;847 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;796 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;807 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;759 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;89,71 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;91,06 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;83,23 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;85,54 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;78,5 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;79,92 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;74,79 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;76,2 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;54 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;124 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;50 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;121 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;44 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;115 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;40 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;111 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;40 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;106 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;92,59 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;97,58 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;81,48 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;92,74 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;74,07 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;89,52 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;74,07 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;85,48 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;1.125 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;1.142 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;1.232 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QII;1.026 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QII;1.049 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QII;1.086 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QIII;956 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QIII;980 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QIII;1.001 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;909 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;931 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;944 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2022QI;867 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2021QI;900 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 52 Melilla;From 1 to 5;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;91,2 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;91,86 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;88,15 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;84,98 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;85,81 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;81,25 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;80,8 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;81,52 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;76,62 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;75,92 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;73,05 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;1.089 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;1.021 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;1.060 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;994 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;934 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;916 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;928 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;869 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;837 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;881 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;825 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;784 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;771 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;743 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;91,28 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;91,48 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;86,42 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;85,22 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;85,11 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;78,96 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;80,9 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;80,8 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;73,96 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;75,51 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;70,09 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;36 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;121 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;172 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;32 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;115 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;170 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;28 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;111 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;164 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;28 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;106 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;160 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;96 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;157 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;88,89 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;95,04 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;98,84 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;77,78 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;91,74 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,35 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;77,78 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;87,6 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;93,02 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;79,34 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;91,28 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1.119 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;1.127 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1.134 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QIII;1.025 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QIII;1.046 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QIII;1.032 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIV;961 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIV;988 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIV;962 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;915 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;915 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QII;868 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QII;875 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;91,6 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;92,81 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;91,01 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;85,88 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;87,67 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;84,83 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;81,19 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;80,69 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;77,02 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;77,16 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1.108 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;1.081 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1.022 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1.017 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;1.002 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;922 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;953 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;946 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;856 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;878 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;812 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;834 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;778 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;91,79 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;92,69 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;90,22 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;86,01 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;87,51 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;83,76 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;81,22 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;79,45 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;77,15 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;76,13 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;11 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;46 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;112 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;8 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;44 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;110 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;8 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;42 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;106 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;37 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;103 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;34 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;97 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;72,73 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;95,65 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;98,21 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;72,73 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;91,3 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,64 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;80,43 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,96 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;73,91 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;86,61 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1.110 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1.126 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;1.128 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIV;1.024 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIV;1.054 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIV;1.037 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2022QI;969 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2021QI;980 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;916 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;932 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QIII;870 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QIII;881 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;92,25 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;93,61 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;91,93 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;86,06 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;86,88 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;81,35 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;82,62 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;77,26 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;78,1 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1.102 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1.046 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;1.017 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1.016 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;978 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;930 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;898 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;875 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;855 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;832 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;812 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;784 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;92,2 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;93,5 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;91,45 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;85,85 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;86,04 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;81,74 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;81,81 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;77,63 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;77,09 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;8 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;80 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;111 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;8 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;76 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;107 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;71 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;105 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;61 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;100 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;58 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;97 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;95 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,4 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;88,75 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;94,59 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;76,25 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;90,09 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;72,5 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;87,39 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 1 to 5;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;195 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;173 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;184 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2022QI;186 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2021QI;172 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the first trimester;2020QI;178 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QII;180 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QII;167 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QII;176 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;173 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;166 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;174 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIV;170 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIV;160 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIV;170 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;95,38 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;99,42 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;96,74 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;92,31 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;96,53 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;95,65 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;88,72 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;95,95 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;94,57 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;87,18 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;92,49 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;92,39 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;187 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;138 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;178 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;137 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;173 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;133 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;167 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;132 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;164 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;126 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;95,19 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;99,28 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;92,51 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;96,38 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;89,3 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;95,65 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;87,7 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;91,3 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;8 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;35 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;8 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;35 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;7 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;34 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;6 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;34 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;6 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;34 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;87,5 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;97,14 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;75 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;97,14 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;75 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,14 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;202 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;170 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;171 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QII;196 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QII;166 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QII;170 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QIII;189 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QIII;162 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QIII;170 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;186 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;158 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;166 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2022QI;154 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2021QI;163 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;97,03 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,65 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;99,42 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;93,56 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;95,29 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;99,42 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;92,08 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;92,94 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,08 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;90,59 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;95,32 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;192 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;138 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;124 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;187 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;134 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;123 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;180 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;130 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;123 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;177 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;126 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;121 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;122 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;119 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;97,4 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,1 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,19 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;93,75 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;94,2 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,19 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;92,19 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;91,3 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;97,58 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;88,41 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;95,97 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;10 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;32 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;47 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;9 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;32 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;47 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;9 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;32 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;47 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;9 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;32 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;45 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;32 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;44 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;90 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;90 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;90 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,74 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;93,62 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;195 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;177 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;180 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QIII;190 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QIII;174 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QIII;179 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIV;188 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIV;168 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIV;175 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;164 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;174 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QII;162 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QII;169 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,44 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,31 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,44 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;96,41 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;94,92 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;97,22 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;92,66 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;96,67 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;91,53 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;93,89 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;193 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;173 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;143 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;188 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;170 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;142 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;186 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;164 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;140 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;160 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;140 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;158 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;135 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,41 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,27 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;99,3 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;96,37 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;94,8 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;97,9 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;92,49 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,9 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;91,33 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;94,41 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;2 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;4 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;37 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;2 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;4 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;37 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;2 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;4 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;35 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;4 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;34 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;4 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;34 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;94,59 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;91,89 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;91,89 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;196 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;171 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;168 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIV;193 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIV;166 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIV;164 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2022QI;161 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2021QI;163 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;157 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;160 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QIII;151 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QIII;157 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;98,47 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;97,08 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;97,62 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;94,15 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;97,02 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;91,81 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;95,24 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;88,3 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;93,45 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;194 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;157 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;138 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;191 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;153 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;135 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;149 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;135 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;145 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;132 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;139 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;129 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;98,45 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;97,45 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;97,83 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;94,9 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,83 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;92,36 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;95,65 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;88,54 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,48 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;2 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;14 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;30 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;2 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;13 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;29 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;12 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;28 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;12 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;28 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;12 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;28 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;92,86 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;96,67 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;85,71 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;93,33 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;85,71 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;93,33 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;85,71 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;93,33 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 6 to 9 employees ;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;201 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;187 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;176 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2022QI;199 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2021QI;182 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the first trimester;2020QI;174 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QII;191 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QII;178 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QII;173 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;188 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;174 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;172 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIV;188 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIV;171 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIV;171 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;99 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;97,33 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;98,86 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;95,02 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;95,19 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;98,3 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;93,53 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;93,05 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;97,73 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;93,53 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;91,44 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;97,16 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;190 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;142 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;189 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;137 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;181 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;133 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;178 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;129 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;178 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;127 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;99,47 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;96,48 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;95,26 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;93,66 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;93,68 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;90,85 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;93,68 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;89,44 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;11 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;45 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;10 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;45 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;10 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;45 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;10 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;45 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;10 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;44 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;90,91 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;90,91 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;90,91 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;90,91 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;97,78 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;185 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;183 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;161 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QII;179 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QII;179 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QII;159 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QIII;173 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QIII;177 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QIII;158 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;173 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;173 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;157 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2022QI;172 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2021QI;155 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 52 Melilla;From 10 to 99;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;96,76 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;97,81 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;98,76 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;93,51 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;96,72 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;98,14 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;93,51 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;94,54 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;97,52 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;93,99 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;96,27 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;175 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;140 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;119 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;169 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;137 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;118 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;163 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;135 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;118 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;163 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;131 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;117 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;131 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;115 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;96,57 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;97,86 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;99,16 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;93,14 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;96,43 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;99,16 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;93,14 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;93,57 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;98,32 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;93,57 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;96,64 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;10 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;43 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;42 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;10 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;42 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;41 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;10 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;42 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;40 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;10 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;42 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;40 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;41 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;40 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;100 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;97,67 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;97,62 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;100 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;97,67 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;95,24 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;100 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;97,67 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;95,24 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;95,35 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;95,24 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;180 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;181 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;164 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QIII;176 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QIII;179 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QIII;163 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIV;176 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIV;176 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIV;163 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;174 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;160 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QII;172 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QII;159 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;97,78 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;98,9 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;99,39 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;97,78 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;97,24 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;99,39 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;96,13 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;97,56 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;95,03 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;96,95 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;177 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;168 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;126 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;173 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;166 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;126 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;173 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;163 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;126 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;161 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;123 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;159 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;122 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;97,74 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;98,81 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;97,74 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;97,02 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;95,83 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;97,62 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;94,64 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;96,83 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;3 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;13 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;38 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;3 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;13 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;3 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;13 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;13 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;13 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;97,37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;97,37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;97,37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;100 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;97,37 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;181 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;184 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;182 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIV;181 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIV;181 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIV;182 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2022QI;181 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2021QI;179 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;177 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;175 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QIII;176 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QIII;173 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;98,37 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;98,37 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;98,35 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;96,2 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;96,15 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;95,65 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;95,05 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;177 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;169 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;139 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;177 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;166 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;139 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;166 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;136 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;162 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;132 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;161 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;130 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;98,22 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;98,22 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;97,84 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;95,86 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;94,96 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;95,27 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;93,53 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;4 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;15 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;43 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;4 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;15 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;43 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;15 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;43 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;15 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;43 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;15 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;43 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;100 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;From 10 to 99;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;4 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;3 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;6 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2022QI;4 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2021QI;3 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the first trimester;2020QI;6 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QII;4 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QII;3 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QII;6 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;4 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;3 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;6 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIV;4 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIV;3 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIV;6 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;4 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;4 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;4 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;4 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;4 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;1 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;1 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;1 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;1 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;1 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;100 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;3 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QII;3 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QII;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QII;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QIII;3 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QIII;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QIII;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;3 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2022QI;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2021QI;4 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;3 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;1 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;100 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QIII;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QIII;2 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QIII;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIV;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIV;2 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIV;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;2 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QII;2 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QII;5 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;4 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;3 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;4 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;3 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;4 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;3 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;3 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;3 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;1 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;2 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;1 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;2 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;1 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;2 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;2 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;2 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;100 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;5 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIV;5 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2022QI;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2021QI;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QIII;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QIII;3 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;5 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;5 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;3 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;.. 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;from 100 to 249;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;2 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;2 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;1 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2022QI;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2021QI;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the first trimester;2020QI;1 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QII;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QII;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QII;1 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;1 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIV;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIV;2 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIV;1 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2022QI;100 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2021QI;100 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Number at the start of the quarter;2020QI;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2022QI;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the first trimester;2020QI;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QII;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QII;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QII;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QIII;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QIII;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QIII;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIV;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIV;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIV;100 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2022QI;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2021QI;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QII;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QII;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIV;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIV;2 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2022QI;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2021QI;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;100 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2022QI;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2021QI;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QII;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QII;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIV;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIV;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2022QI;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2021QI;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QII;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QII;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;0 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;.. 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort January 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QIII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QIII;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2022QI;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2021QI;2 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QIII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QIII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QIII;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIV;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIV;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIV;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2022QI;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2021QI;100 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QIII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QIII;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2022QI;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2021QI;2 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;100 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QIII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QIII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QIII;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2022QI;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2021QI;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;0 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;.. 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort April 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;1 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;2 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;1 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QIII;1 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QIII;1 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIV;1 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIV;2 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIV;1 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;2 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;1 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QII;2 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QII;1 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QIII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QIII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QIII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QIII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIV;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIV;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2022QI;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2021QI;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QII;100 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;2 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QIII;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QIII;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIV;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIV;2 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIV;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;2 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QII;2 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QII;1 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QIII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QIII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QIII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;100 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QIII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QIII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QIII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIV;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIV;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIV;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QII;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QIII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QIII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QIII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;0 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2022QI;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2021QI;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;.. 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort July 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;1 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;1 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;2 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIV;1 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIV;1 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIV;2 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2022QI;1 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2021QI;2 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;1 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;2 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QIII;1 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIV;100 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIV;100 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIV;100 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIV;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2022QI;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2021QI;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QII;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QII;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QIII;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QIII;100 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Total;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;2 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIV;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIV;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIV;2 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2022QI;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2021QI;2 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;2 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QIII;1 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QIII;2 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIV;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIV;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIV;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIV;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIV;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIV;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2022QI;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2021QI;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QII;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QII;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QIII;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QIII;100 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Sin ERTE;Percentage of survivals in the fourth semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2022QI;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2021QI;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the second trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QIII;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QIII;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Survival in the third trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIV;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIV;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Number at the start of the quarter;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIV;0 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIV;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIV;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the first trimester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2022QI;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2021QI;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the second semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QII;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QII;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the third semester;2020QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QIII;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2022QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QIII;.. 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2021QI;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIV;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QIII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QII;"" 52 Melilla;De 250 o más;Cohort October 1;Con ERTE;Percentage of survivals in the fourth semester;2020QI;""